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Chronic kidney disease (CKD) patients have a shorter life expectancy than healthy 
individuals, from the premature development of cardiovascular disease due to traditional and 
non-traditional risk factors. It is therefore pertinent that management of CKD be aimed at 
modifying these cardiovascular disease risk factors. Exercise therapy, in particular aerobic 
exercise, in the end stage kidney disease population has been shown to decrease 
cardiovascular disease risk factors and subsequent cardiovascular disease. However, 
randomized exercise training trials are scarce in the stage 3-4 CKD cohort. High intensity 
interval training (HIIT) is a promising exercise training approach that has been shown to 
elicit greater improvements in cardiovascular disease risk factors than moderate intensity 
continuous training (MICT) in other chronic disease populations. However, HIIT has not yet 
been investigated in patients with CKD. This thesis comprises two sections, each containing a 
randomised control trial (RCT) investigating the effects of exercise training in CKD patients.  
Section 1 contains data from the Landmark III (LM3) trial, which investigated the effects of a 
nurse-led, multi-disciplinary lifestyle intervention (LI) in 187 CKD patients. Testing of both 
LI and standard care (control) groups occurred every 6 months for 3 years. The exercise 
training in the LI consisted of a combination of individualized aerobic and resistance training 
and encouraged patients to participate in higher intensity exercise if possible. The main study 
in Section 1 assesses the change in various outcome measures after 3 years of LI (Chapter 6). 
Section 1 also includes baseline cross-sectional analyses (Chapter 3) and 12 month sub-
studies (Chapters 4 and 5).  
Section 2 contains the second trial that investigated the feasibility and efficacy of a 12 week 
HIIT program in CKD patients. Recruitment for the HIIT study was through participants who 
had completed the LM3 study.  
Chapter 1 provides an introduction to the studies, including the aims of the thesis. Topics 
reviewed include; pathophysiology of CKD, exercise capacity, autonomic dysfunction, 
haemoglobin, muscle atrophy, oxidative stress, inflammation, blood lipids and HIIT. Section 
1 starts with the detailed methods of the LM3 study (Chapter 2). Further methods applicable 
to specific studies are reported in the relevant chapter.  
Chapter 3 investigates the determinants of reduced muscle strength at baseline through a 
cross-sectional analysis of the LM3 study. This study identified the association of oxidative 
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stress with low muscle strength and reduced lean mass. The relationship was independent of 
known influences on muscle mass and strength.  
The feasibility and determinants of the LI group participating in higher intensity exercise 
training in the first 12 months of the LM3 study was investigated in Chapter 4. The findings 
identified that higher intensity exercise training was indeed feasible in the CKD cohort, with 
the number of participants reporting higher intensity exercise increasing from 20% to 43%. 
Reported higher intensity exercise during the LI was also associated with the greatest 
exercise capacity at 12 months. Furthermore, the analysis identified haemoglobin to be the 
greatest predictor of individuals reporting higher intensity exercise.  
Chapter 5 investigates the agreement between creatinine and cystatin-C estimated glomerular 
filtration rate (eGFR) measurements in patients completing 12 months of the LM3 study. This 
chapter explores whether discrepancies in the CKD Epidemiology Collaboration (CKD-
EPI)cystatin-C, CKD-EPIcreatinine and modification of diet in renal disease (MDRD) eGFR 
equations occur after an exercise intervention. It was identified that cystatin-C based eGFR 
measurements were considerably lower than creatinine based eGFR measurements. Despite 
this discrepancy at baseline, the agreement between the different GFR estimates did not 
change after exercise training.  
Chapter 6 contains the main study from LM3, which investigates the changes in 
cardiorespiratory fitness, exercise capacity, functional capacity, blood biochemistry, 
anthropometry measures and other cardiovascular disease risk factors after 3 years of LI 
compared to the control group. The primary finding from this study was the ability of a long-
term LI to significantly increase physical activity levels, exercise capacity and autonomic 
function and decrease arterial stiffness in patients with CKD.  
Section 2 includes a systematic review and meta-analysis of HIIT in patients with 
cardiometabolic diseases (Chapter 7). This review investigated the efficacy and safety of 
HIIT compared to MICT in individuals with a population sample of chronic disease, where 
poor lifestyle was considered a main contributor to the disease. The meta-analysis was 
performed using oxygen uptake (VO2peak or VO2maximum) as the primary outcome 
measure, however the influence of HIIT on all cardiovascular disease risk factors was 
explored. It was identified that HIIT provokes nearly twice the increase in VO2peak 
compared to MICT. 
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Chapter 8 in Section 2 investigates the feasibility of HIIT and the efficacy of HIIT compared 
to MICT in improving cardiovascular disease risk factors. It was identified that HIIT was a 
feasible option for patients with CKD. However, the improvements in cardiorespiratory 
fitness and exercise capacity were slightly greater in the MICT than the HIIT group, although 
the changes were not statistically significant. Participants from the HIIT group also reported 
higher levels of enjoyment from the intervention, as measured by the Physical Activity 
Enjoyment Scale.  
Chapter 9 provides a summary of the outcomes from all studies. This chapter discusses how 
this thesis has extensively contributed to the current knowledge in exercise training in CKD 
patients. Based on the findings, it is recommended that a combination of aerobic and 
resistance training, with some higher intensity exercise if possible, be prescribed to patients 
with CKD to elicit the greatest health outcomes. Important factors to consider with exercise 
training and testing of CKD patients, such as the effects of certain medications and hydration 
status on physiological responses, are also explored. Further, this chapter suggests future 
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Chapter 1.  
Introduction and general review of the 
literature 
  




Chronic kidney disease (CKD) is a debilitating public health problem, reported to affect 
approximately 16% of Australian adults.(1) Moreover, CKD patients often have a shorter life 
expectancy than that of healthy individuals due to the premature development of 
cardiovascular disease.(2) This is partly due to the association of CKD with lifestyle related 
traditional cardiovascular disease risk factors such as hypertension, diabetes, 
hypercholesterolemia and left ventricular hypertrophy. It has also been reported that non-
traditional risk factors such as anaemia, abnormal phosphate-calcium metabolism, 
inflammation and oxidative stress may contribute to the accelerated burden of cardiovascular 
disease.(3)  
The economic burden of kidney disease in the years of 2004 and 2005 has been estimated at 
almost $900 million, which is equivalent to 1.7% of total health care expenditure (Australian 
Institute of Health and Welfare, 2013). Dialysis is the major contributor to this cost, 
accounting for 2/3 of the total expenditure. Many of the adverse events associated with CKD, 
such as kidney failure and cardiovascular disease, can be delayed with effective treatment. As 
such, management of CKD should be aimed at modifying these cardiovascular disease risk 
factors.(4)  
 
1.1.1 Classification of CKD 
CKD can be defined and classified according to abnormalities of kidney structure or function, 
present for > 3 months, with implications for health.(5) In particular, the criteria for CKD 
diagnosis is: duration of >3 months, based on documentation or inference, of GFR <60 
ml/min/1.73m2) (GFR categories G3a-G5 [Table 1.2])(5), or kidney damage as defined by 
structural abnormalities or functional abnormalities other than decreased GFR (Table 1.3).(6) 
Commonly, initial screening of kidney dysfunction occurs through general practitioners by 
detection of urinary sediment and assessment of blood biochemistry. Urinalysis allows 
detection of albuminuria (Table 1.2), proteinuria, creatinine and urea, all of which can 
provide indications of kidney damage.(7) The prognosis of CKD by GFR and albuminuria 
has been reported by KDIGO 2012 (Table 1.2).(5) 
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Table 1.1 Criteria for CKD (either of the following present for >3 months) (KDIGO, 
2012)  
Markers of kidney 
damage (one or more) 
Albuminuria (AER ≥30mg/24 hours; ACR ≥30mg/g [≥3 mg/mmol]) 
Urine sediment abnormalities 
 Electrolyte and other abnormalities due to tubular disorders 
 Abnormalities detected by histology 
 Structural abnormalities detected by imaging 
 History of kidney transplantation 
Decreased GFR GFR <60 ml/min/1.73m2 (GFR categories G3a-G5) 
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Table 1.2 Prognosis of CKD by GFR and albuminuria categories (KDIGO, 2012) 
    Persistent albuminuria categories 
    A1 A2 A3 
    Normal to mildly increased Moderately increased Severely increased 
































G1 Normal or high ≥90 Low risk Moderately increased risk High risk 
G2 Mildly decreased 60-89 Low risk Moderately increased risk High risk 




High risk Very high risk 
G3b Moderately to 
severely decreased 
30-44 High risk Very high risk Very high risk 
G4 Severely decreased 15-29 Very high risk Very high risk Very high risk 
G5 Kidney failure <15 Very high risk Very high risk Very high risk 
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1.1.2 Measurement of kidney function 
There have been a number of proposed ways to measure kidney function. Quantifying the 
clearance of an exogenous marker such as inulin, is accepted to be the reference method for 
measuring renal function,(8) however it is not used routinely due to its complexity in testing. 
More commonly, indirect assessment of endogenous markers to provide an eGFR is used for 
routine clinical measurements.(9) These formulas use biomarkers of either creatinine, or 
cystatin-C in serum, plasma or urine, alongside age, sex and race to estimate filtration rates. 
The four most frequently used eGFR equations are: modification of diet in renal disease 
(MDRD),(10) CKD-EPI creatinine (CKD-EPIcr)(11), CKD-EPI cystatin-C (CKD-
EPIcys)(12) and CKD-EPI creatinine-cystatin-C (CKD-EPIcr-cys)(12). The original MDRD 
equation used a 6 variable estimate (serum creatinine, age, sex, race, serum urea nitrogen and 
albumin concentrations),(13) however this was later simplified to 4 variables (creatinine, age, 
sex and race).(14) The 4-variable MDRD equation was shortly after re-expressed for use with 
standardized serum creatinine assays (isotope-dilution mass spectrometry).(10) The MDRD 
equation was shown to be more simplistic than the Cockcroft-Gault formula, as it did not 
require a patient’s weight for the equation.(15) More recently it was proposed that CKD-
EPIcr provided a more precise estimate of GFR and categorization for risk of mortality 
compared to the MDRD study equation.(16) CKD-EPIcr was developed using the same 
variables as MDRD but with different coefficients, which created a moderate improvement in 
overall accuracy.(17) Furthermore, the MDRD equation has only been validated in eGFR <60 
ml/min/1.73m2 whereas the CKD-EPI equation has been validated to eGFR 90 
ml/min/1.73m2.(5) It has been suggested that standardized serum creatinine assays be used as 
a first test for assessing eGFR in adults and that CKD-EPIcys be used a confirmatory test if a 
below normal creatinine eGFR is detected.(18) The combination of both creatinine and 
cystatin-C used in the CKD-EPIcr-cys equation may provide the most accurate assessment of 
kidney function.(18-20)  
 
1.1.3 Causes of CKD 
Diabetes, hypertension and glomerulonephritis, are the leading causes of end stage kidney 
disease in all developed and many developing countries.(21) Indeed, the rising prevalence of 
CKD(22) is likely attributable to the increase in diabetes and hypertension in the aging 
population. Diabetic nephropathy occurs as a consequence of prolonged exposure of the 
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microvasculature to elevated blood glucose levels. Glomerulonephritis refers to a range of 
primary conditions which cause inflammation and damage to the glomerulus.(23) Managing 
hypertension and glycaemic control are the most important early interventions in slowing the 
progression of diabetic nephropathy if albuminuria is present. Specifically, first line medical 
management for early stage CKD guidelines are treatment of hypertension and proteinuria 
through angiotensin converting enzyme inhibitors or, angiotensin receptor blockers and 
lifestyle changes. Second and third line anti-hypertension therapies include β-blockers, 
diuretics and calcium channel blockers.(24)  
 
1.1.4 Exercise as therapy 
Cardiorespiratory fitness is a known predictor of morbidity and mortality outcomes both in 
healthy and chronic disease populations.(25-28) The increase in cardiovascular mortality in 
CKD patients is hypothesised to occur as a result of the myriad of metabolic co-morbidities 
which are associated with this population. However, the resistance to improvement in 
cardiovascular disease risk factors with traditional strategies, suggests that other mechanisms 
may be at play. Consequently, the use of exercise therapy may provide an additional 
treatment to reducing cardiovascular disease risk factors. Indeed, it has been reported in 6213 
men aged 59.0±11.2 years, that every 1-MET increase in exercise capacity results in a 12% 
improvement in survival.(29)  
According to Exercise and Sports Science Australia, exercise training for patients with CKD 
should include aerobic, resistance and flexibility exercises and the contribution of each 
should be based on clinical judgement.(30) Furthermore, it is recommended that resistance 
training be performed twice weekly on non-consecutive days. It is also advised that 
appropriately trained and qualified personnel, such as an Accredited Exercise Physiologist, 
should design and deliver exercise programs, taking into account individual patient needs. 
Individual recommendations by stage of CKD or treatment plan do not currently exist.(31) 
The Kidney Disease- Improving Global Outcomes group (KDIGO) recommends encouraging 
lifestyle modification in patients with CKD to lower blood pressure and improve long-term 
cardiovascular outcomes.(32) In particular, they recommend undertaking an exercise program 
compatible with cardiovascular health and tolerance for at least 30 minutes, 5 days/week. 
Despite not having recommendations specific to CKD, the American College of Sports 
Medicine suggests older adults, or younger individuals with chronic conditions, undertake 
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either moderate intensity aerobic exercise for at least 30 minutes on most days of the week, or 
vigorous intensity exercise for 20 minutes on a least 3 days/week.(33) They also recommend 
whole body resistance training on at least 2 non-consecutive days/week and flexibility 
training for at least 10 minutes, 2 days/week. The Swedish exercise guidelines by Heiwe et al. 
for CKD and kidney transplant are slightly different to the guidelines mentioned above. 
Specifically, they recommend moderate intensity aerobic exercise 3x/week for 60 minutes, 
resistance training for 3x/week (80% 1RM), muscular endurance training 3x/week (50% 
1RM) and functional training 3x/week (ie. walking, balance and coordination training).(34)  
 
1.1.5 Thesis introduction 
The American College of Sports Medicine (ACSM) guidelines for older adults/clinical 
populations suggests that to achieve health enhancing benefits, a combination of resistance 
and aerobic exercise training should be utilized.(35) The primary study in this thesis, the 
Landmark III (LM3) trial, investigated the effects of a nurse-led, multi-disciplinary lifestyle 
intervention (LI) in 187 CKD patients for 3 years. The exercise training in the LI consisted of 
a combination of individualized aerobic and resistance training, in order to elicit the greatest 
health outcomes possible. The multi-disciplinary nature of LM3 was designed to target the 
complex and co-morbid nature of this disease. The objective of the 3 year intervention was 
aimed at not only testing the magnitude of health improvements but also the feasibility of 
such programs in this representative cohort of CKD patients. It was the goal of the study to 
identify whether this type of multi-disciplinary practice could target sustainable behaviour 
changes and be integrated as standard clinical management in the future. Once the 
effectiveness of this style of intervention in improving health outcomes is identified, the next 
step forward in exercise and kidney research is to ascertain a generalized optimal exercise 
prescription. This thesis includes a comparison of two different types of exercise training 
styles; the combination aerobic and resistance training in a long-term predominantly home-
based program in the LM3 study (Section 1) and a comparison of 12 weeks of supervised 
high intensity interval training (HIIT) and moderate intensity continuous training (MICT) 
(Section 2). However, an optimal dose-response for exercise prescription in CKD patients 
still warrants considerably more research. 
The overall aim of the LM3 study was to identify whether a nurse-led exercise and LI can 
improve cardiovascular disease risk factors and clinical outcomes. This study comprises a 
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representative cohort of CKD patients from the Nephrology Department at the Princess 
Alexandra Hospital in Brisbane, Australia. As such, the participants in the study are 
representative of the general CKD population, with a high number of co-morbidities and 
incidence of cardiovascular disease. This alone makes this study unique to other exercise 
studies in kidney disease patients which have excluded patients with significant 
cardiovascular disease. Therefore, these findings can be extrapolated to the general CKD 
population. The goal of the study was to investigate if a multi-disciplinary co-ordinated 
clinical care approach was effective in improving cardiovascular disease risk factors over an 
extended period.  
HIIT has recently gained popular interest due to its success in improving a number of health 
outcomes in chronic disease populations, however this is yet to be studied in patients with 
kidney disease. Therefore, Section 2 aims to explore whether HIIT is a feasible option for 
CKD patients. The goal of this study was to provide further evidence on the most effective 
type of aerobic exercise prescription, which may influence future exercise guidelines for the 
CKD population. 
 
1.2 Thesis aims 
1) To review the literature on all topics covered in the thesis, including pathophysiology of 
CKD, exercise training in CKD patients and specific effects on- autonomic function, muscle 
atrophy and blood biochemistry. 
2) To investigate the determinants and predictors of reduced strength and lean mass in 
patients with CKD. 
3) To investigate the feasibility and determinants of CKD patients reporting higher intensity 
exercise in a 12 month exercise program. 
4) To assess the agreement of creatinine and cystatin-C based eGFR measures in CKD 
patients completing a 12 month exercise program. 
5) To determine the effects of a 3 year lifestyle modification on cardiovascular disease risk 
factors in patients with CKD. 
6) To systematically review and meta-analyse HIIT in cardiometabolic lifestyle diseases. 
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7) To compare the feasibility and efficacy of HIIT versus MICT in patients with CKD. 
 
1.3 General review of the literature 
This thesis encompasses studies involving the effects of different approaches to exercise 
training on numerous physiological systems and biochemical processes. Therefore, the 
review of the literature has been written to give the necessary background for the reader to 
understand the current literature on each topic. Further summarised backgrounds are provided 
in each study chapter as all studies have, or will be, submitted to peer-reviewed journals.   
 
1.3.1 Aerobic exercise 
Ten published studies have investigated the effects of aerobic exercise training on a variety of 
outcomes in patients with CKD (Table 1.4). The study by Eidemak et al. (1997) (n=30) was a 
randomized control trial with participants undertaking 3 exercise sessions per week for 18 
months.(36) The findings from the study indicate an increase in VO2peak of 8% in the 
intervention group and a decrease of 10% in the control group.(36) Likewise, Toyama et al. 
(2010) (n=19) used a non-randomized selection of intervention and control groups and found 
similar improvements in VO2peak in the intervention group (10%) and similar decline in the 
control group (14%).(37) In this study Toyama et al. (2010) used a combination of 3 
supervised and unsupervised sessions per week for 12 weeks. Boyce et al. (1997) (n=8) 
performed a supervised cross-over design trial for four months with participants attending 
three sessions per week.(38) The intensity of the training sessions were progressively 
increased from 50-70% of heart rate reserve. The investigators of this study found a 
significant increase in VO2peak after the training period with a subsequent decrease after 2 
months of de-training. The findings by Eidemark et al, (1997), Toyama et al. (2010) and 
Boyce et al. (1997) suggest that non-exercising CKD patients experience a decline in 
cardiorespiratory fitness which can be successfully ameliorated with aerobic exercise 
training.  
Pechter et al. (2003) (n=26) used a non-randomized selection of intervention and control 
groups who trained for 12 weeks and Leehey et al. (2009) (n=11) conducted an RCT for 24 
weeks.(39, 40) However in contrast to the above studies, Pechter et al. (2003) and Leehey et 
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al. (2009) found no significant change in VO2peak in the intervention group compared to the 
control group. The study by Pechter et al. (2003) comprised two supervised sessions per week 
for 12 weeks. The study was considered low intensity by the investigators and although was 
monitored by a heart rate monitor the exact intensity was not reported. The exercise training 
protocol was described as vertical exercises in the pool, which may indicate that this modality 
of training is not sufficient to improve cardiorespiratory fitness. Furthermore, as 
cardiorespiratory testing occurred on a bicycle ergometer, the specificity of the aquatic 
training may have limited the transferrable improvements in fitness to the post-test. However, 
the sessions were only performed twice per week, which may also have contributed to the 
lack of significant progression in VO2peak. Although, this study did find an improvement in 
peak load in the intervention group, which may indicate health enhancing physiological 
adaptations, such as intrinsic changes in skeletal muscle,(41) which are occurring 
independently of changes in cardiorespiratory fitness. The lack of change in cardiorespiratory 
fitness in the study by Leehey et al. (2009) may be due to the high dropout rate experienced 
in the study. After 20 participants were recruited and consented, 7 subjects were not 
randomized due to: not meeting screening laboratory tests (n=1), a positive stress test (n=2), 
investigator decision (n=2), patient wish (n=1) and commencement of haemodialysis (n=1). 
A further two patients dropped out of the control group due to investigator decision and 
patient wish after randomization, leaving seven subjects in the intervention group and only 
four in the control group. The high drop-out rate may mean the remaining sample is biased 
and not representative of the CKD population. This issue highlights the difficulty in 
performing exercise studies in this population. Indeed, the limitation of reduced sample size 
in diminishing statistically significant cardiorespiratory fitness changes is likely, considering 
the study by Mustata et al. (2010), which also had both supervised and unsupervised sessions, 
had a significant improvement in VO2peak in the intervention group with a sample 
population nearly twice the size (n=20). The RCT by Mustata et al. (2010) showed an 
increase in VO2peak, despite an adherence of 80% in the supervised period and only 20% 
adherence reported in the home sessions.  
Kosmadakis et al. (2011), Watson et al. (2013) and Viana et al. (2014) published papers from 
the same trial investigating a non-randomized walking intervention performed 5x/week for 6 
months.(42-44) The first 20 participants were allocated to the exercise group and the 
following 20 participants were allocated to the control group. In addition, the 40 participants 
were randomized to four groups of bicarbonate supplementation of 24 mmol/l (exercise vs. 
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control) or 29 mmol/l (exercise vs. control). Watson et al. (2013) identified that exercise 
training depleted amino acid concentrations in participants receiving standard oral 
bicarbonate supplementation (24 mmol/l). However, participants randomized to receive 
additional oral bicarbonate supplementation (29 mmol/l) found that this depletion in amino 
acid concentrations was avoided. Significant improvements in exercise tolerance, weight loss 
and improvements in quality of life were reported in the publication by Kosmadakis et al. 
(2011) of the same study, however there were no significant changes in lean mass.(42) 
Furthermore, there was no net decrease in myofibrillar proteolysis.(44) These findings may 
suggest that despite additional blood buffering, aerobic exercise isn’t sufficient in stimulating 
hypertrophy in CKD patients. Viana et al. (2014) found a reduction in the ratio of plasma IL-
6 to interleukin-10 (IL-10) levels, suggesting an anti-inflammatory effect of regular aerobic 
exercise.(43) Indeed, frequency of exercise training may be important to anti-inflammatory 
response, as the authors also identified significant changes in IL-6 and IL-10 after an acute 
bout of exercise.  
Baria et al. (2014) randomized 27 sedentary, obese men to either aerobic exercise or control 
group in a 2:1 ratio.(45) Participants randomized to the aerobic exercise were able to choose 
between exercising in a supervised gym based setting (n=10) or at home (n=8), both for three 
sessions per week for 12 weeks. The modality of aerobic exercise was unspecified for both 
gym and home based settings. Baria et al. (2014) showed that 12 weeks of mild to moderate 
intensity (ventilatory threshold equivalent to 40-60% of maximum VO2) gym based aerobic 
exercise training can significantly reduce visceral fat, as measured by abdominal computed 
tomography and waist circumference.(45) Furthermore, when a home-based exercise group 
was given the same exercise instructions, diminutions in visceral fat and waist circumference 
were trending towards significance. This study also identified a significant increase in leg 
lean mass in the gym based group only. Furthermore, the investigators from this study found 
similar enhancements in both VO2peak, six minute walk time and sit to stand test in both 
supervised gym based and home based exercise.(45) Centre based and home based 
improvements inVO2peak and sit to stand were statistically significant from baseline, 
however they weren’t significantly different from each other. These findings provide support 
for economical home-based programs which can provide similar benefits to supervised gym-
based sessions.
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Table 1.3 Summary of studies investigating the effects of aerobic exercise training 
Author (year) Exercise:control Design Intervention Duration Exercise group outcomes 
Eidemak et al. (1997) 15:15 RCT Unsupervised, 













Boyce et al. (1997) 8 Cross-over Supervised, 60 
minutes, 3x/week 
4 months ⇑ VO2peak 
⇑ Blood pressure 
⇔ LV function 
⇑ Muscle strength 








12 weeks ⇔ VO2peak 
⇑ Peak O2 pulse 
⇑ Peak ventilation 
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⇑ Body mass index 
⇑ Total cholesterol 
⇑ Oxidative stress 
⇔ Blood pressure 








⇔ Exercise duration 
⇔ Proteinuria 
⇔ eGFR 




⇔ Body composition 
⇔ Blood pressure 
Mustata et al. (2010) 10:10 RCT Supervised + home 
based, progressed 
1 month 
supervised + 11 
⇑ VO2peak 
⇑ Endurance time 
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⇔ Quality of Life 
 
Toyama et al. (2010) 10:9 Non-random  Supervised + home 
based, 30 minutes, 
2x/week 
12 weeks ⇑ AT-VO2 
⇑ Lipids 
⇑ eGFR 










home based, 30 
minutes, 5x/week 
6 months ⇑ Exercise tolerance 
⇑ Quality of life 
⇑ reported uraemic symptoms 
⇑ BMI 
⇔ Blood pressure 
⇔ Cardiovascular function 
⇔ Lean mass or fat mass 




to usual or 
additional 
Unsupervised, 
home based, 30 
minutes, 5x/week 
6 months Standard bicarbonate: 
⇔ Blood lactate 
⇓ Intramuscular free amino acids 
⇔ Anabolic indicators 
⇔ Myofibrillar proteolysis 
Additional bicarbonate: 





⇑ Blood lactate 
⇑ Intramuscular free amino acids 
⇑ transcription MuRF1 
⇔ Other anabolic indicators 
⇔ Myofibrillar proteolysis 
Viana et al. (2014) 20:20 for exercise 
program. 
Randomized 






home based, 30 
minutes, 5x/week 
6 months ⇑ Anti-inflammatory effects 
⇑ T-lymphocyte and monocyte 
activation 
⇔ Immune cell numbers 
⇔ Neutrophil degranulation responses 
⇔ Proteinuria 
⇔ Blood pressure 




RCT Supervised or 
unsupervised, 30 
minutes, 3x/week 
12 weeks Centre: 
⇑ Speed achieved at VO2peak 
⇑ Sit to stand 
⇑ Six minute walk test 
⇑ Visceral fat, waist circumference and 
total body fat 
⇑ Leg lean mass 
⇑ eGFR 
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⇑ Blood pressure 
Home: 
⇑ Speed achieved at VO2peak 
⇑ Sit to stand 
⇑ Six minute walk test 
⇔ Visceral fat, waist circumference and 
total body fat 
⇔ Leg lean mass 
⇑ Blood pressure 
⇔ eGFR 
eGFR= estimated glomerular filtration rate; RCT= randomized control trial; AT= anaerobic threshold; AIx= augmentation index. ⇑ = positive 
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1.3.2 Resistance exercise 
Six published studies from three trials have investigated the effects of resistance exercise 
training in patients with CKD (Table 1.4). Castaneda et al. (2001 and 2004) (n=26), 
Balakrishnan et al. (2010) (n=23) and Watson et al. (2014) (n=38) conducted RCTs,(17, 46-
48) whereas Heiwe et al. (2001 and 2005) studied self-selected groups of CKD patients in an 
exercise (n=12), non-exercise control, (n=5) and healthy exercise group (n=6).(49, 50) All 
exercise sessions were performed in a supervised environment three times per week for 12 
weeks. The trial by Castaneda et al. and Balakrishnan et al. performed 3x 8 repetitions at 60% 
1-repetition maximum (1RM) and the trial by Heiwe et al. performed 3x 20 repetitions at 
80% 1RM respectively. The trial reported by Castaneda et al. (2001 and 2004) and 
Balakrishnan et al. (2010) found significant enlargements in both type 1 and type 2 muscle 
fibre cross-sectional area of the vastus lateralis and upper and lower body strength.(17, 46, 
47) Balakrishnan et al. (2010) also found significant increases in skeletal muscle 
mitochondrial content DNA copy number, supporting the anabolic benefit of resistance 
training in CKD patients. This improvement occurred despite a low-protein diet prescribed to 
participants. On the other hand, Heiwe et al. (2005) found no statistical differences in muscle 
fibre type proportion between CKD patients and healthy controls at baseline, with no change 
after exercise training.(49) However, the study did identify a significant increase in muscular 
strength measured by 1RM. The lack of morphometrical changes in this study may indicate 
neural adaptations instigated the improved muscle function. Heiwe et al. (2001) found the 
resistance training intervention group had significant increases in walking distance compared 
to the control group.(50) Watson et al. (2014) conducted a parallel randomized control 
feasibility study in where intervention participants underwent 8 weeks of progressive 
resistance exercise training. Participants attended the supervised sessions 3x/week and 
performed 3 sets of 10-12 leg extensions at 70% of estimated 1RM.(48) Watson et al. (2014) 
found that 8 weeks of progressive resistance training increased muscle anatomical cross-
sectional area, muscle volume and knee extensor strength.(48) 
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Table 1.4 Summary of studies investigating the effects of resistance exercise training 
Author (year) Exercise:control Design Intervention Duration Outcomes of exercise  
Castaneda et al. (2001) 14:12 RCT Supervised, 45 
minutes, 3x/week 
12 weeks ⇔ Thigh computed tomography 
⇑ Type I and II cross-sectional area 
⇔ BMI 
⇓ GFR 
Castaneda et al. (2004) 14:12 RCT Supervised, 45 
minutes, 3x/week 
12 weeks ⇓ IL-6 and CRP 
⇑ Type I and II cross-sectional area 
⇔ BMI 
⇑ muscle strength 
Balakrishnan et al. (2010) 13:12 RCT Supervised, 45 
minutes, 3x/week 
12 weeks ⇑ Type I and II cross-sectional area 
⇑ Muscle strength 
⇑ mtDNA copy number 







12 weeks Both exercise groups: 
⇑ Muscle strength 
⇑ Six minute walk time 
⇑ Timed up and go 
⇔ Muscle endurance 
⇔ Quality of life 
Heiwe et al. (2005) 7:5 + healthy Non- Supervised, 30 12 weeks ⇑ Muscle strength 






minutes, 3x/week ⇔ Muscle endurance 
⇔ Type I, IIA, IIB cross sectional 
area 
⇔ Type I, IIA, IIB proportion 
Watson et al. (2014) 20:18 RCT Supervised, 3x/week 8 weeks ⇑ Quadriceps cross-sectional area 
⇑ Quadriceps volume 
⇑ Knee extensor strength 
⇑ Endurance capacity 
⇔ Exercise tolerance 
BMI= body mass index; eGFR= estimated glomerular filtration rate; RCT= randomized control trial. ⇑ = positive change; ⇓ negative change; ⇔ 
no change. 
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1.3.3 Combination training 
Five published studies from four trials (three non-randomized and 1 RCT) investigated the 
effects of combination exercise training (aerobic and resistance) in patients with CKD (Table 
1.5). Clyne et al. (1991) (n=19) conducted three supervised training sessions per week for 12 
weeks.(51) Participants were instructed to exercise at 60-70% of their maximal capacity. 
Whereas, the intervention in the study by Cook et al. (2008) (n=54) included three 
unsupervised sessions per week for 12 months in obese patients with stage 2-5 CKD.(52) The 
intervention was a combination of aerobic, thera-band and hand weight exercises which also 
included a calorie restricted diet with weight loss agent (Orlistat). Both Clyne et al. (1991) 
and Cook et al. (2008) found significant improvements in exercise capacity and 6 minute 
walk time with combination training, respectively.(51, 52)  
Greenwood et al. (2012) (n=77) provided a 12 week renal rehabilitation program to patients 
with stage 3-4 CKD, maintenance haemodialysis and post kidney transplant.(53) Training 
consisted of two supervised sessions per week and one home session and the training 
programme included aerobic exercise (rating of perceived exertion [RPE] 13-15), strength 
conditioning, muscular endurance and balance training. Greenwood et al. (2012) also 
identified significant improvements in exercise capacity (shuttle walk) and functional ability 
(Duke’s activity status index, timed up and go, stair climb and sit to stand test) in stage 3-4 
CKD, haemodialysis and post-transplant patients after 12 weeks of combination training.(53)  
Gregory et al. (2011) and Headley et al. (2012) conducted a 48 week randomized supervised 
combination exercise training program on 21 patients with stage 2-4 CKD.(54, 55) The 
exercise group completed 48 weeks of aerobic exercise at 50-60% of VO2peak. From weeks 
24 to 48 participants were allowed to include 1-2 sets of 10-15 repetitions of six resistance 
exercises. Gregory et al. (2011) identified no significant changes in immunoreactive IGF-1, 
IGF-II, bioactive IGF-1, IGFbinding protein-1 or IGFbinding protein-2 after 48 weeks of 
combination exercise training.(54) Headley et al. (2012) found a significant time interaction 
between the exercise and usual care group for VO2peak.(55) The exercise group showed 
modest improvements in VO2peak, however it is interesting to note the decline of 2.8 
ml/kg/min at 48 weeks in the usual care group.(55) This decline in fitness in the control 
group is consistent with the findings from aerobic training studies by Boyce et al. (1997) and 
Toyama et al. (2010).(37, 38) 
Chapter 1 Introduction and general review of the literature   
45  
Table 1.5 Summary of studies investigating the effects of combination (aerobic and resistance) exercise training 
Author (year) Exercise:control Design Intervention Duration Exercise group outcomes 






3 months ⇑ Exercise capacity 
⇑ Muscle strength 
⇔ Total haemoglobin 
⇔ Blood volume 
⇔ eGFR 
⇔ Blood pressure 
⇔ Echocardiographic variables 





12 months ⇑ Weight 
⇑ BMI 
⇑ Waist circumference 
⇑ Six minute walk time 
⇑ Timed get up and go 
⇑ Duke’s activity status index 





12 weeks ⇑ Exercise capacity 
⇑ Functional ability 
⇑ Anxiety and depression 
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minutes 
Gregory et al. (2011) 10:11 RCT Supervised, 10-45 
minutes, 3x/week 
48 weeks ⇑ VO2peak 
⇑ Total treadmill time 
⇔ IGF system 
⇔ eGFR 
Headley et al. (2012) 10:11 RCT Supervised, 10-45 
minutes, 3x/week 
48 weeks ⇑ VO2peak 
⇑ Resting heart rate 




eGFR= estimated glomerular filtration rate; RCT= randomized control trial; LDL= low-density lipoprotein; IGF= insulin-like growth factor. ⇑ = 
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1.3.4 High intensity interval training 
Exercise therapy, in particular aerobic exercise, in the CKD population has been shown to 
decrease cardiovascular disease risk factors and subsequent cardiovascular disease,(38) 
however there has been little work comparing the effectiveness of different exercise 
prescriptions. HIIT has been shown to be superior to MICT in improving fitness and 
decreasing cardiovascular disease risk in both healthy populations and other chronic diseases, 
however is yet to be studied in the CKD population. HIIT involves alternating short bursts of 
high intensity exercise with rest periods or light exercise. Numerous studies in athletes and 
the general population have shown that increasing the intensity of exercise augments the 
training stimulus and associated adaptations such as increased oxygen uptake and anaerobic 
capacity.(56, 57) This implies that the same health enhancing benefits could be gained in a 
lesser amount of time; a more efficient option for those citing lack of time as a barrier to 
exercise.(58, 59) Moreover, short bursts of activity may address another common limiting 
factor, lack of motivation. It may be a more enticing option than the prospect of continuously 
exercising for an extended period of time. HIIT may also be a more suitable way for people 
with poor exercise capacity to reach intensity levels that are capable of achieving health-
enhancing benefits. Short work periods at a higher intensity allow a reduction in ventilatory 
response and resultant dyspneoa which in many chronic disease patients would be a limiting 
factor to continuous exercise.(60-62) Although the Cochrane review by Heiwe et al. indicates 
that vigorous intensity exercise is more effective than moderate intensity in improving a 
number of health outcomes in CKD patients, the definition in this paper of vigorous intensity 
exercise is >60% (whether it is a percentage of maximum heart rate (MHR) or VO2peak is 
not defined) which is not in line with the current Australian position statement on exercise 
intensity terminology.(31, 63) This statement defines vigorous intensity exercise as >70<90% 
MHR, with high intensity exercise defined as >90%. This thesis investigates the feasibility 
and determinants of vigorous and high intensity exercise. 
The feasibility of HIIT in other clinical populations has been investigated. Askim et al. 
(2014) found that it was feasible for recent stroke patients to participate in 4x4 minutes of 
HIIT. Although there was no significant change in VO2peak there was a significant 
improvement in six minute walk time.(64) The study by Keteyian et al. (2014) found 
significant improvements in VO2peak in HIIT compared to MICT (3.6±3.1 vs. 1.7±1.7 
ml/kg/min2) in patients undergoing cardiac rehabilitation, using the 4x4 approach.(65) HIIT 
has also been shown to improve VO2peak in chronotropically incompetent heart transplant 
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recipients without improvements in cardiac function, suggesting improvements in autonomic 
control.(66) On the other hand, Currie et al. (2013) found similar improvements in VO2peak 
and flow mediated dilatation between HIIT and MICT groups in patients with coronary artery 
disease.(67) In this study, the HIIT group performed 1 minute intervals with 1 minute 
recovery. These findings provide insight into a dose-response relationship which provides a 
time efficient alternative to traditional, moderate intensity activity with similar benefits. 
Koufaki et al. (2014) compared the effectiveness of HIIT and MICT in patients with chronic 
heart failure.(68) Participants performed a work to recovery ratio of 1:2, with 30 second work 
intervals, three times a week for 24 weeks. The patients in this study had particularly low 
levels of cardiorespiratory fitness (15.3±4.7 ml/kg/min2). They found that HIIT was well 
tolerated and despite a considerably shorter training time, had the same benefits in physical 
function as MICT. As suggested by the authors, the potential for using HIIT in 
deconditioned, cachetic patients with low exercise tolerance is of value in the context of 
energy preservation and time efficiency. This is particularly relevant for CKD patients in the 
more severe stages of renal disease, as these patients often experience significant muscle 
wasting and the reduced strength is likely contributing to the low exercise capacity in this 
population.(69) 
A study by Keating et al. (2014) in overweight adults found that sprint intervals of 30-45 
seconds at 120% VO2peak could elicit the same improvements in 50-60% of the time taken 
for the same gains from MICT.(70) However, it was identified that MICT and not the sprint 
intervals reduced total body and android fat. The difference between high intensity aerobic 
intervals and sprint intervals on weight loss should be further investigated. 
There are a number of different factors to consider when prescribing HIIT, which may 
influence the magnitude of change. A common approach in measuring exercise intensity is to 
achieve a percentage of MHR. A study by Aamot et al. (2014) assessed whether RPE is a 
valid method for achieving target exercise intensity during HIIT.(71) They found when 
patients were told to aim for an RPE corresponding to 85% peak heart rate (PHR), the actual 
blinded heart rate was 82% PHR. Therefore, using heart rate monitors encourages a slightly 
higher intensity of exercise. However, if a patient is on β-blockers than it seems reasonable to 
suggest that a 3% discrepancy is preferable to exclusion from this type of activity all together. 
Given the high prevalence of cardiovascular disease in the CKD population, there are a 
number of CKD patients who are prescribed β-blocker medication.(72) Ensuring the right 
protocol for measuring exercise intensity in the CKD population specifically on this 
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medication is important for maximising the outcomes of exercise training. Therefore, the 
HIIT study in Chapter 8 utilizes both heart rate and RPE for assessing appropriate intensities.  
 
1.3.5 Cardiorespiratory fitness and exercise capacity 
Cardiorespiratory fitness is highly associated with mortality,(73) and is found to be 
significantly lower in CKD patients when referenced against healthy normative values.(74) 
Specifically, patients with stage 3-5 CKD are reported to have VO2peak levels 50-80% of the 
VO2peak of healthy individuals.(75) Changes in body composition, specifically an increase in 
adiposity and a decrease in lean mass, are common in the pathogenesis of kidney disease and 
has likely influences on exercise capacity.(76) A limited number of studies have looked at the 
effects of exercise training in improving cardiorespiratory fitness in CKD patients, with 
mixed protocols and subsequently varied results.(36-40, 77) It is not known whether the 
increase in cardiorespiratory fitness is influencing the development of cardiovascular disease, 
morbidity or mortality rates. Nonetheless, considering a 1 ml/kg/min increase in VO2peak has 
been associated with an approximate 15% decrease in risk of death in patients it seems likely 
that the improvements in cardiorespiratory fitness in the reviewed studies in CKD patients are 
influencing mortality rates.(78) However, in order to influence future health outcomes, it is 
important to assess whether these improvements in cardiorespiratory fitness and exercise 
capacity can be maintained with a long-term exercise training program.  
Due to the limited research on the effects of exercise training in improving cardiorespiratory 
fitness in CKD patients, cardiorespiratory fitness is an important outcome of this thesis. The 
LM3 study investigates the effects of cardiorespiratory fitness and exercise capacity on 
aspects of cardiovascular health over 3 years.  
 
1.3.6 Oxidative stress 
One of the aims of this thesis is to investigate the contribution of oxidative stress to reduced 
strength and lean mass. Elevated oxidative stress levels have been reported in CKD and are 
associated with poor clinical outcomes.(79) Oxidative stress occurs when the reactive 
oxidative species (ROS) outbalances total antioxidant capacity.(80) The increase in oxidative 
stress in CKD patients is due in part to two reasons. Firstly, CKD patients have impaired 
endogenous production of antioxidants, which disturbs the homeostatic balance of anti and 
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pro-oxidants.(81) Secondly, there is an increase in ROS. One of the ways ROS is formed, is 
as a byproduct of leaked electrons in the electron transport system of the mitochondria. 
Nicotinamide adenine dinucleotide phosphate, is an electron carrier (Nox-4 in particular) and 
is most abundantly expressed in the kidneys.(82) Upregulation of Nox-4 by uraemia from 
kidney dysfunction results in electron leaking in mitochondria and increased ROS 
production.(83) 
Although it is likely that the uraemic environment is promoting oxidative stress, in the 
reverse situation high levels of oxidative stress may also be advancing kidney dysfunction. 
As elevated oxidative stress levels contributes to mitochondrial dysfunction, and as the 
kidneys rely heavily on aerobic metabolism, a decrease in the adenosine triphosphate 
produced may result in renal cell apoptosis. It is also likely that mitochondrial dysfunction 
would contribute to the reduced exercise capacity common in this population. The 
contribution of oxidative stress to the reduced strength which is common in CKD patients is 
investigated in Chapter 3. It has been reported that exercise training can improve anti-oxidant 
status (as measured by glutathione peroxidase) and lipid peroxidation (as measured by 
malondialdehyde and 4-hydroxalkenals) in patients with CKD.(39) Whether this also 
improves the gold standard oxidative stress biomarker, F2-isoprostanes, is yet to be 
established. Our group is currently examining the change in oxidative stress parameters after 
12 months of the LM3 study in patients identified as having elevated levels of F2-
isoprostanes, however these findings are not published in this thesis. Also, the contribution of 
oxidative stress to autonomic dysfunction is discussed in Appendix 11.8. 
 
1.3.7 Haemoglobin 
An aim of this thesis is to identify determinants of participating in higher intensity exercise. It 
seems likely that the fatigue that occurs from low haemoglobin may limit the motivation to 
participate in high intensity exercise. Anaemia is prevalent in CKD and may also contribute 
to the reduced exercise capacity that is connected with this population. Reduced haemoglobin 
can limit VO2max, through the reduced oxygen-carrying capacity of the blood.(84, 85) The 
kidneys synthesise and secrete most of the body’s endogenous erythropoietin (EPO)- the 
hormone that regulates red blood cell production.(86) EPO travels to the bone marrow to 
stimulate the differentiation and proliferation of erythroid progenitor cells. As a result EPO 
causes an increase in circulating red blood cell concentration. In CKD patients, the release 
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and synthesis of EPO is impaired by the damaged kidneys- leading to a decrease in red blood 
cell production, with the low haemoglobin resulting in subsequent anaemia.(87) The degree 
of renal impairment affects the likelihood of a CKD patient developing anaemia. The 
prevalence of anaemia in patients with CKD increases as the GFR progressively falls. 
McClellan et al. (2004) identified the common occurrence of anaemia in 5222 males and 
females with CKD, with 47.7% of patients with haemoglobin <12 g/dL.(88) It has been 
reported that in 5 European countries (n=4591), 60% of haemodialysis patients were 
administered intravenous iron and 75% were administered EPO.(89) 
The fatigue that occurs in lower haemoglobin levels may influence the inclination to 
participate in higher intensity exercise. A few studies have indirectly assessed the influence 
of haemoglobin on physical performance. Leikis et al. (2006), followed 12 stage 3-4 CKD 
patients over two years and identified that VO2peak declined, alongside renal function, 
despite maintenance of haemoglobin levels.(90) This suggests that anaemia is not the only 
factor influencing exercise performance. However, the haemoglobin levels were considerably 
high in this study for a CKD cohort (12.9±9.0 g/dL). Likewise, Kaysen et al. (2011) found 
haemoglobin to be inversely related with physical function questionnaire but not Short 
Physical Performance Battery.(91) Similarly, studies by Painter et al. (1994) and Marrades et 
al. (1996) found minimal improvements in aerobic exercise capacity despite significant 
increases in haemoglobin concentration with EPO therapy.(92, 93) Furthermore, the study by 
Marrades et al. found an increase in arterial O2 content of 59%, with only 33% increase in 
VO2 in the leg at peak exercise, due to a fall in femoral venous blood flow. This may indicate 
an alteration in the microvasculature of renal patients, which is reducing the ability to 
increase exercise capacity even after EPO therapy. Nonetheless, exercise training may 
augment the uptake of oxygen in the muscle, thus complementing EPO therapy.(92) On the 
other hand, McMahon et al. (1999) identified that by normalizing haemoglobin levels in end 
stage renal failure patients with lower than normal exercise capacity, they were able to 
substantially improve exercise performance.(94) Although it was identified by the authors 
that there was a distinct advantage in achieving the target haemoglobin, values were still 
below age-matched sedentary controls. Mancini et al. (2003) also found a significant increase 
in VO2peak after 3 months of EPO therapy compared to a control group.(95) It is unclear 
whether low haemoglobin levels limit the likelihood of a patient with CKD performing 
vigorous or high intensity exercise training.  
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It has been suggested that exercise training can increase total haemoglobin and red cell mass 
by stimulating erythropoiesis with hyperplasia of the haematopoietic bone marrow.(96) 
However, the effects of exercise training on counteracting haemoglobin have been 
controversial.(96) Furthermore, it is not clear whether exercise can upregulate EPO in 
patients with kidney damage. Indeed, only two exercise studies in CKD patients have 
reported haemoglobin levels and both found no change after exercise training.(38, 51) 
Chapter 4 identifies the influence of lower haemoglobin on the ability to undertake high 
intensity exercise. Chapter 6 also explores the change in haemoglobin over the 36 month 
exercise training period. 
 
1.3.8 Other blood biochemistry 
Dyslipidaemia is a risk factor for kidney disease progression suggested to occur by increased 
ROS induced activation of nuclear kappa factor B.(97) This subsequently causes elevation of 
interleukin-6 (IL-6), which causes tissue injury through glomerulosclerosis.(98) A meta-
analysis on ten aerobic exercise training studies (n=1 260) in patients with cardiovascular 
disease reported increases in high-density lipoproteins (HDL) and decreases in triglycerides 
(TG), with no change in total cholesterol (TC) and low density lipoprotein (LDL).(99) 
Toyama et al. (2010) found an increase in HDL and a decrease in TG and LDL after aerobic 
exercise.(37) Conversely, Headley et al. (2012) found that LDL and TG were actually 
increased after 48 weeks of combination exercise training, despite no difference in dietary 
intake between the exercise and control groups.(55) Eidemak et al. (1997) also identified a 
significant increase in TC in the exercise group.(36) However, this study doesn’t report 
change in body weight, which may have influenced the findings. On the other hand, the 
aerobic exercise studies by Boyce et al. (1997), Leehey et al. (2009) and Pechter et al. (2003) 
found no change in blood lipids.(38-40) Chapter 6 of this thesis explores the changes in the 
blood lipid profile over 36 months. 
Progression of kidney dysfunction appears to cause elevated inflammatory cytokines, which 
can contribute to a number of metabolic disease processes.(100) Indeed, our group has 
previously shown a positive association between uraemic toxins and elevated inflammation 
markers.(101) There is a potential for an increase in insulin growth factor (IGF)-1 to provide 
an anabolic effect in CKD patients.(102) However, there is a variable response of IGF-1 to 
exercise training in other populations.(103) Chapter 6 explores the change in inflammation as 
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measured by CRP over the 36 month exercise training period. Inflammation has also been 
suggested to contribute to muscle wasting in the CKD population. Chapter 3 investigates the 
contribution of inflammation markers (IL-6, tumour necrosis factor- α [TNF-α], interferon- γ 
[IFN-γ] and CRP) alongside other variables, to reduced strength in CKD patients. 
 
1.3.9 Body composition  
Body composition has been suggested to be a significant contributor in the reduction of 
exercise capacity in CKD.(104) A decline in kidney function is often associated with 
impaired muscle protein leading to skeletal muscle atrophy and a resultant loss in strength. 
(105, 106) Decreases in strength can greatly impact on functionality and the ability to 
perform daily tasks with ease. The findings from Chapter 6 highlight the influence of strength 
on reduced exercise capacity. Reduced functional strength may be a significant contributor to 
the low quality of life and depression that is consistently reported in this population. (107) 
Furthermore, skeletal muscle atrophy is associated with a 3-fold increase in mortality over a 
4-6 year period in dialysis patients.(108) Suggested factors in the development of muscle 
wasting in CKD are metabolic acidosis, excess angiotensin II and inflammation.(106) As 
previously mentioned, one mechanistic pathway of muscle atrophy may be through increased 
oxidative stress. The increase ROS inhibits the phosphorylation of Akt (a protein 
kinase)(109) which in turn reduces the phosphorylation of the forkhead transcription factors. 
This increases the expression of the E3 ligase, atrogin-1/muscle atrophy F-box.(105) The 
increase in atrogin-1/muscle atrophy F-box recognises specific muscle proteins to increase 
their degradation by the UPS.(110, 111) In turn, this increase in degradation results in muscle 
atrophy.(112)  
Increases in body mass can also contribute to the progression of kidney dysfunction through a 
rise in metabolic waste. Consequently there is hyperfiltration of the nephrons, which 
ultimately leads to nephron loss. However, this hyperfiltration of the glomerulus has been 
shown to improve with weight loss.(113) The change in body composition over 3 years in 
CKD is an important outcome in this thesis, particularly identifying the effects of an exercise 
intervention on lean mass and body fat percentage.  
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1.3.10 Autonomic function 
An aim of this thesis is to investigate the change in autonomic function after an exercise 
training intervention. It has been suggested that a significant contributor to sudden cardiac 
death in the kidney disease population may be autonomic dysfunction.(114) Heart rate 
variability (HRV) can be used to non-invasively measure autonomic function. Autonomic 
dysfunction is thought to be more prevalent in the CKD population through damage caused by 
uraemic neuropathy.(115) The combination of uraemic neuropathy in CKD and glycaemic 
neuropathy in diabetes has been identified by lower HRV in patients with CKD and diabetes 
compared to patients with just CKD. (Appendix 11.7).(116) Whether or not the combination of 
uraemic and glycaemic neuropathy in patients with both CKD and diabetes is more resistant to 
improvements with exercise training is yet to be studied. A study looking at the initiation of 
haemodialysis in improving HRV in patients with and without diabetes found significant 
changes in CKD patients without diabetes, with no changes found in CKD patients with 
diabetes.(116) Exercise studies have shown significant increases in HRV, and therefore 
autonomic function, in both uraemic haemodialysis patients (117) and diabetes (118). Exercise 
training may reduce sympathetic dominance. As sympathetic dominance is associated with 
increased ventricular ectopic frequency, the shift in sympathovagal balance with regular 
exercise training may inhibit dangerous arrhythmias.(119) Headley et al. (2012) identified that 
48 weeks of combination exercise preserved heart rate recovery, whereas the usual care group 
showed a significant decline in the same measure.(55) The authors also identified a significant 
reduction in resting and ambulatory heart rate after the exercise intervention which was not 
identified in the usual care group. These findings suggest a favourable influence of exercise 
training on parasympathetic tone. Chapter 6 looks at the change in HRV time parameters 
Standard deviation of the N-N interval (SDNN) and Root mean square of the standard 
deviation (RMSSD) and frequency parameters total power (TP), very low frequency (VLF), 
low frequency (LF) and high frequency (HF) after 36 months of exercise training. Appendix 
11.9 looks at the longitudinal effects of an exercise intervention on HRV, heart rate recovery 
and chronotropic incompetence in intervention and control patients. 
 
1.3.11 Arterial stiffness and hypertension 
Whether a change in arterial stiffness occurs after both three years of combination exercise 
training and 12 weeks of HIIT is another aim of this thesis. The increased risk of mortality in 
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CKD patients may be explained by the predisposition of patients to vascular calcification. 
The prevalence and severity of vascular calcification is reported to increase with progressive 
worsening of kidney function.(120) Disordered bone mineral metabolism occurs in kidney 
dysfunction and results in hypercalcaemia, hyperphosphatemia, and 
hyperparathyroidism.(121, 122) If plaque exists through atherosclerosis then hypercalcaemia 
will promote its calcification.(121) Vascular calcification thickens the arterial wall and causes 
a loss of elasticity, or, arterial stiffness. Arterial stiffness is an important prognostic marker of 
mortality as it influences left ventricular hypertrophy, coronary artery disease and increases 
the likelihood of a cardiac event occurring.(123) The translation of vascular calcification into 
arterial stiffness can be measured by pulse wave velocity (PWV) and augmentation index 
(AIx) by pulse wave analysis (PWA).(124) Mustata et al. (2011) found a 12 month exercise 
intervention to improve AIx.(77) Although, PWV was not measured in this study (and is 
considered the gold standard measure of non-invasive arterial stiffness measures), this 
reduction in AIx is a promising indicator of the benefits of exercise training on arterial 
stiffness.  
 
Hypertension has a bi-directional involvement in the pathophysiology of CKD. Hypertension 
subsequent to kidney dysfunction occurs as a result of a positive sodium balance causing 
elevated extracellular fluid volume. The increased extracellular volume tracks with a decrease 
in eGFR.(125). Arguably, one of the most important cardiovascular modifications in treating 
CKD is controlling blood pressure. PWA is a technique which allows calculation of central 
blood pressure at the ascending aorta by using applanation tonometry of the radial artery. It 
has previously been shown that 20 weeks of progressive resistance training is effective in 
reducing central blood pressure in older adults.(126) However, the effects of exercise training 
on central blood pressure in CKD patients has not been investigated. Measurement of arterial 
stiffness (PWV and AIx) and central blood pressure (PWA) was assessed every year in the 3 
year LI study (Chapter 6) as well as before and after 12 weeks of HIIT (Chapter 8), to 
determine if long term exercise training improves these ‘non- traditional’ cardiovascular 
disease risk factors. 
 
1.3.12 Safety of exercise training 
As this thesis contains a focus on high intensity exercise training and this has previously been 
suggested to be unsafe for certain individuals,(127) it is important to investigate the safety of 
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this form of training in CKD patients (Chapter 4, 7 and 8). In a position stand by Exercise and 
Sports Science Australia (ESSA), it is reported that the weight of evidence suggests it is safe 
for people with CKD to exercise and that the risk associated with remaining inactive is far 
greater.(30) Indeed, Heiwe and Jacobson et al. (2011) report that no fatal or serious exercise 
related adverse events have been reported by exercise studies.(31) Although, this finding may 
be attributable to many exercise studies excluding CKD patients with cardiovascular disease. 
Before commencing an exercise program it is suggested that patients first undergo a thorough 
medical review including assessment of: blood pressure, medication usage, biochemistry, 
haematology and 12-lead electrocardiogram (ECG) exercise testing. It is suggested by ESSA 
that in addition to the American College of Cardiology Foundation/ American Heart 
Association(128) reported contraindications to exercise, specific contraindications to CKD 
should be: electrolyte abnormalities, in particular hypo/hyperkalaemia, pulmonary congestion 
and peripheral oedema. 
 
1.3.13 Multi-disciplinary treatment of CKD 
There are a number of cardiovascular risk factors which can progress renal damage. Indeed, 
risk factors such as obesity, poor blood glucose control, sarcopenia and low cardiorespiratory 
fitness are difficult for Nephrologists or Physicians to effectively treat alone. Individualized 
multi-disciplinary care, often nurse-led, can promote self-care and modify negative lifestyle 
habits, which in turn ameliorates renal function decline and reduces the risk of future 
cardiovascular disease.(129) Studies on multi-disciplinary care in patients with CKD have 
had varied results. Three studies have shown no improvement in renal function, mortality or 
cardiovascular risk factors.(130-132) However, only one of these multi-disciplinary teams 
included a dietician and none included an exercise physiologist. On the other hand, two 
randomized control trials have shown improved survival (133) and slower decline in eGFR 
with multi-disciplinary management.(134) Again, neither of these trials included exercise 
training support. Furthermore, a questionnaire completed by 142 multi-disciplinary renal care 
professionals indicated that only 42% of professionals discussed and encouraged physical 
activity and only 18% actually facilitated physical activity implementation.(135) A multi-
disciplinary team including professionals such as a nurse practitioner, dietitian, exercise 
physiologist, diabetic educator, psychologist and social worker, has the potential to 
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specifically target many of the risk factors associated with decline in renal function and 
progression of cardiovascular disease in CKD patients, rather than by treatment from a 
Nephrologist alone. However, the literature indicates inclusion of an exercise professional in 
these multi-disciplinary teams has previously been omitted. Thus, the addition of exercise 
support within multi-disciplinary care in this thesis is novel in patients with CKD. This thesis 
focusses specifically on the exercise training prescription and fitness related outcomes of the 
presented study. 
 
1.3.14 Summary of exercise training in CKD patients 
The effects of aerobic training, resistance training and a combination of the both have been 
investigated in 21 published studies from 14 trials with 453 participants with CKD. Of these 
14 trials, 50% are RCT’s. Despite exercise guidelines for CKD patients recommending a 
combination of aerobic and resistance exercise for the greatest health benefits,(30) only four 
trials have used this type of training, with only one RCT.(54, 55) The majority of studies 
excluded patients with cardiovascular disease or did not report inclusion or exclusion criteria. 
Due to the high prevalence of cardiovascular disease in this population, this significantly 
limits the generalizability of the findings. The heterogeneity of the protocols of the reviewed 
studies makes it difficult to compare the mean differences between groups. However, the 
weight of evidence suggests that both aerobic and a combination of aerobic and resistance 
exercise improves cardiorespiratory fitness and exercise capacity. Furthermore, the two 
studies which did not show increases in VO2peak had methodological limitations. 
Considering the well-recognized correlation between cardiorespiratory fitness and mortality 
in other populations,(78) the robust increases in VO2peak would suggest that the exercise-
induced adaptations are providing significant health benefits to CKD patients.  
The majority of studies which utilized resistance training interventions indicated an 
improvement in muscle strength, function and size. These findings suggest that resistance 
training does have the potential to ameliorate the muscle atrophy which is common in this 
population. Although the research is limited, it seems reasonable to propose that exercise 
training has the potential to improve other cardiovascular disease risk factors such as arterial 
stiffness, blood pressure, blood lipids, oxidative stress and inflammation. There also seems to 
be a benefit to quality of life and functional ability. However, the effects of exercise training 
on kidney function, the progression and development of cardiovascular disease, morbidity 
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and mortality are still unknown. The majority of findings suggest that kidney function is not 
affected by exercise training, although the sample size needed (n>1000)(136) to adequately 
assess this change has not been studied. Although the benefits of exercise training in CKD 
reported in the literature are promising, significantly more research is needed to delineate the 
effects of exercise on the above outcomes.  
The diverse protocols in the studies reviewed make it difficult to ascertain an optimal 
exercise prescription for CKD patients. However, in line with current guidelines and the 
above studies, a study investigating exercise training in CKD patients should consist of a 
combination of aerobic and resistance exercise to elicit the greatest health outcomes. 
 
1.3.15 Chapter summary 
The review of the literature in this chapter has identified the high prevalence of 
cardiovascular disease risk factors in CKD. Considering the high rate of cardiovascular 
events in this population, it seems that the current therapeutic targets to improve the 
prognosis of CKD are ineffectual. Exercise therapy is a currently underutilized strategy in 
improving health outcomes in CKD patients, in particular compared to other chronic diseases. 
As such, exercise training has great potential to play a significant role in standard clinical 
treatment. Large randomized control trials are lacking in the CKD population and thus 
exercise guidelines in these patients are based on limited evidence. Many CKD clinical 
guidelines suggest that regular exercise training should be included in standard patient 
management. However it seems that specific advice and recommendations are deficient, 
which is likely contributing to the high sedentary rates of CKD patients. This chapter 
explored risk factors of both kidney disease progression and cardiovascular disease and the 
potential benefit exercise training may have in ameliorating these risks. The chapter also 
identified previous exercise trials in CKD patients, and how the current thesis can fill the 
gaps of missing research areas. 





SECTION 1- Landmark III 






Chapter 2.  
                         Methods 
  
Section 1; Chapter 2 Methods  
61  
2.1 Introduction 
This chapter describes the protocols and outcome measures from Section 1, the Landmark III 
study (Longitudinal Assessment of Numerous Discrete Modifications of Atherosclerotic Risk 
in Kidney disease). All measures were performed according to the standard operating 
procedures at the Cardiovascular Imaging Research Group at the Princess Alexandra 
Hospital. The general methods are described in detail below, and methods specific to 
individual chapters are described in each relevant chapter. The methods specific to the HIIT 
study only are described in Chapter 8. 
 
2.1.1 Study 1 
The LM3 study is described herein as Study 1. The study was registered at the Australian and 
New Zealand Clinical Trials Registry- www.anzctr.org.au (Registration Number 
ANZCTR12608000337370). The primary outcomes of the study were to limit the progression 
of cardiovascular disease by targeting cardiovascular risk factors with exercise training and 
lifestyle modification. The study was powered to assess change in atherosclerotic burden, 
measured by carotid intima media thickness. This was assessed by ultrasound imaging in 
three planes. Secondary outcomes were development of new areas of poor heart flow 
measured by stress echocardiography and endothelial function measured by brachial artery 
reactivity. These measures are not included in this thesis. The primary outcome for this thesis 
is the change in VO2peak over three years.  
 
2.1.2 Study population 
Participants were recruited from the Nephrology Department at the Princess Alexandra 
Hospital, and Logan Hospital, Brisbane, Australia. The patient information and consent form 
is attached in Appendix 11.1. Unlike previous exercise studies in CKD patients, participants 
from this study were not excluded if they had cardiovascular co-morbidities, thereby ensuring 
the studied cohort is generalizable to the CKD population. At baseline the cohort was 
generalizable to the stage 3-4 CKD population. Although no population data exists for stage 
3-4 CKD patients in Australia, a cohort study in Spain had similar baseline values for age 
(Spain vs. Australia 68±13 vs. 60.4±8.7 years), BMI (28.4±4.9 vs. 31.9[7] m/kg2), diabetes 
(40.8 vs. 40.5%), eGFR MDRD (28±8 vs. 39.3±8.2 ml/min/1.73m2), hypertension (92.7 vs. 
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94.8%), haemoglobin (128±1.6 vs. 133.8±15.3 g/L), resting systolic blood pressure (141±19 
vs. 138.4[29.7] mmHg) and resting diastolic blood pressure (76±11 vs. 80.2[14.5] mmHg). 
From both the Princess Alexandra Hospital and the Logan Hospital, 2 231 CKD patients were 
screened for eligibility for the LM3 study. From the 2 231 patients screened; 1 392 were 
considered ineligible based on the below inclusion and exclusion criteria; 416 were 
monitored for potential future participation; 236 declined participation and 187 were 
ultimately randomized to the study. Therefore, from the initial screening, 8.4% of participants 
were randomized to participate in LM3. The final participation numbers for each analysis is 
outlined in each chapter in Section 1. 
 
2.1.3 Study design 
LM3 was a three-year prospective open-labelled trial assessing nurse-led multi-disciplinary 
care versus standard nephrological care. It was a multi-centre trial, with the LI taking place at 
either the Princess Alexandra Hospital or Logan Hospital. After obtaining written informed 
consent, participants attended the Princess Alexandra Hospital for baseline testing.  
 
2.1.4 Randomization 
Participants were randomized into one of two arms after baseline testing- the lifestyle 
intervention (LI) or standard care in a ratio of 1:1 by the Clinical Trial Co-ordinator using a 
computer random assignment program. A person external to the study also witnessed the 
randomization of all participants. Randomization contained 3 levels of stratification: renal 
function (eGFR high [>44 ml/min/1.73m2] or low [≤44]), sex and diabetes status (yes or no). 
Eligibility for inclusion was confirmed through baseline testing. Any participants with 
cardiac abnormalities identified at baseline testing were referred to a Cardiologist for a 
clinical decision regarding his/her appropriateness to be included before randomization. The 
Exercise Physiologists in the program were not blinded, as they provided the exercise 
delivery and the majority of data collection. 
 
2.1.5 Inclusion criteria 
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Subjects with stage 3 or 4 CKD (modification of diet in renal disease [MDRD] eGFR 25-60 
ml/min/1.73m2) were included. Participants were aged 18 to 75 years and had at least one of 
the following risk factors at the time of enrolment – blood pressure or lipids not at target; 
overweight (body mass index [BMI] >25 kg/m2); and poor diabetic control (haemoglobin 




2.1.6 Exclusion criteria  
Intervention for, or, symptomatic coronary artery disease (within 3 months), current heart 
failure (New York Heart Association class III and IV), significant valvular heart disease, 
Cardiologist deemed not suitable, pregnant or planning to become pregnant and life 
expectancy or anticipated time to dialysis or organ transplant <6 months. 
 
2.1.7 Ethics 
The study protocol was approved by the Princess Alexandra Human Research Ethics 
Committee (HREC 2007/190). All patients gave written, informed consent to participate in 
this study. 
 
2.1.8 Lifestyle Intervention 
In addition to the nephrological and general practitioner care provided to CKD patients, 
intervention participants were also treated by a multidisciplinary team consisting of Exercise 
Physiologist, Nurse Practitioner, Dietician, Psychologist and Diabetic Educator. A Social 
Worker was also available if needed. Participants trained for eight weeks for a minimum of 
two times per week with an Accredited Exercise Physiologist. After the eight weeks of gym 
based training, patients completed a home program for 34 months with regular gym refresher 
sessions, and regular follow-up via telephone phone calls and/or email exchange.  
Exercise prescription included a combination of aerobic and resistance training and was 
individualised (based on co-morbidities, motivation and interests) so as to promote the best 
adherence to the program and to optimise fitness adaptations. In line with ACSM exercise 
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training guidelines for older adults, it was the goal of the program for patients to achieve at 
least 150 minutes of moderate intensity exercise and two sessions of resistance training per 
week.(33) Additionally, higher intensity exercise was encouraged where possible. The initial 
gym session with the Exercise Physiologist included goal setting, establishing previous 
exercise experience and enjoyed activities, and identifying any potential barriers to exercise. 
A typical gym session consisted of 20-30 minutes of aerobic training on the treadmill or bike, 
20 minutes of whole body resistance training followed by another ten minutes of aerobic 
training on the bike or rower. The first four weeks of the program was focussed on building 
confidence with a variety of different exercises, improving fitness and educating patients on 
the benefits of exercise training. The following two weeks were concentrated on exercises 
that could be incorporated into a home program based on any equipment the patient may 
already have, or useful fixtures around the house (ie. steps or benches). The final two weeks 
of the gym based sessions were predominantly patient led, to ensure their clarity and 
understanding of the correct technique for the home-program. During the gym based sessions, 
resistance exercises were based on theraband and swiss ball exercises, so familiarity with this 
equipment could be attained before use in the home program. On completion of the eight 
week gym-based training, participants were provided with the necessary tools (swiss ball and 
theraband) and education (a home program and an exercise booklet with different exercise, 
tips and goals) to become as physically active as possible. A typical home program 
comprised of whole body resistance training exercises, utilizing the swiss ball and theraband, 
for approximately 20-30 minutes, 2-3 days per week, with moderate to high intensity aerobic 
exercise on most days of the week. The use of the thera-band and swiss ball decreases the 
need for expensive resistance training equipment and allows home-based training. Again, the 
exercises as well as the intensity, was individualized according to each patient’s condition, 
home equipment and interests. The telephone follow-up calls were completed approximately 
every week for the first three months, every fortnight from month 6-8 and once a month 
thereafter, or as needed. Regular gym refresher sessions were also offered to participants to 
utilize as needed ie. (a range from once a week to once every 6 months, depending on the 
participants needs and inclination). The telephone follow-up calls and gym refresher sessions 
were an opportunity to increase motivation to exercise by modifying the exercise prescription 
as appropriate as well as encouraging accountability through the regular check-ins. 
Furthermore, the telephone follow-ups calls allowed an opportunity to address any relevant 
disruptions or barriers to exercising and provide suggestions to increase adherence.  
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In the initial four weeks, patients also attended weekly Dietician and Psychologist group 
sessions. The focus of these sessions were on behaviour and lifestyle change to assist weight 
loss. The weekly topics were- 1) goal setting, guide to a healthy diet and self-monitoring, 2) 
cholesterol, fats, sugars, salt and healthy meal plans, 3) motivation to change, 4) 
carbohydrate, glycaemic index, label reading, recipe modification and shopping trolley. A 
workbook was also provided to the participants with the discussed topics and self-monitoring 
exercises to assist with evaluation and goal setting. Subsequent to the 4 week program, 
regular contact with the dietician was made both in person and on the telephone as necessary. 
Furthermore, quarterly appointments with the nurse practitioner occurred for the remainder of 
the intervention. Patients also had access to a social worker, diabetes educator and 
psychologist as required. 
 
2.1.9 Control 
Patients randomized to the control group underwent standard nephrological care according to 
clinical guidelines. Medications were prescribed by physicians as needed and patients were 
referred to other health professions or specialists as required. 
 
2.1.10 Trial visits 
Participants were required to attend 7 trial visits for testing throughout the research program 
(Figure 2.1). At baseline, 12 months, 24 months and 36 months participants underwent a full 
battery of tests. These were: blood analyses, anthropometric measures, dual-energy x-ray 
absorptiometry (DEXA), heart rate variability (HRV), pulse wave velocity (PWV), pulse 
wave analysis (PWA), resting echocardiography, stress echocardiography, endothelial 
structure and function (carotid intima media thickness and brachial artery reactivity), peak 
oxygen uptake (VO2peak), physical activity questionnaire (Appendix 11.2) and functional 
tests. The echocardiography and endothelial function measures are not included in this thesis. 
Functional tests consisted of hand grip strength, the get up and go test and 6 minute walk test. 
Functional tests were completed every six months, so in addition to the four above mentioned 
visits, they were also performed at 6 months, 18 months and 30 months. Likewise, blood 
analyses, physical activity questionnaire, blood pressure and anthropometric measures were 
also performed at every six month visit. Tests were performed in the same order for every 
participant at each visit. 





Figure 2.1 Timeline of trial visits for study 1 
 
2.1.11 Patient history 
Previous history of cardiovascular disease risk factors such as diabetes status, 
hyperlipidaemia and hypertension was based on patient’s hospital files. The presence of a 
prior cardiac event was defined as being either: 1) non-fatal myocardial infarction, defined as 
elevated cardiac enzymes such as creatine kinase and troponin-1 alongside either, typical 
symptoms, development of pathological Q waves, acute ischaemic changes evident on ECG, 
or coronary intervention, 2) angina, 3) coronary artery bypass graft or 4) percutaneous 
coronary intervention. Peripheral vascular disease was defined as typical claudication pain, 
history of angioplasty, bypass or amputation. Ischaemic heart disease (IHD) was defined as 
previous MI or angina.  
 
2.1.12 Medications 
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Medication usage was recorded at each visit, however dosage was not documented. 
 
2.1.13 Physical Activity 
The self- reported Active Australia questionnaire (Appendix 11.2) was used to assess average 
weekly physical activity levels from the preceding 6 months.(137) Questions in the Active 
Australia used in the data analysis are; average time weekly, in the past 6 months, for time 
spent walking (for at least 10 minutes without stopping), time spent doing moderate intensity 
activity and time spent doing vigorous activity. Questions on the previous weeks activity 
were also asked, however due to the possibility of reporting a non-representative week, the 
average week in the past 6 months was used for analysis. The questions were asked by an 
Accredited Exercise Physiologist to avoid any misunderstanding and clarity was checked on 
each question. Participants were required to provide details of the activity that they reported 
in each of the three categories (walking, moderate and/or vigorous) in order to monitor any 
over-representation of an activity. Standardized examples for each category (eg. moderate = 
gentle swimming/social tennis/golf; vigorous = jogging/cycling/aerobics/competitive tennis) 
were provided to the participant as suggested on the Active Australia questionnaire. The total 
physical activity time is the sum of walking time, moderate intensity exercise and vigorous 
intensity exercise. According to the International Physical Activity Questionnaire, metabolic 
equivalent tasks (MET) intensities were calculated by time in each intensity multiplied by 
either 8 (vigorous), 4 (moderate) or 3.3 (walking), respectively (www.ipaq.ki.se). Total MET 
minutes is calculated by the addition of vigorous MET minutes, moderate MET minutes and 
walking MET minutes. The Active Australia questionnaire has been reported to have good 
validity and reliability in population studies,(138) overweight men and women,(139) middle 
aged women(140) and community-dwelling older adults.(137) However, this measure has not 
been validated in the CKD population. 
 
2.1.14 Exercise capacity 
The test protocol was determined by the Duke Activity Status Index (Appendix 11.3), which 
was completed by the participants.(141) The Duke Activity Status Index has previously been 
established as a reliable estimate of exercise capacity in patients with stage 3-4 CKD, 
particularly when eGFR is <35 ml/min/1.73m2.(142) Based on participant’s responses to this 
Section 1; Chapter 2 Methods  
68  
questionnaire they performed either the Bruce (estimated VO2peak >34.66 ml/kg/min), Balke 
(estimated VO2peak 18.38-34.65 ml/kg/min) or Naughton (estimated VO2peak <18.37 
ml/kg/min) protocols (Table 2.1). The determination of the appropriate protocol was based on 
an estimated time on the treadmill of approximately 10 minutes.(143) The same protocol was 
then used for each subsequent visit. 







Bruce (144)    
1 3 2.7 10 
2 3 4 12 
3 3 5.5 14 
4 3 6.8 16 
5 3 8 18 
6 3 8.9 20 
Balke (145)    
1 2 5.5 2 
2 1 5.5 3 
3 1 5.5 4 
4 1 5.5 5 
5 1 5.5 6 
6 1 5.5 7 
7 1 5.5 8 
8 1 5.5 9 
9 1 5.5 10 
10 1 5.5 11 
11 1 5.5 12 
12 1 5.5 13 
Naughton (146)    
1 2 1.6 0 
2 2 3.2 0 
3 2 3.2 3.5 
4 2 3.2 7 
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5 2 3.2 10.5 
6 2 3.2 14 
7 2 3.2 17.5 
8 2 3.2 22 
9 2 3.2 25.5 
10 2 3.2 29 
 
A graded maximal treadmill test was used to assess exercise capacity (estimated METs) with 
concurrent 12-lead ECG monitoring. METs were provided by the treadmill software (CASE 
V6.51, GE Medical Systems, Milwaukee, WI, USA) from the treadmill speed and incline at 
completion of the test. The final MET value was calculated by linear interpolation of the 








2.1.15 Maximal oxygen uptake  
Cardiorespiratory fitness was assessed by maximal oxygen uptake (VO2peak) by breath by 
breath indirect calorimetry (Vmax29c, SensorMedics, Yorba Linda, CA, USA) using the 
peak 20 second average of the final minute of exercise. Gas analysers and the flow meter 
were calibrated before each use. Achieved VO2peak was compared to predicted normative 
data for women, [VO2 peak = (14.7 – (0.13 * age))*3.5],(148) and men [VO2 peak = (18.4 – 
(0.16 * age))*3.5].(29) 
 
2.1.16 Six minute walk test 
The six minute walk test provided a measure of functional capacity. The six minute walk test 
is a quick and inexpensive performance based measure and reflects the ability to undertake 
day to day activities.(149) Specifically, it was assessed by the total distance walked in six 
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minutes over a 20m track. Participants were required to cross the 20m line with both feet 
before turning around to complete the next lap. If necessary, a trundle wheel was used to 
measure the additional distance between laps on cessation of the test at six minutes. The use 
of walking aids were allowed if essential to completion of the test and it was ensured that the 
same conditions were adhered to at each visit. 
 
2.1.17 Get up and Go test 
Muscular power and agility was assessed using the get up and go test, as per the instructions 
outlined in Hruda et al. (2003).(150) Participants were timed as to how long it took them to 
rise from an un-armed chair (without using their arms to push up from their legs) and walk 
three metres, cross a line with both feet, turn around and sit back down again. The test was 
performed three times and the fastest time was used for future analyses. 
 
2.1.18 Grip strength 
Grip strength was measured using a hand grip dynamometer (Jamar 5030 J1, Bolingbrook, 
IL, US). Each participant received the same instructions after a demonstration by the tester, 
and the hand grip was adjusted accordingly for the participants comfort. Participants 
undertook the test 6 times, alternating between each hand, with an approximate 30 second 
rest between each trial. The maximum grip strength was attained from the highest reading of 
either hand. Age predicted grip strength values were calculated by a predictive equation for 
males and females reported by Desrosiers et al. (1994).(151)  
 
2.1.19 Anthropometry 
Anthropometric measures were made at each 6 month visit. Height (centimetres) and weight 
(kilograms) were recorded according to standard techniques. Waist and hip measurements 
were attained, to the nearest 0.5 centimetres. The waist was identified as the midpoint 
between the bottom of the lowest rib and the iliac crest. The hip measurement was taken 
standing with feet together at the greatest protuberance of the buttocks. 
 
2.1.20 Lean Mass 
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DEXA, using whole body composition analysis was used to assess body fat percentage and 
lean mass (Hologic QDR 4500A Version 12.6, Massachusetts, USA). Percentage of lean 
mass was calculated as the proportion of lean mass to total mass. Appendicular lean mass was 
calculated from the average of the 4 limbs. The DEXA underwent verification using a spine 
phantom before each day of testing and step phantom before each week of testing. Analysis 
of each scan was performed according to Hologic landmarks. There was a period of time 
during the study where the DEXA machine could not be used due to software issues. As such, 
DEXA scans were not performed on all patients at all visits. The number of patients who had 
DEXA’s performed is indicated in each individual chapter. Regardless, as the period of time 
the DEXA was not in use was at random and patient recruitment is staggered over the 5 
years, the patients who did undergo DEXA’s scans are likely to be representative of the 
whole cohort.  
 
2.1.21 Blood biochemistry 
Blood biochemistry was assessed from a sample obtained by venipuncture after an overnight 
fast. Serum and plasma vacutainers (BD vacutainers, Franklin Lakes, NJ, USA) were used to 
collect 10 mL venous blood samples following an overnight fast. Ethylenediaminetetraacetic 
acid vacutainers (BD vacutainers, Franklin Lakes, NJ, USA) were used to collect blood 
samples for oxidative stress measures. Haemoglobin, phosphate, creatinine, corrected 
calcium, albumin, urea, lipids, bicarbonate, glucose, and insulin were measured using 
standard techniques in a National Association of Testing Authorities accredited pathology 
laboratory at the Princess Alexandra Hospital. Insulin resistance was computed using the 
homeostatic model assessment of insulin resistance method (HOMA-IR).(152) The formula 
used is: 
HOMA-IR= Glucose (mmol/L) x insulin 
            22.5 
Fasting blood samples were performed prior to any other testing. Beta-blocker medication 
was withheld the morning of testing. 
 
2.1.22 Oxidative stress 
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Samples were stored on ice before being centrifuged at 2500 rpm for 10 min. Plasma was 
stored at -80°C with butylated hydroxytoluene (10 µL of 100 mM to each 1.5 mL eppendorf 
tube) to prevent artefactual oxidation.  
 
Total F2-isoprostanes 
Samples were analysed in duplicate using a method developed in our laboratory.(153) Total 
F2-isoprostanes were extracted from plasma after saponification with methanolic NaOH. 
Samples were spiked with 8-iso-PGF2α-d4 (Cayman Chemicals, Ann Arbor, MI, USA) as an 
internal standard and incubated at 42°C for 60 minutes. Samples were then acidified to pH 3 
with hydrochloric acid, and hexane added and samples mixed for 10 minutes before 
centrifugation. The supernatant was removed and the remaining solution extracted with ethyl 
acetate and dried under nitrogen. Samples were reconstituted with acetonitrile, transferred 
into vials with silanized glass inserts and dried. Derivatization with 
pentafluorobenzylbromide and diisopropylethylamine and incubation at room temperature for 
30 minutes followed. Samples were then dried under nitrogen before pyridine, 
Bis(trimethylsilyl)trifluoroacetamide 99% and Trimethylchlorosilane 1% were added and 
incubated at 45°C for 20 minutes. Finally, hexane was added samples were mixed, then 1μl 
was injected for analysis using gas chromatography tandem mass spectrometry (Version 
6.9.2, Varian, Australia) in negative chemical ionization mode.  
Patients were grouped by normal (≤250 pg/ml) or elevated (>250 pg/ml) oxidative stress 
according to plasma F2-isoprostanes levels. This was based on using a value 1.5 standard 
deviations (SD) from mean values obtained from a previous study on apparently healthy 18-
30 year old males and females from our laboratory.(154) 
 
GPX 
Plasma glutathione peroxidase (GPX) activity was measured via the oxidation of 
nicotinamide adenine dinucleotide phosphate (NADPH) to NADP+ by modifying previous 
methods (155, 156) for analysis on a Cobas Mira automated spectrophotometer (Roche 
Diagnostics, Switzerland). The main reagent contained a KH2PO4 buffer, EDTA, glutathione 
reductase, glutathione and NADPH in NaHCO3. The main reagent and sample were 
monitored at 340 nm for 200 s.  




Plasma total antioxidant capacity (TAC) was measured spectrophotometrically (Cobas Mira, 
Roche Diagnostics, Australia) using an adapted method (157). Plasma was incubated with 
met-myoglobin and 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid) diammonium salt 
(ABTS). After incubation, hydrogen peroxide was added and the sample incubated again. 
Absorbance was measured to determine total antioxidant capacity.  
 
Protein carbonyls 
Protein carbonyls were analysed using an adapted version of the methodology from Levine et 
al.(158) Duplicate plasma samples were incubated with 2,4 Dinitrophenylhydrazine in 2.5M 
hydrochloric acid (HCl) while plasma blanks were incubated in HCl only. All samples were 
then precipitated with trichloroacetic acid (TCA) on ice and centrifuged for 10 minutes. 
Supernatants were discarded and the pellets resuspended in TCA and again centrifuged as 
above. Supernatants were removed and the pellets resuspended in ethanol:ethylacetate solution. 
After centrifugation as above the pellets were washed twice more with the ethanol:ethylacetate 
solution, resuspended in a guanidine hydrochloride solution, and absorbance read at 370 nm 
with correction at 650nm (Fluostar Optima, BMG Labtech, Offenburg, Germany). Protein 
carbonyl concentration was normalised to plasma protein content measured using a Pierce BCA 
protein assay kit (Thermo Scientific Australia).  
 
2.1.23 Inflammation 
Inflammation markers IL-6, TNF-α and INF-ɣ were measured by an 
electrochemiluminescence technique using Human Pro-inflammatory 4-plex Ultra-sensitive 
Kit with the Sector Imager 6000 from Meso Scale Discovery (Gaithersburg, USA). The 
assays were performed according to the manufacturer’s instructions. CRP was measured in a 
National Association of Testing Authorities accredited pathology laboratory at the Princess 
Alexandra Hospital. 
 
2.1.24 Creatinine and cystatin-C measurements 
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Creatinine was measured by the Jaffe method on a Beckman DxC800 general chemistry 
analyser (Beckman Coulter Diagnostics, Brea, CA, USA). A particle-enhanced 
immunoturbidimetric assay (Cystatin C Tina-quant Roche/Hitachi- Roche Diagnostics 
GmbH. Mannheim Germany) on a COBAS Mira clinical autoanalyser (Roche Diagnostica 
Switzerland), was used to perform serum cystatin-C measurements according to the 
manufacturer's instructions. Control and calibration materials were provided by Roche 
Diagnostics. A 2-reagent assay system was used, in where reagent 1 is a buffer and reagent 2 
is a suspension of latex particles coated with rabbit anti-cystatin-C specific polyclonal 
antibodies. The sample is mixed with reagent 1 in a cuvette and incubated for 3 minutes, after 
which reagent 2 is added. After 7.5 minutes from the start of the cohesion reaction, of 
wavelength 550 nm, the absorbance difference was measured. All cystatin-C measures were 
performed in duplicate and the average was taken. If there was a difference of greater than 
10% between 2 measures, a 3rd measure was taken and if the 3 values were similar, the 
average was taken, or if an outlier of the 3 was detected it was deleted.  
 
2.1.25 Biochemistry coefficients of variation 
The coefficients of variation (CV) for oxidative stress measures were determined by the 
average inter-assay variability in all samples performed in duplicate. The oxidative stress 
CV’s were: F2-isoprostanes- 7.6%, GPX- 2.4%, TAC- 1.9% and protein carbonyls- 7.9%. All 
cystatin-C samples were performed in duplicate, and the average inter-assay CV was 3.8%. 
The inflammation measures were performed in duplicate, with CV’s of less than 20% 
considered acceptable, as per the manufacturer’s recommendation. The average inter-assay 
CV’s for inflammation measures were: INF-α- 7.6%, TNF-γ- 4.5% and IL-6- 4.4%.  
 
2.1.26 eGFR measurements 
Four measures of renal function were assessed by eGFR; MDRD study equation (2006),(14) 
CKD-EPI creatinine equation (2009),(11) CKD-EPI cystatin-C equation (2012)(12) and 
CKD-EPI creatinine-cystatin-c equation (2012)(12). Table 2.1outlines the calculations used 
for each formula. All eGFR’s are made relative to a surface area of 1.73m2. The eGFR used 
for inclusion in the LM3 study is by the MDRD calculation. 
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Table 2.2 eGFR calculations 
Name Sex Cr Cys Equation 
MDRD 
(2007)(10)  
   175xcr-1.151xage-0.203(x1.212, if black),(x0.742,if female) 
CKD-EPIcr 
(2009)(11) 
F ≤0.7  144x(cr/0.7)-0.329x0.993age(x1.159,if black) 
  >0.7  144x(cr/0.7)-1.209x0.993age(x1.159,if black) 
 M ≤0.9  141x(cr/0.9)-0.411x0.993age(x1.159,if black) 
  >0.9  141x(cr/0.9)-1.209x0.993age(x1.159,if black) 
CKD-EPIcys 
(2012)(12) 
F  ≤0.8 133x(cys/0.8)-0.499x0.996agex0.932 
   >0.8 133x(cys/0.8)-1.328x0.996agex0.932 
 M  ≤0.8 133x(cys/0.8)-0.499x0.996age 
   >0.8 133x(cys/0.8)-1.328x0.996age 
CKD-EPIcr-cys 
(2012)(12) 
   130x(cr/0.7)-0.248x(cys/0.8)-0.375x0.995age(x1.08,if black) 
MDRD= modification of diet in renal disease; CKD-EPI=CKD epidemiology collaboration; 
cr=creatinine; cyst=cystatin-C; F=female; M=male 
 
2.1.27 Vascular structure and function 
Applanation tonomotrey was used to measure central PWV from the carotid and femoral 
arteries. The measurement was performed alongside a recording of an ECG R wave using a 
3-lead configuration (SphygmoCor 8.1, AtCor Medical, Sydney, Australia). The pulse wave 
distance was determined from the sternal notch to femoral pulse distance minus the sternal 
notch to carotid pulse distance. Using the distance and time between ventricular contractions 
at each pulse, PWV was estimated. PWV measures were performed in duplicate and the 
average value was taken. The CV of PWV from all visits was 6.9%. 
AIx was determined using a commercial device (SphygmoCor 7.1; AtCor Medical, Sydney, 
Australia) through PWA by applanation tonometry of the radial artery. AIx was determined 
by the ratio of augmented pressure to central pulse pressure. Radial artery waveform was 
calibrated against the mean of duplicate brachial blood pressure measurements. PWA 
measurements were accepted if the operator index was ≥80 and the indices in the Quality 
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Control section were suggested by SphygmoCor to be inside the limits (pulse height 
variation, diastolic variation and shape deviation). All PWA measures were performed in 
duplicate and the average value was taken. The CV of AIx from all visits was 10.2%. 
 
2.1.28 Heart rate variability 
Participants completed a supine 5 minute resting ECG recording before the maximal exercise 
stress test. Three Ag/AgCl electrodes were used in a modified lead II Einthoven configuration 
connected to an analysis program (SpyhmoCor 8.1, AtCor Medical, Sydney, Australia). The 
R-R interval tachogram was analyzed in Kubios (2.1, Kuopio, 2012) by which ectopic beats 
were removed using linear interpolation of the previous and subsequent beats. HRV was 
assessed by time and frequency domain parameters. Standard deviation of the N-N interval 
(SDNN) was used as the global time domain measure of HRV. The root mean square of the 
standard deviation (RMSSD) of the R-R intervals was also calculated. For the frequency 
domain, HRV was divided by spectral power analysis into high frequency (0.15-0.40 Hz) 
(HF), low frequency (0.04-0.15 Hz) (LF), and very low frequency (0.0033–0.04 Hz) (VLF) 
powers. Total power (TP) was also calculated as a sum of all frequency powers. 
 
2.1.29 Haemodynamics 
Resting blood pressure was taken at the brachial artery after 5 minutes of quiet rest using an 
automatic machine (BPM-300, VSM MedTech, Vancouver, Canada). The average of three 
measurements taken at 1 minute intervals were used for analysis. Peak exercise blood 
pressure was taken from the last stage completed in the maximal treadmill test using a 
mercury sphygmomanometer. Central blood pressure was determined using a commercial 
device (SphygmoCor 7.1; AtCor Medical, Sydney, Australia) through PWA by applanation 
tonometry of the radial artery. PWA measurements were taken in a quiet room after the 
DEXA scan, HRV and PWV had been performed, thus the patient had been lying supine for 
approximately 20-30 minutes. Patients abstained from any caffeine or stimulants on the 
morning of testing. 
Twenty-four hour average blood pressure measurements were recorded using ambulatory 
blood pressure monitoring (A&D Medical TM-2430, California, USA). Blood pressure 
recordings were taken every 30 minutes from 6:00am-10:00pm (day) and every hour from 
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10:00pm to 6:00am (night). The data was downloaded after each 24 hour period and averages 
were calculated by the A&D software for the total 24 hours, day time and night time.  
 
2.2 Study 2 
As study 2 is only reported in one chapter, any additional methods not already described, are 
reported in Chapter 8 only. 
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Background: Patients with CKD have impaired muscle metabolism, resulting in muscle 
atrophy. Oxidative stress has previously been identified as a significant contributor to muscle 
atrophy in other populations, but the contribution in CKD is unknown. The aim of this study 
was to investigate the association between oxidative stress, grip strength and lean mass in 
patients with CKD.  
Methods: This is a cross-sectional study of 152 participants with stage 3 or 4 CKD (eGFR 25-
60 ml/min/1.73m2). Outcome measures include grip strength (dynamometry), lean mass 
(DEXA), oxidative stress (plasma total F2-isoprostanes, protein carbonyls), inflammation 
(interleuking-6 [IL-6], tumour necrosis factor- α [TNF-α] and interferon- γ [IFN-γ]), 
cardiorespiratory fitness (VO2peak) and standard clinical measures. 
Results: Thirty four (22.4%) CKD patients had elevated oxidative stress levels (plasma F2-
isoprostanes >250 pg/ml), with 82% of patients below age-predicted grip strength normative 
values. There was a significant negative association between plasma F2-isoprostanes and grip 
strength (r=-0.251) and lean mass (r=-0.243). There were no associations with inflammation 
markers. Multiple linear regression identified plasma F2-isoprostanes as a significant 
predictor of grip strength independent of other predictors; sex, diabetes status, body mass 
index (BMI), body fat percent and phosphate (adjusted R2=69.5, p<0.001). 
Conclusions: Plasma F2-isoprostanes were independently associated with reduced strength in 








Patients with CKD develop muscle wasting, which significantly influences muscular 
strength.(106) Skeletal muscle atrophy is associated with a 3 fold increase in mortality over a 
4-6 year period in dialysis patients.(108) The aetiology of muscle atrophy in CKD is multi-
factorial and associated with metabolic acidosis, excess angiotensin II and inflammation, 
however to our knowledge the contribution of oxidative stress in pre-dialysis patients has not 
been studied.(106)  
Oxidative stress occurs when there is a disruption of redox signalling and control 
pathways.(159) A well-documented target of oxidative injury is lipid peroxidation of 
arichidonic acid, which produces F2-isoprostanes.(79) As such, plasma F2-isoprostanes are 
the gold standard for quantifying oxidative stress.(160) Other common assays or biomarkers 
of oxidative stress in CKD patients include advanced oxidation of protein products, protein 
carbonyls, γ-Glutamyl transpeptidase and malondialdehyde.(79). Protein carbonyls quantify 
reactive species damaged proteins, however this assay is not a specific measure of oxidative 
stress as it also measures glycated proteins and bound aldehyde.(79) Reduced total 
antioxidant capacity (TAC) and glutathione peroxidase (GPX) may also indicate a 
disturbance of the redox signalling pathways. Elevated oxidative stress levels, measured by 
plasma free F2-isoprostanes, protein carbonyls and protein reduced thiol content, have been 
reported in moderate-severe CKD.(161) Oxidative stress is suggested to be associated with 
inflammation, endothelial dysfunction and malnutrition in the uraemic population, thereby 
synergistically contributing to atherogenecity and risk of a cardiovascular event 
occurring.(162) Despite the multi-factorial nature of oxidative stress in renal patients, it has 
been suggested that the retention of oxidised solutes is likely a major contributor to the 
disease process.(80) Only one small study has investigated the effects of oxidative stress and 
muscle atrophy in renal patients. Crow et al. (2007) identified that haemodialysis patients 
(n=10) had significantly reduced diameter size of type I and II muscle fibres when compared 
to sex-matched controls.(163) However, the authors found no clear association between an 
oxidative stress marker, serum malonaldehyde, and muscle fibre diameter. Whether an 
increase in oxidative stress with CKD influences muscle atrophy and strength is yet to be 
examined.  
Grip strength is well recognized as an indicator of overall upper body strength(164) and 
provides risk estimates similar to those of quadriceps strength.(165) It has been suggested 
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that muscle strength is a greater predictor of mortality than muscle mass.(165) Moreover, it 
has been reported that hand grip strength is a reliable measure of lean body mass in both men 
and women with chronic renal failure.(166) Due to the strong validity and accessibility of 
grip strength measures in the community, this study focused on grip strength as a primary 
measure of strength. 
The aim of this study was to investigate the association between oxidative stress, grip 
strength and lean mass in patients with CKD. It was hypothesised that CKD patients would 
have impaired muscle function, evidenced by grip strength lower than age-predicted 
normative values. Furthermore, it was hypothesised that oxidative stress would be negatively 
associated with lean mass and grip strength.  
 
3.3 Methods 
The data from this study is a cross-sectional baseline analysis of LM3 on 152 subjects with 
stage 3-4 CKD. Patients were grouped by normal (≤250 pg/ml) or elevated (>250 pg/ml) 
oxidative stress based on plasma F2-isoprostanes. Age predicted grip strength values were 
calculated by a predictive equation for males and females reported by Desrosiers et al. 
(1994). Appendicular lean mass percentage was calculated from the average of the 4 limbs. 
DEXA was performed on a representative sub-set of patients due to limited machine 
availability (n=75). As the machine availability was random and patient recruitment was 
staggered, this sub-group of patients is still likely to be representative of the whole cohort.  
 
Statistics 
Mean±standard deviation (SD) was used to describe baseline characteristics, with 
percentages used to describe frequencies for categorical variables. Median and interquartile 
range (IQR) was used to describe not normally distributed and log transformed variables. A 
one-way analysis of variance (ANOVA) with a Bonferroni post-hoc analysis was used to 
determine between group differences of grip strength tertiles. Univariate associations 
between variables and grip strength were evaluated using Pearsons correlation of coefficient. 
Not normally distributed variables were transformed using the natural logarithm. Spearmans 
Rho was used for not normally distributed variables that were not able to be transformed. 
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Significant univariate associations were included in a multivariate model to identify 
independent correlates, using the enter method. Regression diagnostics were assessed for 
identification of collinearity and variance inflation factor issues. Statistical analysis was 
performed using IBM SPSS statistics 21 (New York, 2012). Statistical significance was 




One hundred and fifty two patients were recruited and eligible for study participation 
between March 2008 and February 2013. Table 3.1 shows the demographic and clinical data 
for this cohort. The mean age of patients was 60 years, the majority were obese and had low 
fitness. Nineteen patients were classified as stage 4 CKD and 141 patients were classified as 
stage 3 CKD. Sixty-eight (43.9%) patients had diabetes. There was no significant difference 
in F2-isoprostanes between patients with stage 3 and 4 CKD (p=0.91) and patients with and 
without diabetes (p=0.75). Thirty four patients (22.4%) had elevated F2-isoprostanes (≥250 
pg/ml). There was no consequent increase in anti-oxidant status in patients with elevated F2-
isoprostanes (GPX= normal F2-isoprostanes group 24.8±2.9 U/L vs. elevated F2-isoprostanes 
group 19.6±0.4, p=0.6; TAC= normal F2-isoprostanes group 1.6±0.1 mmol/L vs. elevated 
F2-isoprostanes group 1.8±0.1, p=0.2). There was also no significant correlation between F2-
isoprostanes, protein carbonyls, GPX and TAC (Table 3.2). There was however a moderate 
correlation between GPX and TAC (r=-0.245, p=0.003).  
 
Table 3.1 Patient characteristics 
Variable  
Age (years) 59.7±10.0 
Female sex (n,%) 65(42.8) 
Diabetes (n,%) 68(44.7) 
eGFR (ml·min·1.73m2) 40.2±9.0 
Body mass index (kg/m2) 33.7[8.1] 
Fat (%)# 36.7±7.7 
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Appendicular lean mass (%)# 60±9.2 
Medications  
Β-blockers (n,%) 47(30.3) 
Angiotensin converting enzymes inhibitor (n,%) 69(44.5) 
Statins (n,%) 83(53.5) 
Blood Biochemistry  
F2-isoprostanes (pg/ml)  193.0[108.5] 
Protein carbonyls (nM/mg) 0.52[0.14] 
Glutathione peroxidase (U/L)  24.2±4.3 
Total antioxidant capacity (mmol/L)  1.7±0.4 
Albumin (g/L) 3.8[5.0] 
Homeostatic model assessment- insulin resistance* (%) 6.5[15.8] 
HaemoglobinA1c* 7.2[1.7] 
Haemoglobin (g/dL) 13.2±1.5 
Phosphate (mmol/L) 1.1±0.2 
Bicarbonate (mmol/L) 26.0±6.5 
Inflammation  
Interferon-ɣ (pg/ml) 1.0[0.7] 
Interleukin-6 (pg/ml) 2.2±2.1 
Tumour necrosis factor-α (pg/ml) 6.8±4.0 
C-reactive protein (mg/L) 5.1[4.8] 
Exercise Parameters  
VO2peak (ml·kg·min-1) 23.3[7.2] 
Physical activity levels (hours/week) 2.3 [3.3] 
Grip strength- best of either hand (kg) 30.7±11.3 
Haemodynamics  
Rest systolic blood pressure (mm/Hg) 137.4±20.9 
Rest diastolic blood pressure (mm/Hg) 81.8±12.4 
#Due to limited machine availability DEXA was performed on n=75 
participants. Mean±standard deviation given for normally distributed 
variables, median [interquartile range] given for not normally distributed 
variables, number (%) given for categorical variables. eGFR=estimated 
glomerular filtration rate. *in patients with diabetes only. 
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Table 3.2 Muscle atrophy variables and univariate relationship with F2-isoprostanes 
Variable r value p value 
Sex 0.21 0.01 
Diabetes status -0.04 0.7 
Age -0.22 0.01 
Glutathione peroxidase 0.02 0.8 
Total anti-oxidant capacity -0.05 0.6 
Protein carbonyls 0.06 0.5 
Albumin  -0.20 0.02 
Homeostatic model assessment- insulin resistance 0.19 0.03 
Interferon-ɣ 0.13 0.2 
Interleukin-6 0.09 0.3 
Tumour necrosis factor-α 0.05 0.6 
C-reactive protein 0.07 0.4 
Haemoglobin -0.20 0.01 
Grip strength  -0.25 <0.01 
Appendicular lean mass %  -0.24 0.04 
Body mass index 0.27 <0.01 
 
F2-Isoprostanes and Muscle Atrophy Markers 
The association between F2-isoprostanes and other muscle atrophy markers are represented 
in Table 3.2. There was a negative association between F2-isoprostanes and grip strength 
(Figure 3.1), and F2-isoprostanes and appendicular lean mass percentage (Figure 3.2). There 
was no significant relationship between F2-isoprostanes and grip strength in patients with 
normal F2-isoprostanes (r=-0.161, p=0.10). There were however, significant associations 
between F2-isoprostanes and sex, albumin, homeostatic model assessment- insulin resistance 
(HOMA-IR), haemoglobin and BMI. There were no associations (p>0.05) with inflammation 
markers INF-ɣ, TNF-α, IL-6 and C-reactive protein (CRP). The power of detecting a 
significant association between grip strength and F2-isoprostanes in 152 participants is 
99.3%. The correlation between grip strength and F2-isoprostanes in patients with BMI <30 
kg/m2 (n=41) was statistically significant (r=-0.353, p=0.03). Despite the significant 
difference in F2-isoprostanes between males and females (males=177±89.1 pg/ml vs. 
females=214.4±99.1, p<0.01), the correlation between grip strength and F2-isoprostanes in 
males was only approaching significance (r=-0.211, p=0.07). Likewise, the correlation 
between grip strength and F2-isoprostanes in females only was not significantly correlated 
(r=-0.039, p=0.7). 




Figure 3.1 Association between F2-isoprostanes and grip strength. r=-0.251, p<0.01 
 
 
Figure 3.2 Association between F2-isoprostanes and appendicular lean mass percentage. 
r=-0.243, p=0.04 
 
Predictors of Grip Strength 
Grip strength was separated into relative tertiles of low (≤25 kg, n=50), moderate (26-35 kg, 
n=43) and high strength (≥36 kg, n=44) (Figure 3.3). There was a significant group difference 
between grip strength tertiles (p<0.01), with post-hoc analyses identifying the low strength 
group to have significantly higher levels of plasma F2-isoprostanes than the high strength 
group (p<0.01). The difference between low strength and moderate strength was approaching 
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significance (p=0.06). It was identified that 82% of all patients had grip strength values 
below their age-predicted grip strength (p<0.001). Factors associated with grip strength are 
shown in Table 3.3. There was a strong correlation between grip strength and appendicular 
lean mass. Multiple linear regression found F2-isoprostanes to be a predictor of grip strength 
(ß=-0.219, p=0.03) independent of other predictors; sex, diabetes status, BMI, body fat 
percentage and phosphate in a model also including age, IFN-ɣ, appendicular lean mass, 
haemoglobin and VO2peak (adjusted R2=69.5, p<0.001).  
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Table 3.3 Factors associated with grip strength 
Variable Univariate 
(r or rs) 
p value Multivariate 
(β) 
p value 
Age  -0.22 0.01 -0.19 0.12 
Sexs -0.73 <0.001 -0.59 <0.001 
Diabetes Statuss -0.31 <0.001 -0.22 <0.01 
eGFR 0.06 0.48   
Body mass index (Ln) -0.23 0.01 0.37 <0.01 
Total antioxidant capacity 0.01 0.89   
F2-Isoprostanes (Ln) -0.25 <0.01 -0.22 0.03 
Protein carbonylss 0.04 0.64   
Glutathione peroxidase 0.01 0.88   
Interferon-ɣs -0.22 0.02 0.05 0.61 
Tumor necrosis factor-α -0.10 0.26   
Interleukin-6 -0.09 0.32   
Phosphate -0.41 <0.001 -0.18 0.05 
Haemoglobin 0.48 <0.001 -0.04 0.71 
Bicarbonates 0.01 0.94   
C-reactive proteins -0.06 0.48   
Albumins 0.13 0.14   
Homeostatic assessment 
  
-0.16 0.07   
VO2peak (Ln) 0.45 <0.001 0.05 0.67 
Physical activity levelss 
 
0.10 0.28   
Appendicular lean mass (%)  0.86 <0.001 -0.06 0.78 
Fat (%) -0.58 <0.001 -0.59 0.013 




This is the first study to investigate the role of oxidative stress in reduced lean mass and grip 
strength in CKD patients. Our main findings were 1) 82% of CKD patients had grip strength 
lower than age-predicted normative values, 2) 22.4% of CKD patients had elevated F2-
isoprostanes, 3) oxidative stress was negatively associated with variables associated with 
muscle atrophy, in particular, appendicular lean mass, grip strength, sex, age, albumin, 
HOMA-IR, haemoglobin and BMI and 4) plasma F2-isoprostanes were an independent 
predictor of reduced grip strength. 
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CKD results in significantly reduced muscle mass and strength.(105) Indeed, it was found 
that 82% of the CKD patients had grip strength lower than age-predicted normative values. It 
is likely that reduced strength is occurring at least partly as a consequence of muscle atrophy, 
evident by the strong positive correlation between grip strength and lean mass. Our findings 
are in support of the literature which identifies reduced strength in CKD patients, as a study 
on haemodialysis patients also found reduced strength to occur as a consequence of reduced 
muscle mass.(76) This is clinically relevant as reduced functional strength is closely 
associated with survival and low muscle mass is a potentially modifiable factor.(167) The 
almost linear relationship that occurs between grip strength and lean mass, supports the use of 
grip strength as an inexpensive and easily used test in the field.  
F2-isoprostanes were elevated in a significant proportion of patients, however there was no 
subsequent increase in anti-oxidant status. In addition, there was no association between 
GPX, TAC and F2-isoprostanes. These findings are supported by Karamouzis et al. (2008) 
who found that as the stage of kidney disease increased, so too did the level of plasma F2-
isoprostanes.(168) This study also found that TAC did not change with advancing CKD 
stages. The disconnect between F2-isoprostanes and GPX and TAC in our findings is 
suggesting that an increase in oxidants is occurring without a compensatory increase in 
antioxidants.(168) This imbalance may be an important finding in elucidating the 
pathogenesis of oxidative injury in CKD patients. This is consistent with findings from Dalla 
Libera et al. (2009) who found an increase in muscle protein carbonylation and a blunted 
expression of stress proteins involved in the anti-oxidant defence in patients with disuse 
muscle dystrophy. As suggested by the authors of this study, future investigations are needed 
to identify the mechanisms responsible for the switching off of these anti-oxidant defences, 
and whether challenging this mechanism can ameliorate muscle atrophy.(169) 
Plasma F2-isoprostane levels were identified to be negatively associated with both lean mass 
and grip strength. This finding suggests a relationship between oxidative stress and resultant 
loss of strength through reduced muscle mass, which has not previously been identified in 
CKD patients. It has previously been reported in haemodialysis patients that inflammatory 
markers are associated with muscle mass.(170) Indeed, inflammatory cytokines have been 
reported to induce myofilament degradation through caspase-3 activation.(171) However, in 
the current study we were not able to demonstrate an independent association between 
inflammatory cytokines and grip strength or lean mass. It is possible that in less severe CKD 
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patients (ie. stage 3-4) oxidative stress may have a more significant contribution to muscle 
wasting than inflammation.  
The significant association of F2-isoprostanes and grip strength in patients with BMI <30 
kg/m2 (n=41) suggests that F2-isoprostanes is not just a marker of muscle function in obese 
patients. However, future studies should identify if this relationship still exists in CKD 
patients with a BMI of <25 kg/m2. Sex and F2-isoprostanes were strongly correlated in all 
patients and yet when separated into males and females the correlation between grip strength 
and F2-isoprostanes was no longer significant. This may indicate that a larger sample size is 
needed to detect significant correlations due to the high variability in F2-isoprostanes. Prior 
studies have reported inconsistent findings on sex differences and oxidative stress 
levels.(172-175) We have shown that female CKD patients have higher levels of F2-
isoprostanes than males. Therefore future large scale studies should identify whether the 
correlations between oxidative stress, lean mass and strength is dependent on sex and whether 
changes in muscle parameters after an intervention differs between males and females. 
Oxidative stress was associated with other variables related to muscle atrophy; 
hypoalbuminemia, increased insulin resistance, anaemia and obesity. These factors have 
previously been proposed as variables associated with muscle atrophy.(176) It has been 
reported that increased ROS bind specific muscle proteins and increases the degradation by 
the Ubiquitin-Proteasome System.(111) This increase in degradation results in muscle 
atrophy.(110) In genetic muscle diseases oxidative stress is implicated as the initiator and 
driver of muscle damage.(177)  
An obvious approach to the problem of reduced strength in CKD is exercise training. This 
potentially has a dual effect of not only strengthening muscle, but also correcting the 
imbalance between oxidative stress and protective anti-oxidant capacity. As exercise 
increases oxygen uptake, there is an acute increase in ROS production through the electron 
transport system.(178) With repeated exercise, anti-oxidant enzymes that combat this 
exercise-induced oxidative stress are upregulated to provide more protection against 
ROS.(179) Indeed, an investigation in exercise induced malondialdehyde in rats also found a 
compensatory increase in glutathione peroxidase and superoxide dismutase.(180) Therefore, 
although exercise can cause acute increases in ROS, long term exercise can prove to be a 
beneficial treatment in improving oxidative stress.(181) The current evidence on the 
protective effects of anti-oxidant therapies in improving kidney function remains 
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equivocal.(182) However, using anti-oxidant therapy to attenuate ROS and increase muscle 
mass in the renal population has not previously been studied.(79)  
Limitations 
The analysis from this study employs a cross-sectional design and therefore causality 
between oxidative stress, reduced grip strength and lean mass cannot be determined. Despite 
the well-recognized validity of grip strength as an indication of overall upper body 
strength,(164) additional measures of strength, such as 1RM testing, may have reinforced the 
findings. It should be noted that whilst DEXA provides an estimate of lean body mass, 
skeletal muscle histology or magnetic resonance imaging to assess fibre and muscle size 
would have provided a better measure of muscle atrophy. Despite this limitation, the 
associations found with lean mass are encouraging, as DEXA has been reported to 
underestimate loss of thigh muscle mass in comparison to MRI.(183) Further work looking at 
the expression of other factors involved in muscle loss, such as atrogin-1 and myostatin in 
muscle biopsies of patients with CKD is required to better understand the role of oxidative 
stress in the pathogenesis of muscle atrophy. 
Another limitation of this study is the classification of normal and elevated F2-isoprostanes 
groups based on healthy participants previously studied in our lab.(154) Aging has a well 
recognized influence on oxidative stress levels.(184) Considering the older age of participants 
in the current study, it would have been ideal to use age matched controls to assess whether 
CKD patients were considered to have normal or elevated levels of F2-isoprostanes. Our 
laboratory has not previously reported F2-isoprostane measures in older adults. Therefore, 
due to variations in laboratory specific protocols and coefficients of variation, age matched 
comparisons could not be performed for the current study. Furthermore, the association 
between grip strength and oxidative stress has a low r value, despite being statistically 
significant. This increases the likelihood that the significant association is a spurious one and 
should be considered when interpreting the findings.  
 
Conclusions  
CKD patients have below average grip strength when compared to age-predicted normative 
values. It was identified that plasma F2-isoprostanes were independently associated with 
reduced strength in CKD patients. The findings from this study may assist in ascertaining 
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appropriately targeted treatments for muscle loss, such as resistance exercises to restore 
muscle strength and long-term exercise training to correct the oxidative stress imbalance.  







Chapter 4.  
Feasibility and physiological and clinical 
determinants of participating in higher 
intensity exercise training 
 
This chapter is in the final stages of preparation for submission to European Journal of 
Applied Physiology. This chapter contains an abridged methods section of the submitted 
manuscript to avoid replication of the methods described in Chapter 2. 
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Background: Higher intensity exercise (vigorous and high intensity) is more beneficial for 
improving cardiorespiratory fitness than moderate intensity exercise in a range of chronic 
disease populations. Understanding why patients would participate in this form of training 
has important implications for exercise prescription. The aim of this study was to investigate 
the feasibility and determinants of participation in higher intensity exercise when prescribed a 
general home exercise program after an initial supervised period. 
Methods: This is an observational sub-study of a randomised controlled trial. Forty-four 
participants with stage 3-4 CKD (eGFR 25-60 ml/min/1.73 m2) were allocated to undertake a 
12 month individualised aerobic and resistance training LI intervention. The goal of the 
intervention was for all subjects to complete 150 minutes/week of moderate intensity exercise 
with included higher intensity exercise if possible. Pre and post intervention measurements 
included a physical activity questionnaire of the preceding 6 months, blood analysis, pulse 
wave analysis (PWA) and a maximal treadmill test to determine cardiorespiratory fitness 
(VO2peak) and exercise capacity (METs). 
Results: At 12 months, the number of patients who reported performing weekly higher 
intensity exercise in the previous 6 months of the intervention increased from 20% to 43%, 
with the number of patients reporting moderate intensity exercise increasing from 16% to 
25%. The number of participants reported not meeting exercise guidelines decreased from 
64% to 32% (<150 minutes/week). Participants exercising at higher intensities had 
significantly (p<0.05) higher cardiorespiratory fitness (27.7±9.4 ml/kg/min), exercise 
capacity (9.8±4.2 METs) and haemoglobin levels (142.9±16.1 g/L) at baseline compared to 
those reporting moderate (23.3±4.5 ml/kg/min, 8±3.1 METs, 129.8±12.9 g/L) and not 
meeting guidelines (19.8±5.1 ml/kg/min, 6±2 METs, 127.3±12.5 g/L). Participants 
completing higher intensity exercise also had a significantly greater exercise capacity at 12 
months (11.9±3.7 METs) than participants reporting moderate intensity exercise (9.2±1.7 
METs) and not meeting guidelines (7.6±3.2 METs). 
Conclusions: The study was successful in increasing higher intensity physical activity in a 
large proportion of patients with CKD. Those who reported higher intensity exercise had 
increased haemoglobin levels, cardiorespiratory fitness and exercise capacity at baseline, 
underlining the importance of these measures in optimising exercise prescription. 





Patients with CKD have a known reduction in exercise capacity,(185, 186) which is one of 
the strongest predictors of mortality(187) and is the likely consequence of multiple 
mechanisms. Despite the recognised benefits of regular moderate exercise in improving 
cardiovascular disease risk factors and maintaining kidney function,(75) recent studies have 
suggested higher intensity exercise is a more effective way of evoking the largest exercise-
induced adaptations in chronic disease patients.(188) The feasibility of this type of training in 
CKD patients is unknown. 
The Active Australia questionnaire has previously been reported to have good validity and 
reliability, with self-reported physical activity closely correlated with accelerometry and 
pedometry measures in middle-aged women (140) and in older adults.(137) This 
questionnaire also has acceptable levels of test re-test reliability for assessing activity status 
and moderate reliability for assessing total minutes of physical activity.(138, 139) 
Furthermore, the Active Australia questionnaire is reported to be a reliable measure of self-
reported physical activity intensity, with significant correlations with accelerometry data in 
overweight adults for each category of exercise intensity (walking, moderate and 
vigorous).(139) Reeves et al. (2010) has also reported the Active Australia questionnaire to 
be responsive to changes in physical activity when compared to a more detailed self-report 
measure.(189) However, the validity and reliability of the Active Australia questionnaire has 
not been assessed specifically in the CKD population. 
Higher intensity exercise (vigorous and high intensity) is defined as physical activity which 
raises heart rate to >70% of heart rate maximum.(63) Identifying predictors of participation in 
higher intensity exercise is essential for targeting individuals more likely to benefit from this 
type of training. This study sought to investigate the feasibility and determinants of 
incorporating higher intensity exercise in a 12 month LI in CKD patients. It was hypothesised 
posteriori that higher intensity exercise would be feasible for patients with CKD, with an 
increase in the number of patients reporting this type of exercise. It was also hypothesised 
that patients reporting higher intensity exercise would have greater exercise capacity at 12 
months than patients reporting moderate intensity exercise not meeting exercise guidelines. 
 




Forty-four patients with stage 3-4 CKD were included in this sub-study. The data from this 
study analyses the intervention arm from the LM3 study. Out of the 82 participants 
randomized to the LI group, 44 participants completed twelve months of the intervention with 
both baseline and 12 month Active Australia questionnaire data. For the purpose of this 
analysis control participants are not included in this observational sub-study. Exercise 
measurements were taken at baseline and 12 months. Achieved VO2 peak was compared to 
predicted normative data for women, [VO2 peak = (14.7 – (0.13 * age)*3.5],(148) and men 
[VO2 peak = (18.4 – (0.16 * age)*3.5. Adverse events were assessed by a Registered Nurse at 
6 months and 12 months.  
 
Statistical analysis 
Mean ± standard deviation (SD) was used to describe baseline characteristics, with 
percentages used to describe frequencies in categorical variables. Median and interquartile 
range (IQR) was used to describe not normally distributed and log transformed variables. 
ANOVA was used to detect significant differences between groups. LSD post hoc identified 
where the significant differences occurred. The Kruskal-Wallis test was used to compare not 
normally distributed variables which did not normalize with log transformation (resting 
systolic blood pressure and central systolic blood pressure) and are reported as median (IQR). 
Univariate associations identified baseline variables with exercise capacity (METs) at 12 
months. A multi-nomial logistic regression was used to identify variables that would predict 
the intensity of exercise that participants would undertake during the 12 month intervention 
(not meeting guidelines, moderate intensity or higher intensity exercise). Due to the high 
number of variables that may influence exercise capacity, and the relatively small sample 
size, a multi-level logistic regression was employed. The three models included in the 
regression analyses; are demographics, blood biochemistry and exercise parameters. Higher 
intensity exercise was used as the reference category, in order to identify the difference in 
participants reporting higher intensity exercise, to both moderate and not meeting guidelines 
groups. In variables that were identified as significantly different between higher intensity 
and moderate intensity exercise, the moderate intensity group was made the reference 
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category in the same multi-nomial logistic regression model in order to identify the odds ratio 
of participating in higher intensity exercise. Significance was set at p <0.05. 
 
4.4 Results 
The intervention significantly increased physical activity levels. At baseline only nine people 
(20%) reported completing higher intensity exercise, and this increased to 19 people (43%) 
after 12 months (Figure 4.1). Baseline characteristics of the study population according to 
their physical activity levels during the intervention are displayed in Table 4.1. There were no 
significant group differences in age, renal function or haemodynamics. However, participants 
who reported performing higher intensity exercise at 12 months had significantly greater 
baseline VO2peak, exercise capacity (METs) (Figure 4.2) and phosphate than participants not 
meeting guidelines. Table 4.2 demonstrates the difference in physical activity levels between 
the groups at 12 months (exercise time, MET minutes, vigorous intensity and moderate 
intensity all p<0.001). Participants reporting higher intensity exercise also had a significantly 
greater exercise capacity at 12 months compared to those reporting both moderate intensity 
exercise and not meeting guidelines (Figure 4.2). Participants in the higher intensity 
(p<0.001) and not meeting guidelines (p<0.01) group also had a significant within group 
change in exercise capacity from baseline to 12 months and comparison of the delta values 
between groups was not statistically significant (Figure 4.3). Haemoglobin levels were 
significantly greater at baseline in the participants reporting higher intensity exercise 
compared to both moderate and not meeting guidelines groups (p<0.01) (Figure 4.4).  
 




Figure 4.1 Number of participants reporting different intensities of exercise at baseline 
and 12 months 
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Table 4.1 Baseline characteristics of participants reporting different exercise intensities 
at 12 months 










60.9±9.9 58.5±8.8 59.1±11.0 0.83 
Sex (males)(%) 6(42.9) 5(45.5) 14(73.7) 0.15 
eGFR (ml/min/1.73m2) 37.6±6.6 38.2±7.4 39.4±8.5 0.79 
Weight (kg) 98.5±20.8 86.5±11.5 84.6±15.5 0.06 
Diabetes status  5(35.7) 4(36.4) 7(36.8) 0.98 
History of CVD     
Myocardial infarction 1(7.1) 1(9.1) 2(10.5) 0.93 
Previous angina 1(7.1) 1(9.1) 3(15.8) 0.63 
Heart failure 1(7.1) 1(9.1) 1(5.3) 0.94 
Hypertension 13(92.9) 10(90.9) 18(94.7) 0.92 
Hyperlipidaemia 9(64.3) 8(72.7) 11(57.9) 0.72 
Peripheral vascular disease 2(14.3) 2(18.2) 4(21.1) 0.84 
Blood Biochemistry     
Haemoglobin (g/L) 127.3±12.5 129.8±12.9 142.9±16.1* <0.01 
Hba1C (%)(diabetes only) 7.3±0.9 7.9±1.2 7.4±1.4 0.73 
Albumin (g/L) 40.1±3.0 37.8±3.8 37.6±4.7 0.20 
C-Reactive protein (mg/L) 4.0[3.3] 5.1[4.4] 2.0[2.3] 0.21 
Exercise parameters     
VO2peak (ml/kg/min) 20.7[7.4] 22.2[6.1] 25.8[10.4]# <0.01 
Below predicted VO2  13/14 11/11 14/19 0.09 
METs 6.0±2.6 8.0±3.1 9.8±4.2# 0.02 
Exercise time (mins/week) 37.5[120.0] 70.0[180.0] 150.0[200.0] 0.10 
Grip (kg) 30.8±13.4 36.0±12.9 38.2±12.7 0.32 
Haemodynamic and vascular     
Peripheral systolic BP (mmHg) 133.0[19.0] 118.0[16.0] 124.5[25.3] 0.72 
Peripheral diastolic BP (mmHg) 76.0[8.8] 76.0[8.0] 76.0[13.3] 0.50 
Central systolic BP (mmHg) 118.8[9.9] 111.5[8.5] 114.8[12.9] 0.13 
Central diastolic BP (mmHg) 77.8[12.5] 77.5[9.0] 76.3[9.3] 0.47 
Medication     
Erythropoietin stimulating agent 
  
0 0 0  
Iron supplementation n, (%) 3(21.4) 1(9.1) 0 0.09 
β-Blocker n(%) 1(7.1) 3(27.3) 5(26.3) 0.34 
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Values are reported as mean±SD for normally distributed variables. Not normally distributed 
and log transformed variables are reported as median [IQR]. Categorical values are presented 
as n(%).  
*= higher significantly different from both moderate and not meeting guidelines 
†= higher significantly different from moderate 
#= higher significantly different from not meeting guidelines 
**= includes both vigorous and high intensity exercise 
CVD= cardiovascular disease; eGFR = estimated glomerular filtration rate; BP = blood 
pressure 
 
Table 4.2 Physical activity levels of patients reporting different exercise intensities at 12 
months 
 








Exercise time (mins/week) 60.0[86.3] 330.0[161.0] 280.0[250.0] <0.001 
Exercise time (MET/mins) 270.0[388.1] 1485.0[720.0] 1320.0[1275.0] <0.001 
Vigorous exercise (mins/week) 0 0 90[120] <0.001 
Moderate exercise (mins/week) 60[86.3] 330[160] 180[130] <0.001 
 
 
Figure 4.2 Effects of exercise intensity after 12 months of exercise training on peak 
exercise capacity at 12 months. Values are mean and SEM, * indicates a significant 
difference between baseline higher and not meeting guidelines groups (p=0.018). ^ 
indicates a significant difference between higher, moderate and not meeting guidelines 
groups at 12 months (p<0.01) 





Figure 4.3 The delta scores of METs from baseline to 12 months between the groups. 
Values are mean and SEM, * indicates a significant within group difference between 
baseline and 12 months; higher (p<0.001) and not meeting guidelines (p<0.01) 
 
Figure 4.4 Effects of baseline haemoglobin on self-reported exercise intensity in a 12 
month intervention. Participants reporting higher intensity exercise had significantly 
higher haemoglobin levels than participants reporting both moderate and not meeting 
guidelines (p<0.01) 




Table 4.3 investigates the baseline association of exercise capacity at 12 months in order to 
identify whether baseline correlates are similar for change in exercise capacity and 
participation in higher intensity exercise. There was a strong positive association between 
baseline haemoglobin and exercise capacity at 12 months (r=0.55, p<0.001)(Table 4.3, Figure 
4.5). A group comparison of differing haemoglobin levels in all patients, demonstrates that 
exercise capacity significantly increases as each level of haemoglobin increases (<115 vs. 
115-130 vs. 130-150 vs. >150 g/L, p<0.01)(Figure 4.6). Other significant associations 
between baseline factors and exercise capacity at 12 months (Table 4.3) were; age, sex, 
diabetes status, BMI, haemoglobinA1c, central systolic blood pressure (all negative), while, 
VO2peak, and grip strength were positively associated with exercise capacity. 
 
Figure 4.5 Association between baseline haemoglobin and exercise capacity at 12 
months. r=0.490, p<0.01 




Figure 4.6 A group comparison on all patients of baseline haemoglobin on exercise 
capacity after 12 month intervention. Participants with haemoglobin levels >150 g/L at 
baseline had significantly higher exercise capacity at 12 months than each of the other 
three haemoglobin groups (p<0.01) 
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Multinomial logistic regression models were conducted to predict the exercise intensity 
reported by participants during the intervention. There were three models used in the 
regression; demographics (age, sex, BMI and diabetes status), blood biochemistry 
(haemoglobin, eGFR and haemoglobina1c) and exercise (VO2peak, physical activity levels 
and grip strength) (Table 4.4). Only the blood biochemistry model identified those reporting 
higher intensity exercise to be different from those reporting moderate and not meeting 
guidelines (chi square = 12.846, p=0.046 with df=6). The Wald criterion (p = 0.04) 
demonstrated that only haemoglobin made a significant contribution to higher intensity 
exercise relative to moderate intensity exercise. The odds ratio indicates that when 
haemoglobin is higher by 1 unit (g/L) participants are 1.1 times more likely to participate in 
higher intensity exercise. When compared to the not meeting guidelines group, for every 1 
Variable Univariate (r) p value 
Age -0.61 <0.001 
Sex -0.44 <0.01 




eGFR 0.01 0.54 
Weight -0.16 0.32 
Body mass index -0.54 <0.001 
Haemoglobin 0.55 0.001 
Albumin -0.15 0.36 
C-reactive protein -0.02 0.91 
VO2peak 0.77 <0.001 
Grip strength 0.66 <0.001 
Exercise time 0.34 0.03 
Resting peripheral SP -0.184 0.26 
Resting peripheral DP 0.15 0.35 
Central SP -0.33 0.04 
Central DP  -0.02 0.91 
eGFR = estimated glomerular filtration rate; SP = 
systolic pressure; DP = diastolic pressure. 
*Ischaemic heart disease=previous angina or 
previous myocardial infarction. 
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g/L increase in haemoglobin, participants are 1.12 times more likely to participate in higher 
intensity exercise (p<0.01). There was a significant difference between the not meeting 
guidelines and the higher intensity group in the demographics model (chi square = 16.002, 
p=0.042 with df=8). For every 1 kg/m2 increase in BMI, patients are 1.4 times more likely to 
report not meeting guidelines exercise (p<0.01).  
 
Table 4.4 Multi-level multi-nomial logistic regression predicting exercise intensity 
 
4.5 Discussion 
This is the first study to investigate the feasibility and physiological and clinical determinants 
of higher intensity exercise in CKD patients. Understanding the role of higher intensity 
training in the CKD cohort is vital, as the superiority of this type of training over moderate 
intensity training in many chronic disease populations has been consistently reported.(188) 
The main findings of this study were, 1) 43% of participants reported higher intensity 
exercise during the 12 month intervention and these participants had significantly greater 
exercise capacity at 12 months than participants reporting both moderate intensity and not 
meeting guidelines; 2) participants reporting higher intensity exercise had significantly higher 
Variable (model significance) Not meeting guidelines  Moderate intensity 
 Exp(B) 
 
p value Exp(B) p value 
Demographics (p=0.042)     
Age 1.1 0.50 1.0 0.77 
Sex 0.8 0.76 0.4 0.26 
BMI 1.4 <0.01 1.1 0.22 
Diabetes status 2.0 0.52 1.4 0.73 
Blood Biochemistry (p=0.046)     
eGFR 1.0 0.80 1.0 0.86 
Haemoglobin 0.9 <0.01 0.9 0.04 
HaemoglobinA1c 0.5 0.14 0.7 0.39 
Exercise (p=0.09)     
VO2peak 3.1 0.08 0.7 0.41 
Grip <0.01 0.95 0.9 0.34 
Physical activity levels 2.7 0.10 1.3 0.26 
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baseline cardiorespiratory fitness, exercise capacity and haemoglobin than participants 
reporting not meeting guidelines; 3) baseline haemoglobin levels was the only variable which 
was significantly higher in participants reporting higher intensity exercise compared to both 
other groups; 4) baseline haemoglobin was strongly associated with exercise capacity at 12 
months and was a significant predictor of participants reporting higher intensity exercise.  
 
Feasibility of higher intensity exercise 
In the present study a large number of CKD patients reported being able to perform higher 
intensity exercise (43%), despite most patients being below their age predicted VO2peak at 
baseline. This finding is clinically significant as recent studies have shown that performing 
higher intensity exercise is associated with greater health benefits when compared to 
moderate intensity exercise.(58) The reported benefits in these studies are increased 
cardiorespiratory fitness,(190-198) mitochondrial biogenesis,(192, 196) improved ejection 
fraction and stroke volume,(193, 197) suppression of fatty acid uptake and lipogenesis(192) 
and an increase in flow mediated dilatation, suggesting improved endothelial function.(191-
193, 196) The CKD population have demonstrated reductions or impaired function in each of 
the above parameters that can potentially be improved with HIIT.(113, 124, 199) It therefore 
seems reasonable to suggest that implementing this type of training may be an effective 
option for CKD patients to improve cardiovascular health. The present study suggests that it 
is feasible for CKD patients to include higher intensity exercise in their training program, 
with 43% of participants regularly undertaking this type of training during the intervention. 
One way of including higher intensity training is to perform intervals- alternating short bursts 
of high intensity exercise with rest periods or light exercise. This type of training may be a 
more suitable way for chronic disease sufferers to achieve health enhancing benefits.  
In this study, participants who reported completing higher intensity exercise had significantly 
greater exercise capacity after the intervention than those performing moderate intensity 
exercise and those categorised as not meeting physical activity guidelines. This is clinically 
significant as for every 1 MET increase there is a 12% reduced risk of mortality.(29) This 
finding may indicate that 60(86.3) minutes (Table 2) of moderate intensity exercise may be 
adequate to elicit a modest increase in exercise capacity in patients with low exercise 
capacity. At baseline the higher intensity group were meeting the Australian exercise 
Section 1; Chapter 4 Feasibility and determinants of participating in higher intensity exercise 
training  
106  
guidelines of 150 minutes/week of moderate intensity exercise (Australia’s Physical Activity 
and Sedentary Behaviour Guidelines 2014), whereas the other two groups were reporting less 
physical activity time in an average week in the 6 months prior to participating in the study. 
This suggests that participation in higher intensity exercise may be dependent on previous 
physical activity levels. It is not particularly surprising that participants reporting higher 
intensity exercise during the intervention had higher physical activity and fitness levels at 
baseline than the other two groups. This finding may indicate that the perceived exertion of 
high intensity exercise is more attainable to someone with a higher fitness level and previous 
physical activity experience, even though participation in higher intensity exercise 
specifically at baseline was relatively low (20%). The aim of this study was to identify 
whether it was feasible for CKD patients to participate in higher intensity exercise. A 
previous study has identified that it is possible for patients with very low fitness levels 
(VO2peak of 13±1.6 ml/kg/min) to participate in high intensity training.(193) However, the 
findings from the current study may suggest that it is most realistic to expect more physically 
active and fitter patients to participate in this type of exercise in an unsupervised home-based 
setting. Alternatively, if patients with lower fitness are prescribed higher intensity exercise, 
they may need greater support to achieve these goals. 
 
Determinants of higher intensity exercise 
Individuals who performed higher intensity exercise were more likely to have normal 
haemoglobin levels at baseline than those who completed both moderate and not meeting 
guidelines. These findings suggest additional considerations may be necessary when 
providing exercise prescription for chronic disease patients with low haemoglobin. Reduced 
haemoglobin can limit VO2max, through the reduced oxygen-carrying capacity of the 
blood.(84) The attenuated oxygen carrying capacity of the blood creates a decrease in 
exercise ability and time to exhaustion.(200, 201) Furthermore, a lack of oxygen to the 
working muscles decreases physical performance by limiting muscular function.(85, 202) 
The kidneys synthesise and secrete most of the endogenous EPO- the hormone that regulates 
red blood cell production.(87) The kidney damage which occurs in CKD, can impair the 
synthesis and release of EPO, resulting in a chronic  reduction in red blood cells.(87) As a 
result of this, anaemia is a common problem in CKD patients, as demonstrated in a study by 
McClellan et al. (2004) of 5222 males and females, in where 47.7% of patients had low 
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haemoglobin <12 g/dL.(88) However, it was identified that only 15.9% of the patients in the 
current study were considered to have low haemoglobin (<12 g·dL-1) at baseline.  
Notwithstanding the physiological influence of anaemia on exercise performance, the fatigue 
that occurs with lower haemoglobin levels may also influence the motivation to partake in 
physical activity and in particular, higher intensity exercise. Some studies have indirectly 
assessed the influence of haemoglobin on physical performance. Leikis et al. (2006), 
followed 12 stage 3-4 CKD patients over two years and identified that VO2peak declined, 
alongside renal function, despite maintenance of haemoglobin levels.(90) However, it should 
be noted the haemoglobin levels were reasonably high in this study (12.9±9 dg/L). Likewise, 
Kaysen et al. (2011) found haemoglobin to be inversely related with a physical function 
questionnaire but not with a short physical performance battery.(91) The findings from the 
present study suggest that haemoglobin levels are indeed a strong predictor of exercise 
capacity at 12 months in CKD patients. The effect of haemoglobin on exercise capacity was 
independent of diabetes status and kidney function. The lack of difference in eGFR and 
physical activity levels between participants with differing levels of haemoglobin, suggests 
that the haemoglobin levels are not just an indication of overall health. Rather, the fact that 
cardiorespiratory fitness, previous physical activity and haemoglobin were all higher in 
participants reporting higher intensity exercise, may suggest that haemoglobin could be used 
as a surrogate marker of exercise capacity. 
As anaemia is associated with increased risks of morbidity and mortality,(89, 203) studies 
have looked at the effects of normalising haemoglobin levels. However, studies looking at 
normalization of haemoglobin levels in CKD and anaemia such as the CREATE,(204) 
TREAT,(205) NEPHRODIAB2(206) and CHOIR(207) studies, have found that correcting 
haemoglobin to normalized levels (130-150g/L) did not improve mortality outcome and 
moreover may be detrimental to cardiovascular health. The avoidance of prescribing 
erythropoietin stimulating agents to CKD patients is due in part to exacerbation of 
hypertension and subsequent increase in events of stroke and mortality.(208) Hypertension is 
the most common complication in CKD and can be aggravated by ESA treatment. Rather 
than promote the normalization of haemoglobin levels in CKD patients, this study aims to 
highlight the effects anaemia may have on participation of high intensity exercise. Exercise 
Physiologists should consider a patient’s haemoglobin levels and tailor exercise training 
programs appropriately. As such, patients with low haemoglobin may require additional 
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supervision and motivation to ensure adherence to the exercise program. Alternatively, it may 
be more suitable to prescribe moderate intensity exercise to patients with lower haemoglobin, 
if that is more likely to be adhered to.  
The lack of association between eGFR at baseline and METs at 12 months may suggest 
kidney function is not a limiting factor in improving exercise capacity.(209) Nonetheless, this 
lack of association may be a reflection of the narrow range of eGFR’s which were included in 
this study. Ischaemic heart disease was also not significantly different between the three 
groups, nor did it correlate with exercise capacity at 12 months. Promisingly, this would 
suggest that existing cardiovascular disease is not a limiting factor in CKD patients 
participating in higher intensity exercise.  
Based on the findings from this study, it seems reasonable to suggest that there are certain 
characteristics which would typify a person most suitable to performing higher intensity 
exercise.(30) Table 4.5 provides a proposed guideline of patient characteristics which may 
elicit the greatest improvements in exercise capacity from higher intensity exercise. This 
guideline is not designed to omit individuals from higher intensity exercise who do not 
possess these attributes, rather emphasising that they may require more supervision or 
guidance in performing this type of exercise. Certainly, exercise prescription requires an 
individualized approach and should be assessed on a case by case basis.  
 
Table 4.5 Proposed guidelines for characteristics of patients most likely to see the 
greatest improvements in exercise capacity from higher intensity exercise, in order of 
significance 
Characteristic Ideal value 
VO2peak (ml/kg/min) >22.1 
METs >7.3 
Grip strength (kg) >34 
Age (years) <61 
BMI (k/m2) <32.4 
Diabetes No 
Haemoglobin (g/L) >133 
Sex Male 
Exercise time (minutes/week) >73.5 
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Not surprisingly, BMI was shown to be a significant contributor to participants reporting not 
meeting physical activity guidelines. This is an obese population and the majority of 
participants were reporting no physical activity at baseline. This association is likely bi-
directional in that being overweight or obese provides a further barrier for participation in 
physical activity.(210) Although it is feasible for obese individuals to participate in higher 
intensity exercise,(196) the breathlessness associated with obesity(211) may limit the 
motivation to participate in this type of exercise. Increased breathlessness associated with 
being overweight may have limited the motivation to participate in higher intensity exercise. 
Indeed, this may be evident in the higher weight seen in the not meeting guidelines group. To 
reverse this cycle it is imperative ways to improve physical activity levels in CKD patients 
are identified. Despite an improvement in physical activity in a number of participants there 
were still 32% of participants not meeting physical activity guidelines after 12 months of the 
intervention. This may suggest that eight weeks of training followed by a home program, 
telephone follow-up calls and gym refresher sessions is not sufficient to maintain physical 
activity for 12 months in many CKD patients. It is likely that for some CKD patients, 




The relatively small sample size is a limitation to the study. It is also an observational study 
of the intervention arm of a randomized control trial and therefore true predictions/causations 
cannot be gained. As this is the first study of its kind, it provides ground work for a 
randomized control trial to establish the longitudinal effects of different exercise intensities in 
CKD patients. Considering the main findings of the paper are based on self-reported exercise 
intensity undertaken throughout the intervention, the use of a recall questionnaire is a 
limitation to this study. The psychometric properties of the Active Australia questionnaire has 
been correlated with pedometer steps and the total physical activity minutes has been 
reported to be significantly correlated with physical function scores, demonstrating 
acceptable convergent validity for community-dwelling older adults.(137) However, another 
study by the same author, reported that some older adults were confused with questionnaire 
phrasing, misunderstood the scope of activities to include in answers, misunderstood the time 
frame of activities to report and struggled to accurately estimate the frequency and duration 
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of their activities.(214) Nonetheless, clarity in the Active Australia questionnaire was ensured 
by administering of the questionnaire by an Exercise Physiologist. However, concurrent use 
of an objective measure of physical activity, such as accelerometry or pedometry, to provide 
cross-validation of the Active Australia questionnaire at certain time points would have 
confirmed the reported physical activity levels. 
This study focusses on the physiological and clinical determinants of participation in higher 
intensity exercise in patients with CKD. There are a number of other social and 
environmental factors which may also influence participation in higher intensity exercise. 
The narrow scope of this thesis to only quantitative outcome measures is a limitation to the 
study. Indeed, other factors such as motivation, education, socioeconomic status, mental 
health, peer influences, nutritional status, physical environment and co-morbidities, to name a 
few, may also influence participation in higher intensity exercise. A prediction model 
including all possible quantitative factors relating to exercise involvement (as mentioned 
above) would help explicate the true range of determinants related to higher intensity exercise 
participation. Future studies investigating the feasibility and determinants of higher intensity 
exercise should also include qualitative analysis of the psychosocial aspects of participation 
in exercise training. Qualitative exploration may also elucidate the enjoyment and motivation 
to undertake this type of training, to ensure long-term exercise adherence. It should also be 
noted that as this is a lifestyle intervention, the impact of patient interactions with the nurse 
practitioner, dietitian, diabetic educator and psychologist may also have provided support to 




The study was successful in increasing higher intensity exercise in some patients with CKD. 
Participants who reported completing higher intensity exercise also had the greatest exercise 
capacity after the 12 month intervention compared to patients reporting moderate intensity 
and not meeting guidelines. Participants who reported performing higher intensity exercise 
were more likely to have higher haemoglobin levels at baseline. These findings suggest that 
in CKD patients haemoglobin levels are a strong predictor of exercise capacity at one-year 
and have a likely influence of fatigue on motivation. This preliminary study provides 
interesting findings and suggestions for future high intensity training to be performed in the 
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CKD population. Future studies should identify whether low haemoglobin levels in CKD 
patients influences the change in exercise capacity with higher intensity exercise. 
Section 1; Chapter 5 Agreement between cystatin-C and creatinine based eGFR estimates 
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5.1 Abstract 
Background: Estimation of glomerular filtration rate (eGFR) using formulae based on serum 
creatinine concentrations are commonly used to assess kidney function. Physical exercise can 
increase creatinine turnover and lean mass; therefore this method may not be suitable for use 
in exercising individuals. Alternatively, cystatin-C based eGFR formulae may be a more 
accurate measure of kidney function in studies examining the impact of exercise in CKD 
patients. The aim of this study was to assess the agreement of four different creatinine and 
cystatin-C based estimates of GFR before and after a 12 month LI intervention. It was 
hypothesised that there would be poor agreement between these measures after 12 months of 
exercise training due to the impact of exercise on serum creatinine.  
Methods: 142 participants with stage 3 or 4 CKD (eGFR 25-60 ml/min/1.73 m2) were 
included. Subjects were randomised into either a control group (standard nephrological care) 
or a LI group (12 months of predominantly home-based aerobic and strength based exercise 
training). Four eGFR formulae were compared at baseline and after 12 months: 1) 
modification of diet in renal disease creatinine (MDRDcr), 2) CKD-epidemiology 
collaboration creatinine (CKD-EPIcr), 3) CKD-EPIcystatin-C (CKD-EPIcys) and 4) CKD-
EPIcr-cys. 
Results: The LI resulted in significant improvements in exercise capacity (1.9±1.8 METs). 
Lean mass (r=0.319, p<0.01) and grip strength (r=0.391, p<0.001) were associated with 
serum creatinine at baseline. However, there were no significant correlations between 
cystatin-C and the same measures. There was no change in lean mass in both control and LI 
groups during the 12 months. CKD-EPIcys was considerably lower than CKD-EPIcr at both 
baseline and 12 months (both groups baseline= -7.9±8.6 and LI at 12 months= -8.4±12.3 and 
Control at 12 months= -13.1±11.8 ml/min/1.73 m2), CKD-EPIcr-cys (both groups baseline= -
3.1±3.7 and LI at 12 months= -2.5±5.5 and Control at 12 months= -4.5±4.5 ml/min/1.73 m2) 
and MDRDcr (both groups baseline= -8.5±8.6 and LI at 12 months= -9.2±12.2 and Control at 
12 months -14.4±11.4 ml/min/1.73 m2).  
Conclusions: Cystatin-C and creatinine based eGFR both provided similar estimates of 
kidney function between baseline and after 12 months of participating in a predominantly 
home-based exercise training program. However, CKD-EPIcys was considerably lower than 
CKD-EPIcr and MDRDcr at both baseline and 12 months. A combination of cystatin-C and 
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creatinine in eGFR measurements may provide the most accurate assessment of kidney 
function in exercising individuals. 
 
5.2 Introduction 
The most common approach used to assess kidney function is by estimation of glomerular 
filtration rate based on serum creatinine concentrations, as it can be calculated routinely from 
standard tests and is inexpensive. Physical exercise can cause an increase in serum 
creatinine;(215) therefore this method may not be suitable for use in exercising individuals. 
Alternatively, cystatin-C based eGFR is suggested to be an improved method for eGFR 
measurement and may provide a more precise estimate of kidney function.(216) The 
agreement between cystatin-C and creatinine based eGFR before and after an LI in CKD 
patients is yet to be studied.  
The current reference method for measuring kidney function is to quantify the clearance of an 
exogenous marker such as inulin to determine GFR.(8) However, this measure is rarely used 
clinically due to the test complexity and cost. Indirect assessment of endogenous markers to 
provide an estimation of GFR is commonly used for routine clinical measurements via 
different formulas.(9) These formulae use either a measure of creatinine or cystatin-C in 
serum or urine, along with patient characteristics; age, sex and race to estimate filtration 
rates. The four most frequently used eGFR equations are: 1) MDRDcr(10), 2) CKD-
EPIcr(11), CKD-EPIcys(12) and CKD-EPIcr-cys(12).  
Creatinine based eGFR measures are commonly used as a ‘first test’ and for routine clinical 
assessment of kidney function.(12, 18) Creatine phosphate is taken up by muscle after it is 
released into the circulatory system following synthesis in the liver. Creatinine is formed as 
the by-product of muscle creatine breakdown during muscle contraction(217) and therefore 
can be directly influenced by muscle mass.(218, 219) This is an important limitation for 
estimation of GFR as muscle mass is often reduced in the CKD population.(219) 
Furthermore, intense exercise may cause a breakdown of muscle leading to an increase in 
serum creatinine levels,(215) potentially making creatinine-based eGFR measures inaccurate 
in individuals participating in higher intensity exercise. Cystatin-C is a low molecular weight 
cystine protease inhibitor that is produced at a constant rate by all nucleated cells and is not 
influenced by muscle mass.(220) The use of cystatin-C in the eGFR equation is suggested to 
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be the gold-standard measure of eGFR due to its increased association with risk of death and 
progression to end-stage renal disease.(221)  
Exercise training is important for patients with CKD as it has been shown to improve 
physical function and cardiovascular disease risk factors in a number of studies.(39, 75, 77) 
Therefore, it is important to identify whether there is a difference in the agreement between 
cystatin-C and creatinine based eGFR measures after exercise-induced adaptations occur. It is 
also important to assess the impact of exercise training on kidney function – such as by 
slowing the rate of decline or the potential for harm by volume depletion. 
The aim of this study was to assess the agreement between cystatin-C and creatinine based 
eGFR estimates following an LI. It was hypothesised that there would be poor agreement 




This study included 142 subjects with stage 3-4 CKD, with 74 participants randomized to the 
intervention group and 68 to the control group (Figure 5.1). This analysis is looking at the 
first 12 months of the LM3 study in both control and intervention groups.  
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Figure 5.1 Consort diagram 
 
Four measures of renal function were assessed by eGFR; MDRDcr – 175 study equation 
(2007),(10) CKD-EPIcr equation (2009),(11) CKD-EPIcys equation (2012)(12) and CKD-
EPIcr-cys equation (2012)(12). All eGFR’s are made relative to a body surface area of 
1.73m2. An improvement in either total MET minutes or vigorous MET minutes is 
determined from the change from baseline to 12 months. Due to the changes in total mass 
influencing the percentage of lean mass, baseline and change in appendicular lean mass are 
reported in absolute values. DEXA was performed on a sub-set of patients due to limited 
machine availability (n=73). Blood was collected after an overnight fast prior to any other 
tests. Participants were asked to refrain from any exercise on the morning of the test. 
 
Statistics 
Mean±standard deviation (SD) was used to describe normally distributed baseline 
characteristics, with percentages used to describe frequencies for categorical variables. 
Median [interquartile range (IQR)] was used to describe not normally distributed variables 
Excluded (n=24) 
Screen fail: n=8 
Unsuitable for intervention: n=6 
 Cardiac: n=3 
 Mobility: n=2 
 Moved inter-state: n=1 




Lost to follow-up: n=1 
Not suitable: n=1 
Moved inter-state: n=2 
Control (n=81) 
Withdrew: n=7 
Lost to follow-up: n=3 
Not suitable: n=1 
Moved inter-state: n=2 
Control (n=68) LI (n=74) 
Assessed for eligibility and 
underwent baseline testing (n=187) 
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and variables transformed by the natural logarithm. Pearson’s correlation coefficient was 
used to assess association for normally distributed and log transformed variables. Spearman’s 
correlation was used for associations of categorical variables, or when when there was at least 
one variable not normally distributed. Comparison between groups was assessed by an 
independent t-test of the delta from baseline to 12 months. The Mann-Whitney U test was 
performed on not-normally distributed variables. Differences between groups for categorical 
variables were analysed using Pearson’s Chi Square test. Within group differences were 
assessed by paired t-tests for normally distributed and log transformed variables. Wilcoxon-
Sign rank test was used for not normally distributed variables. Participants were considered to 
have improved their lean mass, grip strength, total MET minutes and vigorous intensity 
exercise if the delta from baseline to 12 months was greater than zero. Bland-Altman analysis 
was used to assess agreement between eGFR measurements using GraphPad Prism 7. All 
other statistical analyses were performed on IBM SPSS Statistics 22. Statistical significance 





There were no significant differences between groups for any of the baseline characteristics 
or medication use (Table 5.1). Patients were on average 62 years of age and generally obese 
with an average body mass index (BMI) of 32 kg/m2. Mean VO2peak for the group was 
considered very poor, according to the American College of Sports Medicine (ACSM) (2010) 
normative values for men and women aged 60-69, at 23.6 ml/kg/min.(222) The number of 
participants who changed their hypertensive or diuretic medication (commenced, ceased or 
no change) was not significantly different between the control and LI groups (Table 5.2). 
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Age (years) 63.5[9.4] 60.5[14.2] 0.23 
Male sex, n(%) 41(60.3) 44(59.5) 0.92 
African American, n(%) 0(0) 1(1.4) 0.34 
Diabetes, n(%) 27(42.2) 32(43.8) 0.85 
Systolic blood pressure (mmHg) 133.0[26.5] 130.0[18.0] 0.18 
Diastolic blood pressure (mmHg) 80.0[12.0] 78.0[10.0] 0.56 
ACE inhibitor, n(%) 34(53.1) 34(47.9) 0.54 
ATRB, n(%) 30(45.5) 44(59.5) 0.10 
Thiazide, n(%) 16(25) 13(18.3) 0.35 
Spironolactone, n(%) 1(1.4) 3(4.9) 0.89 
Loop diuretics, n(%) 14(20.6) 15(21.2) 0.24 
Statin, n(%) 41(64.1) 46(64.8) 0.93 
ACE=angiotensin-converting-enzyme; ATRB=angiotensin receptor blocker. Median[IQR] 
and n(%) is reported 
 
Table 5.2 Change in hypertensive and diuretic medications during the 12 month study 
period 
Medication Control LI p value 
 Commenced Ceased Commenced Ceased  
ACE inhibitor, n(%) +1(1.5) -5(7.4) +1(1.4) -7(9.5) 0.83 
ATRB, n(%) +4(5.9) -2(2.9) +6(8.1) -6(8.1) 0.30 
Thiazide, n(%) +1(1.5) -2(2.9) +1(1.4) -3(4.1) 0.90 
Spironolactone, n(%) 0 -2(2.9) 0 0  
Loop diuretics, n(%) +6(8.8) -3(4.4) +4(5.4) -3(4.1) 0.76 
ACE=angiotensin-converting-enzyme; ATRB=angiotensin receptor blocker 
 
Fitness measures 
Table 5.3 demonstrates the baseline and within group changes in all patient characteristics in 
the LI and control groups. Compared to the control group, the LI group had significant 
(p<0.05) improvements in VO2peak and METs and a close to significant (p=0.05) increase in 
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6 minute walk time. There were also treatment effects of get up and go time, moderate 
intensity activity, time spent walking and total activity, such that there was a significant 
improvement in the LI compared to the control group. There were no significant (p>0.05) 
between-group differences in appendicular lean mass, grip strength or vigorous intensity 
exercise. There were also no within group changes in lean mass or vigorous intensity exercise 
in the LI group.  
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Table 5.3 Change in patient characteristics, exercise parameters and eGFR 
measurements from baseline to 12 months 
 
  
Variable Control LI p value 
 Baseline Δ 12m Baseline Δ 12m 
Weight (kg) 94.9±22.2 1.3±4.5* 93.9±20.3 -1.8±6.1*# <0.01 
Body mass index (kg/m2) 33.3±6.9 0.5±1.6* 33±6.1 -0.6±2.2*# <0.01 
VO2peak (ml/kg/min) 23.2±5.4 -0.9±4.2* 23.2±7.6 1.7±3.7*# <0.01 
Exercise capacity (METs) 7.5±2.6 -0.1±1.9 7.5±3.7 1.9±1.8*# <0.001 
6 min walk (m) 483.8±95.9 3.0±67.9 493.8±106.4 29.5±63.9* 0.05 
Grip strength (kg) 32.8±10.3 -1.6±6.7 35.4±11.8 -2.2±7.2* 0.67 
Get up and go (s) 4.8(1.3) 0.4(1.1)* 5.1(2.0) 0.0(1.1)# 0.02 
Appendicular lean mass (kg) 23.6±5.7 0.0±0.0 24.1±5.6 0.0±0.0 0.31 
Walking/week (hours) 0.7(2.3) 0.0(1.0) 0.7(2.0) 0.5(1.6)*# 0.02 
Moderate/week (hours) 0.0(0.0) 0.0(0.0) 0.0(0.0) 0.2(1.5)*# <0.01 
Vigorous/week (hours) 0.0(0.0) 0.0(0.0) 0.0(0.0) 0.0(0.3) 0.27 
Total activity (hours) 1.2(3.5) 0.0(2.7) 1.0(3.0) 1.8(3.2)*# <0.01 
Total activity (METhours) 3.8(13.5) 0.0(11.0) 3.3(11.8) 8(13.7)*# <0.01 
Kidney function measures  
Creatinine (µmol/L) 143.8±33.3 4.6±26.8 150.3±33.9 6.3±29.2 0.75 
Cystatin-C (mg/L) 2.1±0.5 0.2±0.4* 2.1±0.5 0.1±0.4 0.14 
MDRDcr (ml/min/1.73m2) 42.7±9.7 0.0±8.1 41.2±9.1 -0.8±8.5 0.62 
CKD-EPIcr (ml/min/1.73m2) 41.9±10.1 -0.2±8.4 40.7±9.6 -0.8±8.9 0.67 
CKD-EPIcys (ml/min/1.73m2) 30.4±8.9 -2.4±6.2* 31.5±10.3 -0.7±7 0.17 
CKD-EPIcr-cys (ml/min/1.73m2) 34.5±8.5 -1.5±6.3* 34.6±9.4 -1.5±5.8 0.97 
Protein:creatinine 38.0(85.5) -0.5(23.8) 38.0(88.8) -1.0(32.8) 0.42 
Albumin:creatinine 14.0(63.5) 0.0(21.5) 14.5(69.4) 0.0(17.7) 0.47 
Delta is calculated by 12 month minus baseline. Mean ± standard deviation is presented for normally 
distributed delta variables. Median(IQR) is presented for not normally distributed delta variables. p 
value presented indicates significance of delta values between groups. 
*= within group statistical significance, # and values in bold in the p value column=between group 
statistical significance of delta values (baseline to 12 months) 
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Kidney function 
Table 5.3 shows no significant within group changes in the LI group for any of the kidney 
function measures. The control group had a significant increase in cystatin-C over 12 months 
with subsequent decreases in CKD-EPIcys and CKD-EPIcr-cys. There were no significant 
between group differences for any of the changes in eGFR measures over the 12 months. 
Further analysis was conducted by combining control and intervention participants and then 
separating into two groups; those that had an increase in lean mass (n=17) and those who 
decreased appendicular lean mass (Table 5.4). There were still no significant changes in any 
eGFR measures between those who increased appendicular lean mass and those who 
decreased appendicular lean mass. Likewise, there was no significant change in eGFR in 
those who did/did not increase their total physical activity time (METhours) (n=72), and 
those who did/did not increase their grip strength (n=45).
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Table 5.4 The difference between those who improved and declined appendicular lean mass, total physical activity time and grip 
strength 
 Appendicular lean mass (kg) Total physical activity time (hours) Grip strength (kg) 
 Improvement Decline p value Improvement Decline p value Improvement Decline p value 
MDRDcr -3.6±7.7 -0.7±5.9 0.24 -1.6±8.7 -2±8.6 0.69 0.3±9.0 1.3±7.7 0.36 
CKD-EPIcr -3.8±7.9 -0.6±5.9 0.21 -1.5±9.0 1.9±9.6 0.79 0.2±9.5 -1.4±7.9 0.35 
CKD-EPIcys -1.1±7.4 -2.5±4.7 0.53 -1.7±7.3 -1±8.6 0.79 -1.4±6.2 -1.9±6.9 0.68 
CKD-EPIcr-cys -2.7±4.9 -2.1±4.8 0.77 -0.4±7.2 -2±5.6 0.37 -1.1±6.1 -2.4±5.3 0.27 
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Association between creatinine and lean mass and strength 
Table 5.5 shows correlations between kidney function estimates with fitness and body 
composition measures in all patients at baseline. Creatinine was significantly associated with 
lean mass (r=0.32, p<0.01) and grip strength (r=0.39, p<0.001). However, Cystatin-C was not 
correlated with lean mass or grip strength. There were also no significant associations 
between the change in creatinine or cystatin-C and the change in fitness and body 
composition measures (Table 5.6). 
 
Table 5.5 Associations between kidney function estimates with fitness and body 
composition measures in all patients with creatinine and cystatin-C based eGFR 
measures at baseline (correlation coefficient presented as r) 
 Baseline (r value) 
 Creatinine Cystatin-C EPIcr EPIcys EPIcr-cys MDRD 
VO2peak (L/min) 0.11 -0.04 0.20* 0.16 0.20* 0.18 
VO2peak/lean (L/min/kg) -0.15 -0.10 0.17 0.12 0.15 0.11 
Appendicular lean mass (kg) 0.32* 0.12 -0.06 0.004 -0.01 -0.05 
Grip strength (kg) 0.39* 0.02 0.01 0.11 0.08 0.03 
*= significantly correlated (p<0.05) 
 
Table 5.6 Associations between delta kidney function estimates with delta fitness and 
body composition measures from baseline to 12 months 




Delta VO2peak (ml/kg/min) 0.01 -0.17 
Delta exercise capacity (METs) 0.02 -0.12 
Delta appendicular lean mass (kg) <-0.01 0.08 
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Agreement of eGFR measures 
Table 5.7 shows the agreement between CKD-EPIcys with the other three estimates at 
baseline in all patients. The Bland-Altman analysis identified CKD-EPIcys and CKD-EPIcr-
cys to be considerably lower than CKD-EPIcr and MDRDcr for estimating GFR. Figure 5.2 
indicates CKD-EPIcys to have lower average values than CKD-EPIcr at baseline in all 
patients (eGFR 7.9 below CKD-EPIcr). This bias was consistent at 12 months in both LI 
(eGFR 8.4 below CKD-EPIcr) and control groups (eGFR 13.1 below CKD-EPIcr). Only 
CKD-EPIcys and CKD-EPIcr are reported in Figure 5.2 (baseline), Figure 5.3 (12 months LI 
patients) and Figure 5.4 (12 months control group) in order to demonstrate the difference 
between cystatin-C and creatinine using similar equations (ie. CKD-EPI equation).  
 
Table 5.7 Bland-Altman agreement of CKD-EPI cys with the other three estimates at 









Figure 5.2 Bland-Altman plots at baseline for CKD-EPIcr compared to CKD-EPIcys. 
CKD-EPIcys minus CKD-EPIcr is divided by the mean of CKD-EPIcys+CKD-EPIcr. 
CKD-EPIcys is shown to be 7.9±8.6 ml/min/1.73m2 less than CKD-EPIcr at baseline 
 EPIcr EPIcr-cys MDRDcr 
EPIcys -7.9±8.6 -3.1±3.7 -8.5±8.6 
EPIcr  7.3±12.7 0.5±1.6 
EPIcr-cys   -7.9±12.1 
Data is reported as bias ± SD of bias. 
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Table 5.8 Bland-Altman agreement of CKD-EPIcys with the other three estimates at 12 
months in LI patients 
 
Figure 5.3 Bland-Altman plots at 12 months in LI patients for CKD-EPIcr compared to 
CKD-EPIcys. CKD-EPIcys minus CKD-EPIcr is divided by the mean of CKD-








 EPIcr EPIcr-cys MDRDcr 
EPIcys -8.4±12.3 -2.5±5.5 -9.2±12.2 
EPIcr  5.9±6.9 -0.5±2.2 
EPIcr-cys   -6.7±6.8 
Data is reported as bias ± SD of bias. 
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Table 5.9 Bland-Altman agreement of CKD-EPIcys with the other three estimates at 12 



















Figure 5.4 Bland-Altman plots at 12 months in the control group for CKD-EPIcr 
compared to CKD-EPIcys. CKD-EPIcys minus CKD-EPIcr is divided by the mean of 




This is the first study to investigate the agreement between cystatin-C and creatinine based 
eGFR measures before and after a 12 month LI. The findings from this study indicate that 1) 
cystatin-C based eGFR estimates are considerably lower than creatinine eGFR estimates; 2) 
the agreement between cystatin-C and creatinine eGFR was consistent at baseline and after 
the LI; and 3) lean mass and grip strength were correlated with creatinine and not cystatin-C 
at baseline. 
 EPIcr EPIcr-cys MDRDcr 
EPIcys -13.1±11.8 -4.5±4.5 -14.1±11.4 
EPIcr  8.6±7.4 -1.0±1.5 
EPIcr-cys   -9.6±7.0 
Data is reported as bias ± SD of bias. 
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The Bland-Altman analysis showed a considerably lower eGFR measured by CKD-EPIcys 
than by CKD-EPIcr and MDRDcr. Not surprisingly, the agreement between CKD-EPIcr and 
MDRDcr was similar. Furthermore, as expected the difference between CKD-EPIcr-cys and 
the other measures was midway between CKD-EPIcr and MDRDcr, and CKD-EPIcys. An 
overestimation of eGFR using the MDRDcr equation has previously been reported by Lamb 
et al. (2003).(223) Although, in this study comparisons are made to creatinine clearance 
rather than CKD-EPI equations or cystatin-C based measures. CKD-EPIcr is thought to 
produce less biased estimates of eGFR at higher levels of kidney function, however is less 
accurate when GFR falls below 60 ml/min/1.73m2.(136) On the other hand, cystatin-C is 
suggested to be a more sensitive marker of GFR than creatinine.(224) This is supported in our 
study, evident by the lower CKD-EPIcys and CKD-EPIcr-cys identified by the Bland-Altman 
plots when compared to CKD-EPIcr and MDRDcr. The lower lean mass and strength in the 
study population (69) may be contributing to the higher CKD-EPIcr and MDRDcr measures 
compared to CKD-EPIcys. Despite the lower CKD-EPIcys at baseline, it is important to note 
the agreement between the cystatin-C and creatinine based eGFR measures do not 
significantly differ after 12 months of exercise training. As CKD-EPIcr and MDRDcr are 
used as routine measurement in standard clinical care, the consistency of these findings 
support the use of creatinine based eGFR measures in exercising individuals. 
The findings from this study identified that lean mass and grip strength were correlated with 
creatinine and not cystatin-C at baseline. This finding is in agreement with evidence that lean 
mass is significantly related to serum and urinary creatinine but not with cystatin-C, even 
after adjustment for physical activity levels.(219) From the baseline findings of creatinine 
correlating with lean mass and grip strength, it would appear that muscle mass and strength 
would be influencing creatinine based eGFR estimates (CKD-EPIcr and MDRDcr). An 
intervention resulting in significant increases in strength and mass such as with a specific 
hypertrophy resistance training program, may potentially provoke a decline in eGFR using 
creatinine based equations. Indeed, the lack of change in lean mass in the current study limits 
the ability to make conclusions regarding the effects of exercise induced gains in lean mass 
on eGFR measures. As such, clinical decisions based on creatinine based eGFR’s of patients 
undertaking hypertrophy training should be considered with caution. Although the small 
sample size limits the ability to detect a significant change in eGFR,(136) the findings from 
this study suggest that resistance exercise as commonly prescribed in a health-enhancing 
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exercise program was not enough to elicit changes in eGFR. It was not expected that this 
intervention would not provide any significant changes in grip strength or lean mass. 
However, in this generalizable CKD cohort the lack of increase in grip strength and lean mass 
is important and warrants further investigation. Future studies should investigate whether 
specific hypertrophy interventions influences creatinine based eGFR measures.  
The equations used to estimate GFR have advanced in precision and accuracy. In 1999, the 
MDRDcr equation was suggested to be more accurate than the accepted Cockcroft-Gault and 
creatinine clearance methods.(13) More recently it was proposed that CKD-EPIcr provided a 
more precise estimate of GFR and categorization for risk of mortality compared to the 
MDRDcr study equation.(16) CKD-EPIcr was developed using the same variables as 
MDRDcr but with different coefficients, which created a moderate improvement in overall 
accuracy.(17) It has been suggested that standardized serum creatinine assays be used as a 
first test for assessing eGFR in adults due to its cost-effectiveness and that Cystatin-C be used 
as a more precise confirmatory test if a below normal creatinine eGFR is detected.(18) 
Banfi et al. (2006) identified elevated serum creatinine concentration levels in athletes 
compared to sedentary controls, likely due to a higher muscle mass in the athletes.(225) It is 
suggested that the observed eGFR reductions are limited to periods when the athlete is 
unaccustomed to the training load. This is not unlike a CKD patient commencing an exercise 
program after an extended sedentary period. However, it is promising to note there was no 
reduction in eGFR in the LI group of the current study, despite a large increase in physical 
activity levels. This is supported by a number of studies who have shown maintenance of 
kidney function with exercise training.(36, 75)  
Participation in higher intensity exercise may be an important consideration in determining 
appropriate kidney function estimates. Indeed, Poortmans et al. (1996) showed that post-
exercise proteinuria was directly related to the intensity of exercise rather than its duration. 
Creatinine is derived almost entirely in the muscle as a by-product of creatine synthesis.(226) 
Subject to the intensity of the exercise, muscle breakdown that occurs during exercise may be 
evident in serum and urine and as such may transiently underestimate kidney function. 
Physical activity undertaken in the 24 hour period preceding testing was not recorded in the 
current study. If the exercise was of high enough intensity it may potentially have resulted in 
transient increases in serum creatinine. Nonetheless, it was shown by Lippi et al. (2008) that 
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there was no difference in half-marathon runner’s serum creatinine levels 24 hours post 
moderate-high intensity exercise. There was, however, a statistically significant difference 
shown immediately post-exercise and a clinically significant difference shown at 3 hours and 
6 hours. Nevertheless, in the current study testing was completed in the morning after an 
overnight fast, and participants were asked to refrain from any exercise the morning of the 
test. Moreover, it has been reported that measuring renal function a day after moderate-high 
intensity exercise does not influence kidney function values.(227) However, it is presumed 
that the rate of creatinine clearance post exercise in half-marathon runners would be higher 
than the creatinine clearance of CKD patients. Therefore, the rate of creatinine clearance in 
the study by Lippi et al. (2008) should be interpreted with caution when extrapolated to the 
CKD population. There are no studies to date which investigate the clearance rate of 
creatinine after an acute exercise session in CKD patients. This is an area which warrants 
further research, to ensure ‘spot’ measures of creatinine based eGFR are not being influenced 
by prior exercise training. Future studies should evaluate creatinine based eGFR clearance at 
regular time intervals following exercise sessions of differing intensities.  
Cystatin-C also has some reported limitations in its use as a kidney function measure, due to 
its associations with cardiovascular disease risk factors. After modelling to adjust for 
measured GFR, Rule et al. (2013) found residual associations of CKD-EPIcys with CKD risk 
factors, including hypertension, BMI, and C-reactive protein (CRP).(20) This confounding 
association makes it difficult to establish whether cystatin-C is a true measure of renal 
function or rather a reflection of CKD risk factors.(220) Due to the limitations of both 
creatinine and cystatin-C, it has been suggested that using the combination of both measures 




A significant limitation which needs to be addressed is the large sample size needed to see a 
change in eGFR. As suggested by Lamb et al (2014), 1000 participants are needed to detect 
differences in accuracy of measurement between MDRDcr and CKD-EPIcys.(136) The 
authors of this pilot study found in 1000 subjects, the simulations showed an 87% power at 
the 5% significance level to detect a difference of 5%. The current study did not have the 
resources to provide longitudinal exercise training on this scale. For this reason, agreement, 
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rather than change, was the focus of this analysis. Future large scale exercise interventions 
comparing creatinine and cystatin-C estimates of GFR measures are needed to explicitly 
address the hypothesis from this study. Also, as mentioned above, not measuring physical 
activity levels the day prior to blood collection is a limitation of the study, as recent physical 
activity may have resulted in transient increases in serum creatinine. 
Another limitation of the study is the use of a ‘spot’ measurement of creatinine and cystatin-
C samples. In the initial phases of the program it is likely that patients were more 
unaccustomed to the exercise training load than closer to the 12 month testing visit. 
Therefore, the relative exercise intensity (and perhaps an increase in training volume) in the 
initial intervention period may have resulted in different creatinine and cystatin-C measures 
than what was observed at 12 months.  
 
Conclusions 
The findings from this study found no difference in the agreement between creatinine and 
cystatin-C estimates of GFR after a 12 month LI. As previously reported, a combination of 
creatinine and cystatin-C based estimates of GFR will undoubtedly provide the most accurate 
estimate of GFR, particularly in light of the considerably lower eGFR found with CKD-
EPIcys than CKD-EPIcr and MDRDcr. However, if only creatinine based measures are 
accessible to the treating Physician, the findings from this study suggest it is reasonable to 
expect creatinine based measures to provide consistent results after prescription of a health-
enhancing exercise program. Future exercise training studies comparing cystatin-C and 
creatinine based eGFR measures in specific hypertrophy and high intensity training programs 
are warranted to confirm the current findings. 
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Chapter 6.  
Effects of a 36 month lifestyle 
intervention on exercise capacity and 
cardiovascular disease risk factors 
 
This chapter contains an abridged methods section to avoid replication of the methods 
described in Chapter 2. 
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6.1 Abstract 
Background: Exercise training has the potential to improve health outcomes in CKD patients, 
by improving fitness and cardiovascular disease risk factors; however the feasibility and 
effectiveness of a long-term lifestyle intervention (LI) that includes predominantly home-
based exercise training has not been investigated in this population. The aim of this study was 
to assess the feasibility and efficacy of a three-year LI on cardiorespiratory fitness, exercise 
capacity, arterial stiffness and autonomic function.  
Methods: Ninety-four patients with stage 3-4 CKD (25-60 ml/min/1.73m2) were randomized 
to either a control group (standard nephrological care) or a LI group. The LI comprised 
aerobic and strength based exercise training, nurse practitioner care, dietary advice and 
diabetic education (if applicable) in addition to usual nephrological care. Outcome measures 
assessed every year included exercise capacity (METs), cardiorespiratory fitness (VO2peak), 
arterial stiffness (pulse wave velocity [PWV] and augmentation index [AIx]) and autonomic 
function (heart rate variability [HRV]). Functional capacity (six minute walk time), physical 
activity levels, grip strength, body composition and standard clinical measures were 
performed every 6 months. 
Results: After 36 months there was a significant increase in physical activity levels in the LI 
group (LI= +112.5±224.5 mins/week), while the control group decreased slightly (= -
12.7±171.1 mins/week, p<0.01). The number of patients in the LI group meeting physical 
activity guidelines (≥150 minutes/week) doubled (baseline = 31.3% to 36 months = 62.2%) 
compared to a decrease in the control group (baseline = 34.9% to 36 months = 30.6%). 
Exercise capacity significantly improved in the LI group (LI= +2.2±2.7, control= -0.2±2.2 
METs, group x time p=0.01) and PWV decreased (LI= -0.1±2.5, control= +0.6±3.1 m/s, 
group x time p=0.03). Furthermore, the LI ameliorated the significant decline in 
cardiorespiratory fitness seen in the control group (VO2peak control= -4.2±4.7 ml/kg/min, 
p=0.01 and LI= -1.2±8.5 ml/kg/min, p=0.92).A multiple linear regression model including 
group allocation, age, baseline grip strength and baseline METs significantly predicted the 
change in exercise capacity from baseline to 36 months (R2=0.47, p<0.01). Within group 
analyses found that the LI significantly improved HRV (total power; LI= +558.0±757.1, 
p=0.01 and control=+150.0±368.3 m/s2 p=0.73).  
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Conclusions: A 3 year LI doubled the number of patients with moderate CKD meeting 
physical activity guidelines, as well as significantly improving exercise capacity and arterial 
stiffness compared to the control group. This study indicates that a LI was feasible and 
effective in CKD patients over 3 years.  
 
6.2 Introduction 
The accelerated cardiovascular disease which is common in patients with CKD means that 
these individuals are more likely to die of cardiovascular disease than progress to renal 
failure.(228) The high prevalence of traditional risk factors in CKD patients does not 
completely explain the increased cardiovascular disease risk and high mortality associated 
with this disease.(229) Non-traditional risk factors, such as reduced exercise capacity may 
account for some of the augmented risk. Indeed, reduced exercise capacity is a stronger 
predictor of survival than many traditional risk factors in end stage kidney disease 
patients.(187) Patients with CKD have significantly impaired cardiorespiratory fitness and 
exercise capacity compared to normative values.(209) It has been suggested that muscle 
wasting, which is common in the CKD population,(106) may be a significant contributor to 
reduced exercise capacity.(230) Physical inactivity, which contributes to a lower exercise 
capacity and cardiorespiratory fitness, is a potentially modifiable cardiovascular disease risk 
factor. Patients with CKD are typically sedentary,(209) thus exercise training seems to be a 
currently underutilized therapy. 
Exercise training should include a combination of aerobic and resistance training,(30) in 
order to target the reduced exercise capacity and muscle atrophy which is prevalent in this 
population.(69, 209) Despite this, only three non-randomized studies and one randomized 
study have used a combined (resistance and aerobic) exercise training approach in CKD 
patients.(51-55) As such, current exercise guidelines for CKD patients are based on limited 
evidence.(30) However, the improvements in outcomes measures in these studies include 
increased exercise capacity,(51-53) cardiorespiratory fitness,(54, 55) muscular strength(51) 
and functional ability(52, 53). Supervised exercise training is suggested to have a cardio-
protective effect and improve cardiovascular disease risk factors such as arterial compliance, 
autonomic control and cardiac function,(231) however this approach is time and resource 
intensive. Considering approximately 16% of the population aged over 25 are reported to 
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have at least one marker of kidney damage,(1) evaluating the effectiveness of economical 
home-based, non-supervised exercise training approaches are warranted.  
Telephone interventions have the potential to cost-effectively reach a broad population.(232) 
Indeed, a six month telephone based intervention by Wilcox et al. (2008) was shown to have 
similar improvements in physical activity as a 20-week group-based lifestyle behaviour 
change program in sedentary adults over 50 years of age.(233) Our group has also conducted 
a predominantly telephone-based intervention of combination aerobic and resistance exercise 
training in patients with type two diabetes mellitus.(212) In this study participants underwent 
four weeks of supervised gym based training followed by 48 weeks of telephone follow-up 
phone calls. This approach resulted in significant improvements in cardiorespiratory fitness 
and body composition. Our group has previously assessed the benefits of a 12 month 
predominantly home-based combination training program with telephone intervention in the 
same CKD cohort as reported in this study.(234) The exercise training was identified to 
improve cardiorespiratory fitness, body composition and diastolic function. However, the aim 
of the current study was to determine whether these enhancements can be maintained for a 
longer period of time. The feasibility of a longer-term home-based combination aerobic and 
resistance training has not been reported in the CKD population. 
Therefore, the aim of this study was to assess the feasibility and efficacy of a LI on 
cardiorespiratory fitness, exercise capacity, arterial stiffness and autonomic function over a 
36 month period. It was hypothesised that the LI would elicit significant improvements in 
cardiorespiratory fitness, exercise capacity, arterial stiffness and autonomic function 
compared to a control group.  
 
6.3 Methods 
Ninety-four patients with stage 3-4 CKD were included in this analysis. The data from this 
randomized control trial (RCT) examines the intervention and control arms over the 36 
month period of the LM3 study. The LM3 study was terminated due to a lack of funding 
before 30 participants could complete the testing at 36 months. These patients were excluded 
from the current analysis. Details of patients included and excluded in this study are outlined 
in Figure 6.1. A comprehensive explanation of the methods and inclusion and exclusion 
criteria are reported in Chapter 2. Tests were performed annually (maximal exercise stress 
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test, DEXA, arterial stiffness and autonomic function) and six monthly (anthropometry, blood 
biochemistry, functional tests, blood pressure measures and physical activity questionnaire). 
The term exercise capacity refers to METs (derived from the treadmill, based on the exercise 
time) and cardiorespiratory fitness refers to VO2peak.(235) Due to limited availability of the 
DEXA machine, only a sub-set of patients had follow-up scans (LI=15, control=8). Also, due 
to limited availability of ambulatory blood pressure monitors, only a sub-set of patients had 
follow-up 24 hour blood pressure monitoring (LI=20, control=17). 
 
Statistical analysis 
Mean±standard deviation (SD) was used to describe normally distributed baseline 
characteristics, with percentages used to describe frequencies for categorical variables. 
Median[IQR] was used to describe not normally distributed variables and variables 
transformed by the natural logarithm. Normality was assessed using the Shapiro-Wilk test 
and visual interpretation of a histogram. Comparison between groups for baseline variables 
was assessed by an independent t-test on normally distributed and log transformed variables. 
The Mann-Whitney U test was performed on not-normally distributed variables. Differences 
between groups for categorical variables were analysed using Pearson’s Chi Square test.  
Within group differences were assessed by paired t-tests for normally distributed and log 
transformed variables. Wilcoxon-Sign rank test was used for not normally distributed 
variables. A GEE was used to assess the main effect of group allocation on each variable, 
including the 4 or 7 visits over the 36 month period as within subject effects. Robust 
estimator was used as the covariance matrix and exchangeable was selected for the working 
correlation structure. A repeated measures ANOVA was used to assess the changes over each 
visit in the fitness measures (physical activity levels, VO2peak, METs and grip strength). 
Friedman’s ANOVA was used to assess the change in physical activity time every 6 months 
due to the not-normal distribution of this variable. Sphericity assumed or Greenhouse-Geisser 
was used as appropriate to detect group x time interactions. LSD post-hoc analyses were used 
to compare main effects of time in each group. A multiple linear regression model was used 
to identify baseline predictors of change in estimated METs from baseline to 36 months using 
the enter method. Variance inflation factor was used to assess collinearity between predictor 
variables. A per-protocol analysis was performed on patients in the LI group who reported 
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achieving physical activity guidelines at the 36 month visit (≥150 minutes in an average week 
in the preceeding 6 months). Paired t-tests were used to investigate significant differences 
between baseline and 36 months in patients meeting physical activity guidelines for the 
variables VO2peak, METs, grip strength and eGFR. All statistical analyses were performed 
on IBM SPSS Statistics 22. Figures were constructed on GraphPad Prism 7. With many 
repeated variables in a large sample size, a small amount of missing data for variables were 
inevitable. The GEE uses an all available pairs approach, therefore participants with missing 
values for certain visits are still included in the analysis. However, the repeated measures 
ANOVA deletes cases with any missing data. The sample size for each repeated measures 




One hundred and eighty-seven participants with stage 3-4 CKD were recruited for this study 
(Figure 6.1). After 163 participants were randomized, 94 patients completed testing at 36 
months. There were 15 patients from each group who were not included in the final analysis 
as they did not complete the entire 36 month period before the study was ceased due to 
funding issues (Figure 6.1). In order to assess the completion percentage of participants who 
were given the opportunity to finish the study, these 15 participants from each group were 
excluded from the total of randomized participants (ie. LI n=67 and control n=66). Therefore, 
it was identified that 71.6% (n=48) of patients completed the LI and 69.7% (n=46) completed 
the control phase.  
There were no significant differences between age, sex or diabetes status between the control 
and LI groups (Table 6.1). The control group had a higher rate of previous myocardial 
infarction, however there were no differences between groups for other cardiovascular co-
morbidities. There were no significant differences between groups for medication use. Table 
6.2 shows diabetes to be the most common known cause of renal disease in both groups. 
  
Section 1; Chapter 6 Effects of a 36 month lifestyle intervention on exercise capacity and 
cardiovascular disease risk factors  
137  
 



















Lost to follow-up: n=3 
Medical: n=5 
Started dialysis: n=1 
Death: n=2 
Control (n=46) LI (n=48) 
Assessed for eligibility and 
underwent baseline testing (n=187) 
Excluded (n=24) 
Screen fail: n=8 
Unsuitable for intervention: n=6 
 Cardiac: n=3 
 Mobility: n=2 
 Moved inter-state: n=1 
Changed mind: n=10 
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Table 6.1 Patient characteristics 
Variable Control (n=46) Lifestyle 
Intervention (n=48) 
p value 
Age (years) 61.4±8.5 59.3±8.9 0.24 
Sex (male) 26.0(56.5) 29.0(60.4) 0.70 
Patient history    
Diabetes 19(41.3) 19(39.6) 0.87 
Hyperlipidaemia 31(68.9) 34(70.8) 0.84 
Myocardial infarction 10(21.7) 3(6.4) 0.03 
Heart failure 1(2.2) 3(6.4) 0.33 
Peripheral vascular disease 5(10.9) 10(21.3) 0.17 
Hypertension 44(95.7) 45(93.8) 0.68 
Stent 6(13) 5(10.6) 0.72 
CABG 4(8.7) 2(4.3) 0.38 
Previous angina 12(27.9) 9(20.9) 0.45 
Medications    
ACEi 25(53.2) 24(52.2) 0.92 
ARB 22(47.8) 28(58.3) 0.31 
Beta-blocker 14(29.8) 18(39.1) 0.34 
Calcium channel blocker 
 
26(56.5) 20(41.7) 0.15 
Thiazide 8(17) 12(26.1) 0.29 
Statin 33(70.2) 28(60.9) 0.34 
Insulin 9(19.1) 11(23.9) 0.58 
Values are mean±SD for normally distributed variables and n(%) for categorical 
variables. Value in bold is statistically significant between groups (p<0.05). 
LI=lifestyle intervention; CABG=coronary artery bypass graft; ACEi=ace 
inhibitor; ARB=angiotensin receptor blocker 
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Physical activity levels 
There was a significant main effect of group over time, with an increase in the LI group for 
time spent walking per week, (delta LI=79.6±180.8, control= -27.9±139.2 minutes), total 
physical activity time per week (delta LI= 112.5±224.5, control= -12.7±171.1 
minutes)(Figure 6.2, n=26 in ANOVA) and total MET minutes per week (delta LI= 
548.0±1335.2, control= -202.0±1096.3 MET minutes, all group x time p<0.01) (Table 6.3). It 
was identified that 31.3% of participants in the LI group were meeting physical activity 
guidelines (≥150 minutes/week) at baseline and this increased to 62.2% at 36 months. On the 
other hand, 34.9% of participants in the control group were meeting physical activity 
guidelines at baseline and this decreased at 36 months to 30.6% (group x time p<0.01). Table 
6.3 shows that 37.8% of participants in the LI group reported going from not meeting 
physical activity guidelines to meeting guidelines. On the other hand, only 11.8% participants 
in the control group reported not meeting guidelines at baseline and meeting physical activity 
guidelines at 36 months.  
 
Cause Control  Lifestyle 
Intervention  
T2DM insulin 9(19.6) 3(6.3) 
T2DM non-insulin 2(4.3) 4(8.3) 
Glomerulonephritis 2(4.3) 5(10.4) 
Polycystic kidney disease 3(6.5) 2(4.2) 
IgA nephropathy 2(4.3) 1(2.1) 
Renal vascular disease 1(2.2) 2(4.2) 
FSGS 1(2.2) 1(2.1) 
Reflux nephropathy 1(2.2) 1(2.1) 
Analgesic nephropathy 0 1(2.1) 
Calculi 0 1(2.1) 
T1DM 0 1(2.1) 
Other 17(37) 16(33.3) 
Unknown 8(17.4) 10(20.8) 
T2DM= Type 2 diabetes mellitus; IgA= 
Immunoglobulin FSGS= Focal segmental 
glomerulosclerosis; T1DM= Type 1 diabetes mellitus 
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Figure 6.2 Total physical activity time measured every 6 months for 36 months 
 







There was a main effect of group over time, with the LI group improving exercise capacity 
compared to the control group (LI= +2.2±2.7, control= -0.2±2.2 METs, group x time p=0.01) 
(Table 6.3). A repeated measures ANOVA (n=57) also demonstrated a significant increase in 
METs at both 12 months, 24 months and 36 months compared to baseline in the LI group 
(time effect p<0.001) with no change in the control group (time effect p=0.82) (Figure 6.3). 




Now meeting guidelines (n,%) 4(11.8) 14(37.8) 
No longer meeting guidelines (n,%) 24(70.6) 20(54.1) 
No change (n,%) 6(17.6) 3(8.1) 
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There was no main effect of group over time for cardiorespiratory fitness, measured by 
VO2peak (p=0.28). However, a repeated measures ANOVA (n=47) identified a significant 
improvement in VO2peak between baseline and visit 3 (12 months) in the LI group (time 
effect p<0.01)(Figure 6.4). In contrast, a significant decline in VO2peak from baseline to visit 
5 (24 months) and baseline to visit 7 (36 months) was identified in the control group (time 
effect p<0.001). However, Figure 6.4 indicates that after the initial increase in VO2peak at 12 
months in the LI group, the decline in cardiorespiratory fitness appears to occur at the same 
rate for both groups. 
There was no significant main effect of group over time for grip strength (Table 6.3). 
However, a repeated measures ANOVA (n=37) showed the control group to have a 
significant decline in grip strength (time effect p<0.01) at visit 5 (24 months), 6 (30 months) 
and 7 (36 months) compared to baseline that was not seen in the LI group (time effect 
p=0.20)(Figure 6.5). However, the results in Figure 6.5 indicate that after the initial increase 
in grip strength at 12 months, the decline rate is similar between groups. There was a main 
effect of group over time approaching significance for the get up and go test (group x time 
p=0.07). A within group analysis showed the control group to significantly increase their get 
up and go time (+0.34[1.1] s, paired t-test p<0.01) with minor non-significant increases seen 
in the LI group (+0.05[1.3] s, paired t-test p=0.77).
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Table 6.4 Effects of a lifestyle intervention on fitness measures in patients with CKD  
Variable Control Lifestyle Intervention Group x time 
Fitness measures Baseline 36mth Baseline 36mth p value 
VO2peak (L/min)(Ln) 2.1[0.9] 1.8[0.7]* 2.0[0.7] 1.8[0.6] 0.92 
VO2peak (ml/kg/min)(Ln) 23.5[7.0] 18.9[6.6]* 21.0[6.7] 22.2[7.6] 0.33 
Exercise capacity (METs)(Ln) 7.3[5.2] 7.0[5.1] 6.3[3.4] 9.3[3.4]* 0.01 
Respiratory quotient 1.03±0.1 1.05±0.2 1.05±0.1 1.07±0.1 0.06 
Six minute walk (m) 492.8±94.7 482.3±98.6 477.7±108.2 493.8±115.7 0.16 
Grip strength (kg) 31.3±11.3 28.7±10.0* 33.0±12.7 30.6±10.1 0.36 
Get up and go (s)(Ln) 5.0[1.7] 5.4[2.1]* 5.1[1.8] 5.4[2.1] 0.08 
Walk time (minutes) 50.0[127.5] 47.5[127.5] 60.0[135.0] 140.0[180.3]* <0.01 
Vigorous time (minutes) 0.0[0.0] 0.0[7.5] 0.0[0.0] 0.0[0.0] 0.11 
Moderate time (minutes) 0.0[0.0] 0.0[0.0] 0.0[0.0] 0.0[71.3] 0.06 
Total time (minutes) 80.0[187.5] 70.0[187.5]* 70.0[155.0] 210.0[295.0]* <0.01 
Total MET minutes  641.5[1314.0] 431.7[1314.0] 438.0[1172.0] 1155.0[1677.2]* <0.01 
Meeting guidelines  15(34.9) 11(30.6)* 15(31.30) 23(62.2) <0.01 
Generalized estimating equations identifying the main effect of group over time on fitness measures performed every 
year (maximal exercise stress test) and every 6 months (functional measures and Active Australia questionnaire). Bold 
group x time p values indicate significance (p<0.05) using the generalized estimating equation. *values in bold indicate 
within group statistical difference from baseline to 36 months (paired t-test<0.05). Normally distributed variables are 
reported as mean±standard deviation. Not normally distributed variables and log-transformed variables are reported as 
median[IQR]. (Ln)= transformed with the natural logarithm for statistical tests. METs=metabolic equivalent task 
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Figure 6.3 Exercise capacity measured every 12 months for 36 months 
 
 
Figure 6.4 Cardiorespiratory fitness measured every 12 months for 36 months 
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Figure 6.5 Grip strength measured every 6 months for 36 months 
 
Body composition measures 
The intervention had no effect on anthropometric and body composition measures; weight, 
BMI, waist:hip, fat mass or lean mass (Table 6.4). Moreover, there were similar non-
significant reductions in fat mass percentage in both control (-1.4±6 %, paired t-test p=0.52) 
and LI groups (-1±5.1 %, paired t-test p=0.46).  
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Table 6.5 Effects of a lifestyle intervention on body composition and anthropometry measures  
 
 Variable Control Lifestyle Intervention Group x time 
Body composition Baseline 36mth Baseline 36mth p value 
Weight (kg)(Ln) 91.5[31.8] 93.6[30.8] 90.5[25.1] 89.4[23.9] 0.40 
Body mass index (k/m2)(Ln) 31.1[9.1] 31.6[7.5] 32.6[7.8] 31.5[9.8] 0.32 
Waist (cm)(Ln) 103.0[30.0] 105.0[19.0] 103.0[38.4] 101.5[25.8] 0.31 
Hip (cm)(Ln) 104.0[16.0] 107.0[15.0] 109.0[70.0] 109.5[25.0] 0.52 
Waist:hip 0.9±0.1 0.9±0.1 1.0±0.1 1.0±0.1 0.38 
DEXA#      
Lean mass (kg) 47.3±10.1 48.9±7.4 54.6±10.0 54.5±10.2 0.44 
Lean mass (%) 58.4±7.3 60.0±5.0 61.8±8.1 62.9±9.4 0.77 
Fat mass (kg)(Ln) 31.5[30.2] 29.1[9.8] 29.4[15.6] 27.1[20.9] 0.36 
Fat mass (%) 38.7±5.1 37.3±5.1 35.3±8.6 34.2±9.9 0.77 
Total mass (kg)(Ln) 79.6[29.9] 81[20.9] 89.8[20.9] 87.4[24.5] 0.44 
Generalized estimating equations identifying the main effect of group over time on body composition measures 
performed every year for the DEXA measures and every six months for the other anthropometry measures. 
Normally distributed variables are reported as mean±standard deviation. Not normally distributed variables and 
log-transformed variables are reported as median[IQR]. (Ln)= transformed with the natural logarithm for 
statistical tests. DEXA= dual-energy x-ray absorptiometry. #Due to limited machine availability DEXA was 
performed in a sub-set of patients (n=23) 
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Blood biochemistry 
The intervention had no main effect of group over time on creatinine, eGFR, blood lipids, C-
reactive protein (CRP) or haemoglobin (Table 6.5). The LI group showed a significant 
decline in eGFR (-3.9±9.0 ml/min/1.73m2, paired t-test p=0.03), although the change in 
creatinine was only mildly and not significantly increased (21.9±56.2 µmol/L, paired t-test 
p=0.31). The LI also had significant decreases in total cholesterol (TC) (-0.5±0.7 mmol/L, 
paired t-test p<0.001) and low-density lipoproteins (LDL) (-0.4±0.6 mmol/L, paired t-test 
p<0.01). 
 
Haemodynamics, vascular function and heart rate variability 
There was no significant main effect of group over time on any haemodynamic variables. 
However, within-group analyses showed the control group to significantly decrease resting 
heart rate (-10.5±12 bpm, paired t-test p<0.01), peak heart rate (-11.2±17.2 bpm, paired t-test 
p<0.01) and peak systolic blood pressure (-26.5±37.8 mm/Hg, paired t-test p<0.01). There 
was a significant main effect of group over time on PWV (p=0.03). Although there were no 
within-group differences for this measure, the LI group had a decrease in PWV (-0.1±2.5 m/s, 
paired t-test p=0.67) and the control group had an increase in PWV (0.6±3.1 m/s, paired t-test 
p=0.12)(Table 6.2). There was a significant improvement in total power (TP) in the LI group 
+558.0±757.1 m/s2, paired t-test p=0.01), however there was no main effect using a GEE 
(group x time p=0.12). Other variables of HRV- standard deviation of the N-N interval 
(SDNN), root mean square of the standard deviation (RMSSD), very low frequency (VLF), 
low frequency (LF) and high frequency (HF) were unchanged over the 3 years in both groups 
(Table 6.6).  
Section 1; Chapter 6 Effects of a 36 month lifestyle intervention on exercise capacity and cardiovascular disease risk factors  
147  
Table 6.6 Effects of a lifestyle intervention on blood biochemistry   
Variable Control Intervention Group x 
time 
Blood biochemistry Baseline 36 mth Baseline 36 mth p value 
eGFR (ml/min/1.73m2) 39.8±8.6 38.6±14.5 38.7±7.8 34.8±11.6* 0.25 
Creatinine (µmol/L)(Ln) 145.0[54.3] 140.5[64.3] 157.5[47.0] 160.5[76.8] 0.31 
Fasting glucose (mmol/L)(Ln)# 7.1[4.0] 7.0[5.7] 6.9[5.0] 6.2[2.9] 0.76 
Total cholesterol (mmol/L)(Ln) 4.3[1.4] 4.4[1.4] 4.6[0.9] 4.0[1.3]* 0.22 
Triglycerides (mmol/L)(Ln) 1.6[1.5] 1.4[1.0] 1.6[1.3] 1.4[0.9] 0.08 
HDL (mmol/L)(Ln) 1.2[0.5] 1.2[0.5] 1.2[0.8] 1.2[0.5] 0.28 
LDL (mmol/L)(Ln) 2.5[1.4] 2.4[1.4] 2.5[0.7] 2.0[0.9]* 0.52 
VLDL (mmol/L)(Ln) 0.7[0.6] 0.6[0.3] 0.7[0.5] 0.6[0.4] 0.26 
C-reactive protein (mg/L)(Ln) 4.0[4.9] 3.2[5.1] 3.2[5.8] 2.3[3.6] 0.77 
Haemoglobin (g/L) 132.3±14.6 130.2±15.5 135.2±16.0 131.7±13.9 0.97 
Haematocrit (%) 40.4±4.0 39.9±4.6 42±4.0 41.0±3.7 0.99 
Generalized estimating equations identifying the main effect of group over time on blood 
biochemistry measures performed every 6 months. Normally distributed variables are reported as 
mean±standard deviation. Not normally distributed variables and log-transformed variables are 
reported as median[IQR]. (Ln)= transformed with the natural logarithm for statistical tests. *values in 
bold indicate within group statistical difference from baseline to 36 months (paired t-test p<0.05). #= 
in patients with diabetes only (n=38). eGFR=estimated glomerular filtration rate; HDL=high-density 
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Table 6.7 Effects of a lifestyle intervention on haemodynamics and vascular function 
Variable Control Intervention Group x 
time 
Haemodynamics Baseline 36 mth Baseline 36 mth p value 
Resting heart rate (bpm) 82.0±10.8 71.5±13.5* 83.5±14.4 79.9±13.5 0.23 
Peak heart rate (bpm) 147.2±18.1 136.1±23.5* 147.8±30.2 144.6±25.9 0.16 
Resting systolic BP (mm/Hg)(Ln) 142.7[35.0] 136.7[28.0] 134.0[24.3] 129.0[22.6] 0.99 
Resting diastolic BP (mm/Hg)(Ln) 80.0[14.7] 77.7[12.4] 83.3[14.3] 80.0[12.4] 0.08 
Peak systolic BP (mm/Hg) 181.6±40.2 155.1±21.2* 167.3±46.1 164.3±24.4 0.73 
Peak diastolic BP (mm/Hg) 85.5±11.4 83.4±10.9 81.9±13.4 81.9±11.2 0.70 
24hr systolic BP (mm/Hg)(Ln)# 136.0[13.0] 137.0[26.0] 128.0[26.3] 129.5[16.8] 0.05 
24hr diastolic BP (mm/Hg)(Ln)# 75.0[12.0] 75.0[16.5] 77.0[14.8] 73.5[11.8] 0.73 
Central systolic BP (mm/Hg)(Ln) 116.5[18.0] 115.5[25.3] 112.0[23.0] 114.5[14.0] 0.52 
Central diastolic BP (mm/Hg)(Ln) 71.0[18.0] 70.0[23.0] 76.5[10.0] 72.0[12.0] 0.77 
Vascular function      
Pulse wave velocity (m/s)(Ln) 9.8[3.2] 9.9[3.8] 9.1[2.9] 8.6[3.9] 0.03 
AIx (%) 24.9±8.7 24.7±10.8 26.6±8.6 26.7±10.8 0.22 
Heart rate variability      
SDNN (m/s)(Ln) 20.7[13.7] 21.4[9.3] 29.9[19.0] 24.6[15.6] 0.89 
RMSSD (m/s)(Ln) 10.9[13.4] 14.2[11.7] 20.0[13.4] 13.1[17] 0.76 
Total power (m/s2)(Ln) 313.0[45.5] 335.0[377.8] 288.0[38.5]^ 576.1[964.6]* 0.14 
Very low frequency (m/s2)(Ln) 115.1[272] 123.6[261.6] 284.3[441.0] 298.7[371.9] 0.46 
Low frequency (m/s2)(Ln) 52.2[119.0] 88.2[106.7] 185.0[306] 92.6[245.5] 0.54 
High frequency (m/s2)(Ln) 31.4[98] 55.3[97.2] 142.2[146.0] 85.8[235.5] 0.98 
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Generalized estimating equations identifying the main effect of group over time on haemodynamic and vascular 
measures performed every year. Normally distributed variables are reported as mean±standard deviation. Not 
normally distributed variables and log-transformed variables are reported as median[IQR]. (Ln)= transformed with 
the natural logarithm for statistical tests. Bold group x time p values indicate significance (p<0.05) using the 
generalized estimating equation.*bold values indicate significant within group difference (p<0.05). ^bold values 
indicate significant between group difference at baseline (p<0.05). BP=blood pressure; SP=systolic pressure; 
DP=diastolic pressure; AIx=augmentation index; SDNN=standard deviation of N-N interval; RMSSD=root mean 
square of the standard deviation. #Due to limited machine availability 24 hour blood pressure monitoring was 
performed in a sub-set of patients (n=37) 
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Per-protocol analysis 
Given that 14 (29.2%) LI participants at 36 months reported not meeting physical activity 
guidelines, analyses were conducted in those who were meeting guidelines. A within group 
analysis of variables from baseline to 36 months was performed in LI patients who reported 
achieving ≥150 minutes in an average week at 36 months (n=34)(Table 6.7). The changes in 
cardiorespiratory fitness (VO2peak) and exercise capacity (METs) over the 3 years were 
similar to the changes found with all participants (Table 6.3). It was established that even in 
the patients meeting physical activity guidelines, VO2peak remained unchanged (paired t-test 
p=0.40) over the intervention, whereas METs significantly increased (paired t-test p=0.01). 
Grip strength was also shown to decline over the 36 months in patients meeting exercise 
guidelines (paired t-test p=0.01). It was identified that in LI patients who were meeting 
physical activity guidelines there was no change in eGFR measures (paired t-test p=0.99), 
which is in contrast to the previous finding which detected a difference in all patients in the 
LI group. There was a significant improvement in the cardiovascular disease risk factors total 
cholesterol and low-density lipoproteins (both paired t-test p=0.03) and total power (paired t-
test p=0.01). 
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Table 6.8 Within group comparison of patients in the lifestyle intervention group who 
achieved physical activity guidelines at 36 months 
Variable Baseline 36 months p value 
VO2peak (ml/kg/min)(Ln) 22.6[9.8] 22.0[11.2] 0.40 
Exercise capacity (METs)(Ln) 8.0[4.8] 9.7[4.5] 0.01* 
Grip strength (kg) 32.0±11.7 28.6±9.3 0.01* 
eGFR (ml/min/1.73m2) 40.3±6.7 40.3±12.8 0.99 
Total cholesterol (mmol/L)(Ln) 4.7[1.1] 4.1[1.6] 0.03* 
Triglycerides (mmol/L)(Ln) 1.1[1.0] 1.1[1.1] 0.63 
High-density lipoprotein (mmol/L)(Ln) 1.4[0.6] 1.3[0.5] 0.10 
Low-density lipoprotein (mmol/L)(Ln) 2.5[0.7] 2.1[1.1] 0.03* 
Very low-density lipoprotein (mmol/L)(Ln) 0.5[0.5] 0.5[0.5] 0.93 
Body fat (%) 32.8±9.5 33.8±9.1 0.57 
Resting average systolic BP (mm/Hg)(Ln) 136.3[23] 132.5[24.3] 0.71 
Resting average diastolic BP (mm/Hg)(Ln) 81.7[17.3] 79.9[9.8] 0.56 
Pulse wave velocity (m/s)(Ln) 8.4[3.1] 8.1[3.5] 0.40 
AIx (%) 24.5±8.9 27.0±11.6 0.37 
Total power (m/s2)(Ln) 287.5[40.0] 577.4[1477.5] 0.01* 
SDNN (m/s2)(Ln) 27.9[16.2] 26.8[17.4] 0.54 
RMSSD (m/s2)(Ln) 19.6[15.4] 14.0[25.3] 0.53 
High frequency (m/s2)(Ln) 113.6[174] 120.2[324.5] 0.31 
Low frequency (m/s2)(Ln) 112.1[315] 89.7[292.0] 0.37 
Very low frequency (m/s2)(Ln) 246.9[412.0] 333.3[533.4] 0.40 
Physical activity guidelines are ≥150 minutes/week of exercise. Normally distributed 
variables are reported as mean±standard deviation. Not normally distributed variables and 
log-transformed variables are reported as median[IQR]. (Ln)= transformed with the natural 
logarithm for statistical tests. *bold values indicate significant within group difference 
(p<0.05). BP=blood pressure; SDNN=standard deviation of N-N interval; RMSSD=root 
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Predictors of changes in exercise capacity  
A multiple linear regression assessed the relationship between baseline variables related to 
fitness and the change in METS from baseline to 36 months. It was identified that sex, 
diabetes status, eGFR, BMI, physical activity levels, VO2peak and PWV were not 
significantly associated with change in exercise capacity (Table 6.8). On the other hand, 
randomization to the LI group and grip strength were positively associated with change in 
METs and age and baseline METs were negatively associated with change in METs. The 
model including these four variables explained 47% of the variability in the change in METs 
(R2=0.47, p<0.01) and had a variance inflation factor <3.  




Group -0.37 <0.01 
Sex -0.25 0.16 
Age -0.38 <0.01 
Diabetes status 0.11 0.38 
eGFR 0.09 0.46 
Body mass index (Ln) -0.27 0.07 
Grip strength 0.46 <0.01 
Total MET minutes 0.04 0.74 
Exercise capacity (METs)(Ln) -0.37 0.01 
VO2peak (Ln) 0.05 0.75 




This is the first long-term RCT to investigate the effects of a LI on fitness and cardiovascular 
disease risk factors in patients with moderate CKD. The main findings from this study are 
that; 1) the LI doubled the number of patients meeting physical activity guidelines, 2) the LI 
significantly improved exercise capacity, 3) the LI significantly increased VO2peak at 12 
months followed by a similar rate of decline as the control group, 4) there was a significant 
decrease in arterial stiffness in the LI group compared to the control group, 5) the LI group 
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significantly improved autonomic function and blood lipids, and 6) group allocation, age, 
baseline grip strength and METs independently predicted the change in exercise capacity 
from baseline to 36 months. 
 
Physical activity 
It was identified that 30.6% of participants in the LI group were meeting physical activity 
guidelines of ≥150 minutes/week(5) in the 6 months preceding participation in the study, and 
this increased to 62.2% on completion of the study at 36 months. This finding is expected to 
be clinically important as it has been identified that physical inactivity is the 3rd biggest 
predictor of cardiovascular mortality in CKD patients, only behind left ventricular 
hypertrophy and smoking.(236) It is estimated that physical inactivity is responsible for 15 
deaths per 1000 person-years.(236) Therefore, employing strategies which improve physical 
activity levels are important in improving outcomes for CKD patients.  
 
Exercise capacity and cardiorespiratory fitness 
The LI was successful in improving exercise capacity, as measured by METs. Furthermore, 
the multiple linear regression model identified group allocation to be the most significant 
predictor of change in exercise capacity. This finding indicates that randomization to the LI 
improved exercise capacity independent of other significant associates- age, baseline exercise 
capacity and baseline grip strength. However, only small, non-significant increases in 
cardiorespiratory fitness, as measured by VO2peak, were seen in the LI group. The greatest 
increase seen in VO2peak at 12 months may be due to the high supervision in the initial 8 
week period and the more frequent gym refreshers sessions and telephone follow-up calls for 
the first year thereafter. Potentially, motivation declined when participants were expected to 
have greater autonomy in completing their home program. There have been a number of 
studies investigating the influence of researcher contact on adherence to exercise training 
programs and health outcomes. Indeed, studies have identified poor adherence, higher drop-
out rates and subsequently a decline in health related outcomes after participants have been 
prescribed a home exercise program following a period of supervised exercise.(237-240) 
However, like the current study, Menses et al. (2011) found that despite a decline in 
adherence to home-based walking training after a supervised period in patients with 
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claudication, initial claudication distance and total walking distance was higher than baseline 
values.(237) A study by Bock et al. (1997), established that exercise maintenance at follow-
up from a home-based period subsequent to supervised training was associated with 
motivational readiness. Further, a study by Loprinzi et al. (2012) reported that breast cancer 
survivors had greater adherence to unsupervised exercise training if they had higher self-
efficacy and behavioural processes at the transition from supervised exercise.(241) The 
regular follow-up telephone calls and gym refresher sessions were designed to maintain the 
support and encouragement that was needed for adherence to the intervention at home. 
Perhaps, mandatory supervised sessions at more regular intervals would have encouraged 
greater adherence for the entire 36 month intervention. Furthermore, ensuring patient self-
efficacy and motivational readiness during the supervised period may have assisted in greater 
outcomes in the home-based period. However, it must be considered that this study was 
designed as a feasible and cost-effective intervention and more frequent supervised sessions 
may not be practical in standard rehabilitation. Future studies should conduct an economic 
analysis comparing the cost of more frequent supervised sessions against the potential 
improvements in health outcomes. This would help determine the most applicable exercise 
prescription that can be realistically incorporated into standard nephrological care. 
Despite the lack of a significant increase in VO2peak in the LI group in the current study, the 
LI seemed effective in ameliorating the significant reduction in cardiorespiratory fitness from 
baseline to 36 months which was seen in the control group. Figure 6.4 clearly demonstrates 
that after the significant increase in VO2peak at 12 months in the LI group, the decline rate is 
similar to that of the control group. Potentially the initial 8 week period of more intensive 
exercise training may have been sufficient to ameliorate the overall decline in fitness from 
baseline at 36 months. The significant reduction in arterial stiffness at 36 months may 
indicate that this more intensive initial period of exercise may have a legacy effect on 
cardiovascular risk factors. Indeed, whether a legacy effect does exist after a short period of 
intense exercise training followed by a maintenance phase of moderate intensity exercise 
warrants further study. This finding has important implications for minimum dose of exercise 
training for cardiovascular response. This decline in fitness in the control group was also 
identified in the study by Headley et al. (2012), who found a similar decrease in VO2peak in a 
usual care control group after 48 weeks of combination training.(55) As every 1 ml/kg/min 
increase in VO2peak is reported to result in a 15% decrease in risk of death in patients with 
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coronary heart disease, preventing this decline has a likely effect on health outcomes in CKD 
patients.(78)  
 
Cardiorespiratory fitness non-responders 
The significant increase seen in METs, without a subsequent increase in VO2peak, indicates a 
disconnect between exercise capacity and cardiorespiratory fitness. The LI group had a 
significant increase in METs at 12 months, which was maintained until 36 months. On the 
other hand, VO2peak increased significantly at 12 months, yet declined to baseline levels by 
the end of the study. This finding may indicate that an improvement in exercise efficiency is 
occurring, rather than a physiological adaptation. Other aspects that can influence exercise 
capacity are the environment, subject motivation and familiarity with maximal testing.(242) 
The findings from the per-protocol analysis of LI patients meeting physical activity 
guidelines also suggests there is an improvement in exercise capacity occurring without a 
subsequent increase in cardiorespiratory fitness. It has been suggested that non-responders to 
changes in VO2peak are not necessarily non-responders in other measurements of training 
response.(243) Scharhag-Rosenberger et al. (2012) found that after middle-aged, untrained 
participants underwent a year of endurance training, some individuals displayed no changes 
in VO2max yet had significant changes in anaerobic threshold and exercise heart rate.(244)  
There may be other mechanisms occurring through the pathogenesis of CKD which are 
dampening the physiological adaptations to exercise training. Indeed, baseline autonomic 
activity has been reported to influence exercise training response.(245-247) A study by 
Huatala et al. (2003) has found baseline HRV in sedentary adults explains 27% of the 
variation in VO2max response after an exercise training program.(248) Our group has 
identified HRV to be lower in CKD patients than age matched healthy controls and found 
HRV in CKD patients to be associated with VO2peak (Appendix 11.7). Therefore, the low 
HRV in this population may be contributing to the lack of response in VO2peak over a long-
term training program. There are no longitudinal studies looking at whether chronic disease 
patients who are non-responders to cardiorespiratory fitness, yet improve other training 
responses such as exercise capacity, can achieve the same health enhancing benefits.(243)  
The results of the linear regression, which identified baseline predictors of change in METs, 
may highlight patients who are not as responsive to a LI. Indeed, the linear regression 
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identified that alongside group allocation, younger age and higher baseline exercise capacity 
and grip strength predicted the greatest change in exercise capacity over 3 years. Although 
this lack of responsiveness in older patients with low exercise capacity and strength may be 
attributed to by physiological limitations, psychosocial factors may also be influencing the 
effectiveness of the LI. It seems reasonable to hypothesise that patients with lower exercise 
capacity and strength have the greatest opportunity for improvement, however this did not 
appear to be the case in the current study. Conversely, older patients with lower exercise 
capacity and strength may potentially need greater supervision and support from an exercise 
physiologist in order to receive the optimal outcomes from an exercise intervention. Indeed, 
patients with these characteristics may need greater support in reaching a higher level of 
exercise intensity and/or greater volume of exercise training. Furthermore, if a reduction in 
strength is a contributing factor in non-responsiveness to change in exercise capacity, a 
greater focus on resistance training may be necessary. Moreover, as the effort required to 
increase exercise capacity may be greater for older patients with lower exercise capacity and 
strength and greater fatigue, working closely with a behavioural psychologist may provide 
the support necessary to improve factors such as motivation and perceived exertion, in order 
to increase exercise duration and frequency.  
 
Arterial stiffness 
It was identified that the LI significantly improved (decreased) patient’s PWV, with no 
changes seen in the control group. Mustata et al. (2010) also identified an improvement in 
arterial stiffness, measured by AIx, after exercise training in patients with stage 3-5 CKD. 
Rather than provide an indirect assessment of the stiffness of the aorto-iliac pathway such as 
with PWV, AIx applies a generalised transfer function to estimate the central pressure 
waveform and provide an indice of systemic arterial stiffness.(249) On the other hand, the 
study by Kosmadakis et al. (2012) showed no change in PWV or AIx after a six month 
walking program.(42) It has been suggested that regular aerobic exercise training increases 
arterial distensibility through improved endothelial function (250) and a reduction in 
sympathetic tone.(247) The magnitude of endothelial cell stretch with shear stress (such as 
which occurs with an increase in pulse pressure during exercise training) determines Akt and 
eNOS phosphorylation.(251) The change in mechano-biochemical signalling with exercise 
training improves vasorelaxation and subsequent compliance of the arterial wall.(252)  
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Patients in all stages of CKD have a known impairment of arterial function compared to 
healthy controls.(120) Dysregulation of the calcium-phosphorous balance, anaemia, 
inflammation and oxidative stress may all contribute to the disease process of vascular 
calcification and endothelial dysfunction.(100, 231) This impairment is significant, as arterial 
stiffness is associated with abdominal aortic, thoracic aorta and coronary artery calcification 
in haemodialysis patients (253) and is an independent risk factor for all-cause and 
cardiovascular disease mortality in patients with CKD.(254) The increase in cardiovascular 
disease risk with greater arterial stiffness is likely due in part to the effects of increased 
arterial pressure on the left ventricle,(255) causing left ventricular hypertrophy and 
subsequent systolic and diastolic dysfunction.(256) Indeed, it has previously been reported by 
our group that 61% of CKD patients have diastolic dysfunction and 8% have systolic 
dysfunction.(234) Consequently, decreasing arterial stiffness with exercise training has the 
potential to improve cardiac function in a large proportion of the CKD population. The 
association of arterial stiffness and cardiorespiratory fitness may also be bi-directional. It 
seems likely that by decreasing arterial stiffness there is a reduction in afterload, which 
increases cardiac output.(257) Therefore, decreasing arterial stiffness in these patients may 
also contribute to improvements in exercise capacity. 
 
Autonomic function 
Carotid artery stiffness is associated with impaired autonomic function. Sympatho-vagal 
balance is affected by greater activation of the arterial baroreceptors, as a consequence of 
increased arterial stiffness.(258) Autonomic dysfunction is also related to an increased risk of 
mortality in haemodialysis patients and therefore seems an important therapeutic target in 
reducing the rate of cardiovascular events in CKD patients.(259) The findings from this study 
indicate a significant improvement in the global HRV frequency parameter, TP, in the LI 
group which was not seen in the control group. Exercise training has been shown to improve 
global HRV time parameters, SDNN and RMSSD, in patients with haemodialysis.(117, 260) 
On the other hand, a study by Camillo et al. (2011) identified changes in SDNN and RMSSD 
after high intensity and not low intensity training in patients with chronic obstructive 
pulmonary disease.(261) This may suggest that higher intensity exercise is necessary to elicit 
changes in HRV time parameters, although, TP wasn’t assessed in this study. The increase in 
shear stress on the arterial baroreceptors which occurs with high intensity exercise 
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encourages vagal outflow as reflected by HF power.(262) It is not clear why improvements in 
TP occurred without improvements in global time, or other frequency parameters. To 
elucidate these findings, future studies in CKD patients should investigate the effects of 
exercise training on 24-hour HRV, which may provide more substantiated results.  
 
Muscle strength 
Grip strength was found to be a significant predictor of change in exercise capacity from 
baseline to 36 months in the multiple linear regression model. This finding may indicate that 
people with greater muscle mass and strength at baseline are more likely to see the greatest 
improvements with exercise training. Furthermore, the decline in grip strength seen in the LI 
group may indicate that the thera-band and body weight exercises used for resistance training 
in this study may not have been sufficient to ameliorate the decline in grip strength. Indeed, it 
was reported in the Active Australia questionnaire that the increase in physical activity was 
predominantly through walking. This may indicate that the prescribed home resistance 
exercises were not being adequately adhered to. Further, it has been identified by Watson et 
al. (2013) that depletion of intramuscular amino acids occurred after a 6 month moderate 
intensity walking program in CKD patients undergoing standard bicarbonate 
supplementation.(44) In particular, there was a diminution in the branched chain amino acid 
L-Leu, which has anabolic effects on skeletal muscle. Conversely, no significant depletions 
of any intramuscular amino acids occurred in the control group who did not exercise. 
Therefore, it seems that the reduction of intramuscular amino acids with aerobic moderate 
intensity training may in fact be limiting the adaptations to changes in lean mass. In light of 
the findings from the current study and Watson et al., to effectively increase lean mass it 
seems imperative to place a significant emphasis on resistance training when prescribing an 
exercise program to patients with CKD. 
 
Kidney function 
The LI group appeared to have a significant decline in eGFR from baseline to 36 months. 
However, in the per protocol analysis there was no difference in eGFR in only those LI 
patients who reported achieving physical activity guidelines. This finding indicates that 
exercising training is not in fact contributing to the decline in eGFR. Rather, it seems the 
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reduced eGFR seen in the LI group may be attributed to a decline in kidney function in 
patients not considered physically active. It is difficult to ascertain the mechanisms as to the 
decline in eGFR in patients not meeting the physical activity guidelines, or alternatively the 
maintenance of eGFR in patients meeting physical activity guidelines. Potentially, the decline 
in eGFR in patients not meeting physical activity may be indicative of patients who have a 
greater disease state and are therefore the more ‘unwell’ patients who are less likely to 
participate in physical activity. On the other hand, the physical activity may have a protective 
benefit against a decline in kidney function and the longer time period in the 36 month 
intervention may demonstrate the natural decline in eGFR (263) in patients not meeting 
physical activity guidelines. The mixed results of exercise training on kidney function in the 
literature make it difficult to ascertain the exact causes of the current findings.   Indeed, most 
studies have reported either no change, (36, 40, 51, 55) or an improvement in kidney function 
measures with exercise training.(37, 39, 45) On the other hand, Boyce et al. (1997) did find a 
decrease in eGFR as measured by creatinine clearance after 4 months of exercise training, 
which was maintained in the two months de-training period once exercise had ceased.(38) A 
patient with a renal trajectory of >3 ml/min/1.73m2 in one year is considered to need closer 
renal follow-up as they are at a greater risk of morbidity and mortality.(264) Therefore, a 
decline of 3.9 ml/min/1.73m2 over 3 years in the LI patients not meeting physical activity 
guidelines is considerably less than what is considered a high risk decline in kidney function. 
As such, it seems reasonable to suggest that the current findings indicate that physical activity 
does provide a protective benefit to kidney function. However, the large sample size needed 
to adequately assess changes in eGFR (~n=1000)(136) indicates any changes in kidney 
function in smaller sample sizes should be interpreted with caution.  
Exercise training only formed part of the nurse-led multi-disciplinary LI. Indeed, nurse 
practitioner care, dietary advice, and diabetic education and psychology (if needed) were also 
likely to contribute to the outcomes of patients in the intervention group. As such it is 
difficult to ascertain the individual influences of each multi-disciplinary professional 
involved in this study. However, it seems reasonable to suggest that changes in physical 
activity and fitness measures, which were the primary outcomes in this chapter, are 
attributable to the exercise training specifically. Although this chapter focusses on the 
influence of exercise training specifically, multi-disciplinary care is still considered best 
practice for holistic treatment of patients with CKD.(265)  
Section 1; Chapter 6 Effects of a 36 month lifestyle intervention on exercise capacity and 
cardiovascular disease risk factors 
160  
Limited statistical power (68.4%) because of the modest sample size in the present study (n = 
94) may have played a role in limiting the significance of the independent t-test of the 
primary outcome, change in VO2peak between groups. A post hoc power analysis revealed 
that on the basis of the mean, a difference in population size of 2.9 ml/kg/min and a mean 
standard deviation between groups of 6.6, a sample size of approximately 164 participants 
would be needed to obtain statistical power (p<0.05) at the recommended .80 level.(266)  
 
Limitations 
There are a number of limitations to the current study. The Active Australia questionnaire is 
based on patient’s recall of their average physical activity levels per week in the previous 6 
months. The use of recall for the measure of physical activity may have limited the accuracy 
of the reporting. However, although wearing an accelerometer may have provided more 
accurate data on physical activity for a single week, the average physical activity recall over 
the 6 month period was important due to the high rate of sickness and injury in many patients. 
Potentially, a 7 day analysis may not have provided a true representation of a standard week. 
The psychometric properties of the Active Australia questionnaire have been correlated with 
pedometer steps and physical function scores in community-dwelling older adults.(137) 
However, a cross-check validation at certain time points with steps recorded by pedometry, 
accelerometry or exercise diary may have confirmed the validity of the Active Australia 
questionnaire in the CKD population. Nonetheless, clarity in the Active Australia 
questionnaire was ensured by administering of the questionnaire by an Exercise Physiologist. 
Furthermore, specific activities reported from the Active Australia questionnaire were not 
recorded. Anecdotally, the activities reported in the Active Australia questionnaire were 
mostly intentional exercise sessions, with the most physical activity time attributed to 
moderate intensity walking with some theraband exercises. Collecting data on the exact 
activities performed throughout the intervention may have provided useful information on 
what activities CKD patients undertake when prescribed an aerobic and resistance home-
based exercise program. However, the aim of this study was to assess the feasibility of this 
type of LI in a real-world setting. The increased burden placed on participants to collect 
detailed self-report diaries for a 3-year intervention would likely result in a higher drop-out 
rate. 
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There are a number of factors which may have influenced physical activity and exercise 
behaviours in this multi-disciplinary LI. As the study was designed as a feasible intervention 
that may be applied in the future in standard nephrological care, the delivery of the 
intervention was based around a standardized structure, yet was still individualized to best 
suit the patient. All multi-disciplinary aspects of the LI differed in timing of contact/visits and 
prescription according to individual needs. As such, this makes it difficult to provide specific 
information on the delivery and consistency of the LI. Furthermore, those patients who 
engaged more readily with the research team may have developed relationships which further 
encouraged their active participation. Due to the long duration of the study and the nature of 
this population, there were inevitably times when due to ill health patients were unable to 
participate in exercise training. Likewise, there were instances when participants refused to 
engage in follow-up telephone calls, gym refresher sessions or nurse practitioner and dietitian 
appointments. As this study aimed to replicate real-world scenarios and outcomes, these 
patients were still included in the final analysis. Therefore, the adherence of the LI differed 
for many people at varying times throughout the 36 month period and as such the efficacy of 
exercise training in this population needs to be considered in regards to the study outcomes. It 
is likely that had this been a shorter intervention with a strict compliance protocol, the 
efficacy of the exercise training on outcomes would have been greater.  
We can only assume that the greatest change in VO2peak seen in the LI group at 12 months is 
due to the initial supervised 8 week period and more concentrated telephone follow-up calls 
and gym refresher sessions in the first year of the study. Conducting another testing session at 
8 weeks would have elucidated whether the greatest changes in cardiorespiratory fitness at 12 
months are indeed attributable to the initial 8 weeks of supervised training. Nonetheless, the 
goal of this study was to assess the effects of longer duration training on fitness.  
Potentially, a bias may exist from the type of patients who are willing to participate in a LI. 
Indeed, despite a cardiorespiratory fitness level below age-predicted normative values,(209) 
participants in this study may have been at a stage of change which is more likely to embrace 
a behaviour modification. Indeed, the control group appeared to slightly increase their level 
of physical activity in the first 18 months of the study.  
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Conclusions 
This study found a 36 month LI doubled the number of CKD patients meeting physical 
activity guidelines. In addition, the intervention resulted in a significant increase in exercise 
capacity over the 36 months and a significant increase in cardiorespiratory fitness at 12 
months followed by a decline rate similar to the control group. Furthermore, there was a 
significant improvement in arterial stiffness and autonomic function in the LI compared to 
the control group.  
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7.1 Abstract 
Background: Cardiorespiratory fitness is a strong determinant of morbidity and mortality. In 
athletes and the general population it is established that HIIT is superior to MICT in 
improving cardiorespiratory fitness. This is a systematic review and meta-analysis to quantify 
the efficacy and safety of HIIT compared to MICT in individuals with chronic 
cardiometabolic lifestyle diseases.  
Methods: Included studies were required to have a population sample of chronic disease, 
where poor lifestyle is considered a main contributor to the disease. Procedural quality of the 
studies was assessed by use of a modified Physiotherapy Evidence Base Database (PEDro) 
scale. A meta-analysis compared the mean difference (MD) of pre vs. post-intervention 
cardiorespiratory fitness (VO2peak) between HIIT and MICT.  
Results: Ten studies with 273 patients were included in the meta-analysis. Participants had 
coronary artery disease, heart failure, hypertension, metabolic syndrome and obesity. There 
was a significantly higher increase in VO2peak after HIIT compared to MICT (MD 3·03 
ml/kg/min, 95% confidence interval [CI] 2·00 to 4·07), equivalent to 9·1%.  
Conclusions: HIIT significantly increases cardiorespiratory fitness by almost double that of 
MICT in patients with lifestyle-induced chronic diseases.  
 
7.2 Introduction 
Lifestyle-induced chronic diseases significantly alter the quality of life of sufferers. In many 
cases the disease itself can be potentially avoided or successfully managed with appropriate 
lifestyle modifications.(267) Diseases such as type II diabetes, atherosclerotic cardiovascular 
disease and the metabolic syndrome are closely related and often stem from the same 
preventable risk factors. Therapy for most chronic diseases involves exercise training to slow 
or reverse disease progression. Despite the known benefits of regular moderate intensity 
exercise in regulating risk factors in chronic disease, the majority of patients are still 
physically inactive.(222)  
Rehabilitation for cardiac patients prior to the 1950’s comprised abstention from all forms of 
physical activity. This was thought to diminish the cardiac load and assist in the reparative 
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process of the healing myocardial scar.(268) Levine and Lown (1952) appear to be the first to 
document challenging the idea of complete immobilization by introducing the then 
controversial ‘armchair treatment’ where patients were encouraged to sit in an armchair as 
much as possible during hospitalization post myocardial infarction.(269) When the weight of 
evidence suggesting the benefits of light to moderate activity in patients with chronic disease 
became irrefutable, exercise guidelines were created for this population.(270) Interval 
training appears to be first studied in cardiac rehabilitation in 1972, when patients were asked 
to cycle at high workloads for 60 seconds with a 30 second rest between intervals. Using the 
intervals, the patients were able to exercise for at least twice as long as what they were able to 
do when cycling continuously.(271) In 1977, a study on healthy participants examined the 
effects of a 10 week program which included a combination of interval and moderate 
continuous training. Interestingly, the authors found a linear increase in VO2max over the 10 
weeks, contrary to the studies hypothesis that the VO2 would plateau over time. (272) In 1979 
it was suggested that high intensity exercise was required to provoke the necessary training 
adaptations needed to improve exercise capacity in patients with recent myocardial 
infarctions.(273) One of the first studies to investigate intense exercise in patients with 
cardiovascular disease, found that if exercise is intense and prolonged enough, than it can 
instigate a reduction in myocardial ischaemia.(274) These findings were revolutionary, as 
they were established before widespread percutaneous coronary interventions were 
performed. From there, differing study protocols in the 1980’s and 1990’s in cardiac patients 
led to conflicting findings that appears to have decreased the interest in this approach.(275-
277) Forty years after the first reported use of interval training in cardiac patients, the interest 
in high intensity interval training (HIIT) in higher risk patients has now led to a number of 
studies in this area.  
HIIT involves alternating short bursts of high intensity exercise with recovery periods or light 
exercise. Studies in athletes and the general population have shown that increasing the 
intensity of exercise amplifies the training stimulus and associated adaptations, such as 
augmenting maximal oxygen uptake, anaerobic threshold, stroke volume, and 
performance.(57, 278) A commonly cited barrier to physical activity is lack of time. 
Including HIIT in a training program implies that greater health enhancing benefits could be 
gained in less time; making HIIT a more time efficient and attractive option. Moreover, short 
bursts of activity may address another common limiting factor, lack of motivation, as it may 
be a more enticing option than the prospect of continuously exercising for an extended period 
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of time. Short work periods at a higher intensity also results in a reduction in the ventilatory 
response and resultant dyspnoea which, in many chronic disease patients, are limiting factors 
to continuous exercise.(61) 
VO2max is a strong predictor of mortality.(279) Indeed, a 1-MET increase is associated with 
a 10-25% improvement in survival.(280) Furthermore, it is established that cardiorespiratory 
fitness is more cardioprotective than overall physical activity levels.(281) This provides 
further evidence regarding the benefits of higher intensity exercise compared to lower 
intensity general physical activity. It seems likely that improving VO2max will improve the 
prognosis of chronic disease patients. 
The aim of this systematic review is to compare and quantify the effects of HIIT against 
moderate intensity continuous training (MICT) in improving VO2max in patients with 
lifestyle-induced chronic diseases. Furthermore, safety of HIIT will be discussed along with 




Electronic searching of the Medline, PubMed, Embase and Cinahl databases were conducted 
from the earliest available date to April 2013, limited to the English language. The Medical 
Subject Heading (MeSH) database was employed to establish all related articles on HIIT and 
chronic disease. MeSH terms used were “cardiovascular diseases” OR “metabolic diseases” 
OR “chronic diseases” and their related terms. Text words used in conjunction with the 
MeSH terms were “high intensity training/exercise”, OR “interval training/exercise”, OR 
“intermittent training/exercise”, OR “low volume training/exercise” OR “aerobic interval 




Only full text, randomised control trials were considered for inclusion. The studies were 
required to have a cardiometabolic chronic disease population, where poor lifestyle is 
considered a main contributor. The main characteristics of such diseases, such as coronary 
artery disease, heart failure, diabetes, hypertension, obesity and metabolic syndrome are 
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recognisable by the common presence of cardiovascular disease risk factors. Other systematic 
reviews on the effects of HIIT have been conducted with specific conditions; pulmonary 
disease(61) and coronary artery disease.(282) Inclusion criteria were: exercise protocols 
using cardiorespiratory exercise training; a comparator group that completed MICT (matched 
to HIIT); an accepted measure of intensity (i.e. heart rate or rating of perceived exertion); 
intervention of four weeks; appropriate intensities for both groups (e.g. 60-75% PHR for 
MICT, 85-95% PHR for the high intensity intervals, or 80-100% peak work rate (PWR)); and 
a direct measure of VO2peak/max. Due to the difficulty of chronic disease patients in 
reaching a plateau in VO2max, VO2peak was reported in nine of the studies.(191, 193-198, 
283, 284) Studies including other activities (e.g. resistance training) on top of the prescribed 
aerobic intervention were also included, provided the same volume and modality of 
resistance exercises were given to both MICT and HIIT groups.  
 
Data collection and analysis 
After full text analysis of the retrieved articles, ten articles were identified to have met the 
inclusion criteria for the purpose of meta-analysis (Figure 7.1). These trials involved 273 
patients consisting of men and women. This included 137 in HIIT groups and 136 in the 
MICT groups. The corresponding authors of two eligible studies were contacted for VO2 data, 
but no information was provided.(285, 286)




Figure 7.1 Systematic flow of article included from initial search to inclusion. The 
systematic review process identified ten articles for inclusion in the meta-analysis 
 
Procedural quality of the studies was assessed by use of the modified PEDro scale. One point 
was awarded for each of the 10 criteria. Review Manager statistical software 5·0 (Nordic 
Cochrane Centre, Copenhagen, Denmark) was used to determine the mean difference and 
95% CI. A forest plot is used to portray the treatment effects of each study.  
 
7.4 Results 
Seven of the ten studies included in this review studied cardiovascular disease (Table 7.1); 
Rognmo et al. (2004),(194) and Moholdt et al. (2005)(283) investigated coronary artery 
disease and Wisloff et al. (2007),(193) Roditis et al. (2007),(284) Freyssin et al. (2012),(198) 
Fu et al. (2011)(197) and Iellamo et al (2012)(195) recruited heart failure patients. Molmen-
Hansen et al. (2012)(191) studied participants with hypertension, Schjerve et al. (2008)(196) 
looked at participants with obesity and Tjonna (2008) investigated the metabolic 
syndrome.(192) Six of the 10 studies were conducted at the same institute, the Norwegian 
University of Science and Technology.(191-194, 196, 283) 
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Table 7.1 Summary of studies comparing the effects of HIIT vs. MICT 
Study Population Intervention Interval 
Parameters 
Program Outcomes of HIIT 
compared to 
MICT 
Rognmo et al., 
(2004)(194) 
21 stable coronary 
artery disease 
patients 
HIIT (n=8), MICT 
(n=9) 
Uphill treadmill walking 
HIIT- 4 x 4 min intervals (85-
95% PHR), 3 min recovery (65-
75% PHR), 33 mins 







Roditis et al., 
(2007)(284) 
21 stable CHF 
patients  




HIIT – 30 sec intervals (120% 
pWR), 30 sec recovery (0% 
pWR), 40 mins 
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HIIT (n=9), MICT 
(n=9), C (n=9) 
Uphill treadmill walking 
HIIT- 4 x 4 min intervals (90-
95% PHR), 3 min recovery (50-
70%), 38 mins 
MICT- 70-75% PHR, 47 mins 















Schjerve et al., 
(2008)(196) 
40 obese patients, 
BMI >30 kg/m2 
HIIT (n=14), MICT 
(n=13), strength 
training (n=13) 
Treadmill walking or running 
HIIT- 4 x 4 min intervals (85-
95% PHR), 3 min recovery (50-
60% PHR), 38 mins 
MICT- 60-70% PHR, 47 mins 








12 weeks all groups 
⇑ VO2peak 






⇔ artery diameter, 
shear rate 
⇓ LDL and body 
weight in MICT 
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Tjonna et al., 
(2008)(192) 
32 patients with 
metabolic syndrome 
HIIT (n=12), MICT 
(n=10), C (n=10) 
Uphill treadmill 
walking/running 
HIIT- 4 x 4 min intervals (90% 
PHR), 3 min recovery (70%), 40 
mins 
MICT- 70% PHR, 47 mins 














⇑ insulin action 
⇑ lipogenesis 
Moholdt et al., 
(2009)(283) 
59 CABG  
HIIT (n=23), MICT 
(n=25) 
Treadmill walking 
HIIT- 4 x 4 min intervals (90% 
PHR), 3 min recovery (70%), 37 
min 





Supervised 5x/week  
4 weeks. 
Unsupervised until 
6mth time point 
After 4 weeks: 
⇔ VO2peak 
After 6 months: 
⇑ VO2 peak 
⇑ HR recovery 
after 6 months.  
⇔ QOL 
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Fu et al. 
(2011)(197) 
45 CHF 




HIIT- 5 x 3 min intervals (80% 
VO2peak), 3  min recovery (40%  
VO2peak), 33 minMICT- 60% 










⇓ BNP, MPO, IL-6 
⇑ QOL 
Freyssin et al., 
(2012)(198) 
26 stable CHF 
patients  
HIIT (n=12), MICT 
(n=14) 
Uphill treadmill walking and 
cycle ergometer 
HIIT – 3 x (12 x 30 sec 
intervals, 60 sec complete rest), 
80% pWR, 5 mins rest between 
sets, 54 mins 








⇑ exercise test 
duration 
⇑ oxygen pulse 
⇑ VO2 at 1st 
ventilator threshold 




HIIT (n=8), MICT 
(n=8) 
Uphill treadmill walking 
HIIT – 4 x 4 min intervals  (75-
80% HRR), 3 min recovery (45-
50% HRR), 20-34MICT – 45-
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Molmen-
Hansen et al., 
(2012)(191) 
88 patients with 
essential 
hypertension stage 
1-2, SBP 140-170 
mmHg and DBP 90-
109 mmHg 
HIIT (n=25), MICT 
(n=23), C (n=25) 
Treadmill walking 
HIIT – 4 x 4 min intervals (90-
95% PHR), 3 min recovery (60-
70%), 38 mins 
MICT – 70% PHR, 47 mins 
C – standard recommendations 
for hypertension, including 







12 weeks  
⇑ VO2peak 




⇑ EF, SV 
⇓ 24 hour SBP 
⇔ LV mass, TPR 
⇑ QOL 
 
Ratio = relationship between duration of interval and recovery. MI = Mean intensity between high intensity interval and recovery. Amplitude = 
difference between interval and recovery intensities, divided by the mean intensity. 1-RM = 1 repetition maximum for plantar flexion, SaO2 = 
oxygen saturation, ABI = ankle brachial index, FMD = flow mediated dilatation, LV = left ventricular, EF = ejection fraction, QOL = quality of 
life, SV = stroke volume, TPR = total peripheral resistance * No within group differences, BNP = brain natriuretic peptide, MPO = 
myeloperoxidase, IL-6 = interleukin-6 
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The quality assessment of the studies was determined by 2 reviewers (Table 7.2). Where 
there was a discrepancy, the average was taken. The studies achieved a mean PEDro score of 
7·35/10. There was no blinding of all assessors in any of the studies reviewed. A between 
groups statistical comparison was provided by all studies with measures of variability given 
for VO2peak. 
 
Table 7.2 Methodology quality of the HIIT studies conducted in chronic disease 
patients. + = criteria is achieved and 1 point is given. - = criteria not achieved. ± = 
whether or not the criteria was met was viewed differently by 2 different reviewers and 
therefore half a point is given 
 1 2 3 4 5 6 7 8 9 10 Total  
Rognmo 2004 + + + + - + + + + - 8 
Roditis 2007 - + - + - + + + + - 6 
Wisloff 2007 + + - + - + + + + - 7 
Schjerve 2008 + + - + + - + + + - 7 
Tjonna 2008 ± + - + - + + + + + 7.5 
Moholdt 2009 + + + + - ± ± + + + 8 
Fu 2011 + + - + - + + + + - 7 
Freyssin 2012 + + - + - - + + + + 7 
Iellamo 2012 + + - + - + + + + - 7 
Molmen-Hansen 2012 + + - + + + + + + + 9 
 
PEDro Criteria: 
1. Eligibility criteria were specified 
2. Subjects were randomly allocated to groups  
3. Allocation was concealed 
4. The groups were similar at baseline regarding the most important prognostic 
indicators 
5. There was blinding of all assessors who measured the primary outcome 
6. Measures of at least one key outcome were obtained from more than 70% of the 
subjects initially allocated to groups 
7. All subjects for whom outcome measures were available received the treatment or 
control condition as allocated or, where this was not the case, data for at least one key 
outcome was analysed by “intention to treat” 
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8. The results of between-group statistical comparisons are reported for the primary 
outcome 
9. The study provides both point measures and measures of variability for at least one 
key outcome 
10. Sample size calculations were explained 
 
Meta-Analysis 
Nine studies included means and SD of VO2peak to allow the calculation of an overall mean 
difference.(191-196, 198, 283, 284) One study provided means ± standard error of mean 
(SEM), allowing the SD to be calculated.(197) Homogeneity between the studies was 
displayed with I2=9%, p=0·36. The mean difference in VO2peak from the ten studies was 
3·03 ml/kg/min (95% CI 2·00 to 4·07), significantly (p<0·001) favouring HIIT (Figure 7.2). 
 
Figure 7.2 Forest plot from meta-analysis of HIIT and VO2 peak. HIIT elicits a 3.03 
ml/kg/min greater mean difference than MICT 
 
  




Seven studies used uphill walking/running on a treadmill as the primary exercise 
modality.(191-196, 283) One study described the exercise undertaken as ‘treadmill walking’, 
therefore the differences in heart rate between intervals could have been achieved either 
through change in speed or change in incline.(283) In three studies, cycle ergometers were 
used for the duration of the program.(197, 198, 284) Freyssin et al. used strengthening, 
stretching and relaxing exercises in addition to the treadmill and cycle program (198). 
Intensity 
Intensities were set based on baseline maximal/peak testing data. Six studies used a 
percentage of PHR or maximal heart rate (MHR), two used a percentage of PWR or peak 
power and two studies used VO2peak/heart rate reserve (VO2R/HRR). The Norwegian studies 
used a heart rate of between 85 and 95% for the high intensity interval with a recovery of 50-
75% MHR.(191-194, 196, 283) Two studies on the cycle ergometer were set at an intensity of 
80 and 120% PWR for the high intensity interval with a passive recovery.(198, 284) The two 
studies using HRR/VO2peak to determine intensity used 75-80% for the interval and 40-50% 
for an active recovery.(195, 197) 
Total Duration 
A common approach to compare HIIT and MICT sessions is to match the energy 
expenditure, resulting in the HIIT session being shorter. Seven of the studies differed the 
duration of the HIIT and MICT so that training sessions were isocaloric.(191-194, 196, 197, 
283) The median duration of exercise times was 38 minutes for the HIIT group and 46 
minutes for the MICT group. One study kept the duration the same between both groups but 
altered the mean intensity between groups.(284) Another study used a different method 
(training impulse method) to alter the duration of each session based on the average change in 
heart rate.(195)  
Interval Duration 
Seven of the studies included high intensity intervals of 4 minutes with 3 minutes of active 
recovery.(191-196, 283) One study included 5x3 minute intervals with 3 minute 
recoveries.(197) Two studies included shorter interval and recovery periods, with 30 seconds 
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used for both interval and recovery,(284) and 30 seconds used for interval and 60 seconds for 
recovery. (198)   
Supervision 
Three studies included both a supervised training component and a self-administered home 
program,(193, 196, 283) the remaining were purely supervised sessions. Direct supervision 
allows the instructor to adjust the intensity, monitor the patient and provide motivation. The 
length of supervised HIIT or MICT within the studies varied from four to sixteen weeks. One 
study was supervised for the first four weeks, thereafter subjects were advised to continue the 
training program at home for the following six months.(283) The studies prescribed three-six 
training sessions/week, with two studies including one home session/week out of the three for 
both HIIT and MICT groups.(193, 196) Due to constant changes in the heart rate response to 
exercise, supervision allows for closer monitoring to ensure rates are within the desired 





There were improvements in VO2peak from both HIIT and MICT in nine of the ten studies 
(Table 7.3).(191-198, 283) The average of pre training values was 22·5 ml/kg/min and 
increased to 27·9 ml/kg/min after HIIT (a 19·4% increase). MICT had baseline values of 
22·6 ml/kg/min that increased to 25·2 ml/kg/min after the intervention (10·3% increase). The 
mean difference in the change in VO2peak between HIIT and MICT was 3·03 ml/kg/min. A 
measure of exercise capacity (six-minute walk test), as well as VO2peak, was assessed in one 
study. It was found that the distance walked improved in both HIIT and MICT groups.(198) 
Cardiometabolic risk factors 
The study by Tjonna et al. found that MICT and HIIT both reduced blood pressure; 
approximately 10 mmHg systolic and 6 mmHg diastolic.(192) Molmen-Hansen et al. also 
showed a significant reduction of 12 mmHg for systolic blood pressure in the HIIT 
group.(191) Other studies showed no change in systolic blood pressure after the 
interventions. Significant reductions in oxidized low density lipoproteins were found in HIIT 
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and not MICT.(192, 193) However, in one study the opposite was found.(196) Furthermore, 
it was established that high density lipoprotein was increased by 25% in the HIIT group.(192) 
These changes were supported by Wisloff et al. who also found an increase in high density 
lipoprotein, lower TG and improved fasting glucose in the HIIT group.(193) An improvement 
in TG was identified by Moholdt et al. for both HIIT and MICT groups.(283) Iellamo et al. 
found no significant differences in the metabolic profile (lipids, HOMA-IR), with the 
exception of an improvement in fasting glucose with HIIT.(195) Fu et al. found 
improvements in oxidative stress/inflammatory markers plasma brain natriuretic peptides, 
myeloperoxidase and IL-6.(197) 
Two studies demonstrated no positive improvements in weight loss, BMI or body 
composition between the HIIT and MICT groups post intervention.(192, 195) Furthermore, 
one study on obese patients reported a greater decrease in body weight with MICT than with 
HIIT.(196) However, reduced fatty acid transport protein-1 and fatty acid synthase levels 
(markers of fatty acid uptake and lipogenesis) were identified, which was associated with 
improvements in anti-insulin receptor activation in HIIT but not MICT.(192) 
The findings from Tjonna et al. showed increased circulating adiponectin and improved 
insulin sensitivity and β-cell function in the HIIT group.(192) No changes in adiponectin 
were found by Moholdt et al. at four weeks, however after the six months intervention both 
HIIT and MICT increased circulating levels.(283)  
Skeletal Muscle 
Three studies identified significant increases in PGC-1alpha, indicating improved 
mitochondrial biogenesis in the HIIT group.(192, 193, 196) These studies also significantly 
increased the maximal rate of Ca2+ reuptake into the sarcoplasmic reticulum by 50- 73%. 
Change in total myoglobin concentration and tissue oxygenation in the vastus lateralis was 
observed in HIIT but not MICT both acutely and after the 12 week intervention.(197) 
Myocardium and Vasculature 
Flow mediated dilatation was improved after both HIIT and MICT in studies that assessed 
endothelial function.(191-193, 196) An increased availability of nitric oxide was found with 
HIIT but not MICT.(192) Furthermore, a greater increase in antioxidant status found in HIIT 
than MICT, supports the finding of increased production and availability of nitric oxide.(193) 
An improvement in antioxidant status was not supported by the findings of Schjerve et 
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al.(196) The heart failure patients demonstrated improved left ventricular ejection fraction by 
10% and a positive reversal of left ventricular remodelling.(193) An improvement in left 
ventricular ejection fraction was also demonstrated by Fu et al., alongside increases in cardiac 
output and total peripheral resistance. (197) In contrast, Iellamo et al. found no difference in 
cardiac output, stroke volume and left ventricular ejection fraction in their heart failure 
patients.(195) The hypertensive patients also had significantly improved ejection fraction, 
stroke volume, systolic flow velocity, end-diastolic volume, early diastolic mitral annulus 
tissue velocity, isovolumic relaxation rate.(191)  
Adherence 
A minimum attendance of 70% and 90% of training sessions was an inclusion criterion for 
four of the studies.(191, 194, 196, 283) Only one participant was excluded from analysis 
from one of these studies based on this criteria.(194) For the first four week supervised period 
of Moholdt et al.’s study, the HIIT group attended 82% of sessions and the MICT group 
attended 84%. The attendance rate during the remainder of the six month home program was 
not identified.(283) Both groups in six of the other studies reported attendance rates above 
85%.(192-195, 197, 198) One study did not mention adherence to the protocol for either 
groups.(284) 
Enjoyment and Quality of Life 
HIIT was reported to be more enjoyable than MICT.(192) Three studies demonstrated that 
HIIT improved quality of life more than MICT, (191, 193, 197) whereas another showed 
similar increases between the two groups (283). Anxiety and depression also had similar 
improvements with both the HIIT and MICT.(198) 
Adverse Events 
Reporting of adverse events are important in determining the safety of applying this type of 
training to high risk populations. No studies described their adverse event monitoring 
protocol. However, four reported no adverse events due to the exercise training (193, 194, 
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Table 7.3 Adaptations occurring significantly more with HIIT compared to MICT 
   VO2peak 
   Systolic and diastolic blood pressure 
   High density lipoproteins 
   Triglycerides and fasting glucose 
   Oxidative stress and inflammation 
   FATP-1 and FAS 
   Adiponectin, insulin sensitivity and β-cell function 
   PGC-1alpha 
   Maximal rate of Ca2+ reuptake 
   Availability of nitric oxide 
   Cardiac function 
   Enjoyment of exercise 
   Quality of life 
FATP-1=fatty acid transport protein 1; FAS=fatty acid synthase 
 
7.5 Discussion 
The main finding from this meta-analysis is that HIIT is superior to MICT in improving 
cardiorespiratory fitness in patients with lifestyle-induced chronic diseases. Indeed, the 
increase in VO2peak with HIIT was almost twice the increase gained from MICT. In addition, 
although there is limited data, HIIT appears to be well-tolerated and safe.  
 
Efficacy 
HIIT increased VO2peak by 5·4 ml/kg/min (19·4%) compared to 2·6 ml/kg/min (10·3%) with 
MICT. It has been shown that a 1-MET (3.5 ml/kg/min) increase is associated with a 10-25% 
improvement in survival.(280) Indeed, the protective role of fitness occurs even in the 
presence of established cardiovascular disease risk factors.(26) Cardiorespiratory fitness is an 
easily modifiable risk factor, therefore identifying the most effective way to improve VO2 
peak should be a health priority.   
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Some of the studies investigated mechanisms explaining the greater improvement of 
VO2peak with HIIT. Peripheral adaptations leading to improvements in cardiorespiratory 
fitness were investigated by measuring PGC-1alpha and Ca2+ reuptake into sarcoplasmic 
reticulum in skeletal muscles. Mitochondrial dysfunction is central to most chronic diseases 
and could play a vital role in the reduced cardiorespiratory fitness that is experienced by these 
populations. Improvements in mitochondrial biogenesis have been demonstrated by increases 
in PGC-1alpha after a single bout of low volume HIIT.(287) Studies by Tjonna et al. and 
Wisloff et al. identified significant increases in PGC-1alpha (138% and 47% respectively), 
indicating mitochondrial biogenesis in the HIIT group.(192, 193) Wisloff et al. found the 
increase in PGC-1alpha to be strongly correlated with improved VO2peak (r=0·72, p<0·01), 
supporting the influence of mitochondrial function on exercise capacity.(193) Mitochondrial 
biogenesis is essential in maintaining structural integrity of skeletal muscle. Daussin et al. 
concluded that fluctuations in adenosine tri-phosphate turnover in interval training, which is 
different to usual steady state conditions of adenosine tri-phosphate production, activates the 
signalling pathways which leads to increases in PGC-1alpha.(288) The increase in PGC-
1alpha identified by Wisloff et al. and Tjonna et al. may translate into improvements in both 
aerobic and functional capacity. Both studies also significantly increased the maximal rate of 
Ca2+ reuptake in the sarcoplasmic reticulum by 50- 60%.(192, 193) The increase in calcium 
cycling reduces skeletal muscle fatigue and would contribute to improvements in muscle 
function and therefore cardiorespiratory fitness. The findings by Fu et al. demonstrate 
repeated bouts of deoxygenation in HIIT but not MICT, which may contribute to the 
observed adaptations to the muscles oxidative capacity.(197)  
Improvement in VO2peak with HIIT can also be explained mechanistically by central factors. 
Findings from one of the studies indicate that HIIT improved ejection fraction in heart failure 
patients to the same degree as treating with angiotensin converting enzyme inhibitors and β-
blockers, outlining the potential for further left ventricular remodelling with HIIT. 
Improvements in cardiac remodelling are supported by the findings of Fu et al., with 
significant reductions in brain plasma natriuretic peptide levels.(197) HIIT may also contest 
modern medical treatments in improving systolic and diastolic blood pressure, with 
significant decreases of 12 mmHg and 8 mmHg respectively, found in hypertensive 
patients.(191) It was also found that myocardial contractile function was improved with HIIT 
in terms of stroke volume, mitral annular excursion, ejection velocity, and systolic mitral 
annular velocity. Besides a small reduction in left ventricular filling pressure with MICT, the 
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above mentioned improvements in systolic and diastolic function with HIIT were not found 
with MICT.  
Conversely, Roditis et al. (284) demonstrated similar improvements in VO2peak for both 
HIIT and MICT groups. Furthermore, the findings suggest that phase II of oxygen kinetics 
(indirect measurement of muscle oxidative capacity), showed superior improvements after 
MICT. The use of 30 second Wingate sprint intervals in this study may highlight the need for 
longer duration of intervals, such as those used in four of the other studies reviewed.(192-
194, 283) Although 30 second intervals are a more time efficient option than endurance 
training (similar improvements shown with ~90% less volume), 30 seconds may not be long 
enough to induce superior health-enhancing benefits.(278) It appears from the studies 
reviewed that HIIT elicits many superior benefits to MICT, in a slightly shorter time period 
(median 38 vs. 46 minutes, respectively). It seems reasonable to suggest, gaining similar 
benefits would require either a longer period of MICT, or an even shorter period of HIIT- 
supporting the ideology of HIIT being a more time efficient option. Future studies should 
identify the minimum amount of HIIT needed to elicit adaptations similar to MICT. Another 
study that did not find a greater benefit of HIIT over MICT, may be due to the method of 
establishing intensity by assessing blood lactate levels.(195)  
The HERITAGE study has established the influence genetic components have on the 
trainability of VO2max in certain individuals, resulting in ‘non-responders’ to exercise 
training.(289) The consistently large improvements in VO2max seen in a variety of cohorts in 
HIIT studies, questions whether this type of training can ameliorate the familial dampening of 
VO2 in these ‘non-responders’. Only 1 study in 1986 has examined the relationship between 
HIIT and hereditary trainability.(290) Although aerobic capacity wasn’t assessed in this 
study, it was found that genotype was associated with anaerobic capacity after a HIIT training 
intervention, suggesting the effectiveness of HIIT is affected by hereditary factors.(290) 
Indeed, in the studies reviewed in the meta-analysis, the SD of the change in VO2peak in the 
HIIT group was 26% (relative to the mean change), whereas the MICT group had only an 8% 
variance. Future studies are needed to further compare the effects of HIIT and MICT on 
VO2peak trainability. 
In addition to cardiorespiratory fitness, efficacy can also be assessed by the effect on 
cardiometabolic risk factors. The studies reviewed found reductions in risk factors in HIIT 
notwithstanding differences in body mass, BMI or weight loss between HIIT and MICT. 
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These findings are supportive of the theory of ‘fitness over fatness’- in that it is more 
beneficial to health to improve physical fitness than focus solely on weight loss. This is 
supported by Terada et al. (2013) who found similar reductions in body fat percentage in 
HIIT and MICT groups after a 5 day/week, 12 week program.(291) Although, weight loss 
was not different between groups, one study found a reduction in fatty acid transport protein-
1 and fatty acid synthase levels in the HIIT group, suggesting suppression of fatty acid uptake 
and lipogenesis. No studies measured visceral adiposity, however increased circulating 
adiponectin levels found with HIIT and not MICT is suggestive of decreased intra-abdominal 
obesity. 
Due to the augmented PHR and cardiac output that is experienced in HIIT, it is likely that 
pulsatile and shear stress are influencing vasculature during periods of intense exercise.(292) 
Interval exercise has been shown to reduce arterial stiffness through increased distensability 
of the vessels.(252, 292) A recent study by Smart (2012) demonstrated no difference in 
fitness and cardiac function between moderate training and intermittent training groups 
matched by volume of work.(293) However, the intervals were not high intensity, suggesting 
that to elicit changes, intervals need to increase heart rate to a certain level. Arterial stiffness 
is a key contributor to a number of cardiovascular conditions that influence mortality through 
cardiovascular disease.(294) Two studies demonstrated higher endothelial derived nitric 
oxide production in the HIIT group.(192, 193) It is suggested that shear stress through an 
increase in pulse and frequency pressure promotes vasodilatory nitric oxide release, thereby 
increasing arterial compliance.(295) This is further supported by Wisloff et al. and Tjonna et 
al. with greater increases in flow mediated dilatation found in HIIT than in MICT.(192, 193) 
The improvements in endothelial function are supported by the findings from Fu et al.(197) 
The study’s findings demonstrate an increase in perfusion and oxygen utilization between 
cerebral and muscular tissues which occurs through increases in shear flow and metabolic 
stress. The increased perfusion to the vastus lateralis and frontal cortex would promote 
increased flow and shear stress, and therefore the release of nitric oxide. 
 
Safety 
The reporting of adverse events enables the safety of the intervention to be inferred to the 
population being studied. Four of the ten reviewed studies reported no adverse events as a 
result of the exercise training.(193, 194, 198, 283) One study that did not mention adverse 
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events did explain that follow-up testing was not performed on five patients due to either 
orthopaedic-related problems or inconvenient program timetable.(284) Other reasons cited 
for loss of patient follow-up were comorbidities (not cited which group),(283) ankle fracture 
in the HIIT group and knee injury in the MICT group.(194) One participant in a MICT group 
died from cardiac causes, however it was stated that this was unrelated to exercise 
training.(193)  
A recent study by Rognmo et al. (2012) aimed to assess the safety of HIIT compared to 
MICT, both during and after exercise, of coronary heart disease patients in cardiac 
rehabilitation.(296) The study of 4846 participants indicated that the risk of a cardiovascular 
event occurring is low in both MICT and HIIT. During this study there was one fatal cardiac 
event during the MICT and two non-fatal cardiac events during the HIIT. The calculated 
event rates were one per 129 456 hours of moderate intensity exercise and one per 23 182 
hours of high intensity exercise. Moreover, when vigorous intensity exercise was energy 
matched with moderate intensity exercise, greater cardioprotective benefits were elicited. To 
accurately assess a cardiac event occurring during training, the study required a sample size 
of >20 500 patients. Despite the study being underpowered,(297) the results explore the 
beneficial dose-response relationship associated with HIIT and the negligible risk that is 
involved.  
The safety of HIIT has been controversial amongst health professionals treating high risk 
populations. This has perhaps been created through a common avoidance of anginal episodes, 
which can sometimes be triggered by high intensity exercise. Although commonly thought to 
be a dangerous by-product of exercise, episodes of controlled ischaemia may actually be 
beneficial in preventing secondary conditions in coronary artery disease via ischemic 
preconditioning.(298) Exercise induced coronary collateral formation is based on vascular 
endothelial growth factor and this adaptation is correlated with exercise intensity. Lu et al. 
(2008) found that exercise-induced intermittent ischaemia promoted coronary angiogenesis 
by vascular endothelial growth factor.(299) The favourable effects of intermittent exercise on 
angiogenesis is further supported in a meta-analysis on peripheral arterial disease.(300) A 
normal cardiac troponin I in the study by Lu et al. indicated that no myocardial damage 
occurred when ischaemia was applied. Lu and co-authors state that HIIT is safe even for high 
risk chronic disease patients with stable angina. Rather than promoting the instigation of 
angina in HIIT, this information is intended to highlight the safety of HIIT in high risk 
populations. Caution should be applied on a case-by-case basis depending on the participants 
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cardiac history. Indeed, despite the patients in the studies reviewed being a high risk cohort, 
patients were only included if their diseases were relatively well-controlled, or stable. 
Therefore, these findings may not be applicable to some patients in these disease groups. 
Table 7.4 provides a suggested guide of contraindications for participation in HIIT in high 
risk patients. In summary, when used with appropriate screening, and communication with 
the patients doctor, HIIT can be a safe option for high risk patients. 
 
Table 7.4 Suggested contraindications to HIIT 
• Unstable angina pectoris 
• Uncompensated heart failure 
• Recent myocardial infarction (<4 weeks) 
• Recent coronary artery bypass graft or  
• Percutaneous coronary intervention (<12 months) 
• Heart disease that limits exercise (valvular, congenital, ischemic,  
• Hypertrophic cardiomyopathy) 
• Complex ventricular arrhythmias or heart block 
• Severe chronic obstructive pulmonary, cerebrovascular disease  
or uncontrolled peripheral vascular disease 
• Uncontrolled diabetes mellitus 
• Hypertensive patients with blood pressure >180/110 (or uncontrolled)  
• Severe neuropathy 
 
Limitations 
Although this review provides the basis for further clinical trials testing of HIIT in 
rehabilitation of chronic disease patients, all studies analysed experienced methodological 
limitations. Although three of the studies used a different training protocol to the other seven, 
the heterogeneity of the VO2peak measure was low (Chi2=9·90, I2=9%, p=0·36).(197, 198, 
284) Due to the relatively recent interest with HIIT in chronic disease, HIIT training 
guidelines have not yet been created. Consequently, current research consists of a variety of 
intervals, intensities and program durations. Furthermore, comparison of studies proves 
difficult when volumes of HIIT and MICT are equated in different ways. There are also 
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discrepancies in the percentage of heart rate used. Some of the studies used a higher 
definition of moderate intensity (75%) to the general intensity of moderate exercise suggested 
by Norton et al (55-70% MHR) and ACSM (60-70% MHR).(63, 193, 194, 222) Not all 
studies included assessor blinding of VO2peak, which may have influenced the testing results. 
Also, studies in cardiac rehabilitation programs may have been guided by other confounding 
factors such as dietary advice or smoking status. A limitation of this review, is that 6 of the 
10 studies reviewed are from the same research group. It is important that these findings are 
replicated in future studies at other institutions. 
The studies reviewed consisted of small sample sizes, with one study including an unequal 
ratio of males to females.(193) Current literature is lacking in HIIT studies on all the chronic 
diseases. This systematic review on cardio-metabolic lifestyle-induced chronic diseases 
would have benefited from studies with other lifestyle diseases such as Type II diabetes and 
CKD. Due to the limited research in this area, a variety of diverse diseases were included 
under the title cardio-metabolic disease for this meta-analysis. However, the pathophysiology 
of the varied diseases may mean HIIT will have different influences on the parameters being 
compared amongst different studies. Research on more chronic diseases will allow specific 
prescription guidelines to be recommended.  
 
Protocol Recommendations 
Future research is needed to establish the optimal protocol of HIIT. However, based on the 
findings from this review, recommendations in Table 7.5 are provided. It is important to note 
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Table 7.5 Protocol recommendations for HIIT 
Frequency 3x/week 
Duration 40 minutes  
Modality Treadmill/hill, cycle ergometer. Increasing speed or incline 
Intensity Interval = 85%-95% PHR 
Rest = Passive – 70% PHR 
Interval times 4x4 minute intervals 
3x3 minute recovery 
Warm-up 
Cool-down  
10 minutes at 60% PHR  
5 minutes at 50% PHR 
PHR=peak heart rate  
 
Mode and Intensity: The duration of intervals can differ greatly in various HIIT protocols. 
Two studies which used shorter duration intervals of 30 seconds both showed no 
improvements and smaller improvements in VO2peak respectively.(198, 284) Studies which 
demonstrated the biggest changes in VO2peak after a HIIT intervention used the 4x4 
approach (4 intervals at 4 minutes each at between 90 and 95% PHR).(191-194, 196, 283) 
The recommendation of the 4x4 approach (~40 minutes duration) in Table 7.5 does not 
preclude shorter duration HIIT protocols as being potentially more appropriate. However, 
more research is needed to compare a shorter duration of HIIT with the current 
recommendation. Furthermore, future research comparing HIIT and MICT should ensure that 
the MICT is kept consistent with current definitions of moderate exercise. 
Recovery: The intensity and duration of the recovery period in HIIT may play just as integral 
role in HIIT as the interval. Past research has suggested that an active recovery is 
recommended in order to effectively aid the process of lactate removal.(301) However, a 
study by Dupont et al. indicated that during the active rest period there was less 
replenishment of oxygen in myoglobin and haemoglobin and a reduced rate of resynthesis of 
phosphocreatine from the previous work phase.(302) Meyer et al’s study on chronic heart 
failure patients found that short intervals (30s) with passive recovery provided the most 
benefit (longest time to exhaustion in an exercise test).(303) This study also determined that 
including a passive recovery instigated a lower RPE as indicated on the BORG scale, despite 
having higher oxygen pulse, which is dependent on stroke volume and arterio-venous 
difference.(303) Logistically it may be more practical and convenient to include an active 
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recovery for the purpose of timing and equipment control, albeit as low intensity as possible. 
To successfully employ HIIT, recovery intensities need to be achieved. If the heart rate is not 
reducing to the required intensity by the end of the recovery period, the interval work rate 
should be adjusted accordingly. 
 
Feasibility 
Indisputably, the success of an exercise intervention and maximising long term benefits relies 
directly on adherence to the exercise program. Central to adherence is enjoyment of the 
activity being prescribed. Bartlett et al found that ratings of perceived enjoyment after HIIT 
were higher when compared to MICT.(304) It was identified in this study that rating of 
perceived exertion had a positive correlation with enjoyment, through a likely combination of 
stimulation and accomplishment. Wisloff et al’s study addresses the feasibility of HIIT being 
performed independently.(193) During home sessions, participants were provided with heart 
rate monitors that recorded heart rate data. These monitors were placed so that they could not 
be seen by the participant. The patients achieved the correct heart rate zones without 
feedback from the heart rate monitor. The design of this study supports the feasibility of 
incorporating HIIT into a real-world situation, where a home HIIT program can be 
successfully prescribed after a familiarization period. This is further supported by Moholdt et 




Given the small number of studies conducted thus far there are still important questions that 
need to be addressed. Similar to current issues with the dose response of less intensive 
exercise, much more work is needed to determine if the recommendations provided here are 
the optimal approach for future studies. Furthermore, it is realistic that most people will 
combine HIIT with MICT, therefore determining the optimal ratio of both types of training 
over longer periods of time is also important. Similarly, current guidelines for all populations 
recommend inclusion of resistance training in an exercise program, yet the interaction 
between HIIT and resistance training is unknown. As it is likely that most people will include 
HIIT and resistance training in the same session, future studies should identify the ratio of 
HIIT and resistance training needed for optimal benefits. 
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Analogous to the clinical trial phases in the development of a new pharmaceutical product, 
the evaluation of HIIT training for patients with cardiometabolic diseases would be in phase 2 
(assessing efficacy). Indeed, guidelines for clinical populations should use the same approach 
and criteria as other therapies (e.g. drugs) with eventual recommendations based on large 
randomized control trials and not on small feasibility and efficacy studies alone.  
Another important question is regarding adherence after the supervised program. Future 
studies should determine whether this approach is sustainable in a non-supervised, home-
based environment.  
 
Consistency of Terminology 
The terminology used to describe HIIT varies across research groups. The Norwegian 
research group that has conducted the majority of studies in this area has preferred the term 
‘aerobic interval training (AIT)’. Other prominent groups have used ‘SIT’ to describe all-out 
supra-maximal (>100% VO2max) intervals in studies with healthy individuals (278, 306), or 
low-volume HIIT when short intervals (~30 seconds) with an intensity <95% are used.(307, 
308) We suggest that the classification scheme shown in Figure 7.3 is used to standardise 
terminology in future studies. This approach is based on 1) the widespread media use of the 
term ‘HIIT’ rather than ‘AIT’ for near-maximal intensity (80-100% PHR) intervals, 2) the 
additional information regarding the intensity of the interval provided by HIIT compared to 
AIT and 3) the need to separate all-out supra-maximal sprint interval training from HIIT as 
there are concerns for the safety of this all-out approach in clinical populations. Indeed, only 
Roditis et al. has performed SIT in chronic disease populations. For safety reasons, Gibala’s 
group in Ontario have modified their low-volume SIT program for a cohort with Type II 
diabetes using a peak intensity of ~90% PHR (rather than an ‘all-out’ effort) for 10x60 
second work bouts. Based on the above recommended terminology, this therefore becomes 
HIIT, rather than SIT.(308) It is also suggested that in comparative studies, the term 
‘moderate intensity continuous training’ (MICT) should be used, where appropriate.  
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This meta-analysis has identified that HIIT has more physiological benefits than MICT in 
lifestyle-induced chronic disease patients. HIIT significantly improved cardiorespiratory 
fitness by almost double that of MICT (19·4% vs 10·3%). This should translate into greater 
decreases in risks of morbidity and all-cause mortality. Incorporation of HIIT into a 
rehabilitation program may be a more achievable way for people with chronic disease to 
reach a level of exercise that promotes health enhancing benefits. These findings suggest that 
future exercise guidelines for lifestyle induced chronic disease should incorporate HIIT. 
There are various logistical considerations that contribute to the feasibility of a HIIT 
program, however if participants are adequately screened and the program is prescribed and 
supervised by appropriately trained and qualified individuals then it should be an achievable 
training option.






Chapter 8.  
The feasibility of high intensity interval 









Background: High intensity interval training (HIIT) has been previously shown to improve 
fitness and decrease cardiovascular disease risk in both healthy and chronic disease 
populations. The impact of HIIT has not previously been studied in the CKD population. The 
aim of this pilot study was to compare the feasibility and safety of HIIT with moderate 
intensity continuous training (MICT) in patients with CKD.  
Methods: Twenty-one participants with stage 3-4 CKD (eGFR MDRD 25-60 ml/min/1.73m2) 
were recruited for this randomized control trial (RCT). Participants were divided into either 
HIIT or MICT for three sessions of supervised exercise training per week for 12 weeks. In each 
session, the HIIT group completed 4 intervals of 4 minutes duration at 85-95% maximum heart 
rate (MHR), interspersed with 3 minutes of active recovery (65% MHR). The total duration of 
exercise time was 40 minutes for the MICT group and 33 minutes for the HIIT group. 
Feasibility was based on completing the prescribed high intensity intervals and safety was 
assessed by asking participants at the end of every session if they had any injuries or incidents 
to report. Additional measures included cardiorespiratory fitness (VO2peak), exercise capacity 
(estimated METS), haemodynamics (blood pressures, pulse wave velocity [PWV] and 
augmentation index [AIx]), body composition (DEXA) and standard clinical measures. These 
were assessed prior to and following the 12 weeks of training. An average rating of perceived 
exertion (RPE) for the session was reported after each session. Exercise enjoyment (Physical 
Activity Enjoyment Scale) was measured post intervention. 
Results: Out of 71 eligible CKD patients approached, 21 agreed to participate and were 
randomized to either HIIT or MICT. Fourteen of these participants (HIIT n=9, MICT n=5) 
completed follow-up testing. Out of a possible 36 sessions, the HIIT group attended, 
median[IQR], 33[7] sessions and the MICT group attended 34[3] sessions. No adverse 
cardiovascular events or musculoskeletal injuries occurred as a result of the training sessions. 
Exercise capacity improved in both groups (HIIT= 0.8±1.2, MICT= 1.3±1.6 METs). The 
average RPE of each session was higher in the HIIT than the MICT group (HIIT= 14.6±2.4, 
MICT= 13.5±2), however participants in the HIIT group reported higher exercise enjoyment 
(HIIT= 71±10, MICT= 63.5±21.4). However, none of the changes in either group were 
statistically significant. 
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Conclusions: This pilot study identified that HIIT is a feasible and safe for patients with 
CKD. It was also identified that HIIT was more enjoyable than MICT despite a higher 
reported RPE during the HIIT.  
 
8.2 Introduction 
Exercise therapy in the CKD population has been shown to improve cardiovascular disease 
risk factors and therefore has a likely impact on health outcomes.(38, 234, 309) Yet, there has 
been little work comparing the effectiveness of different exercise prescriptions in this 
population. HIIT has been shown to be superior to MICT in improving fitness and decreasing 
cardiovascular disease risk in both healthy and chronic disease populations.(188, 282, 310, 
311) However, this type of training is yet to be evaluated in CKD patients.  
HIIT may be an ideal way to improve the low cardiorespiratory fitness which is prevalent in 
the CKD population. This type of training involves alternating short bursts of high intensity 
exercise with active recovery at a lower intensity. Interval training allows individuals to work 
harder than otherwise would be possible at steady state, thereby increasing cellular and 
systemic stress and subsequent training adaptations.(312) Indeed, data pooled on 112 
coronary heart disease patients identified exercise intensity as a significant predictor of an 
increase in VO2peak.(313) This type of training may also be ideal for improving 
cardiorespiratory fitness in patients with low exercise tolerance who have difficulty 
performing continuous exercise.(312)  
HIIT may be a more enticing option than the prospect of continuously exercising for an 
extended duration. Indeed, Jung et al. (2014) found that 44 inactive adults who completed 
both a HIIT and MICT training session reported greater enjoyment of the HIIT sessions, with 
similar task self-efficacy between HIIT and MICT.(314) In this study HIIT was also the 
preferred exercise modality over MICT. The enjoyment of HIIT in chronic disease 
populations has not yet been studied. Indeed, the self-efficacy of sedentary CKD patients 
with low exercise capacity completing HIIT may be dissimilar to what is seen in healthy 
populations. However, informal comments from patients with metabolic syndrome in the 
study by Tjonna et al. (2008) reported HIIT to be motivating due to the varied procedure and 
MICT to be ‘quite boring’.(192) The greater enjoyment may be pertinent for increasing 
adherence in this highly sedentary population.(315) The safety of high intensity training in 
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coronary heart disease patients has been assessed by Rognmo et al. (2012).(296) The findings 
from this study indicate the risk of a cardiovascular event occurring is similar between HIIT 
and MICT in 4846 coronary heart disease patients. 
The aim of this study was to investigate the feasibility and safety of HIIT in patients with 
CKD. It was hypothesised that HIIT would be feasible for CKD patients, with no untoward 
events occurring as a result of exercise training. It was also hypothesised that HIIT would be 




Twenty-one patients with stage 3-4 CKD (eGFR MDRD 25-60 ml/min/1.73m2) were recruited 
for this pilot RCT. Participants were recruited from the LM3 cohort on completion of their 
involvement in the study. Testing was undertaken at the St Lucia campus, The University of 
Queensland. Exercise training was undertaken in equipped gyms at the University of 
Queensland, The Princess Alexandra Hospital, Logan Hospital and Browns Plains Community 
Centre, Brisbane, Australia. Appendix 11.4 details the study patient information and consent 
form. Randomization was stratified by two levels- sex and diabetes status. Allocation was 
concealed to the assessors, as participant details were emailed to a person external to the study 
for randomization. Participants were randomized in a 1:1 ratio into HIIT or MICT. 
Measurements were taken at baseline and 12 weeks (Figure 8.1).  
 
 
Figure 8.1 Study design  
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Inclusion and exclusion criteria 
As participants were recruited from the LM3 study- the same inclusion criteria were in place. 
Furthermore, patients with an exercise stress test positive for ischaemia identified by their last 
LM3 visit, or significant cardiac history, were assessed by their cardiologist prior to enrolment. 




Participants undertook three sessions of exercise training per week for 12 weeks, supervised by 
an Accredited Exercise Physiologist. Exercise intensities for each group were based on their 
MHR achieved in the initial maximal stress test. The high intensity group were eventually 
completing a 4x4 protocol that consisted of 4 intervals of 4 minutes duration interspersed with 
3 minutes of active recovery. The intervals were progressed between 80-95% of MHR over the 
12 weeks and the recovery intervals were set at 65% MHR. The MICT group trained at an 
intensity of 65% MHR for approximately 40 minutes per session. The time spent on the 
treadmill for the MICT group was approximately isocalorically matched to the HIIT group 
based on ACSM’s estimated energy expenditure calculations for walking.(222) Both HIIT and 
MICT groups performed a warm-up at 50-60% of MHR for five minutes and a cool down at 
the same intensity for three minutes. Table 8.1 shows the progression of target heart rates and 
interval times over the 12 week program, and how it compares to time spent training in the 
comparison MICT group. The initiation at 80% MHR for 3 minute intervals in the HIIT group 
allowed patients to ease into the program, as some participants (those who had been allocated 
to the control group of LM3) had no history of exercise training. By week 9 all HIIT subjects 
were training 4x4 minutes at 95% MHR. A treadmill was the primary modality of exercise, 
however one participant completed the training on a cycle ergometer due to musculoskeletal 
limitations. The speed and inclination of the treadmill was continually adjusted to ensure that 
the heart rate was being maintained at the desired target. Typically, subjects preferred their 
intervals to be increased by incline walking rather than running. As such, there would be a 
small increase in the speed and a significant increase in the gradient for each interval. On 
average it would take participants approximately 2 minutes to reach their desired heart rate. The 
speed and incline would be adjusted to ensure participants heart rate stayed at this desired rate 
(within ~3 beats/minute). A maximum ratio of 2 participants per 1 Accredited Exercise 
Physiologist ensured accurate maintenance and adjustment of treadmill control to maintain the 
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desired heart rate. After familiarization with the training, participants were more autonomous in 
making these changes; however the Exercise Physiologist was always supervising. Typically, 
the target recovery heart rate would be reached two minutes into the recovery. A heart rate 
(HR) monitor was used to assess training intensity in patients not on beta-blockers (n=11). 
Participants on beta-blockers (n=4) used BORG’s RPE scale to assess intensity rather than 
heart rate (Appendix 11.6).(316) The MICT group and the HIIT recovery interval was 
prescribed an RPE of ~12-14, whereas the high intensity interval was prescribed an RPE of 
≥16.(63) 
 
Table 8.1 Progression of target heart rates and interval times over the 12 week training 




















1-2 4x3:00 80 3x2:00 65 26 30 
3-4 4x3:00 85 3x2:00 65 26 31 
5-6 4x3:00 90 3x2:00 65 26 38 
7-8 4x4:00 90 3x3:00 65 33 40 
9-12 4x4:00 95 3x3:00 65 33 40 
MHR=maximum heart rate; MICT=moderate intensity continuous training 
 
Outcome measures 
Outcome measures were performed at baseline and 12 weeks. Measurements were taken prior 
to randomization and within one week of completing the training intervention. Patients were 
asked to abstain from taking their beta-blocker medication on the morning of testing. Detailed 
protocols for the outcome measures that are the same as those in the LM3 study are reported in 
Chapter 2. 
Safety 
Patients were asked at the end of each session whether there were any concerns or problems 
which had occurred during the exercise session. Patients were also instructed to inform the 
research staff if there were any medical issues which had occurred during the intervention 
period. Adverse events were reported by research staff in an incident report form.  
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Fitness and physical activity 
Cardiorespiratory fitness was assessed by peak oxygen uptake (VO2peak) using indirect 
calorimetry and the peak 15 second average VO2 during the final minute of exercise (Parvo 
Medics TrueOne 2400, UT, USA). The test protocol (Bruce, Balke or Naughton) was 
determined by the Duke Activity Status Index (141) and the same protocol was replicated 
post intervention. Exercise capacity (METs) was assessed by the treadmill software based on 
the time on the test (CASE V6.51, GE Medical Systems, Milwaukee, WI, USA). As the 
assessor also conducted the exercise training sessions, they were not blinded to the group 
allocation of participants performing the post exercise stress test. However, motivation and 
encouragement was kept consistent for every participant. The self- reported Active Australia 
questionnaire was used to evaluate average weekly physical activity levels from the 
preceding six months. Baseline total physical activity was calculated from the addition of 
walking, moderate intensity and vigorous intensity time in an average week in the preceding 
six month period.  
Enjoyment and perceived exertion 
Exercise enjoyment was assessed by the Physical Activity Enjoyment Scale (Appendix 11.5). 
The seven-point Likert scale questionnaire was administered to participants on completion of 
the intervention at 12 weeks. The overall perceived intensity of the training sessions was 
measured by RPE on completion of each training session and the mean RPE across all 
sessions was calculated.  
Body composition 
DEXA, using whole body composition analysis was used to determine body fat percentage 
and lean mass (Hologic QDR 4500A Version 12.6, Massachusetts, USA). Lower limb lean 
mass is reported as the sum of the lean mass in both legs.   
Blood biochemistry 
Fasting blood samples were performed prior to any other testing. Serum vacutainers (BD 
vacutainers, Franklin Lakes, NJ, USA) were used to collect 10 ml venous blood samples 
following an overnight fast. Creatinine was measured by the Jaffe method on a Beckman 
DxC800 general chemistry analyser. Blood biochemistry was assessed through venipuncture 
after an overnight fast.  
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Haemodynamics and vascular function 
Applanation tonometry was used to measure central PWV (SphygmoCor 8.1, AtCor Medical, 
Sydney, Australia). Central blood pressure and AIx were determined through pulse wave 
analysis (PWA). PWV and PWA measures were taken in duplicate and the average value was 
reported. Peak exercise blood pressure was measured during the last stage completed in the 
maximal treadmill test using a manual mercury sphygmomanometer. Blood pressure was also 
measured prior to exercise training and on completion of the training session. 
 
Statistics 
Mean±standard deviation (SD) was used to describe normally distributed baseline 
characteristics, with percentages used to describe frequencies for categorical variables. 
Normality was assessed by the Shapiro-Wilk test. Comparison between groups was assessed 
by an independent t-test of the delta from baseline to 12 weeks. Delta data is reported as 
mean±SD or median[IQR] based on normality of the delta values. Mann-Whitney U test was 
performed on not-normally distributed variables. Differences between groups for categorical 
variables were analysed using Pearson’s Chi Square test. Within group differences were 
assessed by paired t-tests for normally distributed and log transformed variables. Wilcoxon-
Sign rank test was used for not normally distributed variables. All statistical analyses were 
performed on IBM SPSS Statistics 22. Power calculations were performed on PS Power and 
Sample Size Calculations Version 3.0. Statistical significance was set at p≤0.05. 
 
8.4 Results 
Table 8.2 outlines the reasons participants declined involvement in the study. Out of the 50 
eligible CKD patients approached who declined participation, nearly half (46%) cited a lack 
of time as a reason for not taking part. Twelve participants were randomized into the HIIT 
group and nine to the MICT group (Figure 8.2). After seven withdrawals, there were nine 
participants who completed the HIIT intervention and five who completed the MICT 
intervention. Two participants from each group withdrew from the study due to a reported 
lack of time. One patient who withdrew from the HIIT group completed the intervention, 
however was unable to complete the follow-up testing due to a bout of rheumatoid arthritis. 
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One participant withdrew mid-way through the MICT due to osteoarthritis knee pain which 
was deemed too painful to continue exercising. The second MICT patient to withdraw was 
due to a hip dislocation which occurred at home. Technical errors occurred in the VO2peak 
post-test of one of the HIIT participants and as such pre and post VO2peak relative, VO2peak 
absolute and respiratory quotient (RQ) data is only reported on eight HIIT participants.  
 
Table 8.2 Reasons given by patients from the LM3 study for not taking part in the 
current study 
Reason for not participating (n=50) (n,%) 
Lack of time 23(46) 
Already does enough exercise 2(4) 
Does not like exercise 4(8) 
Lack of transport 4(8) 
Too far to drive to gym 4(8) 
Currently injured 2(4) 
Too old 1(2) 
Maybe- then unresponsive 5(10) 
No reason given 4(8) 
Doesn’t like VO2 mouthpiece 1(2) 
 
  














Figure 8.2 Consort diagram 
 
Patient characteristics 
Table 8.3 shows no significant differences in patient characteristics between the HIIT and 
MICT groups. However, there were a greater number of participants in the MICT group on 
insulin. On average, patients had moderate CKD with an eGFR of 34 ml/min/1.73m2 and 
were considered obese with an average BMI of 31 kg/m2. There were an equal number of 
patients with diabetes in both groups. The HIIT group reported performing higher levels of 
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Table 8.3 Patient characteristics 
Variable HIIT (n=9) MICT (n=5) p value 
Age (years) 60.9±6.3 62.8±10.5 0.67 
Female sex  3(33.3) 1(20) 0.60 
eGFR (ml/min/1.73m2) 33.8±10.8 34.8±8.2 0.86 
Diabetes status  4(44.4) 4(80) 0.20 
BMI (kg/m2) 31.7±5 29.9±6.2 0.57 
Previous physical activity levels 
(hours/week) 
3.5[4.7] 1.5[4.0] 0.15 
History    
Hyperlipidaemia  4(44.4) 4(80) 0.20 
Myocardial infarction  1(11.1) 1(20) 0.65 
Peripheral vascular disease  1(11.1) 0 0.44 
Hypertension  9(100) 5(100)  
Stent  0 1(20) 0.16 
Medication    
Ace-inhibitor  5(55.6) 4(80) 0.36 
β-blocker 2(22.2) 2(40) 0.48 
Thiazide 1(11.1) 1(20) 0.65 
Statin 5(55.6) 3(60) 0.87 
Insulin 0 3(60) <0.01 
Allopurinol 4(44.4) 0 0.08 
Data is presented as mean±SD. Not normally distributed variable presented as 





Feasibility and safety 
Both groups completed a similar number of exercise sessions (Table 8.4). All patients in the 
HIIT group achieved their target heart rate for each interval. No adverse events occurred as a 
result of exercise training. However, pre-existing osteo-arthritis of the knee did deter one 
participant in the MICT group from continuing with the program. 
 
Fitness measures 
Both groups had improvements in cardiorespiratory fitness and exercise capacity but there 
were no significant group differences in relative or absolute VO2peak in both groups (Figure 
8.3a,c).  
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Anthropometry 
The HIIT group had no change in weight and the MICT group experienced minor weight loss 
(-1.3±1.9 kg). There were no changes in both groups for body fat percentage. There was also 
no change in lean mass in the HIIT group, however the MICT group had a reduction in lean 
mass, although this change was not significant. 
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Table 8.4 Baseline and changes in primary and secondary outcome measures 
 HIIT  MICT   
Variable Baseline Change Relative 
change 
(%) 




Fitness measures        
Estimated METs 9.8±3.4 0.8±1.2 7.6 8.8±3.4 1.3±1.6 12.9 0.52 
VO2peak (ml/kg/min) 22.3±7.6 0.1±2.4 0.6 21.7±6.1 1.6±2.3 6.9 0.31 
VO2peak (L/min) 1.97±0.6 0.03±0.3 1.5 1.80±0.4 0.06±0.1 3.2 0.86 
RQ 1.08±0.1 0.02±0.1 1.8 1.1±0.1 -0.04±0.1 -3.8 0.40 
Anthropometry        
Weight (kg) 86.2±9.6 0.1±2.0 0.1 84.9±25.3 -1.3±1.9 -1.6 0.22 
Body fat (%) 37.7±8.2 0.1±1.5 0.3 35.1±5.6 0.2±2.8 0.6 0.92 
Lower limb lean mass (kg) 18.0[3.0] -0.1[0.4] 0.6 16.9[12.3] -0.5[4.1] -2.9 0.68 
Haemodynamics and vascular        
Systolic BP (mmHg) 124.6±15.0 0.9±15.5 0.7 126.0±12.
 
3.0±9.9 2.3 0.89 
Diastolic BP (mmHg) 80.6±6.7 -0.9±7.9 -1.1 76.3±7.8 -10.5±31.8 -16 0.42 
Peak systolic BP (mmHg) 176.7±25.0 -3.6±26.6 -2.0 171.6±14.
 
-14.4±14.5 -9.2 0.42 
Peak diastolic BP (mmHg) 77.8±11.5 6.4±16.3 7.6 72.2±14.2 -11.6±12.9 -19.1 0.06 
Central systolic BP (mmHg) 118.3±12.7 1.8±16.4 1.5 118±22.5 -3.6±18.6 -3.1 0.62 
Central diastolic BP (mmHg) 78.4±13.1 3.1±14.3 3.8 76.2±7.8 -3.4±9.9 -4.7 0.44 
Resting heart rate (bpm) 66.3±10.5 -2.7±7.6 -4.2 70.7±14.2 -0.3±7.4 -0.4 0.61 
Peak heart rate (bpm) 142.1±28.8 3.1±13.0 2.2 141.0±33.
 
-7.4±24.8 -5.5 0.36 
Pulse wave velocity (m/s) 9.0[4.2] -1.7[2.3] -23.3 * * * * 
AIx (%) 26.6±9.3 0.9±6.8 3.3 20.6±17.3 3.9±11.0 15.9 0.57 
Average systolic BP (mmHg)# 131.6±9.2 -3.3±7.3 -2.6 130.9±6.9 -2.2±8.6 -1.7 0.83 
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Average diastolic BP (mmHg)# 75.9±3.7 -1.1±2.8 -1.5 72.9±11.4 -1.7±2.4 -2.4 0.73 
Post intervention  12 weeks   12 weeks   
Physical activity enjoyment 
 
 71±10.0   63.5±21.4  0.54 
Sessions attended  33.0[7.0]   33.5[3.3]  0.53 
Rating of perceived exertion  14.6±2.4   13.5±2.0  0.49 
*Only n=2 participants had PWV performed in the MICT group, therefore no comparisons were performed. Data is presented as mean±SD. 
Not normally distributed variable presented as median[IQR]. The p value is of the delta value between groups. Change data is calculated by 
the 12 week value minus the baseline value. #Values reported in the baseline column are the average of the blood pressures recorded before 
each exercise session. The change value reported is the average change in blood pressure following each session. BP= blood pressure; bpm= 
beats per minute 
























Figure 8.3 a) change in VO2peak in each participant in the HIIT group. b) change in METs in each participant in the HIIT group. c) 
change in VO2peak in each participant in the MICT group. d) change in METs in each participant in the MICT group




Figure 8.4 Change in estimated METs for both HIIT and MICT groups. Data is presented as 
mean and SD 
Enjoyment and perceived exertion 
The physical activity enjoyment scale identified that participants in the HIIT group enjoyed the 
exercise intervention more than participants in the MICT group but this was not statistically 
significant (Table 8.4 and Figure 8.5). There were also no significant differences between HIIT and 
MICT in any of the 12 questions separately (Figure 8.5). Participants in the HIIT group also 
reported slightly higher average RPE over the 12 weeks compared to the MICT group. 
 
 
Figure 8.5 Scores from the physical activity enjoyment scale for HIIT and MICT groups. 
Physical activity enjoyment questions are on a 1-7 Likert scale with a maximum possible score 
of 84. Data is presented on a boxplot with median, first and third quartiles and minimum and 
maximum error bars 
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Figure 8.6 Physical activity enjoyment scale in HIIT and MICT 
       1 2 3 4 5 6 7 
1. I find it unpleasurable                4.6                    6.3  I find it pleasurable 
2. It’s not fun at all           5.1  5.3   It’s a lot of fun  
3. I feel bad physically while doing it               5.9        6.5  I feel good physically while doing it 
4. It’s not very invigorating               4.8                  6.2  It’s very invigorating 
5. It’s not at all gratifying              6.1  6.8 It’s very gratifying 
6. It’s not at all exhilarating            5.3 5.4  It’s very exhilarating 
7. It’s not at all stimulating           5.5 5.6   It’s very stimulating 
8. It’s not at all refreshing                 4.8          5.8   It’s very refreshing 
9. I find it tiring after             5.3 6  I find it energizing after 
10. It doesn’t give me a strong sense of accomplishment                     5.5  5.9  It gives me a strong sense of accomplishment 
11. I am very frustrated by it                 5.5     6.2  I am not frustrated by it at all 
12. I wouldn’t recommend this type of training to my friends            6.4      7 I would recommend this type of training to my friends 
TOTAL              5.3  5.9 
HIIT is represented in bold figures in a surrounding circle. MICT is represented italic figures in a surrounding rectangle. 
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Haemodynamic and vascular function 
None of the haemodynamic or vascular function variables had significant between or within group 
differences (Table 8.4). Although, resting HR decreased in the HIIT group and remained the same 
in the MICT group. Systolic blood pressure was reduced after training in both groups, however the 
change seen in the HIIT group was slightly greater than in the MICT group. The reduction in 
diastolic blood pressure after each session was similar between groups. Both central systolic blood 
pressure and diastolic blood pressure increased in the HIIT group and decreased in the MICT group. 
Due to measurement difficulties only two participants in the MICT group had the PWV 
measurement completed. PWV in the HIIT group decreased after 12 weeks. There was a greater 
increase in AIx in the MICT group than in the HIIT group.  
 
8.5 Discussion 
This is the first study to investigate the effects of HIIT in patients with CKD. The main findings are; 
1) HIIT is a feasible option for some CKD patients, 2) no adverse events occurred as a result of 
either HIIT or MICT and 3) the improvements in exercise capacity and cardiorespiratory fitness 
were greater after MICT than HIIT. 
 
Feasibility of HIIT 
The findings from this study indicate that HIIT is a feasible training option for patients with CKD. 
Participants in the HIIT group attended a median of 33 out of 36 sessions and all participants 
reached the desired heart rate in the high intensity intervals. CKD patients have a high degree of co-
morbidities and general lethargy and whether this impedes the ability of these individuals to 
successfully complete HIIT has not previously been studied. The feasibility of HIIT in patients with 
low exercise capacity and significant co-morbidities, such as in this population, is supported by 
Wisloff et al. (2007). Wisloff et al. identified that patients age 75.5±11.1 years with stable heart 
failure post-infarction with an average VO2peak of 13±1.6 ml/kg/min were able to successfully 
complete HIIT and improve cardiovascular disease risk factors.(193) It seems that the malaise 
experienced by CKD patients does not limit the ability to participate in HIIT. 
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In this study, the majority of patients performed uphill walking for their high intensity intervals. 
However, there were some participants who preferred to complete their training using running or 
cycling intervals. This was entirely dependent on the patient’s preference and any musculoskeletal 
conditions. There are a number of exercise modalities which can be used to perform HIIT, such as 
swimming, rowing and resistance training. Aamot et al. (2013) found that participants in Norway 
performing HIIT at home in their own chosen modality, whether it be cross-country skiing, cycling 
or cross-training, still met their target HR using a HR monitor.(317) Furthermore, a study by Lunt et 
al. (2014) used the 4x4 protocol in outdoor group sessions.(318) Even though the authors found 
improvements in VO2peak to be slightly lower than previously observed in other studies, this study 
recognized the feasibility of HIIT in a real world setting. 
 
Safety of HIIT 
The findings from this study indicate that HIIT is safe for CKD patients, with no adverse events 
occurring as a result of the exercise training. As previously suggested in Chapter 7 (Table 7.4), 
HIIT is appropriate for part of the population. It is suggested that patients considered ‘high risk’ 
seek medical clearance to identify any underlying cardiac conditions which may be exacerbated by 
HIIT. As participants in this study had finished the LM3 study, they all had at least 2-4 exercise 
stress tests, supervised by a Nephrologist and reviewed by a Cardiologist. They also underwent 
extensive blood work and review every 6 months. This 12 week study also had both pre and post 
exercise stress tests supervised by a Nephrologist. Consequently, there were no underlying diseases 
detected that were likely to be aggravated by high intensity exercise. In routine practice, Exercise 
Physiologists working with CKD patients may not have access to this level of screening. Therefore, 
adequate medical clearance from the treating physician will assist in identifying the suitability of a 
patient for HIIT. Nevertheless, the risk of a cardiovascular event occurring has reported to be 
similar between HIIT and MICT in 4846 coronary heart disease patients.(296) Furthermore, a study 
in patients with heart failure with reduced ejection fraction showed no change in cardiac troponin, 
C-reactive protein (CRP), brain natriuretic peptide, or significant arrhythmias after either HIIT or 
MICT.(319) More detailed studies in CKD patients specifically are necessary to adequately assess 
the safety of HIIT. 
 
Efficacy of HIIT 
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The findings from this pilot study indicate that HIIT induces similar benefits in exercise capacity as 
MICT. The increase in METS in both groups (HIIT= 0.8±1.2, MICT= 1.3±1.6) are clinically 
significant as it has been reported that for every 1 MET increase there is a 17% reduced risk of 
mortality.(26) The differences were not statistically significant; however this is a pilot study that 
does not have the required sample size to assess changes in fitness. Indeed, based on the observed 
mean difference in VO2peak between the two groups (1.5 ml/kg/min) and high standard deviation 
of the mean difference (2.35 ml/kg/min), the power of this study to detect a significant difference 
(α=0.05) was only 15%.  
The observation that the MICT group had slightly greater improvements in exercise capacity and 
cardiorespiratory fitness was likely due to having considerably lower physical activity levels and 
fitness at baseline. This study did not show the same improvements in cardiorespiratory fitness as 
other cardiometabolic populations.(188, 320) This could be due to a combination of the small 
sample size and heterogeneous nature of the CKD population. Indeed, McCann et al. (2012) 
identified a significant variation in response to HIIT in patients with type 2 diabetes, which was 
independent of compliance. Furthermore, any physical activity performed outside of scheduled 
exercise sessions may also explain the lack of difference between groups. The current study 
identified three patients in the HIIT group to decline in VO2peak, despite compliance to the exercise 
sessions and heart rates. The significant improvement in exercise capacity in two (patient #4 and #9) 
of these patients who declined VO2peak (and only a minor decline in exercise capacity in the third 
patient [patient #8]),(Figure 8.3) may indicate a resistance to physiological changes in 
cardiorespiratory fitness. This finding is similar to the findings from the main LM3 study. Non-
responders to changes in cardiorespiratory fitness with exercise training is discussed in more detail 
in Chapter 6. This trend of increasing exercise capacity without a parallel increase in 
cardiorespiratory fitness in this CKD cohort warrants further investigation.  
Although 12 weeks has been shown to be sufficient in improving cardiorespiratory fitness, a longer 
duration intervention may have elicited greater improvements in the current study.(283) The 
progression of the intensities over the 12 weeks was designed to gradually increase confidence and 
self-efficacy with this style of training. Perhaps if week one of training commenced at a higher 
percentage of MHR for 4 minutes rather than 80% MHR for 3 minutes, greater improvements may 
have been observed. The ability of the patients to effectively complete 4x4 minute intervals at 95% 
MHR indicate that starting at this intensity in future studies may be possible.  
Vigorous exercise has been shown to cause greater transient decreases in blood pressure post-
exercise than moderate or low intensity exercise in hypertensive males.(321) The findings from our 
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study indicate a drop in systolic blood pressure from pre to post exercise training in both exercise 
groups, with a greater decrease seen in the HIIT group. However, these findings were not 
statistically significant. Brito et al. (2014) also identified a greater post-exercise hypotensive 
response in high intensity resistance exercise (80% 1RM) than moderate intensity resistance 
exercise in elderly hypertensive patients.(322) These findings are further supported by Whyte et al. 
(2010) who found a transient decrease in systolic blood pressure 24 hours post two week sprint 
interval training intervention, which was not maintained at 72 hours.(323) This study also found a 
reduction in forearm vascular resistance within the first minute of recovery. These acute decreases 
in blood pressure post-exercise highlight the potential for chronic improvement in blood pressure if 
regular exercise is maintained. Our findings also demonstrated a considerable improvement in PWV 
in the HIIT group. Furthermore, AIx was found to increase slightly in the HIIT group, with a greater 
increase seen in the MICT group. The concurrent occurrence of post-exercise hypotension and 
decreased arterial stiffness as measured by PWV after interval training is similarly identified by 
Tordi et al. (2009).This is likely indicative of the shear stress that occurs during HIIT which 
increases elasticity of the vessel walls, thereby creating a greater stimulus for adaptation.(292)  
The findings from our study indicate an improvement in weight in the MICT group, with no change 
in the HIIT group. Although HIIT has been shown in other studies to be superior in improving 
cardiorespiratory fitness, MICT is often reported to be superior for weight loss.(324) In light of this 
evidence, prescribing exercise should be focused around the desired outcome. Both reduced 
cardiorespiratory fitness and increased weight are cardiovascular disease risk factors. This finding 
supports a combination approach of HIIT, MICT and resistance training (to ameliorate muscle 
atrophy) to provide the best health outcomes in CKD patients. 
 
Exercise enjoyment 
The greater reported enjoyment in the HIIT group is important as it has implications for exercise 
adherence and long-term behaviour changes. It has previously been shown that participants are 
more likely to continue to perform high intensity exercise compared to moderate intensity training 
after their respective intervention,(325) likely due to a higher reported enjoyment of the high 
intensity sessions. To our knowledge, a study by Oliveira et al. (2013) has been the only study to 
compare enjoyment during HIIT or MICT.(326) The authors reported negative feeling scale 
responses in HIIT compared to MICT. However in this study the work interval was set at 100% 
VO2peak for 2 minutes, with passive rest periods. Half of the participants could not complete the 
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HIIT session, therefore the reduced self-efficacy of not being able to complete the sessions likely 
affected the enjoyment of the exercise. Future studies should investigate enjoyment of the exercise 
during traditional aerobic intervals of 85-95% MHR and shorter sprint intervals ≥100% VO2max as 
defined by our group in Chapter 7 (Figure 7.3)(188) to confirm these findings.(188) The benefit of 
using the Physical Activity Enjoyment Scale post intervention is the low burden to participants. 
However, despite a higher burden, this study may also have benefited from including measures of 
enjoyment and self-efficacy at each training session. Indeed, in addition to assessing the reflective 
feelings of enjoyment after completing the intervention, gauging the enjoyment of the exercise 
immediately after the session may provide some indication as to the likeliness of adherence to this 
type of training in a real world setting. Furthermore, the Exercise Task Self Efficacy scale can be 
utilized upon completion of the exercise session to assess participants confidence in their ability to 
repeat that exercise session at various time frequencies.(327) For example, this scale asks questions 
such as- how confident are you that you can complete an exercise training session such as the one 
performed today 3 times per week for the next 4 weeks? Participant responses to these questions 
would also be helpful in assessing the likelihood of HIIT being adhered to in an unsupervised real-
world environment. The Feel Scale can be used to measure general affective valence.(328) This 
would have been helpful in assessing the feelings of patients (ie. pleasure/displeasure) pre, 
immediately post and 20 minutes post exercise training.(314) Use of qualitative measures of the 
HIIT intervention may also have provided some greater insight into the feasibility of this type of 
training. Indeed, semi-structured interviews pre and post intervention may have explored 
motivators, enablers and barriers to participation in the study. 
 
Barriers to exercise participation 
It is interesting to note the reasons for not partaking in the current study from approached patients 
from the LM3 study. These findings may provide insight into barriers to exercise participation in 
the chronic disease population. Namely, “lack of time” was cited as the most common reason for 
not being involved in the study. These findings suggest that using a shorter duration HIIT approach 
may be necessary to encourage exercise participation in CKD patients. The 4x4 HIIT protocol is not 
considerably shorter in time than the MICT protocol. However, the protocol is considered time-
efficient, as improvements in VO2peak are double the improvements that occur with MICT.(188) 
Therefore, to see the same increases in fitness, a significantly greater amount of time would need to 
be spent completing MICT. Although, considering lack of time is cited as the biggest barrier to 
exercise participation, perhaps the greater increases in VO2peak should be sacrificed for similar 
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improvements in fitness with considerably less exercise time. The low participation rate also 
occurred in the study by Terada et al. (2013).(291) The researchers from this study found that from 
126 patients who showed interest in joining the exercise study, only 15 were randomized and 
completed the program. However, the patients who did commence the study attended either their 
HIIT or MICT training 5 days/week for 12 weeks with 97.2% attendance rate with no drop outs.  
 
Assessing intensity of exercise 
McCann et al (2012) used HRR ((maximum HR – rest HR) + rest HR) to measure intensities of 
training in patients with diabetes.(329) This might be an ideal alternative to MHR when measuring 
intensity in some CKD patients, due to the regular occurrence of high resting HR and low MHR. In 
these individuals, calculating a percentage of MHR allows only a small difference in work rate 
between the interval and recovery intensities. Furthermore, the 65% of MHR used in the MICT 
group is often too close to the resting HR to expect a reasonable change to occur. If this situation 
occurred in the current study participants were advised to maintain an exercise intensity between 
12-14 on the RPE scale. An individualized approach using either HRR or MHR may provide more 
achievable targets and therefore greater outcomes. On the other hand, using a percentage of 
VO2peak, as opposed to HR, may provide more accurate measurement of energy expenditure and 
metabolic strain. Indeed, high intensity intervals performed at 85-90% VO2peak would provide a 
fixed work rate, without the limitation of haemodynamic variability using MHR during the training 
sessions. However, identifying the practicality of using MHR was important for this feasibility 
study, due to the ease of HR monitoring in real-world settings.  
The low RPE reported by the HIIT group (14.6±2.4) may also explain why the improvements in 
HIIT were not as great as expected. Patients were asked to rate their perceived exertion over the 
whole exercise session, therefore including rest intervals. However, as high intensity HR’s should 
correlate with an RPE of 16-18, it was expected that the overall RPE would be higher than what 
was reported. These low RPE values were being reported despite all patients reaching their target 
heart rate percentage. This finding may indicate that basing intensity on a percentage of MHR may 
not be ideal in CKD patients. In fact using target heart rates may limit the capacity of the patient to 
train at a high intensity. It has been suggested by Guiraud et al. (2010) that manipulating walking or 
running velocity to maintain heart rate in a target zone may lead to a decreased VO2max as a result 
of cardiovascular drift.(127) Indeed, using an RPE rather than heart rate target may be desirable for 
some CKD patients.  
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The optimal dose of HIIT 
The time effectiveness of certain HIIT protocols is one of its primary advantages. However, with 
the 4x4 protocol the time difference with MICT is minimal. This HIIT protocol was selected due to 
its superior benefits in health outcomes compared to MICT in similar chronic disease 
populations.(188) Indeed, the reported two-fold improvements in fitness with HIIT compared to 
MICT in a similar time duration means the 4x4 is a time efficient approach. However, if lack of 
time was proving to be a barrier to exercise participation, a shorter duration protocol which allowed 
similar improvements in fitness to MICT may be warranted. As such, it is unknown whether the 
duration of this type of training would be a deterrent in real-world settings. However, more recently 
a study by Tjonna et al. (2013) found that 1x4 minute intervals 3x/week improved VO2max by 
10%, compared to a 13% increase in healthy men who undertook 4x4 minute intervals 
3x/week.(330) The study by Tjonna et al. provides important foundations for future time efficient 
and efficacious aerobic HIIT protocols to be explored, however this needs to be confirmed in 
chronic disease populations. Alternatively, a modified 4x4 protocol may provide a more time 
efficient strategy. Perhaps, if the recovery interval was shortened, the time benefit may prove more 
enticing to patients.(318) Whether this would evoke the same physiological adaptations would need 
to be investigated. It has been suggested that HIIT of less than 1 minute may not be feasible in older 
adults.(331) Although low volume HIIT is enticing from a time efficiency perspective, the effort 
required may be impractical for many individuals.(332) Indeed, short work intervals would require 
the participants to reach the desired HR rapidly. The benefit of the 4 minute intervals is that it 
gradually increases the HR for approximately the first two minutes and then maintains the HR for 
the following two minutes. It has been suggested that high intensity intervals between 2-4 minutes 
could be difficult or unsafe for patients and could lead to non-compliance of the training 
program.(127) The ability of the patients in the HIIT group in the current study to adhere to this 
type of training with high attendance rates and successful achievement of the HR intensities, 
indicate that this is not the case. Substantially more research is needed on the dose-response 
relationship of HIIT in achieving the greatest adaptations with the least amount of time. A balanced 
training approach is important and future studies should also identify the effectiveness of 
incorporating HIIT and MICT with resistance training in future exercise studies in CKD patients. 
 
Including HIIT in exercise guidelines 
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The benefits of aerobic exercise and resistance training in CKD patients have previously been 
reported, with an emphasis on moderate intensity exercise.(75) Before current exercise guidelines in 
CKD patients can include HIIT as standard clinical practice there needs to be large scale RCT’s 
looking at patient safety, prognosis and compliance with HIIT. Given the promising results found in 
other clinical populations, further investigation of this type of training is essential. Furthermore, 
future research should investigate HIIT in conjunction with MICT and resistance training to 
replicate real world exercise prescription. Due to the heterogeneous nature of the CKD population it 
is likely the dose and ratio of exercise types should be individualized to promote the best possible 
health outcomes. As suggested by Arena et al. (2013) to support the clinical application of HIIT into 
standard practice, research needs to demonstrate physiologic benefit, functional and quality of life 
benefit, low adverse event rate, superiority to current clinically accepted exercise programs, high 
level of patient compliance, cost efficacy and decrease in morbidity and mortality.(333) 
 
Limitations 
There are a number of limitations to this study. Firstly, the sample size was not sufficient to detect a 
mean difference in fitness outcomes between HIIT and MICT groups (study power 15%). The 
change in SD of VO2peak in our cohort was significantly larger than the assumed VO2peak SD 
previously reported in cardiometabolic patients.(188) Secondly, there was a lack of blinding of the 
technicians in the exercise tests, due to limited resources. Regardless, the same instructions and 
encouragement were given to each patient to avoid any bias. Thirdly, although the baseline 
characteristics of this cohort were older adults, obese, had low cardiorespiratory fitness and appear 
to be typical of a CKD patient, the generalizability of the participants may be limited. Potentially, 
the individuals who volunteered to participate in a high intensity training study may be more 
motivated to make a significant lifestyle change. Indeed, the previous physical activity levels were 
high compared to the general population of the CKD patients from the LM3 study at baseline. 
Furthermore, although Table 8.2 demonstrates that 50 LM3 patients declined participation in this 
study, this may not be a true representation of the CKD population willing to participate in an 
exercise study. The participants had already demonstrated some level of compliance and high self-
efficacy, evident by their participation in the previous LM3 study. As such, caution should be taken 
in extrapolating the high adherence rates in this specialized cohort to the general CKD population. It 
is also likely that the long duration of the LM3 study may have resulted in study fatigue and 
contributed to the high decline rate in the HIIT study. It would have been ideal to recruit 
participants with limited physical activity levels at baseline, however due to the difficulty in 
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recruiting CKD participants for exercise studies, the small sample size would have made the study 
unfeasible. Indeed, the intervention may have had a greater impact and benefit in patients who were 
not as physically active prior to participation in the study. However, the current study was still 
worthwhile in the studied cohort, as despite their reasonably high levels of baseline physical activity 
levels, their cardiorespiratory fitness were still low. Thus, it is likely that their exercise routines 
would benefit from optimization. Fourthly, monitoring the dietary intake of participants in both 
groups may have elucidated the differences in weight loss between groups. Lastly, blood pressure 
measures were performed before and after each session on all patients purely for safety reasons. 
Therefore, a strict protocol on time and rest period was not adhered to before taking the 
measurements. Rather, reporting of this measure was a post-hoc analysis and designed to give a 
general indication of the change in blood pressure as would occur in the normal supervised exercise 
setting. Generally the same protocol was followed each time, with patients instructed to rest for a 
few minutes before both pre and post exercise blood pressures were taken.  
 
Conclusions 
This pilot study identified that HIIT is feasible and safe for patients with CKD. It was also 
identified that HIIT was more enjoyable than MICT despite a higher reported RPE. The exercise 
capacity and cardiorespiratory benefits were greater in the MICT group, however this may be 
attributable to the higher baseline levels of activity and fitness in this group. Nonetheless, the study 
was underpowered to detect statistical differences between groups. Based on these findings, both 
HIIT and MICT are feasible options for CKD patients and exercise prescription should be based on 
patient history and interest. The higher enjoyment may indicate that adherence to HIIT may be 
greater than MICT. This pilot study provides evidence of the potential benefit of HIIT in the CKD 
population.
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9.1 Summary 
This thesis has contributed significantly to a range of areas relevant to exercise training in patients 
with CKD. The review of the literature in Chapter 1 identified the high prevalence of cardiovascular 
disease risk factors in patients with CKD. By exploring previous exercise trials in CKD patients it 
was identified that aerobic, and a combination of aerobic and resistance exercise training, 
significantly improves cardiorespiratory fitness and exercise capacity. Resistance training studies 
also appear to increase muscle strength and cross-sectional area. Based on the positive findings 
from the reviewed studies, it seems likely that exercise training plays an important role in the 
prognosis of patients with CKD. However, the review of the literature identified that further 
research is required, as most exercise studies in the CKD populations have excluded patients with 
cardiovascular disease, have small sample sizes or are not randomized control trials (RCT). 
Furthermore, only 1 RCT has investigated the effects of combination aerobic and resistance 
training, despite this being the recommended approach to exercise training by Exercise and Sports 
Science Australia. Moreover, no studies have investigated the effects of high intensity interval 
training (HIIT) in CKD patients. 
The LM3 study, reported in Section 1, is the largest exercise trial in CKD patients to date and 
provides important practical findings for the renal community. Reduced strength has previously 
been reported in CKD patients; however this is the first study to elucidate the extent of this 
impairment. Indeed, it was identified that 82% of patients had grip strength below age-predicted 
normative values (Chapter 3). It was also identified that elevated oxidative stress was independently 
associated with reduced strength. The findings from this study provide insight into the potential for 
more targeted treatments (eg. antioxidants or strength training) in restoring the reduced strength and 
lean mass losses seen in this population. Chapter 4 identified the feasibility of CKD patients 
participating in higher intensity exercise. Participants who reported completing higher intensity 
exercise had the greatest exercise capacity after 12 months of exercise training compared to patients 
reporting moderate intensity and those not meeting guidelines. Furthermore, by identifying baseline 
haemoglobin levels as a significant predictor of participation in higher intensity exercise, patients 
with suitable haemoglobin levels can be recognized and targeted for this type of training. The 
paucity of research in exercise in CKD patients have precluded inferences to be made on the 
agreement of kidney function measures after an exercise intervention. Chapter 5 is the first study to 
assess the agreement between cystatin-C and creatinine based eGFR measures before and after a 
combination aerobic and resistance, home-based exercise training program. It was identified that 
cystatin-C eGFR was considerably lower than creatinine based estimates. However, this 
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discrepancy was consistent after 12 months of exercise training. This finding may suggest that an 
exercise training program as commonly prescribed to CKD patients does not influence either 
cystatin-C or creatinine based eGFR measures. Although, the difference between the measures may 
indicate a combination of cystatin-C and creatinine eGFR measure could provide the most 
representative measure of kidney function. The primary finding from this thesis is the feasibility of 
a long-term lifestyle intervention (LI) in significantly increasing physical activity levels and 
exercise capacity in patients with moderate CKD (Chapter 6). The improvement in arterial stiffness 
seen in the LI group also suggests that this model is effective in reducing cardiovascular disease 
risk. This is an important finding considering the high prevalence of cardiovascular co-morbidities 
and obesity in this population. The findings from this thesis provide support for the prescription of 
exercise training in standard nephrological care. 
The LI in study 1 utilized a multi-disciplinary approach to promote long-term behaviour change. 
Other health professionals involved in this study included a nurse practitioner, dietitian, exercise 
physiologist as well as a diabetic educator and psychologist if needed. This thesis specifically 
focussed on the contribution of exercise training to health outcomes. Although it is reasonable to 
suggest that exercise training explicitly contributed to improvements in physical activity and fitness 
measures, the influence on haemodynamics, biochemistry and vascular cardiovascular risk factors is 
unknown. Although, the LI group showed no change in weight or body fat percentage, which may 
indicate the dietary advice was not as effective in improving outcomes as expected. Furthermore, 
encouragement of physical activity by the other health professionals may have also contributed to 
improvements in physical activity adherence and fitness measures. Although this collaborated 
approach is ideal for multi-disciplinary care, for the purpose of this thesis it does make it difficult to 
delineate the specific impact of the exercise training on health outcomes. Indeed, multi-disciplinary 
encouragement of physical activity in standard nephrological care may be beneficial in maintaining 
positive exercise behaviour. On the other hand, the psychologist in this study was only utilized as 
needed for patient concerns unrelated to exercise. Perhaps if a psychologist was also involved in 
promoting lifestyle change, greater improvements in physical activity and diet adherence may have 
been perceived. Indeed, the collaboration of an exercise physiologist with a psychologist may 
encourage long-term behaviour change. Furthermore, the findings from Chapter 4 and Chapter 6 
indicate that the patients with higher baseline fitness levels had the greatest changes in fitness 
measures after the intervention. The whole cohort had strength and fitness below age-predictive 
normative values, was obese and had multiple co-morbidities, so adherence to the LI in the patients 
who are considered ‘fitter’ is still worthwhile for improving health outcomes. However, patients 
with lower fitness and perhaps greater disease state may have the most to benefit from a LI. 
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Strategies to target these patients is vital in improving health outcomes in the entire CKD cohort. 
Again, working closely with behavioural psychologists may be helpful in optimizing the LI to see 
the greatest outcomes in all patients. These patients may also require closer supervision and support 
and may benefit from increasing accountability through instruments such as regular food and 
exercise diaries.  
The meta-analysis in Chapter 7 (Section 2) has identified that HIIT has more physiological benefits, 
and has nearly twice the improvement in cardiorespiratory fitness than MICT in lifestyle-induced 
chronic disease patients. The meta-analysis did not include any studies of patients with CKD, as this 
thesis is the first to report on the effects of HIIT specifically in the CKD population. This study was 
also the first to provide important considerations, contra-indications and protocol recommendations 
for HIIT training in chronic disease patients. Chapter 8 identified that HIIT is a feasible option for 
patients with CKD and was reported to be more enjoyable than MICT. Although the improvements 
in cardiorespiratory fitness were similar between the groups, the greater enjoyment may suggest that 
HIIT may be better adhered to in this sedentary population. Considering the lack of statistical 
changes in the HIIT study due to the small sample size, the addition of more quantitative and 
qualitative analysis to establish self-efficacy, affect and adherence may have provided more useful 
information in this feasibility study. 
 
Considerations for exercise training CKD patients 
There are number of factors to consider when exercise training or testing patients with CKD. It is 
pertinent for exercising CKD patients to be educated on the occurrence of post-exercise 
hypotension, which may be exacerbated if patients are taking anti-hypertensive medications such as 
α-blockers, calcium channel blockers or vasodilators. If the exercise is taking place in the gym 
setting, ACSM suggests blood pressure should be assessed before commencement of an exercise 
session.(222) Relative contraindications to exercise testing is systolic blood pressure >200 mm/Hg 
and/or diastolic blood pressure >110 mm/Hg. Patients with exaggerated blood pressure responses to 
exercise may also require regular assessment of blood pressure during an exercise session. ACSM 
suggests maintaining systolic blood pressure below 220 mm/Hg and/or diastolic blood pressure 
<105 mm/Hg during exercise. Although, for maximal exercise testing it is reasonable to continue 
exercise up until systolic blood pressure 250 mm/Hg and/or diastolic blood pressure 115 mm/Hg. It 
is also recommended that regular checking of blood pressure and ECG monitoring occurs during 
exercise, particularly when electrolyte abnormalities are present. If patients have diabetes then it is 
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important to check blood glucose levels before and after every training session. Assessing post-
exercise blood glucose levels in patients with diabetes is particularly important if they are on beta-
blockers, as the adverse effect on thermoregulatory function may not only increase the 
predisposition to hypoglycaemia, but may also mask the manifestations. Patients with diabetic 
nephropathy should be checked regularly for other microvascular complications, such as the 
presence of any foot ulcers. Such patients should also be instructed and educated on appropriate 
breathing during resistance exercise to ensure intraocular pressure is not significantly elevated. Due 
to the high prevalence of obesity in CKD, a significant number of patients suffer from osteoarthritis. 
As such, exercise prescription should be aimed at accommodating suitable, as well as non-painful, 
exercises to ensure exercise adherence and enjoyment. Patients should also be educated on the 
deleterious effects non-steroidal anti-inflammatory medication can have on kidney function. 
An important consideration when exercising patients with CKD is to ensure appropriate hydration 
status. Dehydration is said to occur when >2% of body weight is lost from water deficit.(334) Short 
term dehydration and reduced blood volume can decrease renal perfusion and can therefore cause 
reductions in eGFR,(335) which may place a comprised CKD patient at risk for acute renal failure. 
It may be important for patients with CKD to begin exercise at a euhydrated state. Of course this 
recommendation is dependent on patient’s individual fluid requirements and whether or not they are 
taking diuretics. In most cases if significant sweating occurs, lost fluids should be replaced during 
exercise or as soon after as possible.  
 
9.2 Future recommendations 
Further studies are necessary to extend the current findings in this thesis and previous research. 
Arguably, the two most important future areas to be investigated are; 1) the effects of a long-term 
exercise intervention on cardiovascular morbidity and mortality, and 2) the effects of exercise 
training on different eGFR measures in adequately powered studies (n=1000). Study 1 (LM3) and 
Study 2 (HIIT) from this thesis have the potential to further contribute to the literature, as reporting 
of some outcome measures were outside the scope of this thesis. Such measures to be analysed and 
published in the future are reported below. 
The muscle wasting which occurs with CKD is an important therapeutic target for not only 
providing physiological improvements in health, but also improvements in psychological well-
being and quality of life. It seems reasonable to suggest that a combination of aerobic and resistance 
training is the most applicable to real-world exercise prescription and addresses the scope of CKD 
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related detriments. Therefore, assessing mitochondrial function and muscle atrophy markers 
through muscle biopsy after combination training programs are warranted. Whether the influence of 
oxidative stress contributes to the impairment of muscle function and structure as assessed by more 
sophisticated measures such as magnetic resonance imaging (MRI) and muscle biopsy should be 
investigated. In particular, HIIT has shown to be effective in improving mitochondrial function in 
other chronic disease populations, and as such a combination training program which also includes 
HIIT should be investigated. Furthermore, future exercise studies should investigate whether a 
combination of HIIT, MICT, resistance and flexibility training has the most comprehensive benefits 
and whether the variety in training modalities is central to exercise adherence. The effectiveness of 
the LI reported in Chapter 6, provides groundwork for future studies to demonstrate whether a 
similar LI results in a reduced burden on the health care system, which would then support the 
inclusion of exercise physiology in standard practice. Studies should perform an economic analysis 
which assesses the cost effectiveness of the LI model compared to the expected reduced cost 
associated with hospitalisation and co-morbidities. Furthermore, the cost of this type of 
predominantly unsupervised LI model should be assessed against more supervised programs which 
have the potential for greater physiological adaptations. 
 
Recommendations for future analyses from the LM3 study 
Only baseline oxidative stress (F2-isoprostanes and protein carbonyls) and anti-oxidant measures 
(glutathione peroxidase and total anti-oxidant capacity) have been measured and reported in 
Chapter 4. Our group are currently analysing the change in oxidative stress measures after the 12 
month LI in patients reported to have high levels of F2-isoprostanes at baseline (≥250 pg/ml). 
Further, exploring these measures every 6 months (7 visits) in all patients would provide interesting 
insight into whether the change in oxidative stress levels are related to the decline in grip strength. 
Currently, baseline and 12 month serum cystatin-C measures have been analysed from the LM3 
study. However, analysis of cystatin-C samples at every 6 month visit should also be measured. 
Comparisons of both creatinine and cystatin-C eGFR measures over 7 visits would be helpful in 
confirming the findings in Chapter 5, and help elucidate the change in eGFR seen in Chapter 6. 
Furthermore, future exercise training studies comparing cystatin-C and creatinine based eGFR 
measures in specific hypertrophy and high intensity training programs are warranted to confirm the 
findings in Chapter 5.  
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Recommendations for future analyses from the HIIT study: 
Patients in the HIIT study also underwent muscle biopsies at baseline and 12 weeks. We have 
collected baseline muscle tissue on 19 participants, of which post exercise muscle biopsies were 
performed on 12 of the participants who completed the HIIT (n=6) and MICT (n=5) protocols. In 
the future our group we will be measuring PGC-1α, PGC-1α4, myostatin, mTOR, p70s6k, rpS6, 4E-
BP1, MuRF, 14 kDa actin fragment and heat shock proteins in these samples. A baseline 
comparison of muscle function in these patients will be compared to physical activity matched 
healthy controls. This cross-sectional analysis will provide further insight into the pathogenesis of 
muscle wasting in CKD patients. Furthermore, the pre and post analysis of muscle tissue in HIIT vs. 
MICT will identify which intensity of aerobic exercise stimulates the greatest improvements in 
muscle function. Reporting of these measures were outside the scope of this thesis, however once 
the muscle analysis is complete, manuscripts of the baseline and intervention data will be prepared 
for peer reviewed journals.  
 
9.3 Conclusions 
This thesis provides novel findings on a range of issues affecting CKD patients. The primary issues 
addressed have been; mechanisms of reduced strength, predictors of higher intensity exercise, 
appropriate kidney function measures after an exercise intervention, the translation of a LI to a 
generalizable CKD cohort and feasibility and efficacy of high and moderate intensity aerobic 
training. By ascertaining the mechanisms and predictors of exercise training, appropriate strategies 
to optimize exercise induced adaptations and adherence can be proposed. The findings from these 
studies indicate that regular exercise training should play an integral part in CKD patients’ lives and 
must be supported in standard clinical practice. Furthermore, to support the success of physical 
activity behaviour change, treating Nephrologists should ensure that exercise professionals are 
involved in rehabilitating appropriate patients. The findings presented in this thesis will assist 
Exercise Physiologists in targeting their exercise prescription to provoke the greatest improvements 
in health pertaining to individual patient needs. This thesis provides convincing evidence as to the 
feasibility and benefits of combination aerobic and resistance home-based exercise training, HIIT 
and MICT in patients with CKD. The findings from these studies will significantly contribute to 
health outcomes of CKD patients. 
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Chapter 11. Appendices 
 
11.1 Patient information and consent form for LM3 
 
PATIENT INFORMATION SHEET -VERSION 7 
STUDY: Landmark 3 – The impact of aggressive risk factor and lifestyle modification in 
patients with CKD utilising a nurse led co-ordinated care approach. 
 
Reason for the Study 
 
The Departments of Renal Medicine and Cardiology at the Princess Alexandra Hospital are 
studying ways of improving the health and management of patients with CKD. 
Patients with CKD have an increased risk of heart disease. We would like to assess the usefulness 
of a new way of providing care to patients who often have complex health issues. The 
LANDMARK TRIAL PROGRAM will be made up of a multidisciplinary team working together 
with your usual kidney doctor to reduce risk factors which contribute to progression of both kidney 
and heart disease. These risk factors include cholesterol, high blood pressure, high blood sugars, 
anaemia, abnormal blood chemistry (high calcium and phosphate), and smoking, overweight and 
poor physical fitness. 
The LANDMARK TRIAL team will include a specialist nurse, diabetes educator, dietician, 
pharmacist, exercise physiologist, psychologist and social worker. Their task is to help work out the 
best way of tackling the risk factors that you have with the aim of improving your kidney and heart 
health. 
The team will focus on: 
  A co-ordinated approach led by specialist nurses to get risk factors to target.  Patients with 
CKD will often be on treatment for risk factors but may be finding it difficult to ‘get to 
target’.  
  Healthy lifestyle - working towards healthy diet and weight, improving fitness. Stopping 
smoking.  
 Education about heart and kidney disease, medications  and why reducing risk factors will 
improve your health 
This study is being done to work out if a multidisciplinary clinic improves heart and kidney health 
for patients. If you agree to participate, you will be randomised to one of two groups, that is, half 
the patients will be allocated to the usual care group and half to the trial clinic group. If allocated 
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to the usual care group you will continue to receive care in the general nephrology clinic exactly as 
you do now. If allocated to the trial clinic group you will receive care under a nurse led 
multidisciplinary team in the CKD clinic, plus your medical appointments (the appointments may 
not need to be so often).   
This will allow us to compare the treatments without bias and study what really happens- not just 
what we expect to happen. 
In the usual care group your treatment will be prescribed (according to current guidelines) by your 
usual doctor. If your doctor thinks that you need to see any additional health professionals (e.g. 
dietician) they will refer you as usual. 
In the trial clinic group, you will be seen by the specialist nurse who will assess how you are well 
you are ‘getting to target’. They will then organise for you to see members of the team that will give 
you additional advice and help work out a plan for you to achieve your risk factor goals. Diet and 
exercise are also very important in improving and maintaining your overall health. Healthy weight 
and fitness can improve blood pressure control, reduce cholesterol and possibly decrease the 
progression of heart and kidney disease. Therefore, after assessment by your doctor, trial clinic 
patients will undergo a Diet, Exercise and Lifestyle program to target weight loss and fitness 
goals.  The Diet and Lifestyle program includes weekly education sessions, over a four-week period 
with a dietician, exercise physiologist and psychologist, focusing on lifestyle changes and a 
sustainable diet designed especially for CKD patients. After this, an individualised maintenance 
program will be developed for you to especially meet your needs. (See Attachment 1) 
The Exercise program will be available to you with a qualified exercise physiologist who will tailor 
a program to meet your individual exercise requirements, and help you with motivation and 
behaviour change. (See Attachment 2). 
In caring for patients with kidney disease, kidney specialists in conjunction with heart specialists 
routinely do tests to assess a patient's heart and blood vessels. We would like tests to be more able 
to predict patients with heart problems. This study aims to investigate other tests, which have only 
recently become available at this hospital. If these new tests prove more accurate in predicting 
which patients will develop heart problems, we will use them routinely. 
The following tests will be for both groups: 
Heart Tests 
After assessment by your doctor, you will undergo an exercise stress echocardiogram to assess the 
likelihood of heart disease being present. This involves taking an ultrasound picture of the heart 
before and immediately after exercise which will involve you walking on a treadmill. The picture is 
obtained by pressing an ultrasound probe on the chest; this transmits sound waves and collects the 
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reflected waves to make a picture of the underlying structures. The test involves attaching you to 
ECG monitoring equipment, taking a picture of the heart at rest and then repeating the picture after 
you have exercised. The procedure will be stopped if you develop any chest pain or heart 
rhythm disturbances while exercising or if you are unable to continue for any other reason. If 
you are unable to exercise, a dobutamine stress echo will be performed instead. This involves taking 
an ultrasound picture of the heart before and immediately after the heart is stressed by giving a drug 
called dobutamine. Dobutamine is a medicine that increases the heart’s workload (similar to 
exercise) when you are resting. The test involves attaching you to ECG monitoring equipment, 
taking a picture of the heart at rest, inserting an intravenous line in order to give the medicine and 
repeating the picture after the medicine has taken effect. This procedure is usually well tolerated, 
and significant side effects (such as heart rhythm disturbances or severe chest pain) occur in about 
three in a thousand patients. The laboratory is fully fitted out with monitoring and safety equipment. 
The procedure is performed under intensive monitoring by a doctor with a nurse and/or echo 
technician, and takes about an hour; we will attempt to arrange it to coincide with other hospital 
appointments so that you do not need to make an extra trip.   
If your heart test shows any signs of significant heart disease, you will be notified and a follow up 
appointment with a cardiologist will be made.  
If it is not medically appropriate to perform an exercise stress echocardiogram OR a 
dobutamine stress echocardiogram, a standard echocardiogram will be performed, at the 
start of the study, at 24 months and the end of the study. 
We will also test the degree of blood vessel damage by tests, which examine the carotid (neck) and 
brachial (upper arm) arteries by ultrasound. The carotid study involves taking a picture of the artery 
by placing a transducer over the neck – the procedure takes about 20 minutes and is painless. The 
brachial artery study involves the same type of picture (this time, of the arm) at baseline, followed 
by blocking of the vessel by inflating a blood pressure cuff for 4 minutes and repeating the images 
after the cuff is deflated. The test is repeated after taking a tablet of nitroglycerine under the tongue. 
Serious complications have not been reported with either of these studies, although inflation of the 
blood pressure cuff may cause pins and needles or arm pain, and nitroglycerine use may cause 
dizziness or headache – but both are temporary.  These imaging studies are performed purely for 
research purposes and obtained at the start of the study and then every 12 months until the 
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We collect approximately 50mls of blood at each visit.  Most of these tests will be part of your 
normal medical care, but some of these tests are not routinely used.  Some of your blood will be 
stored and tested for a range of proteins that may be associated with an increased risk of heart 
disease and we wish to study them in detail to determine if they are useful in predicting who will 
develop heart disease in the future.  If this is the case, then we may be able to use them routinely in 
the future. There is NO storage of DNA or genetic material. 
Your usual clinic bloods tests may also be taken at this time so you will only have one needle. 
 
Urine tests 
At baseline only, we will ask you to collect your urine in a special container over a 24-hour period.  
This will help us to measure the components of your urine, and helps to assess how your kidneys 
function.  You will be asked to return the collection to your nearest Queensland Health facility for 
analysis.  
We collect approximately 50mls of urine at baseline and all other visits.  This is part of your normal 
medical care, but some of your urine may be stored and tested for a range of proteins that may be 
associated with an increased risk of heart disease and we wish to study them in detail to determine if 
they are useful in predicting who will develop heart disease in the future.  
 
Body Composition 
As part of the nutritional assessment data we will gather at your visits, we would also like to use a 
test to look at your body composition.  This test is called DEXA (dual x-ray absorptiometry) and 
involves using non-invasive x-ray imaging to assess abdominal and subcutaneous fat distribution 
and lean body mass.  It is a simple procedure which requires you to lie flat on a bed for about 30 
minutes whilst imaging takes place.  This procedure will allow us to gain more exact information 
about your body composition.  These will be performed at Baseline, 12months, 24 months and 36 
months. 
At baseline only, the amount of water in your body will also be measured using a bioelectrical 
impedance analysis technique.  You will not be asked to undertake this test if you have a pacemaker 
or metal implants.  This procedure will take 5 to 10 minutes.  You will be required to lie flat while 
we place small electrodes on your hands and feet, which sends a very small electric current.  You 
will feel slight tingling at the site of the electrodes.  It is a safe and simple technique that is often 
used in practice. 
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Lateral Lumbar X-Ray 
To further assess the health of your blood vessels we will do an X-ray of the major vessel in your 
abdomen, the aorta.  This helps us identify whether any calcium is present, which is a sign of blood 
vessel damage.  This will involve one non-invasive X-ray image being taken while you are 
standing.  It only takes a few seconds.  This will be done at baseline and 36 months.  This research 
involves exposure to a very small amount of radiation.  As part of everyday living, everyone is 
exposed to naturally occurring background radiation and receives a dose of about 2 millisieverts 
(mSv) each year.  The effective dose from this study is about 1 mSv.  At this dose level, no harmful 
effects of radiation have been demonstrated as any effect is too small to measure.  The risk is 
believed to be very low. 
 
Quality of Life Questionnaires and Interviews 
As we are looking at the best way to provide care to individuals with CKD, you will also be asked 
to complete quality of life questionnaire every 6mths whilst you are enrolled in the study.  The 
questionnaire asks your opinion of your quality of life as related to your kidney disease and helps us 
to understand your experience.  The questionnaire will take approximately 10 minutes to complete.  
Your responses on this questionnaire will be kept strictly confidential. 
 
You may also consent to take part in the ‘Quality of Life Substudy’ where we will ask you to 
participate in an interview that will explore further your expectations of treatment and experiences 
in living with CKD. We plan to interview approximately 30 patients in each group. You will be 
asked to sign a separate consent section if you choose to participate in these interviews and another 
patient information sheet regarding the interview will be provided. 
 
Confidentiality 
At all times your confidentiality will be respected. No information regarding your medical history 
will be divulged and the results of any tests involving you, which may be published, will be done in 
such a way that your anonymity will be preserved. 
Participation in this study is voluntary and you may withdraw your consent to be involved in the 
study at any time without affecting your treatment. Furthermore, consent to participant in the trial 
will not affect your right to obtain compensation in the event of injury that was proven to be related 
to the research. 
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Length of the Study 
 
Whichever group you are assigned to, we will follow you for 3 years. 
Your general practitioner and other treating practitioners will be notified of your involvement in the 




Further information or queries can be directed to: 
Dr Nikky Isbel Department of Renal Medicine 
 Princess Alexandra Hospital 
 Phone: 3240 5080 or 3240 2111 
 
Professor Tom Marwick University Department of Medicine 
 Princess Alexandra Hospital 
 Phone: 3240 5346 or 3240 2111 
 
Dr Jeff Coombes                                    School of Human Movement Studies 
                                                                 The University of Queensland  
                                                                 Phone: 07 33656767 
11.1.1.1  
The Princess Alexandra Hospital  Princess Alexandra Hospital  
Research Ethics Committee  Ipswich Road, Woolloongabba  
 Phone: 3240 5856 
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TREATMENTS IN THE FOCUS GROUP 
 
 
NUTRITION AND LIFESTYLE PROGRAM- Attachment 1 
 
If you are allocated to the focus group, a 4-week lifestyle program focusing on a healthy sustainable 
diet, improving fitness and behaviour changes necessary for maintaining change, will be run by the 
Dietitian, Exercise Physiologist, Psychologist and also include Social Work input. 
 
The groups will meet once per week for 2hrs for 4 consecutive weeks. We aim to have 12 or less 
people in each group.  
A subset of patients will be asked to complete a 7 day food diary, approximately 45 in each group. 
This helps us understand better what your dietary intake is like and will give us a good guide as to 
where we can make some changes if needed during your 4 week program. You will need to 
complete the diary at your baseline, 1 year and 3 year visit. 
 
Lifestyle Program Structure 
 
Week 1 – Goal Setting, Guide to a Healthy Diet, Self-Monitoring– Dietitian/Psychologist 
Week 2 – Cholesterol, Fats, Sugars, Salt, Healthy Meal Plan - Dietitian 
Week 3 – Motivating change - understanding Eating and Exercise Behaviours, Triggers, Rewards, 
Problem Solving, Self-Esteem, Barriers to Change –Psychologist 
Week 4 –Food Label reading, Recipe Modification, - Dietitian 
 
You will also be given a workbook which will contain information on the above topics, self-
monitoring exercises, homework and evaluation. 
 
Individual Dietary Reviews: 
After the group sessions are completed, you will be seen on an individual basis for the remainder of 
the trial, as determined by the dietician and as negotiated with you depending on your needs.  
Reviews will either be in person or via telephone. This allows a more flexible and sustainable 
structure of care. 
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Group Meetings: 
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EXERCISE AND LIFESTYLE PROGRAM- Attachment 2 
 
 
Exercise Training for CKD patients in Landmark 3. 
 
A full exercise program as outlined below will be available to you. You can meet with your exercise 





The exercise training intervention will be provided in two stages – an initial, eight-week supervised, 
gym-based training program with additional home-based training (stage one), followed by home-
based training with regular telephone exercise counselling and gym refresher sessions (stage two). 
 
You will begin by attending a 30 minute consultation session with an accredited exercise 
physiologist. During this session you can provide details on your exercise history, discuss likes and 
dislikes, barriers and opportunities to exercise. This will help us design an individualized exercise 
program for you. The program will consist of both moderate-intensity cardiorespiratory exercise 
and resistance training, and will be designed according to fitness and any health problems you may 
have. 
 
During stage one, it will be recommended that you attend the Lifestyle Clinic at the Princess 
Alexandra Hospital as well as doing home based exercise. The number of sessions/week will 
depend on your individualized exercise program taking into account your medical history. The 
cardiorespiratory training will be chosen based on your preference. A variety of options will be 
given to you so that you may choose with the help of your trainer. 
 
After the completion of the first stage of your individual intervention program, you will continue to 
exercise at home. We will continue to provide support via the phone weekly for three months, 
fortnightly for three months and monthly thereafter for the remainder of the study or as required.  
The telephone exercise counselling will aim to monitor and record your levels of exercise and 
physical activity, as well as ensure you can achieve, maintain and where possible, increase the 
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amount of exercise you do through motivation, changing the exercise prescription where necessary, 
and implementing strategies to account for disruption to the exercise routine.  
 
As part of evaluating how your training is going, we will measure your central blood pressure. This 
will be done at the same time as you attend the echo department for you hearts tests. 
 
Central blood pressure will be measured whilst you are lying down, seated and standing, as well as 
during very light exercise similar to activities of daily living (cycling on a bike for about 10 
minutes).This is measured by placing a probe lightly on the surface of your skin at the artery in your 
wrist, neck and upper thigh.  Upper arm blood pressure will also be recorded by the usual method of 
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11.2 Active Australia questionnaire 
 
ACTIVE AUSTRALIA SELF-REPORT PHYSICAL ACTIVITY MEASURE The following 
questions are about the physical activity you did IN THE LAST WEEK:  
 
1A. IN THE LAST WEEK how many times have you walked continuously, for at least 10 
minutes, for recreation/exercise or to get to or from places?  
 
___times  
1B. What do you estimate was the total time that you spent walking in this way IN THE 




2A. IN THE LAST WEEK how many times did you do any vigorous gardening or heavy 
work around the yard which made you breathe harder of puff and pant?  
 
___times  
2B. What do you estimate was the total time that you spent doing vigorous gardening or 




The next question excludes household chores or gardening or yardwork  
 
3A. IN THE LAST WEEK, how many times did you do any vigorous physical activity which 
made you breathe harder or puff and pant? (e.g. jogging, cycling, aerobics, competitive 
tennis, etc.)  
 
___times  
3B. What do you estimate was the total time that you spent doing this vigorous physical 




The next question excludes household chores or gardening or yardwork  
 
4A. IN THE LAST WEEK how many times did you do any other more moderate physical 
activity (e.g. gentle swimming, social tennis, golf etc.)  
 
___times  
4B. What do you estimate was the total time that you spent doing these activities IN THE 




The next three questions are about your average WEEKLY level of activity IN THE LAST SIX  
MONTHS  
 
5A. On average, IN THE LAST SIX MONTHS how much time did you spend each week 
walking for recreation/exercise or to get to or from places? (This is walking continuously for 
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The next question excludes household chores or gardening or yardwork  
 
5B. On average, IN THE LAST SIX MONTHS how much time did you spend each week 
doing vigorous physical activity which made you breathe harder or puff and pant? (e.g. 




The next question excludes household chores or gardening or yardwork  
 
5C. On average, IN THE LAST SIX MONTHS how much time did you spend each week 
doing any other more moderate physical activity that you haven’t already reported. (e.g. 
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Participant Information Sheet 
 
 
Title: The effects of high intensity interval training on exercise capacity in patients with CKD. 
 
Principal Investigator: Kassia Weston, PhD student,  
School of Human Movement Studies, The University of Queensland. 
Email: kassia.weston@uqconnect.edu.au 
Phone: 3176 7650 
 
Supervisor: Professor Jeff Coombes,  
School of Human Movement Studies, The University of Queensland. 
Email: jcoombes@uq.edu.au 
Phone: 3365 6767 
 
This document has been designed to invite you to voluntarily participate in a research study looking 
at the effects of exercise training on CKD. Please feel free to discuss your participation, or anything 




CKD (CKD) is associated with an increased risk of death from cardiovascular disease (CVD). This 
is largely due to the likelihood of CKD to be a associated with lifestyle related cardiovascular risk 
factors such as high blood pressure, diabetes and high cholesterol. Furthermore, patients with CKD 
endure significant muscle wasting which greatly impacts quality of life. As the disease progresses, 
so does the muscle breakdown. For this reason, sufferers of CKD experience muscle cramping, 
fatigue and reduced exercise capacity. 
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Exercise therapy, in particular aerobic exercise, in the CKD population has been shown to decrease 
these cardiovascular risk factors and subsequent CVD, however the most effective training intensity 
is yet to be identified. Short bursts of high intensity exercise has been shown to be superior to long 
duration moderate exercise in improving fitness and decreasing cardiovascular risk in both healthy 
populations and other chronic diseases, however is yet to be studied in the CKD population. As 
exercise capacity is widely known to be associated with cardiovascular risk, the effects of the 
different training intensities will be assessed through a maximal exercise stress test. Additionally, 
the effects of training intensity on muscle breakdown will be assessed through whole body x-ray 
and muscle biopsies.  
 
Subject involvement: 
Participation in this study will require 4 visits to the University of Queensland (UQ), St Lucia for 
testing, 2 visits before the training program and 2 after. You will also be required to attend the UQ 
gym, Princess Alexandra Hospital, Logan Hospital, or Browns Plains Community Clinic, for 
3x/week training sessions. During your testing visits at UQ you will undertake a maximal treadmill 
test and measures of your heart through looking at the pulse in your neck, hip and wrist. Fat mass 
and muscle mass will also be looked at through a body composition x-ray. We will also require a 
small muscle biopsy to be taken from your right thigh with the aid of a local anaesthetic, to look at 
the effects of exercise on reducing muscle breakdown.   
Additionally, your daily levels of activity will be measured in two ways on four occasions; initially, 
at week 6 and 12 of the protocol and 6 weeks after you finish the program. Firstly, you will be 
required to wear an accelerometer (a small unobtrusive device that is worn on the hip on an elastic 
belt) and inclinometer (worn on the thigh attached with and adhesive patch) to objectively measure 
physical activity over 7 consecutive days. You will be given the monitors at the time of attending 
the University for testing or training and will be required to complete a log to record when the 
devices are worn over the 7-day period. Secondly, you will be required to complete two telephone 
interviews with a project investigator where you will be asked to recall your activities over the last 
48 hours. This will be conducted on two occasions on either a Sunday or a Monday. The interview 
will take approximately 45 minutes and will be scheduled at a time that is convenient to you.  
After the initial testing, you will be randomly selected to go into one of 2 groups- a high intensity 
interval exercise group or a moderate continuous exercise group. The exercise intervention groups 
will undertake 12 weeks of either short bursts of high intensity training interspersed with periods of 
light exercise, or moderate intensity longer duration exercise. All training will be undertaken on a 
treadmill and intensity will be increased by increasing the incline of the treadmill, simulating uphill 
walking. Exercise will be appropriately progressed through the 12 weeks. Free parking is provided 
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at all locations for all visits involved with the study. At the end of the intervention both groups will 
complete their second visit for testing to compare the differences. All training groups will be 
supervised by a qualified Exercise Physiologist. The exercise intervention groups will complete 3 
supervised training sessions per week. There will be 10 people randomly selected to go into each of 
the 2 groups. On completion of the study, you will receive your individual results as well as the 
group findings. 
 
Information on muscle biopsy: 
Muscle biopsy is a commonly performed procedure in both research and medical diagnosis of 
muscle disorders. As CKD is associated with a breakdown of muscle, we aim to find out the causes 
of this muscle wasting and whether exercise can improve this decline. The procedure will be 
performed by a medical doctor trained in muscle biopsies.  
The muscle over your lower thigh on your right leg will be thoroughly cleaned before a local 
anaesthetic will be injected into the skin. You may feel a momentary stinging sensation, as with all 
needles. The use of anaesthetic minimises any discomfort, however during the procedure you may 
feel slight pressure. A biopsy needle will be inserted through a small incision (approximately 4-
5mm) and a small piece of muscle (~100 mg) will be removed. The biopsy itself only takes a few 
seconds. Your leg will be iced and a compression bandage applied to minimise the chance of 
bruising. When the anaesthetic wears off you may feel a tightness in the muscle as if you have 
bumped your leg. 
Potential Risks: 
The risk of an allergic reaction to the anaesthetic is low at less than 1 in 1 000 000. 
The risk of a skin infection is less than 1 in 1 000 and can be minimised by keeping the injection 
site clean and dry until it heals. However, if redness or swelling does occur after the procedure, 
contact the attending physician immediately. 
The chance of numbness over the site is approximately 1 in 5000, however it would not be enough 
to affect daily activities and would resolve within a year. 
A 4-5 mm scar may also occur as a result of the biopsy. 
Other risks involved with the study: 
CKD is associated with an increased risk of cardiovascular disease so there is a small risk to the 
subjects of a cardiac event occurring during exercise. Supervising Exercise Physiologists are well 
trained to recognise and prevent any early signs and symptoms of a cardiac event occurring. 
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As with any exercise there is an associated risk of musculoskeletal injuries. If randomized to an 
exercise intervention, you will undergo a thorough warm-up procedure before each exercise session 
to reduce the chance of any injury occurring.  
 
An x-ray scan is used to determine fat mass and muscle mass and involves emission of low dose 
radiation. However, approximate dosage received from one scan (62 mSv) equates to less than 9 
days of natural background radiation and the risk level of associated cancers is classed as extremely 
low. 
 
Injuries related to participation in the study: 
If you think you have any side effects that are related to the muscle biopsy or any other aspect of the 
study, you should immediately notify Professor Robert Fassett. He may be reached at the 
Department of Renal Medicine, Royal Brisbane and Women’s Hospital. Phone: 0419399571 (24 
Hour contact number).  
If you have a study-related illness, the investigator and the study staff will make sure that you 
receive necessary treatment. The University of Queensland provides indemnity insurance coverage 
for all potential damage or loss that may be sustained as a result of negligence carried out in the 
course of performing this activity.  
 
Benefits: 
This study will answer a number of questions relating to the effects of exercise training on CKD. 
Furthermore, we are looking to see the effects different training intensities have on the deterioration 
of kidney function and the symptoms associated with this disease. By determining the best mode of 
exercise we will be able to better treat and improve the lifestyles of people with CKD. If this study 
is shown to improve kidney function, cardiovascular risk factors, muscle strength and cramping 
then it may be implemented as standard hospital care in the future. 
 
Confidentiality: 
Personal information gained from the study such as muscle volumes, fitness and cardiovascular 
measures will be recorded but not identified to any one individual. Once all the measures are 
completed and the study outcome is verified, subject data will be de-identified and filed in a locked 
cabinet within the supervisors office in the Princess Alexandra Hospital. To ensure longevity of the 
data, results will also be kept in a password locked computer with access granted only to the 
primary investigators. Data will be kept for a minimum of 5 years at the university before being 
shredded. 








Current involvement in other research studies 
Organ transplant 
History of significant coronary artery disease 
Inability to provide fully informed written consent 
 
Ethical considerations: 
This study has been reviewed and approved by the University of Queensland and Princess 
Alexandra, Human Research Ethics. Should you wish to discuss the study with someone not 
directly involved, in particular in relation to matters concerning study policies, information about 
conduct of the study or your rights as a participant, or should you wish to make independent 
complaint, you can contact:  
The Coordinator or Chairperson, Human Research Ethics Committee, The University of   
Queensland, St Lucia QLD 4072, phone 07 3365 4584 or The HREC Coordinator, Metro South 
Hospital and Health Service Human Research Ethics Committee (EC00167), Centres for Health 
Research, Princess Alexandra Hospital, Ipswich Road Woolloongabba QLD 4102, phone 07 3443 
8049, email: PAH_ethics_research@health.qld.gov.au 
 
If you wish to discuss this study with someone directly involved in this research you are free to 
discuss your participation with the principal investigator- Kassia Weston on (07) 3176 7650. 
It is a requirement of the Investigator that the informed consent process has taken place with the 
subject and that the subject: 
meets all study inclusion criteria;  
was appropriately consented (as described above);  
understands the requirements of the study; and  
has received a copy of the informed consent document.  
PARTICIPATION IS ENTIRELY VOLUNTARY AND SUBJECTS ARE FREE TO 
WITHDRAW FROM THIS STUDY AT ANY TIME WITHOUT PENALTY. 
 
Participant Consent Form 
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Title: The effects of high intensity interval training on exercise capacity and cardiovascular 
risk in CKD. 
The investigators of this study conform to the principles governing the ethical conduct of research, 
and will protect the safety, interests and well being of subjects at all times. This form, the 
information sheet has been given to you in the interest of your own protection. They contain an 
outline of procedures and possible risks involved. By signing this consent form you are indicating 
that: 
You have read and understand the information sheet for this study and are aware of the risks 
involved. 
 To the best of your knowledge you do not meet any of the criteria for exclusion from the study. 
You acknowledge that participation in this study involves you undergoing a muscle biopsy, body 
composition x-ray and maximal treadmill test; and wearing an accelerometer and inclinometer to 
measure physical activity.  
You are aware that you are able to withdraw from the study at any time without prejudice from 
either the University of Queensland or Princess Alexandra Hospital. 
 You understand that due to limited funding you are unable to receive any compensation for your 
participation, besides parking remuneration.  
You understand that the data you provide to the researchers is confidential and can be identifiable 
only to the primary investigators even if the study is published. 
You have been given the opportunity to discuss the study contents with one of the investigators 
prior to starting the study and that all questions you have asked have been satisfactorily answered. 
 
I agree to participate in the procedures outlined in the patient information sheet to the study: The 
effects of high intensity interval training on exercise capacity and cardiovascular risk in CKD. 
 
                                                                                                 
     Name of Participant                 Date                             Signature 
Date of Birth:   / /  
Address:            
            
Declaration by researcher: I have given a verbal explanation of the research project, its procedures and risks and I 
believe that the participant has understood that explanation. 
 
                                                                                                 
     Kassia Weston                 Date                             Signature 




                                                                                                 
     Name                            Relationship                   Contac 
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11.5 Physical activity enjoyment scale 
 
This questionnaire is designed to assess your enjoyment of the exercise training that you undertook (either high intensity interval training or moderate intensity continuous 
training) for the 12 weeks at the University of Queensland. Please answer honestly about your feelings regarding your enjoyment during the exercise sessions. With these 
answers we are looking to compare the enjoyment of high intensity interval training versus moderate intensity continuous training, which may affect adherence to particular 
exercise programs. Please circle the number on the scale which reflects how you feel for each of the 12 statements. 
 
1. I find it pleasurable     1 2 3 4 5 6 7 I find it unpleasurable 
2. *It’s no fun at all     1 2 3 4 5 6 7 It’s a lot of fun 
3. I feel good physically while doing it   1 2 3 4 5 6 7 I feel bad physically while doing it 
4. *It’s not very invigorating    1 2 3 4 5 6 7 It’s very invigorating 
5. It’s very gratifying     1 2 3 4 5 6 7 It’s not at all gratifying 
6. *It’s not at all exhilarating    1 2 3 4 5 6 7 It’s very exhilarating 
7. It’s very stimulating     1 2 3 4 5 6 7 It’s not at all stimulating 
8. *It’s not at all refreshing    1 2 3 4 5 6 7 It’s very refreshing 
9. I find it energizing after     1 2 3 4 5 6 7 I find it tiring after 
10. *It doesn’t give me a strong sense of accomplishment         1       2 3 4 5 6 7 It gives me a strong sense of accomplishment 
11. I am not frustrated by it at all    1 2 3 4 5 6 7 I am very frustrated by it 
12. *I wouldn’t recommend this type of training to my friends 1 2 3 4 5 6 7 I would recommend this type of training to my 
friends 
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11.7 Cardiorespiratory fitness is associated with autonomic function in patients 
with chronic kidney disease  
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ABSTRACT 
Background: CKD (CKD) patients have reduced cardiorespiratory fitness  which is associated with 
a higher incidence of cardiovascular disease and mortality. In healthy individuals the function of the 
autonomic nervous system (ANS) is positively related to cardiorespiratory fitness, however this has 
not been investigated in CKD patients. This study aimed to determine the relationship between 
cardiorespiratory fitness and ANS function in CKD patients. A further aim was to compare ANS 
function of CKD patients with and without diabetes mellitus (DM) and the relationships with 
cardiorespiratory fitness. 
Methods: Seventy-two patients with stage 3 or 4 CKD were included in the study (eGFR 25-60 
mL/min//1.73 m2). Twenty-seven patients without DM [CKD DM-], 45with DM [CKD DM+]) and 
22 healthy controls were investigated. Autonomic function was assessed through measurement of 
time, frequency and non-linear components of heart rate variability (HRV) obtained through 5-
minute supine electrocardiography recordings. Cardiorespiratory fitness (VO2peak) was assessed 
via a treadmill exercise stress test.  
Results: Patients with CKD exhibited significantly (P<0.05) lower HRV and VO2peak compared 
with healthy controls. Similarly, the majority of HRV parameters and VO2peak in CKD patients 
with diabetes were significantly (p<0.05) lower compared to CKD patients without diabetes. There 
were significant (p<0.05) relationships between VO2peak and a number of measures of HRV for all 
CKD patients (standard deviation of RR intervals [SDNN], r=0.34; root mean square of successive 
RR interval differences [RMSSD], r=0.30; high frequency [HF], r=0.28; low frequency [LF], 
r=0.30; short term variability [SD1], r=0.31; long term variability [SD2], r=0.32) and those without 
diabetes (SDNN, r=0.29).  
Conclusion: Patients with CKD exhibited compromised HRV that was related to cardiorespiratory 
fitness, suggesting a link between autonomic dysfunction and cardiorespiratory fitness in CKD 
patients. The additional presence of DM resulted in lower HRV and cardiorespiratory fitness in 
CKD patients, with cardiac autonomic dysfunction possibly a result of combined uremic and 
glycaemic neuropathy. Further studies are needed to examine and identify an optimal exercise 
program for CKD patients to improve cardiorespiratory fitness and cardiac autonomic function. 
  




Diabetes mellitus (DM), CKD (CKD) and cardiovascular disease (CVD) together account for 
approximately one quarter of the total disease burden in Australia, and two-thirds of total 
deaths.(336) These diseases (DM, CKD and CVD) are intricately linked, with DM the most 
common cause of CKD. The most common cause of death in patients with DM or CKD is 
CVD,(337, 338)which could in part be due to autonomic nervous system (ANS) dysfunction, in 
particular cardiac autonomic neuropathy. ANS dysfunction, as measured by heart rate variability 
(HRV) has been linked to increased cardiovascular associated mortality.(339) Examination of ANS 
dysfunction has been conducted in other chronic disease populations (340, 341) with HRV 
providing a simple, non-invasive, reproducible and cost-effective marker of ANS function.(342)  
The pathophysiology of CKD and DM has been suggested to contribute to ANS dysfunction, albeit 
through separate mechanisms.(343, 344) Renal impairment may result in an accumulation of 
neurotoxic solutes in the blood, leading to uremic neuropathy and autonomic dysfunction.(343) 
Alternatively, hyperglycaemia in DM may result in glycaemic neuropathy and subsequent ANS 
dysfunction.(344) Regardless of the mechanism, the disease burden of both CKD and DM is 
significant,(345) with both conditions associated with reduced cardiorespiratory fitness compared to 
healthy controls.(346, 347) Establishing the relationship between cardiorespiratory fitness and heart 
rate variability is important as both contribute independently to high mortality rates.(62) Fitness 
represents a potentially modifiable risk factor, thus if a relationship exists exercise training may be a 
suitable countermeasure to improve autonomic dysfunction. Previous studies have demonstrated 
HRV parameters to be related to cardiorespiratory fitness,(348) however this relationship has not 
been investigated in patients with CKD.  
The aim of this study was to determine the relationship between HRV and cardiorespiratory fitness 
in CKD patients. We also sought to compare the HRV and cardiorespiratory fitness of CKD patients 
with and without DM. It was hypothesized that HRV parameters would be significantly associated 
with cardiorespiratory fitness for all CKD patients, with CKD patients exhibiting greater ANS 
dysfunction than healthy controls. Furthermore, we expected that CKD patients with DM would 
have lower HRV parameters than CKD patients without DM.  
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PARTICIPANTS AND METHODS 
This study was a cross-sectional analysis of the ‘LANDMARK 3’ (Longitudinal Assessment of 
Multiple Discrete Atherosclerotic Risk Factors in Kidney Disease) study that investigated the 
effects of a lifestyle intervention on cardiovascular risk factors in CKD patients. Seventy-two 
participants aged 18 to 75 years with stage 3-4 CKD (estimated glomerular filtration rate (eGFR) 
between 25 and 60 ml/min/1.73m2) were included in this study. Inclusion criteria: Aged 18 to 75 
years and at least one of the following risk factors – blood pressure or lipids not at target; 
overweight (BMI >25); and poor diabetic control (haemoglobin A1c >7%). Exclusion criteria were: 
intervention for, or, symptomatic coronary artery disease (within 3 months), current heart failure 
(New York Heart Association class III and IV) or significant valvular heart disease, pregnant or 
planning to become pregnant and life expectancy or anticipated time to dialysis or organ transplant 
< 6 months. The CKD patients with diabetes group consisted of patients with type 1 and type 2 
diabetes. The study protocol was approved by the Princess Alexandra Human Research Ethics 
Committee (HREC 2007/190), and was registered at www.anzctr.org.au (Registration Number 
ANZCTR12608000337370). Patients provided written and informed consent. Results for a group of 
healthy, age-matched adults (controls, n=22) were obtained from a sub-population of a previous 
study (349) for comparison with the current study population. 
 
Heart rate variability 
Patients rested in the supine position for at least 5 minutes in a quiet room with no disturbances. 
Measures were performed after an overnight fast followed by a light meal approximately 30 
minutes before testing. All caffeinated products, smoking and alcohol were abstained from for at 
least 12 hours prior to testing. A standard 3-lead electrocardiograph was recorded continuously for 
5 min. R-R intervals were determined automatically from the 3 lead ECG recording using 
Sphygmocor 8.2 (AtCor Medical, Sydney, Australia) and exported for analysis. The R-R interval 
tachogram was then visually inspected for any artifacts or ectopic beats that were then replaced with 
linearly interpolated values calculated from the preceding and proceeding beats. Entire recordings 
of RR intervals were detrended using a smoothness priors regularization procedure before the time, 
frequency and non-linear domain HRV parameters outlined in Table 1 were calculated (Kubios 
HRV v2.0 software, 2008, Finland).(349)  
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Chronotropic incompetence 
Heart rate (HR) was measured immediately after the termination of the exercise stress test at one, 
two, and three minutes into the cool-down period. HR at each of these time-frames was subtracted 
from peak HR of the exercise stress test. Heart rate recovery (HRR)-1, HRR-2, and HRR-3 are used 
to describe the overall HRR at those respective time points. Chronotropic incompetence was 
determined by calculating the percent HR reserve (%HR reserve). The following equation used in 
this study was taken from the Framingham Heart Study(350) with the recommendation that patients 
are deemed chronotropically incompetent with a %HR reserve of <80: 
% HR − Reserve = (HR stage− resting HR)(APMHR − resting HR) 𝑥 100 
‘HR stage’ refers to the HR corresponding to the end of the exercise stress test stage. In this study, 
stage 2 is used to calculate %HR reserve, meaning that patients must have at least completed two 
stages on the exercise stress test. APMHR was calculated as 208 - (0.7 x age). 
 
Cardiorespiratory fitness 
Cardiorespiratory fitness, exercise capacity, PHR and peak BP were obtained during a treadmill 
exercise stress test using the Bruce protocol. Cardiorespiratory fitness was measured by peak 
oxygen uptake (VO2peak) and was determined by expired gas analysis (Vmax29c, SensorMedics, 
CA, USA) using the peak 20 second average of the final minute. Exercise capacity was measured 
by estimated metabolic equivalent tasks (METS)(General Electric Case, Wisconsin, USA) at peak 




During rest and exercise, BP was recorded manually from the right brachial artery using an aneroid 
dial and mercury sphygmomanometer and stethoscope. Arterial stiffness measures were obtained 
after 10 minutes of supine rest using tonometry of the femoral and carotid pulses 
(Sphygmocor,AtCor Medical, Sydney, Australia). Measures of LDL, HDL, TC, TG, urea and eGFR 
were assessed from blood samples collected via venipuncture and standard laboratory techniques 
following an overnight fast. Patients on Β-blockers withheld their Β-blocker medication for at least 
24 hours prior to testing. The Modification of Diet in Renal Disease-175 formula was used to 
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calculate eGFR.(14) Data on patient demographics, comorbidities and current medications were 
obtained at the baseline visit. Physical activity levels were determined using the self-report Active 
Australia Questionnaire.(137)  
 
Data Analysis 
Data was analysed using GraphPad Prism (GraphPad, La Jolla, USA). Normality of distribution 
was assessed using the Kolmogorov-Smirnov test. Parametric one-way ANOVA with a Tukey post-
hoc test was used to compare normally distributed variables between the control, all CKD patients, 
CKD with diabetes mellitus (DM+) and CKD without diabetes mellitus (DM-) groups. The CKD 
DM+ and CKD DM- makes up the all CKD group, in order to demonstrate differences between the 
healthy control and CKD patients, before analyzing differences between diabetes and no diabetes in 
CKD. Non-parametric Kruskal-Wallis tests with Dunn’s post-test were used to compare skewed 
variables. Correlations between variables were assessed using Pearson correlation or Spearman’s 




Clinical characteristics of the CKD patients and controls are displayed in Table 2. All CKD patients 
had significantly (p<0.05) higher BMI resting blood pressure, and significantly lower VO2peak 
compared to the healthy control group. There were 27 patients with CKD and clinically diagnosed 
DM (CKD DM+), and 45 patients with CKD alone (CKD DM-) participating in this study. 
Compared to CKD DM- patients, CKD DM+ patients displayed significantly (p<0.05) lower 
VO2peak, estimated METS, resting diastolic blood pressure, peak diastolic blood pressure, and 
significantly higher pulse wave velocity (PWV), and incidence of hyperlipidaemia (Table 2). 
 
Heart rate variability parameters between groups 
The HRV parameters for all groups are displayed in Table 3. Compared to the control group, all 
CKD patients exhibited lower HRV for 6 out of the 11 parameters including RMSSD, pNN50, HF, 
LF, SD1 and SD2. Comparisons between CKD patients indicated that HRV for CKD DM+ patients 
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was significantly (p<0.05) lower compared to CKD DM- patients for 7 out of the 11 HRV 
parameters investigated: SDNN, RMSSD, pNN50, HF, LF, SD1 and SD2.  
 
Heart rate variability and cardiorespiratory fitness 
Table 4 shows a number of significant (p<0.05) correlations between VO2peak and HRV (i.e. 
SDNN (Figure 1), RMSSD, HF, LF, SD1 and SD2) in all CKD patients. When CKD patients were 
separated based on diabetic status, SDNN was significantly (p<0.05) associated with VO2peak for 
the CKD DM- subjects. There were no significant associations between VO2peak and HRV 
parameters for the control or CKD DM+ groups. Weekly physical activity was not significantly 
(p>0.05) associated with for any of the CKD groups, but was significantly associated with 
SDNN (Figure 1), SD2 (r = 0.25, p<0.05) and LF(r = 0.28, p<0.05) for all CKD patients. There 
were no significant associations between chronotropic incompetence measures and SDNN. 
 
DISCUSSION 
This is the first study to investigate the relationship between HRV and cardiorespiratory fitness in 
CKD patients. The main findings were that: 1) CKD patients have compromised HRV which was 
related to low cardiorespiratory fitness; 2) CKD patients with DM have decreased HRV and 
cardiorespiratory fitness compared to those without DM; 3) physical activity levels were not 
associated with cardiorespiratory fitness but were related to HRV for all CKD patients. Together, 
this data suggests that improving cardiorespiratory fitness and physical activity in CKD patients 
may lead to an improvement in heart rate variability. Future longitudinal studies are needed to test 
this hypothesis.  
The current study demonstrated that CKD patients both with and without DM had significantly 
decreased HRV parameters compared to healthy control subjects. This supports previous 
studies,(115, 259) which indicate autonomic dysfunction in renal patients, suggested to be 
attributable to uremic neuropathy. The uremic environment associated with renal dysfunction may 
result in generalized axonal loss and demyelination of neurons, resulting in subsequent autonomic 
dysfunction.(351)  
Whilst the findings demonstrated CKD patients to have lower HRV compared to healthy controls, 
most HRV parameters were significantly lower for CKD DM+ patients compared to CKD DM- 
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patients. This is consistent with previous research.(352) More recently, Myonopoulou et al. (2010) 
and Chandra et al. (2012) (353) reported that the majority of 24-hour HRV measures from Holter 
ECG recordings were significantly lower for CKD DM+ patients compared to CKD DM- patients. 
This lower HRV and decreased autonomic function may result from the combined effects of 
glycaemic and uremic neuropathies on cardiac innervation. In patients with DM, hyperglycaemia 
has been observed to contribute to autonomic dysfunction by first decreasing the activity of 
parasympathetic nerves (leading to sympathetic augmentation) and then later affecting the 
sympathetic nerves.(344, 354) The significant decrease in both LF and HF measurements in the 
current study provides further support for the damage to both parasympathetic and sympathetic 
modulation possibly due to advanced autonomic denervation.(339) The exact mechanistic pathways 
for the impact of uremic induced neuropathy on ANS activity remains to be clarified and warrants 
further investigation, including trialling approaches known to enhance ANS activity such as regular 
exercise.(355)  
Regular exercise has been reported to enhance cardiorespiratory fitness in a range of clinical 
populations (75, 356) with cardiorespiratory fitness regarded as an independent predictor of 
mortality.(26, 357) It is well reported that cardiorespiratory fitness is lower for CKD patients 
compared to healthy controls.(309) In the current study, CKD patients with DM exhibited decreased 
cardiorespiratory fitness and HRV compared to those without DM. Furthermore, the relationship 
between HRV and cardiorespiratory fitness was only apparent for the CKD patients without DM. A 
similar association between HRV and cardiorespiratory fitness has also been noted previously in 
healthy populations.(358) It may be reasonable to suggest that damage to the ANS by uremic and 
importantly glycaemic neuropathy may result in decreased cardiorespiratory fitness through 
chronotropic incompetence, a restriction in the ability to raise heart rate during exercise.(359) 
However, this study found no association between chronotropic measures and the global measure of 
HRV, SDNN. This may indicate that autonomic dysfunction is influencing cardiorespiratory fitness 
through mechanisms other than chronotropic incompetence. Previous studies have identified 
chronotropic incompetence due to cardiac autonomic neuropathy in diabetic patients,(360, 361) 
although the exact mechanisms for this change remain unclear. The decreased cardiorespiratory 
fitness observed in CKD patients is likely multifactorial and identifying the mechanisms through 
which autonomic dysfunction leads to reduce cardiorespiratory fitness warrants further 
investigation. 
It is interesting to note that both cardiorespiratory fitness and weekly physical activity levels were 
significantly associated with HRV (SDNN) but they were not related to each other in the present 
study. A lack of association between physical activity and measures of cardiorespiratory fitness 
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have previously been reported.(362) This may reflect the importance of exercise intensity (e.g. 
moderate or high intensity exercise) in improving cardiorespiratory fitness. Furthermore, the 
correlation between cardiorespiratory fitness and physical activity with HRV may indicate that 
physical activity is influencing cardiac autonomic function in patients with CKD. Exercise intensity 
has been suggested to play an important role in HRV adaptations (355) with renal patients reported 
to enhance HRV with regular exercise training (117, 260) although this is not always observed.  
Interestingly, the findings from this study also demonstrated that PWV was significantly greater for 
CKD DM+ patients compared to CKD DM- patients. PWV is an indicator of arterial stiffness and 
has been shown to predict cardiovascular mortality in patients with DM.(363) A previous study has 
shown PWV to be significantly and independently correlated with autonomic neuropathy.(363) 
Several reasons for this have been suggested, including that arterial stiffness may contribute to 
autonomic neuropathy (aortic and carotid wall stiffness may impair baroreceptor function). It has 
been suggested that damage can occur to the autonomic nerves passing signals from the baroceptors 
to the medulla oblongata, and from the medulla oblongata to the cardiovascular system, which may 
result in dysfunction of the baroreceptor reflex.(364) In contrast, it has also been suggested that 
autonomic neuropathy may influence the elastic properties of the arteries.(365) Increased arterial 
stiffness in CKD DM+ patients may decrease the degree of stretch of the baroreceptors in the aortic 
arch and carotid sinus, thereby decreasing baroreceptor activation and impairing blood pressure 
regulation.(366) Regardless of aetiology, increased arterial stiffness appears to be linked with 
autonomic dysfunction, and could be involved in the decreased cardiorespiratory fitness of CKD 
DM+ patients compared to CKD DM- patients. For example, recent research has suggested that the 
HRV measure of LF may reflect baroreceptor reflex modulation and not sympathetic tone as 
previously thought.(367) Therefore, the significantly decreased LF observed in CKD DM+ patients 
in the current study may indicate decreased activity of the baroreceptor reflex. Impairment of the 
baroreceptor reflex may contribute to exercise intolerance, as blood pressure changes associated 
with exercise could not be corrected as quickly or efficiently as in a healthy individual. Increases in 
rate and force of cardiac contraction in response to decreased blood pressure would be impaired, 
resulting in chronotropic incompetence. 
There were several strengths to the current study, including the large sample size across different 
populations and the use of non-linear measures of HRV. These HRV measures have been reported 
to be superior to conventional time and frequency domain HRV measures.(368) The current study 
also possessed some limitations. Firstly, this study was a cross-sectional analysis of the CKD 
population and therefore could not definitively deduce causality. Secondly, 5-minute recordings of 
HRV were used instead of 24-hour Holter monitoring that may provide greater details of longer-
Chapter 11 Appendices   
274  
term ANS function. Nonetheless, the current HRV results were significant and provide a unique 
examination of HRV and cardiorespiratory fitness in CKD patients. The use of the Active Australia 
questionnaire is well validated in the older population,(137) however without an objective measure 
of physical activity such as use of a pedometer or accelerometer, the questionnaire may have 
resulted in over-reporting by the patients. In an attempt to limit over-reporting, the questionnaire 
was administered by an Exercise Physiologist, with each question carefully explained with 
examples. The use of negative chronotropic drugs, such as Β-blockers, may also influence heart rate 
variability. Although participants were asked to refrain from taking this medication at least 24 hours 
prior to testing, some residual medication may still influence heart rate. Finally, not all variables 
were available for the control group, with future studies potentially providing greater comparisons. 
In summary, our study was the first to investigate the relationship between HRV and 
cardiorespiratory fitness in CKD patients. The main findings were that CKD patients exhibited 
compromised HRV compared to healthy controls, which positively correlated with 
cardiorespiratory fitness in CKD DM- patients only. Additionally, CKD patients with DM exhibited 
lower HRV and cardiorespiratory fitness compared to those without DM. Further studies are needed 
to examine and identify if exercise training is able to impact HRV in patients with DM and CKD. 
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Table 1 Heart Rate Variability (HRV) parameters  
Frequency domain HRV measures Unit Description 
LF Low frequency power (0.04 - 0.15Hz) ms2 Correlated to both 
parasympathetic and sympathetic 
modulations. 
HF High frequency power (0.15 - 0.4Hz) ms2 Indicator of parasympathetic 
modulations. 
LF/HF  Ratio of LF/HF No 
units 
Indicator of sympathovagal 
balance. 
 
Time domain measures of HRV Unit Description 
pNN50 Ratio between the number of pairs of 
adjacent NN intervals differing by 
more than 50ms and the total number 
of NN intervals 
% Reflects high frequency heart 
rate variations due to 
parasympathetic modulation. 
SDNN Standard deviation of all NN intervals ms Indicator of overall HRV 
RMSSD Square root of the mean of the squares 
of successive R-R interval differences 
ms Reflects high frequency heart 
rate variations due to 
parasympathetic modulation. 
Indicates short-term HRV 
components. 
Non linear measures of HRV Unit Description 
SD1 Short axes of the Poincare plot ms Reflects short-term 
instantaneous RR modulation 
and parasympathetic activity. 
SD2 Long axes of the Poincare plot ms Reflects long-term RR 
modulation and overall HRV. 
SampEn Sample entropy  Estimates the predictability or 
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randomness (i.e. complexity) of 
the data 
Alpha1 Short-term fractal scaling exponent, 
based on four to 16 beats. 
 Quantifies the presence or 
absence of fractal-like 
correlations. Scaling exponent of 
1 indicates normal cardiac 
health, 0.5 indicates random 
dynamics or white noise, while 
1.5 is highly correlated but of 
non power law or brown noise. 
Alpha 2 Long-term fractal scaling exponent, 
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Table 2 Clinical characteristics of control adults and CKD patients with and without diabetes 
mellitus.  
  Control  
(n = 22) 
All CKD 









  (n = 27) (n = 45) 
Demographics     
Age (years) 64.5 (4.5) 63.0 (4.3) 64.0 (4.5) 60.1 (6.9) 
Sex      
Female (%) 36.4 48.4 48.1 42.2 
Body Mass Index (kg/m2) 25.5 (5.6) 31.1 (4.7)* 33.2 (3.4)* 30.7 (4.3)* 
Current smokers (%) 0 15.7 7.4 20.9 
Comorbidities     
Hyperlipidaemia (%) - 69.6 88.5 58.1# 
Hypertension (%) 31.6 95.7* 100.0* 93.2* 
Peripheral Vascular Disease (%) - 16.2 23.1 11.9 
Past Myocardial Infarction (%) 0 20.3 30.8* 14 
Blood biochemistry     
HDL cholesterol (mmol/L) 1.1 (0.3) 0.9 (0.5) 1.2 (0.4) 
LDL cholesterol (mmol/L) 2.4 (0.3) 2.2 (0.3) 2.6 (0.3)# 
Total cholesterol (mmol/L) 4.4 ± 1.2 3.9 ± 1.5 4.7 ± 0.9# 
Triglycerides (mmol/L) 1.6 (0.5) 1.6 (0.4) 1.6 (0.6) 
eGFR (mL/min/1.73m2) 38.2 ± 12.6 36.7 ± 10.3 39.0 ± 13.8 
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Urea(mmol/L) 9.6 (2.4) 9.8 (3.0) 9.3 (2.2) 
Hemodynamic values     
Resting SBP (mmHg)  130.0 (13.3) 137.0 (11.0) 126.0 (14.0) 
Resting DBP (mmHg)  73.2 ± 9.8 69.1 ± 9.9 75.6 ± 9.0# 
Peak SBP (mmHg)  170.0 (10.5) 170.0 (10.0) 170.0 (14.0) 
Peak DBP (mmHg) 
 
 80.0 (10.0) 80.0 (0.0) 89.0 (1.5)# 
Resting heart rate (bpm) 62.8 ± 8.2 79.6 ± 13.1 83.3 ± 15.7 77.3± 10.7 
Peak heart rate (bpm)  147.0 ± 19.7 142.2± 19.1 149.9 ± 19.7 
Pulse wave velocity (m/s)  0.55 (1.30)# 10.60 (2.90) 7.85 (2.45)# 
Medications     
Beta blockers (n,%) 14.3 39.7 15, 53.8 16, 31.0 
ACE inhibitors (n,%) 44.4 50 16, 57.7 25, 45.2 
Metformin (n,%)  5.8 4, 15.4 0, 0# 
Insulin (n,%)  24.6# 17, 65.4 0, 0# 
Sulfonylurea (n,%)  1.4 1, 3.7 0, 0 
Thiazolidinedione (n,%)  9.7# 7, 26 0, 0# 
Statins (n,%) 37.5 70.6 25, 88.5* 30, 59.5 
Exercise Parameters     
 (mL/kg/min) 34.7 (5.6) 21.4 (3.8)
* 19.2 (2.5)* 23.5 (3.6)*# 
Respiratory Quotient  1.05 (0.08) 1.00 (0.14) 1.06 (0.07) 
Weekly physical activity (mins)  80.0 (130.0) 45.0 (93.8) 125.0 (115.0) 
Estimated METS  7.2 ± 3.1 6.0± 2.4 8.0± 3.1# 
Chapter 11 Appendices   
279  
LDL: Low-density lipoprotein; HDL: high-density lipoprotein; eGFR: estimated glomerular 
filtration rate; DBP: diastolic blood pressure; SBP: systolic blood pressure; ACE: angiotensin 
converting enzyme. 
Normally distributed quantitative variables are reported as mean ± standard deviation (SD). Not 
normally distributed variables are reported as median (IQR). Categorical variables are reported as % 
(percentage of patient group positive for that characteristic).  
*Significantly (p<0.05) different to control 
# Significantly (p<0.05) different to CKD patients with diabetes mellitus  
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Table 3. Comparison of heart rate variability (HRV) parameters between CKD patients with 
and without diabetes mellitus 
 Control  
(n = 22) 
All CKD  
(n= 72) 
CKD with 
diabetes mellitus  
(n = 27) 
CKD without 
diabetes mellitus  
(n = 45) 
Time domain 
parameters 















17.5 (7.4) * 
10.5 (8.7) * 
0.0 (2.0) * 
 
 
30.4 (6.7) # 
19.4 (5.9) # 







SD1 (ms)  
SD2 (ms) 
Alpha1 










54.3 ± 17.6 
1.137 ± 0.299 
0.949 (0.153) 








34.6 ± 16.7* # 
1.148 ± 0.252 
1.059 (0.092) 







7.3 (6.3) * 
24.3 ± 14.0 * 
1.108 ± 0.282 
1.086 (0.171) 




168 (135)* # 
1.6 (1.2) 
 
14.1 (3.8) # 
40.8 ± 15.1 * # 
1.171 ± 0.233 
1.045 (0.098) 
1.413 ± 0.280 
Variables are reported as mean ± standard deviation (SD). 
* Significantly (p<0.05) different to control  
# Significantly (p<0.05) different to CKD (CKD) patients with diabetes mellitus  
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Parametric (r value) and non-parametric (rho value) correlations between and heart rate 
variability shown. * p<0.05, ** p<0.005. 
 
 




Figure 1 Relationships between VO2peak and weekly physical activity levels (WPA) with SDNN in 
all CKD patients.  
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Abstract 
Background: Elevated oxidative stress is a hallmark of patients with CKD (CKD). Reduced heart 
rate variability (HRV) is also prevalent in CKD and is associated with increased morbidity and 
mortality. The relationship between oxidative stress and HRV has not been investigated in the CKD 
population. 
Methods: 78 patients with stage 3-4 CKD (MDRD eGFR 25-60 mL/min/1.73 m2) provided blood 
for the assessment of plasma total F2-isoprostanes, glutathione peroxidase activity and total 
antioxidant capacity. Time and frequency HRV parameters were collected after five minutes in a 
supine position. Additional blood measures, such as lipids and inflammatory markers were also 
obtained. 
Results: Participants with elevated F2-isoprostanes had a reduced HRV as measured by the standard 
deviation of the normal-normal intervals (SDNN). A number of HRV parameters were found to be 
inversely correlated with F2-isoprostanes, including SDNN (r= -0.337; p= 0.003), very low 
frequency (r= -0.281, p= 0.013), low frequency (r= -0.315, p= 0.005) and total power (r= -0.288, p= 
0.01). Multiple linear regression found F2-isoprostanes to be an independent predictor of SDNN 
(β= -0.272, p= 0.01). F2-isoprostanes and male sex explained 28.7% of the variance in SDNN 
(p<0.01).  
Conclusion: Oxidative stress is significantly and independently associated with HRV in patients 
with CKD. 
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INTRODUCTION 
Elevated oxidative stress is common in patients with CKD (CKD).(161) Oxidative stress occurs 
when there is a disruption in redox signalling and control pathways.(159) Elevated oxidative stress 
may contribute to a multitude of disease pathways including a variety of cardiovascular conditions 
(369), the mortality rates of which are increased in the CKD cohort.(370, 371) The gold standard for 
the measurement of oxidative stress injury is plasma total F2-isoprostanes, the by-product of lipid 
peroxidation.(372)  
Patients with CKD also exhibit a reduction in heart rate variability (HRV).(373) HRV is a measure 
of the constantly deviating R-R interval and, thus the balance between the dual 
sympathetic/parasympathetic stimulation of the pacemaking sino-atrial node in the heart.(374) A 
reduction in HRV is indicative of cardiac autonomic dysfunction and associated with increased 
morbidity and mortality.(114, 375) Indeed, sudden cardiac death is a significant problem reportedly 
contributing to up to 60% of cardiovascular mortality in dialysis patients, increasing with each stage 
of CKD.(376) It has been suggested that impaired baroreflex effectiveness through autonomic 
dysfunction can initiate fatal arrhythmias and sudden cardiac death.(377, 378) Despite many time 
and frequency parameters that can be attained from a single heart rate variability measure, standard 
deviation of normal-normal intervals (SDNN) is used as a global measure of HRV.(379) A reduced 
SDNN value indicates reduced HRV and therefore autonomic dysfunction.(380)  
Previous studies have investigated the relationship between HRV and elevated oxidative stress in 
diseases such as hypertension (340, 381) and diabetes.(382, 383) Pavithran et al. (2008) found that 
heart rate variability was significantly lower in hypertensive patients compared to the control 
group;(340) a finding that was replicated by Thiyagarajan et al. (2013) in pre-hypertensive 
subjects.(381) In like manner, Ziegler et al. (2004) found that oxidative stress biomarkers were 
increased and antioxidant levels decreased in diabetic patients with peripheral neuropathy.(383) 
They also found that oxidative stress was even more marked in patients who had dual peripheral 
and cardiac neuropathy. What remains unclear, is the relationship between CKD and oxidative 
stress in the pathogenesis of cardiac autonomic neuropathy. Investigating the relationship between 
oxidative stress and HRV is of particular importance as it can assist in further developing our 
understanding and, therefore, treatment of poor clinical outcomes in CKD patients. Therefore, the 
purpose of this study was to determine the association between oxidative stress and HRV in the 
CKD population. It was hypothesised that elevated plasma F2-isoprostanes would be associated 
with reduced heart rate variability within patients with stage 3-4 CKD.  
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SUBJECTS AND METHODS  
The data from this study is a cross-sectional analysis of the ‘LANDMARK 3’ study (Longitudinal 
Assessment of Multiple Discrete Atherosclerotic Risk Factors in Kidney Disease), looking at the 
effects of a lifestyle intervention in CKD. 78 subjects with stage 3 or 4 CKD (MDRD eGFR 25-60 
mL/min/1.73 m2) were included in this study. Patients were aged between 18 to 75 years and had at 
least one of the following risk factors – blood pressure or lipids not at target; overweight (BMI >25 
kg/m2); or poor diabetic control. Exclusion criteria were life expectancy less than 6 months, 
pregnancy, enrolment in another research study or organ transplant recipient.  
 
The study protocol was approved by the Princess Alexandra Human Research Ethics Committee 
(HREC 2007/190), and was registered at www.anzctr.org.au (Registration Number 
ANZCTR12608000337370). Patients provided written and informed consent. 
 
Routine Blood Biochemistry 
Blood measures of lipids, haemoglobin, phosphate, creatinine, CRP, magnesium, albumin, glucose 
and insulin were conducted using standard laboratory techniques through venepuncture after an 
overnight fast. Insulin resistance was computed using the HOMA-IR method.(152) Estimated 
glomerular filtration rate (eGFR) was determined using the Modification of Diet in Renal Disease-
175 formula.(14) Insulin resistance was computed using the HOMA-IR method.(152) Patients were 
asked to refrain from taking their β-blocker medication at least 12 hours before testing.  
 
Inflammation 
Inflammation markers interleukin-6 (IL-6), tumour necrosis factor alpha (TNF-α) and interferon 
gamma (INF-ɣ) were measured by an electrochemiluminescence technique using Human Pro-
inflammatory 4-plex Ultra-sensitive Kit with the Sector Imager 6000 from Meso Scale Discovery 
(Gaithersburg, USA). The assays were performed according to the manufacturer’s instructions with 
coefficients of variation less than 20% being considered acceptable, as previously described.(384)  
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Heart rate variability 
After 5 minutes of supine rest HRV was recorded from a supine 5 minute 3 lead ECG recording that 
was conducted in a quiet room with no disturbances (such as talking or coughing). The R-R interval 
tachogram was visually inspected and any ectopic beats or artefacts were removed by linear 
interpolation of the preceding and proceeding beats. Software (Kubios version 2.1, Kuopio, 
Finland) was used to detrend the data using a smoothness priors regularization procedure before 
calculating the time, frequency and non-linear domain HRV parameters. A number of time and 
frequency parameters of HRV were assessed. Time parameters included the standard deviation of 
RR intervals (SDNN), the root mean square of differences in successive RR intervals (RMSSD), the 
number of successive RR intervals greater than 50ms (NN50), and the proportion of NN50 intervals 
in the entire recording (pNN50). Frequency parameters included a spectral power analysis 
incorporating very low frequency (VLF; ≤0.04 Hz), low frequency (LF; 0.04-0.15 Hz), high 
frequency (HF; 0.15-0.4 Hz) and total power (TP). All HRV measures are described in table 1. The 
LF/HF ratio was also computed using these values. SDNN was used in regression analyses as it is 




Samples were analysed in duplicate. Total F2-isoprostanes were analysed using a gas 
chromotography mass spectrometry protocol developed in our laboratory.(153) The coefficient of 
variation for this assay is 4.5%. Patients were divided into two groups based on their plasma F2-
isoprostane levels: normal (<250 pg/ml) and elevated (≥ 250 pg/ml). This was based on using a 
value 1.5 standard deviations from mean values from a previous study on apparently healthy 18-30 
year old males and females from our laboratory.(154)   
 
Plasma Glutathione Peroxidase Activity 
Samples were measured in duplicate using an automated method adapted from Wheeler et al. as the 
rate of oxidation of NADPH at 340nm in a coupled reaction, cycling oxidised glutathione to 
reduced glutathione using glutathione reductase.(156) These measures were performed on an 
autoanalyser (Cobas Mira, Roche Diagnostica, Switzerland). The laboratory coefficient of variation 
for this assay is 2.4% 
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Plasma Total Antioxidant Capacity 
Total antioxidant capacity was measured using a modified version of an assay previously 
described(385) and adapted for a Cobas Mira autoanalyser (Cobas Mira, Roche Diagnostica, 
Switzerland.). Briefly, plasma was incubated with met-myoglobin and 2,2'-azino-bis(3-
ethylbenzothiazoline-6-sulphonic acid (ABTS). After incubation, hydrogen peroxide was added and 
the sample incubated again. Absorbance was measured spectrophotometrically to determine total 
antioxidant capacity. The laboratory coefficient of variation for this assay is 1.9%. 
 
Statistics 
Mean ± standard deviation (SD) was used for the description of normally distributed baseline 
characteristics. Log transformed and not normally distributed variables were reported as median 
(IQR). Frequencies were used to describe categorical variables. Study variables that did not exhibit 
normal distribution were transformed using the natural logarithm. These included: F2-isoprostanes, 
VLF ms2, LF ms2, HF ms2, LF: HF, TP ms2, TG, IFN and CRP. A series of Independent Sample T 
tests were used to compare variables between the normal and elevated F2-isoprostanes group. Non-
parametric tests were performed on not normally distributed variables that did not normalise after 
log transformation. Mann-Whitney-U tests were used for the remaining variables that were not 
normally distributed, which included: age, NN50, pNN50, HDL, TC, HOMA, Mg, IL6, TNF, 
albumin, HbA1c. A Pearsons Chi square test was used for categorical variables. Bivariate 
correlations between plasma F2-isoprostanes and HRV variables were assessed using Pearsons 
correlations for normally distributed data and Spearmans Rho for data that was not normally 
distributed or categorical. A multiple linear regression using the enter method was undertaken with 
SDNN as the outcome measure against all variables that exhibited a significant univariate 
association with SDNN. Significance for all tests was assumed at the p<0.05 level. The statistical 
program used for the analysis was SPSS 20 (IBM, New York, USA).  
 
RESULTS 
The characteristics, medications, heart rate variability parameters and biochemical measures of the 
study participants are presented in Table 2. 16 Patients were identified as having elevated levels of 
F2-isoprostanes. Patients with elevated F2-isoprostanes had significantly (p<0.05) reduced HRV 
measures of SDNN, VLF and LF. Compared to historical healthy control data from a similar age 
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category from our group, the elevated F2-isoprostanes group had significantly reduced SDNN, 
RMSSD, pNN50(%), HF, LF and LF:HF ratio. 
Table 3 shows F2-isoprostanes of all patients to be inversely correlated with SDNN, STD HR, VLF, 
LF and TP. Mean RR, RMSSD and HR also had an inverse correlation which was approaching 
significance. 
Patients were asked to abstain from taking their β-blocker medication at least 12 hours prior to 
HRV testing. However, to ensure residual β-blocker medication was not influencing the findings, a 
sub-analysis on patients not on β-blockers was also performed (normal F2-isoprostanes n=39, 
elevated F2-isoprostanes n=14). In addition to SDNN LF this analysis also identified the LF:HF 
ratio and STD HR to be lower in the elevated F2-isoprostanes group. In the sub-analysis VLF was 
trending towards significance (p=0.083) (table 4). The sub-analysis on patients not on β-blockers 
also identified the same significant correlates with F2-isoprostanes (STD HR, SDNN, VLF, LF and 
TP) (table 5). 
A multiple linear regression model (Table 6) found F2-isoprostanes to be an independent predictor 
of SDNN (β=-0.272, p=0.01), along with sex (β=-0.263, p=0.014). A model that included the 
significant bivariate associates (HbA1C, diabetes status, F2-isoprostanes and sex) explained 28.7% 
of the variance in SDNN (p<0.01).  
 
DISCUSSION 
The findings from this study indicate that CKD patients with elevated plasma F2-isoprostanes have 
evidence of autonomic dysfunction. Time parameters of HRV, SDNN, and frequency parameters, 
VLF and LF were significantly reduced in patients with high levels of plasma F2-isoprostanes. An 
analysis of all patients identified significant inverse relationships between F2-isoprostanes and a 
number of HRV parameters including SDNN, STD HR, VLF, LF and TP. Mean RR, RMSSD and 
HF were approaching significance. A sub-analysis of patients not on β-blockers confirmed 1) the 
difference in HRV parameters between normal and elevated F2-isoprostanes groups and 2) and the 
inverse correlation between HRV parameters and F2-isoprostanes. Furthermore, a multiple linear 
regression identified plasma F2-isoprostanes to be an independent predictor of global HRV 
measure, SDNN.  
Due to the complexity of HRV there are a number of time and frequency parameters that should be 
considered. Generally, time domain parameters are thought to give a global measure of autonomic 
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activity, whereas frequency parameters provide an indication of autonomic balance.(386) Our study 
found significant reductions in a number of both time and frequency parameters in the patients with 
elevated plasma F2-isoprostanes. The reduction in SDNN indicates an overall decrease in 
autonomic function. Furthermore, the frequency data showed that reductions in VLF and LF were 
associated with increased plasma F2-isoprostanes. It is commonly accepted that HF relates to 
parasympathetic function and that VLF and LF are more representative of the sympathetic 
contribution.(379) Although not statistically significant, HF was also considerably lower in the 
elevated F2-isoprostanes group, suggesting global autonomic dysfunction of both parasympathetic 
and sympathetic nervous systems. When the HRV values in the elevated F2-isoprostanes group 
were compared to the historical healthy control data previously recorded in our group, it was found 
that CKD HRV values were significantly lower. Despite no normative values for HRV existing, this 
comparison highlights the impairment of HRV in CKD patients with elevated F2-isoprostanes. This 
study also identified no significant differences between GPX and TAC in the normal and elevated 
F2-isoprostanes groups. The disconnect between F2-isoprostanes and GPX and TAC in our findings 
may be suggesting that an increase in oxidants is occurring without a compensatory increase in 
antioxidants.(168) This imbalance may be important in the pathogenesis of oxidative injury and 
therefore autonomic dysfunction in CKD patients. 
In the case of CKD, it is understood that elevated oxidative stress is present relatively early during 
the disease progression. Kidney disease is associated with a decrease in antioxidant scavenging 
enzymes and increase in the production of ROS, thereby leading to oxidative stress.(387) 
Furthermore, previous studies have found that the level of oxidative stress continues to increase as 
CKD progresses.(168, 388) A study by Dounousi et al. (2006) found a significant correlation 
between increasing oxidative stress levels and declining kidney function, as measured by 
eGFR.(388)  
A number of studies have suggested a role of oxidative stress in the development of the autonomic 
neuropathy in other populations. Oxidative stress has been associated with a decrease in cardiovagal 
modulation in pre-hypertensive subjects.(381) Additionally, reduced HRV has been associated with 
air pollutant-induced oxidative stress.(389, 390) A study similar to the current investigation, in 
patients with diabetes, found that oxidative stress levels are enhanced prior to the development of 
polyneuropathy and remain high within this cohort.(383)  
The relationship between oxidative stress in CKD and cardiac autonomic function has not been well 
studied. Although the precise mechanistic pathways through which reactive oxygen species cause 
autonomic damage remains unclear, it has been hypothesised that oxidative stress leads to neuronal 
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injury in a variety of different ways. For example oxidative stress can cause damage to proteins and 
lipids that contribute to axonal transport.(391) It has also been well documented that cellular 
stressors, such as ROS, can lead to mitochondrial damage causing damage to the electron transport 
chain and upregulating the release of pro-apoptotic proteins, such as cytochrome C. This, in turn, 
activates the caspase cascade system, which ultimately leads to apoptosis of neurons.(392, 393) 
Therefore, large-scale neuronal apoptosis could be considered a potential hypothesis for the 
observed decrease in autonomic stimulation.(382) It should also be noted that a build-up of uremic 
toxins, as seen in CKD, may be a source of ROS, although the role that uric acid plays in the 
genesis of ROS remains unclear.  
Clinically, a greater understanding of the pathological processes leading to decreased HRV can 
provide a potential therapeutic target. Oxidative stress has been shown to lead to the proliferation of 
various pathologies and we have shown that it has a relationship with reduced autonomic function. 
Thus, it can serve as a potential therapeutic target with the aim of restoring cardiac autonomic 
function. Some studies have suggested possible anti-oxidant therapies to specifically target ROS 
(e.g. α-tocopherol, vitamin C, N-acetylcysteine), however, a lack of a clinically valid global marker 
for oxidative stress means that the current evidence of their efficacy is lacking.(182) Other studies 
have established that regular exercise can protect against oxidative stress by promoting up-
regulation of anti-oxidant enzymes in response to the acute increases in ROS which occur with 
exercise training.(179)  
 
Limitations 
Due to the cross-sectional design of this study and the corresponding analysis, a direct causative 
link between oxidative stress and reduced heart rate variability cannot be inferred. However, it is 
evident that a relationship between these two factors exists and further study in this area is needed. 
An additional confounder arises from the fact that the HRV data was extracted from a 5 minute 
ECG reading. Ideally, a 24 hour ECG would provide greater accuracy in determining the patient’s 
level of heart rate variability due to the natural physiological variation of the heart. The use of 
negative chronotropic drugs such as β-blockers may influence HRV. Participants were asked to 
refrain at least 12 hours prior to testing, however some residual medication may still be in effect. 
However, the normal F2-isoprostanes group were actually the ones with greater β-blocker use 
(which would lower HRV), so it does not appear that the difference in β-blocker medication 
between the groups would be influencing the current findings. 




In summary, CKD patients with elevated plasma F2-isoprostanes also display reduced HRV 
parameters. It was also identified that F2-isoprostanes independently predicted SDNN, a global 
measure of HRV. These findings are clinically significant, as by identifying oxidative stress as an 
associate with autonomic dysfunction, appropriate therapeutic targets may be able to be investigated 
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Frequency domain HRV measures Unit Description 
LF Low frequency power (0.04 - 0.15Hz) ms2 Correlated to both 
parasympathetic and sympathetic 
modulations. 
HF High frequency power (0.15 - 0.4Hz) ms2 Indicator of parasympathetic 
modulations. 
LF/HF  Ratio of LF/HF No 
units 
Indicator of sympathovagal 
balance. 
 
TP Total Power ms2 A global measure of HRV. 
Calculated from the addition of 
VLF, LF and HF 
Time domain measures of HRV Unit Description 
pNN50 Ratio between the number of pairs of 
adjacent NN intervals differing by 
more than 50ms and the total number 
of NN intervals 
% Reflects high frequency heart 
rate variations due to 
parasympathetic modulation. 
SDNN Standard deviation of all NN intervals ms Indicator of overall HRV 
RMSSD Square root of the mean of the squares 
of successive R-R interval differences 
ms Reflects high frequency heart 
rate variations due to 
parasympathetic modulation. 
Indicates short-term HRV 
components. 
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Table 2 Characteristics, medications, heart rate variability parameters and biochemical measures of 
CKD patients.  









Age (years) (M-W U) 59.8 ± 10.2 56.6 ± 11.8 0.364 
BMI (kg/m2) 33.0 ± 6.5 34.0 ± 6.9 0.604 
Diabetes Status (%) 26 (41.9%) 5 (31.3%) 0.569 
eGFR (mL/min/1.73m2) 41.1 ± 9.7 40.9 ± 8.1 0.952 
eGFR Rate of Change 0.05 ± 0.5 -0.1 ± 0.1 0.415 
Medications 
β-Blockers (%) 23 (29.9%) 2 (2.6%) 0.055 
Angiotensin Converting Enzyme 
Inhibitor (%) 
31 (40.3%) 5 (6.5%) 0.163 
Statins (%) 61 (79.2%) 16 (20.8%) 0.535 
Blood biochemistry 
Total Cholesterol (mmol/L) (M-W U) 4.2 ± 1.0 5.3 ± 1.2 0.014 
Triglyceride (mmol/L) 1.7 ± 0.8 2.8 ± 3.1  0.03 
HDL cholesterol (mmol/L) (M-W U) 1.1 ± 0.4 1.6 ± 0.9 0.007 
LDL cholesterol (mmol/L) 2.6 ± 0.9 2.6 ± 0.9 0.943 
Glutathione Peroxidase (GPx) (U/L) 24.6 ± 4.0 23.4 ± 4.8   0.216 
Total antioxidant capacity (mmol/L) 1.7 ± 0.2 1.8 ± 0.2 0.635 
Albumin (g/L) (M-W U) 38.0 ± 2.6 37.4 ± 4.2 0.845 
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Haemoglobin (g/L) 132.5 ± 14.5 130.5 ± 15.5 0.628 
Phosphate (mmol/L) 1.1 ± 0.2 1.1 ± 0.2  0.733 
Magnesium (mmol/L) (M-W U) 0.8 ± 0.1 0.9 ± 0.1 0.500 
HOMA (M-W U) 8.7 ± 21.1 7.7 ± 11.3 0.537 
HaemoglobinA1c (%) (M-W U) 6.5 ± 1.4 6.2 ± 0.5 0.590 
Interferon-γ (ng/mL) 1.3 ± 2.8 0.7 ± 0.5 0.528 
Tumour Necrosis Factor α (M-W U) 
(ng/mL) 
6.7 ± 3.4 7.2 ± 3.8 0.520 
C-Reactive Protein (mg/L) 3.8 ± 3.6 5.2 ± 3.8 0.481 
Heart Rate Variability 
Mean RR (ms) 895.0 ± 167.9 837.5 ± 114.8 0.2 
Mean HR (1/min) 69.5 ± 13.4 73.0 ± 10.4 0.334 
STD HR (1/min) 2.2 ± 0.8 1.8 ± 0.7 0.102 
SDNN (ms2) 29.3 ± 13.2 20.9 ± 8.8 0.018 
RMSSD (ms2) 18.9 ± 10.7 15.1 ± 8.3 0.190 
Very Low Frequency (VLF) (ms2) 530.8 ± 656.7 212.4 ± 159.3 0.039 
Low Frequency (LF) (ms2) 318.7 ± 580.9 106.4 ± 128.3 0.037 
High Frequency (HF) (ms2) 405.4 ± 1556.1 108.4 ± 105.3  0.400 
Total Power (TP) (ms2) 1254.8 ± 2588.7 427.2 ± 289.6  0.085 
LF:HF (ms2) 2.5 ± 2.5 1.8 ± 1.5 0.099 
NN50 (count) (M-W U) 10.8 ± 20.7 4.2 ± 7.0 0.138 
pNN50 (count) (M-W U) 3.5 ± 7.3 1.2 ± 2.0 0.125 
(M-W-U) = Mann-Whitney-U test; CCB= calcium channel blocker. Values are reported as mean ± 
SD for normally distributed variables, or median (IQR) for not normally distributed or log 
transformed variables. 
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Table 3 Bivariate relationships between plasma F2-isoprostanes and HRV parameters. 
 F2-isoprostanes 
HRV Parameter r Value p Value 
Mean RR (ms) -0.200 0.079 
Mean HR (1/min) 0.178 0.119 
STD HR (1/min) -0.248 0.029 
SDNN (ms2) -0.337 0.003 
RMSSD (ms2) -0.198 0.083 
Very Low Frequency (ms2) -0.281 0.013 
Low Frequency (ms2) -0.315 0.005 
High Frequency (ms2) -0.190 0.095 
Total Power (ms2) -0.288 0.01 
LF/HF (ms2) -0.156 0.173 
(S) = Spearmans Test 
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Table 4 Heart rate variability parameters of CKD patients not on β-blockers.  







Mean RR (ms) 876.6 ± 148.6 846.4 ± 100.9 0.487 
Mean HR (1/min) 69.4 (14.9) 74.2 (15.2) 0.611 
STD HR (1/min) 2.2 ± 0.9 1.7 ± 0.7 0.042 
SDNN (ms2) 29.5 ± 14.4 19.8 ± 6.9 0.019 
RMSSD(ms2)  17.9 (14.3) 13.8 (15.3) 0. 399 
Very Low Frequency (VLF) (ms2) (M-W-U) 266.9 (657.9) 152.0 (202.2) 0.083 
Low Frequency (LF) (ms2) (M-W-U) 179.2 (277.8) 47.9 (82.2) 0.009 
High Frequency (HF) (ms2) 91.7 (189.9) 70.1 (163.2)  0.408 
Total Power (TP) (ms2) 759.7 (1179.4) 387.0 (431.6)  0.096 
LF:HF(ms2) 1.7 (2.4) 1.5 (2.2) 0.05 
NN50 (count) 4.0 (16.3) 0.0 (8.0) 0.607 
pNN50 (count) 1.2 (4.8) 0.0 (2.2) 0.503 
(M-W-U) = Mann-Whitney-U test. Values are reported as mean ± SD for normally distributed 
variables, or median (IQR) for not normally distributed or log transformed variables. 
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Table 5 Bivariate relationships between plasmaF2-isoprostanes and HRV parameters on CKD 
patients not on β-blockers. 
  F2-isoprostanes 
HRV Parameter r Value p Value 
Mean RR (ms) -0.203 0.149 
Mean HR (1/min) 0.195 0.166 
STD HR (1/min) -0.363 0.008 
SDNN (ms2) -0.416 0.002 
RMSSD (ms2) -0.254 0.07 
Very Low Frequency (ms2) (S) -0.282 0.043 
Low Frequency (ms2) (S) -0.351 0.011 
High Frequency (ms2) -0.261 0.062 
Total Power (ms2) -0.333 0.016 
LF/HF (ms2) -0.141 0.32 
(S)= Spearman’s Test 
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Table 6 Bivariate and multivariate associations with SDNN 
 SDNN (ms2) 
Variable r Value p Value β p Value 
Age (years) (S) -0.205 0.076   
Sex (S) -0.366 0.001 -0.263 0.014 
BMI (kg/m2) 0.044 0.710   
Diabetes Status (S) -0.344 0.002 -0.228 0.064 
eGFR (mL/min/1.73m2) 0.131 0.257   
Blood Biochemistry 
Glutathione Peroxidase (U/L) 0.050 0.666   
Total Antioxidant Capacity 
(mmol/L) 
0.112 0.332   
Plasma F2-isoprostanes (pg/mL) -0.337 0.003 -0.272 0.010 
Albumin (g/L) (S) 0.165 0.151   
Phosphate (mmol/L) 0.145 0.210   
HOMA-IR (S) 0.226 0.053   
HbA1c (%) (S) -0.417 0.000 -0.145 0.239 
C Reactive protein (mg/L) 0.104 0.372   
Medications 
β-Blockers (%) (S) 0.074 0.525   
Angiotensin Converting Enzyme 
Inhibitor (%) (S) 
-0.027 0.816   
Statins (%) (S) 0.200 0.081   
(S)= Spearman’s Test 
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Figure 1. Relationship between SDNN and plasma F2-isoprostanes in patients with CKD (r=0.337, 





Chapter 11 Appendices   
301  
 
11.9 Changes in cardiorespiratory fitness are associated with changes in 
autonomic function in patients with chronic kidney disease 
 
Huppertz N1, Weston KS1, Isbel, NM2,3, Howden EJ1,4, Coombes JS1 
1School of Human Movement Studies and 2Medicine, University of Queensland, Australia 
3Department of Nephrology, Princess Alexandra Hospital, Brisbane, Queensland, Australia 
4University of Texas, Southwestern Medical Centre, Dallas, Texas, US 
 
This manuscript is currently being prepared for submission to the European Journal of Applied 
Physiology. This work is by an Honours student under the supervision of Kassia Beetham and Jeff 
Coombes. The data was collected by Kassia Beetham and Erin Howden but was analysed and 
reported by Nina Huppertz. 
Corresponding Author: 
Dr Jeff S. Coombes 
School of Human Movement Studies 
The University of Queensland 
Brisbane, Queensland, 4072 
AUSTRALIA.  
Phone: +61 07 3365 6767  

































Purpose- To investigate the effects of a 12-month lifestyle intervention (LI) on autonomic nervous 
system function, as indicated by heart rate variability, heart rate recovery, and heart rate reserve. 
 
Methods- 120 patients (54 females) with stage 3 or 4 chronic kidney disease participated in the 
study. Exercise training consisted of an 8-week individualized training program supervised by a 
clinical exercise physiologist for 2-3x/week. Patients were then provided with a swiss ball, a 
theraband, and given a home program to complete for the remaining 8 months. Patients received 
regular telephone follow-up calls and gym refresher sessions. Cardiorespiratory fitness (VO2peak) 
was determined from a graded exercise stress test and indirect breath-by-breath calorimetry. Heart 
rate variability (standard deviation of NN intervals [SDNN], root mean square of successive 
differences [RMSSD], very low frequency [VLF], low frequency [LF], high frequency [HF], and 
total power [TP]) were measured for 5 minutes in the supine position in a quiet temperature 
controlled environment. Heart rate at one, two, and three minutes following peak exercise was 
subtracted from peak heart rate, measured in a supine position, to determine the heart rate recovery. 
Chronotropic competence was derived using a percent heart rate reserve formula from the 
Framingham Heart Study. 
 
Results- There were significant (p<0.05) improvements in the LI group from baseline to 12 months 
compared to changes in the control (CON) group with absolute VO2peak (LI +0.1±0.3, CON -
0.1±0.3 L/min), relative VO2peak (LI +1.8±3.8, CON -1.0±3.9 ml/kg/min), resting DBP (LI -
6.0±15.5, CON 0.5±14.1 mmHg), and LF power (LI 214.6±723.9, CON -108.2±506.9). There were 
no significant improvements in any other autonomic function variables in both the LI and CON 
group. However, when both groups were combined, the change in relative VO2peak was significantly 
associated with the change in heart rate recovery at one minute (r=0.287, p=0.01) and two minutes 
(r=0.218, p=0.05), and high frequency heart rate variability (r=0.288, p=0.05). 
 
Conclusion- Changes in cardiorespiratory fitness are associated with an improvement in autonomic 
function. 
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Compared to a healthy adult population, the risk of cardiovascular disease (CVD) is remarkably 
greater in patients with chronic kidney disease (CKD), where the likelihood of experiencing 
cardiovascular mortality is much higher than reaching end-stage kidney failure (Tonelli et al, 2006; 
Gansevoort et al, 2012). Since CVD is the primary cause of death at every stage of kidney disease, 
it is important that the CKD population is regarded as one of the highest risk groups for the disease 
(Tonelli et al, 2006). 
 
This study focuses on autonomic nervous system (ANS) dysfunction, a significant contributor to the 
increased risk of CVD (Bronas, 2009). ANS dysfunction can be evaluated by a variety of measures 
including resting heart rate variability (HRV), heart rate reserve (HR reserve) during exercise, and 
heart rate recovery (HRR) after exercise. HRV is the interaction of the sympathetic nervous system 
(SNS) and parasympathetic nervous system (PNS) to regulate heartbeat. HRR is measured as the 
number of decreased heart beats per each minute following peak exercise. HR reserve is a measure 
of chronotropic competence with patients deemed as having a chronotropic incompetent response if 
unable to utilize >80% of their HR reserve (Lauer, 2004). Patients with chronotropic incompetence 
are incapable of sufficiently increasing their HR to correspond with the increase in exercise 
demands (Brubaker et al, 2011). The aforementioned autonomic function parameters are predictors 
for all-cause and cardiovascular mortality with low levels reflecting an increased risk of mortality in 
a variety of clinical populations (Lauer et al, 1999; Chacko et al, 2008; Georgoulias et al, 2009).  
 
Despite no studies investigating the impact of lifestyle interventions on autonomic function in 
patients with CKD, patients undergoing dialysis have shown improvements in HRV parameters as a 
result of two hours of intra-dialysis exercise training on three days a week in a one year intervention 
program (Kouidi et al, 2010). HRR also improved in response to a one-year lifestyle intervention 
that included regular exercise in patients with type 2 diabetes mellitus (T2DM) (Ribisl et al, 2012). 
Home-based exercise of a moderate intensity over a 6-month period has also shown improvements 
in HRR in patients with coronary artery disease (Neves et al, 2011), while partial reversal of 
chronotropic incompetence was identified in patients with stable heart failure after a 30-minute 
exercise intervention that occurred three times a week for 24 weeks (Keteyian et al, 1999).  
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Though there is ample evidence illustrating improvements in autonomic function as a result of 
lifestyle changes and exercise training in other clinical and diseased populations, there are no 
indications to suggest whether the same benefits can occur in patients with stage 1 to 4 CKD. The 
aim of this study is therefore to investigate the impact of a 12 month LI on parameters of autonomic 
function, specifically HRV, HRR, HR reserve and chronotropic response in patients with stage 3 or 
4 CKD. It is hypothesized that HRV, HRR, HR reserve and chronotropic response will improve as a 
result of the LI. Furthermore, it is hypothesized that changes in cardiorespiratory fitness (VO2peak) 




Setting & Participants 
The data from this study originates from the prospective randomized controlled trial ‘LANDMARK 
3’ (Longitudinal Assessment of Multiple Discrete Atherosclerotic Risk Factors in Kidney Disease). 
Patients were recruited from the chronic kidney disease population attending the Department of 
Nephrology, Princess Alexandra Hospital in Brisbane, Australia. Patients aged 18 to 75 with CKD 
stages 3 and 4 (eGFR: 25-60 ml/min/1.73m2) were invited to participate in the study, with the 
exclusion criteria containing patients that i) were pregnant or breast feeding, ii) had a life 
expectancy of 6 months or less, iii) a current involvement in other research studies, or iv) was or 
expecting to be a recipient of an organ transplant.  
 
The study protocol was approved by the Princess Alexandra Human Research Ethics Committee 
(HREC 2007/190), and the University of Queensland Medical Research Ethics Committee (MREC 
2008000184). The study was registered with the Australian and New Zealand Clinical Trials 
Registry (ANZCTR; www.anzctr.org.au), Registration Number ACTRN12608000337370. 
 
Study Design 
Subsequent to obtaining written informed consent, patients completed a baseline visit that included 
resting brachial blood pressure measured by mercury sphygmomanometry (BP), anthropometry 
(weight and height), resting and exercise electrocardiograph (ECG) recordings, cardiorespiratory 
fitness and exercise capacity (VO2peak and METS) measures. Patients were randomized to the 
lifestyle intervention group or standard care control group. The standard care control group received 
treatment as per normal according to their nephrologist. After 12 months of receiving either the 
lifestyle intervention or standard care, patients completed a full series of tests identical to that of the 
baseline visit. 




Patients in the LI group received 8 weeks of individualized exercise training under supervision. In 
the initial 8 weeks, patients were required to attend an hour-long exercise session 2 to 3 times per 
week. The sessions were individualized based on each patient’s needs and comorbidities. However, 
the majority of sessions consisted of 20-30 minutes of aerobic exercise, 20 minutes of resistance 
training, and a 10 minute cool-down period. Throughout the 8 weeks of supervised training 
sessions, the aim was to develop confidence in performing exercises and teach the patient an array 
of exercises that could be safely performed at home. Exercise progression was tailored accordingly. 
Subsequent to the 8 weeks, patients were provided with a swiss-ball, therabands, and an exercise 
handbook to encourage independent home exercises. The aim was to complete at least 150 minutes 
of moderate to high intensity aerobic exercise and two resistance training sessions per week, as 
appropriate. Patients were then regularly contacted via telephone; weekly in the first month, then 
monthly afterwards. Patients were also provided with the opportunity to attend refresher supervised 
exercise sessions as needed. In the initial 4 weeks of the LI, patients also attended weekly dietician 
and psychologist group sessions. Regular contact, as well as quarterly appointments, with the nurse 
practitioner and dietician occurred for the remainder of the intervention. 
 
Outcome Measures 
Cardiorespiratory Fitness and Exercise Capacity 
Participants completed a standardized maximal treadmill exercise stress test (protocol: Bruce, 
Naughton, Balke or modified Balke). Before, during, and for five minutes after the exercise stress 
test, a 12-lead ECG was recorded (CASE, GE Medical Systems, Milwaukee, WI, USA). 
Cardiorespiratory fitness, measured as peak oxygen uptake (VO2peak) was determined by breath-by-
breath indirect calorimetry (Vmax29c, Sensor Medics, CA, USA) during the exercise stress test. 
Exercise capacity was calculated as metabolic equivalents (METs) based on the grade and speed of 
the treadmill at the termination of the test.  
 
Heart Rate Variability (HRV) 
Participants completed a supine 5 minute resting ECG recording before the maximal exercise stress 
test. Three Ag/AgCl electrodes were used in a modified lead II configuration connected to an 
analysis program (SpyhmoCor 8.1, AtCor Medical, Sydney, Australia). The R-R interval tachogram 
was analyzed in Kubios (2.1, Kuopio, 2012) by which ectopic beats were removed using linear 
interpolations of the previous and subsequent beats. HRV was assessed by time and frequency 
domain parameters. For the time domain, consecutive R-R intervals were measured against the 
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number of total beats. The standard deviation of N-N intervals (SDNN) is used as the global 
measure of HRV. The root-mean square of the successive differences (RMSSD) of the R-R 
intervals is also calculated. For the frequency domain, HRV was divided by spectral power analysis 
into high frequency (0.15-0.40 Hz) (HF), low frequency (0.04-0.15 Hz) (LF), and very low 
frequency (0.0033–0.04 Hz) (VLF) powers. Total power (TP) was also calculated as a sum of all 
frequency powers. 
 
Heart Rate Recovery (HRR) 
HR was measured immediately after the termination of the exercise stress test at one (HRR-1), two 
(HRR-2), and three (HRR-3) minutes into the cool-down period. HR at each of these time-frames 
was subtracted from peak HR of the exercise stress test. HRR-1, HRR-2, and HRR-3 are used to 
describe the overall HRR at those respective time points.  
 
Heart Rate Reserve (HR reserve) 
Chronotropic competence was determined by calculating the percent HR reserve (%HR reserve). 
The following equation used in this study was taken from the Framingham Heart Study (Lauer et al, 
1996) with the recommendation that patients are deemed chronotropic incompetent with a %HR 
reserve of <80: % HR − Reserve = (HR stage− resting HR)(APMHR − resting HR) 𝑥 100 
‘HR stage’ refers to the HR corresponding to the end of the exercise stress test stage. In this study, 
stage 2 is used to calculate %HR reserve, meaning that patients must have at least completed two 
stages on the exercise stress test. APMHR was calculated as 208 - (0.7 x age). 
 
Statistical Analyses 
The Kolmogorov-Smirnov test was used to determine normality of distribution for all variables. 
Non normally distributed variables [control: METs, HR reserve, HF(%), VLF(ms2), LF(ms2), 
HF(ms2), TP(ms2), HF(n.u.), LF/HF ratio; intervention: VO2(L/min), VO2(ml/kg/min), peak HR 
60s, peak HR 180s, SDNN, HF(%), VLF(ms2), LF(ms2), TP(ms2)] were transformed using the 
natural logarithm [X=log(X)]. Paired t-tests were used to determine within group differences 
between baseline and 12 month values. Non-parametric Wilcoxon signed-rank test was used for not 
normally distributed variables that were not able to be transformed. Independent samples t-test was 
used to identify significant differences between groups at baselines as well as group differences of 
the change from baseline to 12 months. Spearmans correlation test was used to determine univariate 
correlations between autonomic function and exercise fitness. Pearsons chi square test was used to 
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determine the difference between groups for categorical variables at baseline.  Mean ± standard 
deviation (SD) was used to describe baseline characteristics and measured outcome variables. 
Median and interquartile range described variables that were not normally distributed. Statistical 
analysis was performe d using GraphPad Prism 6 (La Jolla, CA, USA). Statistical significance was 




120 patients that met the inclusion criteria were included in the analysis. The clinical characteristics 
at baseline are summarized in Table 1. Patients had a mean age of 62 years and were obese 
(median[interquartile range]) (31.6[7.6]). There were no statistical differences between the control 
and intervention group in any of the baseline variables.  
 
Baseline vs. 12 Months 
Baseline and the change scores to 12 months for the control and intervention group on all measured 
variables are summarized in Table 2. The control group showed significant decreases for absolute 
VO2 (p=0.04), peak HR (p=0.01), peak SBP (p=0.002) and DBP (p=0.003) at the end of the 12 
months. The intervention group showed significant improvements in a number of exercise 
parameters, specifically increasing absolute VO2 (p=0.03), relative VO2 (p=0.003), METs 
(p<0.001), and decreasing resting HR (p=0.04). Resting SBP (p=0.05), resting DBP (p=0.01), and 
peak DBP (p=0.03) additionally decreased in the intervention group. HR reserve decreased by a 
mean of 12.2% in the intervention group (p=0.02). No other significant differences were seen for 
any other autonomic function parameters in both the control and intervention groups from baseline 
to 12 months. 
 
Control vs. Intervention  
The change scores from baseline to 12 months between the control and intervention group are 
summarized in Table 2. The findings illustrate that the control and intervention group differed in 
delta absolute VO2 (p=0.003), relative VO2 (p=<0.001), METs (p<0.001), resting DBP (p=0.03), 
and LF (ms2) power (p=0.05), with the intervention group improving as a result of the LI. 
Additionally, no changes in other autonomic function parameters were statistically different 
between the two groups. 
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Autonomic Function and Exercise Parameters 
The association between the change from baseline to 12 month values in HR variability, HR 
recovery, and HR-reserve variables to the change in relative VO2 for all patients are represented in 
Table 4. Specifically, HF (ms2) power showed a significant association with cardiorespiratory 
fitness (r=0. 0.288, p=0.05). In addition, both HR recovery at 1 and 2 minutes showed a significant 
association as well (r=0.287, p=<0.01) (r=0.218, p=0.05). No associations were seen between 




This is the first study to investigate the impact of a 12 month LI on autonomic function through 
measurement of HRV, HRR, HR-reserve and chronotropic response in patients with stage 3-4 CKD. 
The findings illustrate that despite the increase in cardiorespiratory fitness and exercise capacity, the 
LI produced no beneficial changes in autonomic function measures outside of LF power. 
Nonetheless, there was a marked association between the change from baseline to 12 months in HF 
power, HRR at 1 minute, HRR at 2 minutes and the change in cardiorespiratory fitness for all 
patients. 
 
The literature on the effect of exercise on autonomic function in the CKD population is scarce, yet 
other studies have demonstrated similar findings to the current study in other healthy and clinical 
populations. The following studies support the present findings in which no or little changes were 
seen in any of the time or frequency HRV domains. Tuomainen et al. (2005) studied the effects of a 
six-year exercise intervention in a population of healthy males. The results suggest no changes in 
HRV, despite the 16% increase in ventilatory aerobic threshold. Change in certain HRV parameters, 
specifically SDNN, TP, VLF, and HF, were nevertheless significantly correlated to the change in 
VO2max in all participants. Oya et al. (1999) found no significant difference in HRV parameters in 
post myocardial infarction (MI) patients after 3 months of exercise training. Despite little 
improvements seen in the early phases of acute MI, these changes were not significant at the end of 
the intervention. On the other hand, Figueroa et al. (2007) showed significant increases in LF and 
HF power after a 16 week exercise intervention in obese women with and without T2DM. Kouidi et 
al. (2010) further consolidated these results in patients undergoing hemodialysis showing marked 
improvements in SDNN and LF/HF ratio after one year of regular cycling and strength exercise 
training. In the present study the mean age of patients is 62 years, a factor that could attenuate the 
impact of exercise on HRV parameters. This is supported by previous literature that highlights 
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additional decreases in short-term supine HRV measurements and overall autonomic function in 
elderly patients, suggesting a reduction in parasympathetic tone (Stein et al, 1999; Fukusaki et al, 
2000; Richard et al, 2011). Although a low HRV has been linked with an increased risk of all-cause 
mortality, there are no accepted normative values for comparison. There is consequently little 
insight into the varying degrees of HRV measures and its clinical impact in the CKD population. 
  
To adjust to the demands of exercise, the ANS activates the SNS and withdraws the PNS to cause 
an increase in HR throughout the exercise duration (Pierpont, 2013; Esco, 2010). Contrariwise, a 
decrease in HR following exercise is characterized by the reactivation of the PNS independent of 
withdrawal of the SNS (Carter et al, 2003; Imai et al, 1994). The intervention group showed an 
increase in HRR at 3 minutes of 2.9 bpm compared to the control group that showed no 
improvement, although these findings are not statistically significant. This trend is supported by 
previous findings that also portray increases in HRR at 3 minutes following exercise (Neves, 2011; 
MacMillan, 2006). Neves (2011) illustrated that a home-based exercise program of moderate 
intensity improved HRR in diabetic patients with CAD over a duration of 6 months. MacMillan 
(2006) also showed an increase in HRR by 13.5% in males and 14.3% in females after exercising 
three times a week for a period of 12 weeks. Patients in this study in both the control and 
intervention group showed normal responses to HRR at baseline as indicated by a decrease of more 
than 18 bpm at one minute following peak exercise (Watanabe et al, 2001). Therefore, the 
expectations for already established normal values to further improve during an intervention may 
not be of any significance. The control group showed a slight, although statistically insignificant, 
decline. It is thus perhaps more important to note that no significant decreases in HRR was seen in 
the intervention group.  
 
The impact of exercise on HR reserve and chronotropic response is a topic rarely explored in the 
clinical population. The findings of this study demonstrate a marked and significant reduction of 
12.2% in HR reserve in the intervention group. Although the controls also showed a similar 
decrease in HR reserve by 10.1%, this was not statistically significant. Keteyian (1999) studied the 
impact of 100 minutes of exercise per week for 24 weeks on HR reserve in patients with stable heart 
failure. The results show an increase in both peak HR and HR reserve, signifying a reversal of 
chronotropic incompetence, with a significant association between the change in peak HR and 
change in HR reserve. The correlation suggests that an increase in HR reserve parallels an increase 
in peak HR. The present study demonstrated no significant increases in peak HR in the intervention 
group, which may explain the lack of improvement in HR reserve. It is also important to note that 
both groups had a chronotropic incompetent response at baseline. 
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Compared to the control group, the intervention group had higher absolute VO2peak, relative 
VO2peak, METs, a lower resting HR, resting SBP, resting DBP, and peak DBP. This is consistent 
with previous research assessing the impact of exercise training in patients with renal dysfunction 
(Clyne, 2004; Deligiannis, 1999; Suh et al, 2002, Violan et al, 2002; Kouidi et al, 2010; Koufaki et 
al, 2002). Unlike the intervention group, the control group showed significant reductions in peak 
HR and peak SBP. It is likely that the significant decrease in cardiorespiratory fitness over the 12 
months in the control group attenuated the exercise capacity and therefore affected the intensity 
reached during the exercise stress test from baseline to 12 months, thereby explaining the lower 
values. 
 
Even though no advances were seen in the autonomic function variables measured outside of LF 
power, the change in HRR at one minute, HRR at two minutes, and HF power from baseline to 12 
months showed a significant association with the change in relative VO2. These relationships 
suggest that a long-term exercise intervention has the potential to improve autonomic function. 
Nevertheless, the impact of exercise on autonomic function may vary with different exercise 
intensities. Martinmaki (2008) demonstrated that high intensity endurance training was more 
effective in improving cardiac vagal tone compared to low intensity endurance training. Trapp 
(2007) similarly reported a greater impact on the ANS in high intensity training compared to steady 
state aerobic exercise. More specifically, high intensity or interval exercise interventions ranging 
from 12 to 24 weeks have been shown to improve HRV, HRR, and HR reserve in the elderly 
patients, patients on beta-blockers, patients with T2DM, and patients undergoing coronary 
intervention (Malfatto et al, 1998; Pichot et al, 2005; Munk et al, 2010; Heydari et al, 2012). The 
aforementioned studies reported increases in maximal oxygen uptake ranging from 16% to 46%. 
The intervention group in this study only showed an increase of 8.0%. The large discrepancy of 
maximal oxygen uptake between the present study and the discussed literature alludes to a probable 
reason for the non-significant or little changes found in autonomic function parameters. For 
autonomic function to markedly improve, it is possible that a large change in cardiorespiratory 
fitness, especially for elderly individuals, needs to be seen. Future research should investigate the 
effects of high intensity exercise training on cardiorespiratory fitness and autonomic function in 
patients with CKD. 
 
It is possible that for improvements in autonomic function to occur, an intensive lifestyle program 
that puts a primary and stronger focus on weight loss in addition to improving cardiorespiratory 
fitness is needed. Ribisl (2012) studied the combined effects of diet and exercise in patients with 
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T2DM, finding that weight loss and fitness gains resulted in a greater improvement in HRR than a 
diabetes support education program after 12 months. The findings also suggest that greater weight 
loss is associated with greater increases in HRR. Brinkworth (2006), on the other hand, showed an 
increase in HRR in overweight males with metabolic syndrome in response to a weight loss 
program alone. Exercise was kept within baseline levels, evident by the lack of significant changes 
in peak HR, physical activity levels, and cardiorespiratory fitness. This attributes the beneficial 
change in HRR purely to weight loss. The intervention group in the present study exhibited no signs 
of significant weight loss, as measured by body mass, from baseline to 12 months. Since the 
average patient is classified as obese, significant weight loss may augment the effect of exercise on 




Despite measuring a number of time and domain frequencies to infer HRV, additional measures 
taken during orthostatic posture and following peak exercise may have provided further insight into 
the impact of exercise on autonomic function in different situational demands. Furthermore, the 





The 12 month LI produced no significant changes in HRV, HRR, HR reserve, and chronotropic 
response in patients with stages 3 or 4 CKD, outside of the improvement in LF power. The change 
in cardiorespiratory fitness is, however, associated with HF power and HRR at one and two 
minutes. Future research is needed to explore the clinical implications and the impact of different 
forms of exercise as a therapeutic intervention on autonomic dysfunction in pre-dialysis CKD 
patients in hopes of reducing the risk of cardiovascular mortality. 
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Table 1. Clinical characteristics of 120 stage 3-4 CKD patients 
 






Age (years) 62[13] 63.5[9] 60[15.2] 
Female sex (%) 54(45) 26(44) 28(46) 
Diabetes (%) 46(38) 24(41) 22(36) 
eGFR (ml/min/1.73m2) 39[13]  40[16] 39[12] 
Weight (kg) 89.9±22.0 89.8±23.2 90.7±21.0 
Body mass index (kg/m2) 31.5[7.5] 30.9[5.4] 32.8[8.4] 
Fat (%) 35.6±7.7 35.4±6.8 35.8±8.4 
Appendicular lean mass (%) 60.6±9.4 60.2±8.9 61±10 
LDL (mg/dL) 2.5[1.0] 2.3[1.3] 2.6[1] 
HDL (mg/dL) 1.1[0.4] 1.1[0.4] 1.1[0.5] 
Total cholesterol (mg/dL) 4.4[1.2] 4.3[1.5] 4.5[1.2] 
Triglycerides (mg/dL) 1.5[1.1] 1.5[1.6] 1.4[1.1] 
ACE inhibitors (n, %) 56, 46.7 31, 52.5 25, 41 
α-blockers (n, %) 9, 7.5 4, 6.8 5, 8.2 
α2-blockers (n, %) 57, 47.5 25, 42.4 32, 52.5 
Β-blockers (n, %) 43, 35.8 28, 47.5 15, 25.0 
Calcium channel blockers (n, %) 50, 41.7 28, 47,5 22, 36.1 
Centrally acting anti-adrenergics (n, %) 2, 1.7 1, 1.7 1, 1.6 
Thiazide (n, %) 23, 19.2 14, 23.7 9, 14.8 
Spironolactone (n, %) 2, 1.7 2, 3.4 0, 0 
Loop diuretics (n, %) 21, 17.5 12, 20.3 9, 14.8 
Nitrovasodilators (n, %) 10, 8.3 7, 11.9 3, 4.9 
Statins (n, %) 70, 58.3 34, 57.6 36, 59.0 
Mean ± standard deviation given for normally distributed variables, median [interquartile range] 
given for not normally distributed variables. Number (%) given for categorical variables. eGFR = 
estimate glomerular filtration rate. LDL = low density lipoproteins. HDL = high density 
lipoproteins. ACE = angiotensin converting enzyme.
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Table 2. Differences between baseline, 12 month, control and intervention values 
Variable Control Intervention 
Characteristics Pre Change Pre Change P-value 
Weight (kg) 91.5±15.0 -3.6±15.4 91.8±16.9 -3.7±20.2 0.1603 
Body mass index (kg/m2)  32.0±4.4 0.6±5.1 32.6±5.6 0.1±7.6 0.4956 
Exercise Parameters      
VO2peak (L/min) 2.1±0.6 -1.0±0.3* 2.0±0.5 0.1±0.3* 0.0028* 
VO2peak (ml/kg/min) 22.7±5.2 -1.0±3.9 22.5±5.6 1.8±3.8* 0.0007* 
RQ 1.0[0.13] 0.01±0.3 1.0±0.1 0.07±0.3 0.2926 
METs 7.3±2.6 -0.1±1.9 7.5±3.6 1.9±1.8* 0.0001* 
Resting heart rate (bpm) 78.3±12.1 -3.0±16.4 82.6±13.8 -4.2±13.9* 0.6887 
Peak heart rate (bpm) 144±17.1 -5.3±14.9* 150±25.6 1.2±21.9 0.0701 
Haemodynamics      
Rest systolic blood pressure (mm/Hg) 130[26] -0.2±25.3 130[20] -7.4±23.5* 0.1525 
Rest diastolic blood pressure (mm/Hg) 80[12] 0.5±14.1 80[10] -6.0±15.5* 0.0322* 
Peak systolic blood pressure (mm/Hg) 180±26 -9.8±24.0* 173[21] -3.6±24.3 0.1834 
Peak diastolic blood pressure (mmHg) 80[20] -4.1±12.0* 82[15] -4.2±13.3* 0.9759 
Heart rate variability      
SDNN (ms) 25.3±12.4 1.3±11.0 29.7±14.3 5.0±26.1 0.4702 
RMSSD (ms2) 13.4[14.6] 0.8±10.0 19.1[13.3] 5.3±22.5 0.3293 
TP (ms2) 976±2607 -447.2±2553 880±979 625±2713 0.1336 
VLF (ms2) 416±548 57.5±573.3 475±578 219.2±1111 0.4725 
LF (ms2) 240±567 -108.2±506.9 250±295 214.6±723.9 0.0452* 
HF (ms2) 374±1615 -295.2±1676 124[138.6] 242.9±845.9 0.1111 
VLF (%) 53.8±21.5 5.3±28.3 52.7±21 -2.2±22.5 0.2750 
LF (%) 24.7[20] -2.0±19.2 24.8±12.5 1.7±15.0 0.4213 
HF (%) 20.5± 17.5 -3.3±21.3 22.5±18.0 0.5±24.5 0.5376 
VLF (Hz) 0.004[0.02] -0.002±0.01 0.008[0.01] 0.001±0.009 0.3126 
LF (Hz) 0.06[0.05] -0.002±0.03 0.07[0.05] -0.001±0.03 0.8493 
HF (Hz) 0.24±0.06 -0.007±0.08 0.24±0.06 0.004±0.09 0.6120 
LF (n.u.) 67.1[42.2] -0.2±26.1 55.9±18.4 1.9±26.4 0.7571 
HF (n.u.) 40.5±22.5 0.2±26.1 44.1±18.4 -1.9±26.4 0.7571 
LF/HF ratio 2.5±2.2 -0.2±2.7 1.3[1.1] 0.4±0.5 0.3441 
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Heart rate recovery      
HRR-1 (bpm) 22[13] -0.5±10.7 22.9±11.3 1.9±19.9 0.4529 
HRR-2 (bpm) 41.3±13.5 -0.6±13.2 39[17.3] 1.9±21.1 0.4882 
HRR-3 (bpm) 48.4±15.7 -1.5±13.5 45.9±13.9 2.9±22.2 0.2664 
Heart rate reserve      
Heart rate reserve (%) 59.6±22.8 -6.0±16.3 60.9±23.9 -7.4±18.6* 0.7178 
Mean ± standard deviation given for normally distributed variables, median [interquartile range] given for not normally distributed variables. RQ = 
respiratory quotient. METs = metabolic equivalents. SDNN = standard deviation of N-N intervals. RMSSD = root mean square of successive 
differences. TP = total power. VLF = very low frequency. LF = low frequency. HF = high frequency. HRR-1: heart rate recovery at 1 minute peak 
exercise. * in change column refers to significant within group differences. * in p-value column refers to significant between group differences. 
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Heart rate variability   
SDNN (ms) 0.001 0.995 
RMSSD (ms2) 0.078 0.621 
TP (ms2) 0.080 0.610 
VLF (ms2) 0.120 0.422 
LF (ms2) 0.041 0.782 
HF (ms2) 0.288 0.050* 
VLF (%) -0.034 0.829 
LF (%) -0.167 0.283 
HF (%) 0.193 0.215 
VLF (Hz) -0.112 0.454 
LF (Hz) 0.210 0.158 
HF (Hz) 0.179 0.228 
LF (n.u.) -0.257 0.081 
HF (n.u.) 0.257 0.081 
LF/HF ratio -0.261 0.077 
Heart rate recovery   
HRR-1 (bpm) 0.287 0.009* 
HRR-2 (bpm) 0.218 0.047* 
HRR-3 (bpm) 0.147 0.204 
Heart rate reserve   
Heart rate reserve (%) -0.048 0.691 
SDNN = standard deviation of N-N intervals. RMSSD = root mean square of successive 
differences. TP = total power. VLF = very low frequency. LF = low frequency. HF = high 
frequency. HRR-1: heart rate recovery at 1 minute peak exercise. 
 
 
 
